
<html lang="en"     class="pb-page"  data-request-id="58deaf2f-c38e-4db3-8334-b82dee55bd15"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-12;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.9b01365;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Dose Predictions for Drug Design" /></meta><meta name="dc.Creator" content="Tristan S.  Maurer" /></meta><meta name="dc.Creator" content="Dennis  Smith" /></meta><meta name="dc.Creator" content="Kevin  Beaumont" /></meta><meta name="dc.Creator" content="Li  Di" /></meta><meta name="dc.Description" content="The efficacious dose of a drug is perhaps the most holistic metric reflecting its therapeutic potential. Dose is predicted at many stages in drug discovery and development. Prior to the 1990s, dose..." /></meta><meta name="Description" content="The efficacious dose of a drug is perhaps the most holistic metric reflecting its therapeutic potential. Dose is predicted at many stages in drug discovery and development. Prior to the 1990s, dose..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 8, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01365" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01365" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01365" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01365" /></link>
        
    
    

<title>Dose Predictions for Drug Design | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01365" /></meta><meta property="og:title" content="Dose Predictions for Drug Design" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0006.jpeg" /></meta><meta property="og:description" content="The efficacious dose of a drug is perhaps the most holistic metric reflecting its therapeutic potential. Dose is predicted at many stages in drug discovery and development. Prior to the 1990s, dose prediction was limited to the drug “working” at a reasonable dose and dose regimen in an animal model. Through the early 2000s, dose predictions were generated at candidate nomination and then refined during clinical development. Currently, dose predictions can be made early in drug discovery to enable drug design. Dose predictions at this stage can identify critical drug properties for a viable dose regimen and provide clinically relevant context to lead optimization. In this paper, we give an overview of the opportunities and challenges associated with dose prediction for drug design. A number of general considerations, approaches, and case examples are discussed." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="The efficacious dose of a drug is perhaps the most holistic metric reflecting its therapeutic potential. Dose is predicted at many stages in drug discovery and development. Prior to the 1990s, dose prediction was limited to the drug “working” at a reasonable dose and dose regimen in an animal model. Through the early 2000s, dose predictions were generated at candidate nomination and then refined during clinical development. Currently, dose predictions can be made early in drug discovery to enable drug design. Dose predictions at this stage can identify critical drug properties for a viable dose regimen and provide clinically relevant context to lead optimization. In this paper, we give an overview of the opportunities and challenges associated with dose prediction for drug design. A number of general considerations, approaches, and case examples are discussed." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0006.jpeg" /></meta><meta name="twitter:title" content="Dose Predictions for Drug Design" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01365"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01365">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01365&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01365&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01365&amp;href=/doi/10.1021/acs.jmedchem.9b01365" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 6423-6435</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01839" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b01297" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Dose Predictions for Drug Design</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Tristan S. Maurer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tristan S. Maurer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tristan+S.++Maurer">Tristan S. Maurer</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dennis Smith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dennis Smith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">4 The Maltings, Walmer, Kent CT14 7AR, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dennis++Smith">Dennis Smith</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kevin Beaumont</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kevin Beaumont</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Beaumont">Kevin Beaumont</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Li Di</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Li Di</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicine Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#91ddf8bfd5f8d1c1f7f8ebf4e3bff2fefc"><span class="__cf_email__" data-cfemail="064a6f28426f4656606f7c63742865696b">[email protected]</span></a>. Phone: 860-715-6172.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Li++Di">Li Di</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6117-9022" title="Orcid link">http://orcid.org/0000-0001-6117-9022</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01365&amp;href=/doi/10.1021%2Facs.jmedchem.9b01365" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 6423–6435</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 8, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 August 2019</li><li><span class="item_label"><b>Published</b> online</span>8 January 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 June 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01365" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01365</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6423%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTristan%2BS.%2BMaurer%252C%2BDennis%2BSmith%252C%2BKevin%2BBeaumont%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D12%26contentID%3Dacs.jmedchem.9b01365%26title%3DDose%2BPredictions%2Bfor%2BDrug%2BDesign%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6435%26publicationDate%3DJune%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01365"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">8292</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">9</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01365" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Dose Predictions for Drug Design&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Tristan&quot;,&quot;last_name&quot;:&quot;S. Maurer&quot;},{&quot;first_name&quot;:&quot;Dennis&quot;,&quot;last_name&quot;:&quot;Smith&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Beaumont&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Di&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;6423-6435&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01365&quot;},&quot;abstract&quot;:&quot;The efficacious dose of a drug is perhaps the most holistic metric reflecting its therapeutic potential. Dose is predicted at many stages in drug discovery and development. Prior to the 1990s, dose prediction was limited to the drug “working” at a reasonable dose and dose regimen in an animal model. Through the early 2000s, dose predictions were generated at candidate nomination and then refined during clinical development. Currently, dose predictions can be made early in drug discovery to enable drug design. Dose predictions at this stage can identify critical drug properties for a viable dose regimen and provide clinically relevant context to lead optimization. In this paper, we give an overview of the opportunities and challenges associated with dose prediction for drug design. A number of general considerations, approaches, and case examples are discussed.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01365&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01365" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01365&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01365" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01365&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01365" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01365&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01365&amp;href=/doi/10.1021/acs.jmedchem.9b01365" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01365" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01365" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01365%26sid%3Dliteratum%253Aachs%26pmid%3D31913040%26genre%3Darticle%26aulast%3DMaurer%26date%3D2020%26atitle%3DDose%2BPredictions%2Bfor%2BDrug%2BDesign%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D12%26spage%3D6423%26epage%3D6435%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=290851" title="Half-life">Half-life</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=292202" title="Drug discovery">Drug discovery</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/12" title="Go to Volume 63, Issue 12"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/jmcmar.2020.63.issue-12/20200625/jmcmar.2020.63.issue-12.largecover.jpg" alt="Go to Volume 63, Issue 12"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_0006.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The efficacious dose of a drug is perhaps the most holistic metric reflecting its therapeutic potential. Dose is predicted at many stages in drug discovery and development. Prior to the 1990s, dose prediction was limited to the drug “working” at a reasonable dose and dose regimen in an animal model. Through the early 2000s, dose predictions were generated at candidate nomination and then refined during clinical development. Currently, dose predictions can be made early in drug discovery to enable drug design. Dose predictions at this stage can identify critical drug properties for a viable dose regimen and provide clinically relevant context to lead optimization. In this paper, we give an overview of the opportunities and challenges associated with dose prediction for drug design. A number of general considerations, approaches, and case examples are discussed.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/63/12"><issue-title>Drug Metabolism and Toxicology</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43436" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43436" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Over the past several years, we have provided perspectives on important ADME (absorption, distribution, metabolism, and excretion) issues for <i>Journal Medicinal Chemistry</i> including half-life,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> clearance,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and volume of distribution.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> While these parameters and associated design concepts are important in themselves, the ultimate relevance is largely realized through their determinant relationship to dose regimen (i.e., dose amount and frequency of administration). In turn, dose regimen has important implications for cost of goods (COG), efficacy, patient compliance, and safety, all of which underwrite the value to the patient and commercial potential of a drug candidate. The implications for COG are somewhat obvious, with higher doses requiring the manufacture and formulation of a larger amount of the active pharmaceutical ingredient (API). Often overlooked however is that while some therapeutic areas may be less impacted by COG, it is absolutely critical in others, such as anti-infectives, in developing countries. Adoption of a new antimalarial for instance may simply come down to price. Numerous analyses indicate that patient compliance to dose regimen is inversely related to dose frequency, with significant improvements with once daily over multiple daily dose regimens across a range of acute and chronic illnesses.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> This can have significant commercial implications within a drug class, with a good example coming from calcium channel blockers. The first calcium channel blocker, nifedipine, exhibited a relatively short half-life in humans requiring three times a day administration to achieve the desire extent and duration of exposure. The frequency of dosing was reduced by slow release formulations which allowed once a day dosing. Despite this, follow-on programs still continued. A basic center was introduced into the calcium channel blocker core structure to yield amlodipine, driving a higher volume of distribution<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and a 48-h half-life commensurate with once daily administration. The slight accumulation of the drug with this half-life resulting in a steady state was forgiving to occasional missed doses. Thus, amlodipine encouraged compliance by once daily administration but was also tolerant of noncompliance. Hence, patients on amlodipine had consistent reductions in blood pressure when measured. As a result, amlodipine became one of the most prescribed antihypertensive drugs ever discovered. Compliance is also affected by the ease of which a drug formulation can be taken. Dose size can lead to unacceptable formulations, particularly where the preferred form is a combination of drugs such as anti-infectives. For example, in the area of malaria where the focus is on a single dose combination cure to remove parasite from the blood, the dose prediction of individual drug components is critical to ensure that the overall size of the single dose treatment is acceptable to the patient. Improvements in compliance have significant health and economic implications. For example, in the U.S. alone, a lack of medication adherence has been reported to be a major cause for drugs not meeting their therapeutic potential, accounting for 125 000 deaths, 10% of hospitalizations and $100–289 billion in health care costs.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Finally, the importance of dose to safety has long been recognized, dating back over 500 years to Paracelcus who noted that “all things are poison, and nothing is without poison, the dosage alone makes it so a thing is not a poison”. Indeed, this concept has been borne out in pharmaceutical research with virtually all drugs exhibiting a therapeutic index between the efficacious and safe dose. This is clearly exemplified by one of the most commonly used drugs, acetaminophen, where the efficacious oral dose is around 1 g, but overdosing above 4 g can cause severe liver toxicity.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> Even in cases of “unpredictable” idiosyncratic toxicity, numerous analyses have shown that daily dose level is an important parameter in discriminating between safe and unsafe drugs.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9−11)</a></div><div class="NLM_p last">Consequently, it is increasingly recognized that dose regimen predictions provide an important context for decision making in preclinical pharmaceutical research and early clinical development. Of particular relevance to drug design, early dose predictions can provide a line of sight to chemists in achieving a balance of properties that is ultimately necessary for clinical success. Quantitative linkage of clinically relevant goals (like dose regimen) to preclinical data and design strategies is expected to improve the probability of technical success and reduce the time it takes to recognize drug candidates once they are conceived and synthesized.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Such has been the case for prospective pharmacokinetic (PK) predictions, which have been widely implemented across the pharmaceutical industry and have contributed to the dramatic and sustained decline in phase I attrition since in the past decade of the 20th century.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The downside of this success in phase I is that more programs are now failing in later, more costly, phases of clinical development (e.g., phase II) due to lack of efficacy and safety.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Although it remains to be seen, the early application of dose predictions for efficacy and safety may help phase II attrition much in the same way that PK predictions have helped with phase I attrition. Of course, dose predictions require prospective prediction of both PK and pharmacodynamics (PD), with key concepts and methods for the latter being at a more nascent stage across the pharmaceutical industry. The purpose of this Perspective is to provide an overview of key concepts, methods, and examples related to dose predictions, with an emphasis on approaches that are of potential value to drug design.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Key Concepts and Considerations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74312" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74312" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Clinical Goal</h3><div class="NLM_p">In order to be useful to drug design, dose predictions must be quantitatively linked to drug properties (physical chemistry, ADME, pharmacology, and toxicology). In order to be meaningful, such dose predictions should be grounded in a quantifiable and clinically relevant goal. Depending on the extent of knowledge surrounding a molecular target, the clinical goal can be as specific as achieving a predefined level of efficacy or as general as ensuring a reasonable probability of testing the therapeutic hypothesis. When there is enough information about the role of a target or pathway in disease, the clinical goal can be based upon a quantifiable reduction in disease severity (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A). Some examples of quantifiable disease severity measures include HbA1c, microbial burden, disease scores, rate of morbidity, and rate of mortality. While dose predictions of this nature are the least arbitrary, this approach is not always feasible given the unprecedented nature of most molecular targets being pursued in pharmaceutical research. In other more common scenarios, it is better to define the clinical goal in terms of testing the therapeutic hypothesis. For example, when there is little to no quantitative information regarding the relevance of a target to disease, a “no-regrets” approach can be considered in which dose predictions target a point very high on the concentration–effect relationship for target modulation (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B). In principle, “no-regrets” dose predictions ensure that the therapeutic hypothesis is tested at a developable dose in the clinic such that there are no regrets about the molecule in the event of a negative POC (proof of concept) study. In practice, the question of how much target modulation constitutes a no-regrets level is relatively arbitrary and, therefore, often a matter of debate. Here, it is important to recognize that there are real and counterbalancing risks to either side of this arbitrary threshold. Setting the level too low carries a risk that the clinical candidate will not have the necessary properties to robustly test the mechanism. Conversely, setting the level too high brings risk of delays due to an unnecessarily high hurdle in design. Finally, in some cases, information regarding differences in target or pathway activity between healthy and disease subjects can provide a slightly more refined approach to dose prediction (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C). In many cases, therapeutic targets are rationalized, in part, on biomarker measurements which report on a degree of dysregulation between disease and healthy conditions. One attractive aspect of this approach, therefore, is that it finds its relevance in the same data which often underwrite the therapeutic hypothesis itself. Regardless of the approach, an understanding of the relationship between dose and target modulation is critical. Dose predictions intended to enable design must codify this relationship in a way that can be informed by data generated in support of lead optimization. This includes data to support a prediction of drug exposure following dosing (i.e., PK) and a prediction of target modulation given the exposure achieved (i.e., PD). As such, careful consideration must be given to translating preclinical PK and PD data in this context for the sake of relevant dose predictions.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Conceptual illustration of three approaches to a quantitative clinical objective in support of design. (A) 80% target modulation is targeted based on an understanding of the relationship between target activity and disease. (B) 80% target modulation is targeted based on a “no-regrets” approach to ensuring that the mechanism will be tested in the clinic. (C) 80% target modulation is rationalized on the basis of data indicating that this is what’s required to restore target activity to healthy levels.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Translating PK Parameters</h3><div class="NLM_p last">As stated above, translation of preclinical data into predicted clinical PK properties governing drug exposure (e.g., half-life, clearance, and volume of distribution) is important in dose regimen prediction. Methods to achieve translation are not reviewed here, since these have been extensively reviewed in previous perspectives in this series.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> Rather, in the following “<a class="ref internalNav" href="#sec3" aria-label="Approaches to Dose Prediction">Approaches to Dose Prediction</a>” section, this Perspective will focus on the appropriate use of predicted PK parameters in this context. However, before PK predictions can be used to support dose predictions, careful consideration must be given to the translation of PD parameters.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Translating PD Parameters</h3><div class="NLM_p">PK parameters are used to relate dose regimen to the time course of exposure. PD parameters are used to relate exposure to the time course of pharmacological response. Both are necessary to predict a dose–response relationship that is useful in drug design. However, there are relatively few generalized methods and examples related to the scaling of PD parameters (e.g., IC<sub>50</sub>, EC<sub>50</sub>, IA (intrinsic activity), <i>E</i><sub>max</sub>, <i>I</i><sub>max</sub>), estimated preclinically, into the clinic.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15−17)</a> One challenge is that, unlike PK parameters, the PD parameters underwriting dose predictions vary widely according to nature of the target, molecular mechanism of action of the drug, and the pharmacological response of interest. Further complicating matters is that many common PD parameters represent a convolution of drug-specific and system specific parameters. While such parameters may provide a statistically robust characterization of data from a given system (in vitro, animal, human), preclinical predictions of human dose require careful consideration of factors that will influence the translation of PD parameters across systems.</div><div class="NLM_p">Of the factors confounding translation, differences in drug exposure across systems are perhaps the most straightforward to understand and account for in predicting dose. Typically, only unbound drug is available to interact with the molecular target. As such, differences in protein binding (e.g., albumin, α-1 acid glycoprotein) and nonspecific partitioning (e.g., lipids, plastics) between systems (in vitro and in vivo, cells and tissues, animals, and humans) can cause significant shifts in the apparent potency of a molecule based on nominal or total drug concentrations. However, even after correction for differences in unbound fraction, apparent discrepancies may exist due to physiological factors that affect distribution of unbound drug to the site of action. Such factors can include the presence or absence of diffusional barriers (e.g., isolated protein versus cell-based assays), differential composition of diffusional barriers (e.g., transporter expression), and differences in pH partitioning across systems. Accounting for such differences in unbound fraction, as well as differences in the rate and/or extent of brain distribution, has been demonstrated to improve translation between in vitro binding affinity and in vivo pharmacology for series of μ-opioid receptor agonists and 5HT2c agonists.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> A good example of the confounding influence of pH partitioning in translation has been provided by Zuhl et al.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In this example, the authors describe a situation where a significant decrease in the selectivity of weakly basic β-secretase inhibitors over cathepsin D (CatD) inhibition was observed in cellular and in vivo systems over that observed for the isolated proteins. It was subsequently shown that the compounds partition into acidic lysosomes where CatD is primarily active, resulting in a significant erosion of the selectivity and unexpected CatD-based ocular toxicity in animals.</div><div class="NLM_p last">In addition to exposure, differences in biological conditions between systems can yield divergent pharmacological responses across systems. Levels of protein expression, concentrations of other ligands and substrates, and dynamic regulation of proteins, ligands, and biomarkers may differ between in vitro and in vivo systems, tissue types, and species. Likewise, experimental conditions in animal models (e.g., measurement of an anti-inflammatory effect in response to an experimentally induced state of inflammation) are frequently different from that relevant to humans. If not considered properly, such differences can provide misleading information regarding the expected clinical potency and intrinsic activity and thereby confound dose predictions. It can often be difficult to understand such differences between systems and their impact on human translation. As such, it is important that in vitro assays are conducted under conditions that are as physiologically relevant as possible. For competitive inhibitors, a classic example is the dependence of IC<sub>50</sub> on the concentration of other substrates or ligands in keeping with the Cheng–Prusoff relationship.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This has been demonstrated for ATP-competitive kinase inhibitors, where the IC<sub>50</sub> typically increases substantially (∼10–100×) between in vitro assays run at ATP concentrations approximating the <i>K</i><sub>m</sub> versus in vivo where ATP is typically present in large excess of the <i>K</i><sub>m</sub>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Because various kinases differ with respect to the <i>K</i><sub>m</sub> of ATP, this can also have important implications for apparent selectivity across kinase panels. For receptors, translation is particularly challenging, where both EC<sub>50</sub> and maximal activity can vary according to receptor expression and concentration of proteins involved in signal transduction (G-protein, β-arrestin, etc.) in keeping with the operational model of drug agonism.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> For example, increased expression of β2 and β3 adrenoreceptors, 5HT<sub>1A</sub>, secretin, and muscarinic receptors has been shown to increase the apparent potency and/or intrinsic activity of agonists to these receptors.<a onclick="showRef(event, 'ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27">(24−27)</a> Ploeger et.al. have provided a review of literature demonstrating how accounting for such differences improves the translation of potency and selectivity of adenosine A1, GABA<sub>A</sub>, and 5HT<sub>1A</sub> agonists between in vitro and in vivo systems and across tissues in vivo.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In addition, these and other theoretical considerations for translating receptor pharmacology between systems have been comprehensively discussed by Kenakin.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Beyond protein concentration, differences in the dynamic regulation of proteins, ligands, and biomarkers between systems can also complicate translation. For irreversible inhibitors, like time-dependent or mechanism-based enzyme inactivators, differences in target protein turnover between systems may confound translation of IC<sub>50</sub>. For in vitro systems containing a fixed amount of enzyme, the IC<sub>50</sub> of a mechanism-based inactivator will continuously decline with time, making it a function of the somewhat arbitrary incubation time employed in the study.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In systems where the target protein is being produced and degraded naturally (e.g., cells, in vivo), mechanism-based inactivation merely affects this balance and IC<sub>50</sub> does not continuously decline with time. However, higher rates of endogenous protein turnover will lead to higher effective IC<sub>50</sub> values. Such differences may contribute to differences in potency between in vitro and in vivo systems and across species. Here, it has been shown that accounting for the kinetics of inactivation and protein turnover improves the translation of inhibitory potency between systems for irreversible CYP3A4 inhibitors.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> In other systems, differences in flux pathways (e.g., metabolic and transport pathways) may complicate translation of effective pharmacological potency between in vitro and in vivo systems. Such concepts are commonly employed in predicting the magnitude of drug–drug interactions for drugs being eliminated by more than one pathway but are less commonly employed in translating PD. However, Li et al. have published an example of this for inhibitors of the NaCT transporter that were being designed to decrease the hepatic influx of citrate from the blood.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In this case, because NaCT-mediated transport of citrate was the primary pathway for citrate elimination in vivo, inhibition of hepatic flux also meant that the driving force for flux (citrate concentrations in blood) was increased upon inhibition. As such, the expected potency for inhibiting hepatic influx was right shifted relative to the IC<sub>50</sub> for transport function, resulting in the need to target a much higher level of drug exposure than would be expected based on in vitro potency. Here it is important to point out that this model-based insight was made possible through leveraging literature data on the disposition of citrate which was available years before the project was initiated. Finally, the dynamic regulation of biomarkers can also confound the translation of pharmacology between systems, particularly when the time-dependent nature of response is inadequately considered. This relates to the fact that biomarkers, as measures of pharmacological activity in vitro and in vivo, are regulated on time scales that are disconnected from the time scale of drug-related changes in the activity of the molecular target. Some biomarkers are regulated on a very short time scale (neurotransmitters, chemicals) and will respond rapidly to pharmacological intervention, while other biomarkers are regulated on a much slower time scale (mRNA, proteins, cells) and require hours to weeks in order to observe a complete response. From a translational perspective, it is important to note that the kinetic regulation of biomarkers can differ between in vitro systems and species. If this property of the system is not accounted for properly, it can introduce dramatic misestimations of key pharmacological properties like potency and maximal activity which underwrite dose predictions. A classic example of this can be seen with the pharmacological response to the anticoagulant warfarin, which blocks the formation of (active) carboxylated clotting factors (e.g., factors II, VII, IX, and X) via inhibition of vitamin K epoxide reductase and a subsequent decrease in the necessary cofactor vitamin K. Following a single dose, very little effect on prothrombin activity is seen at peak warfarin concentrations which occur shortly after administration (hours). However, the maximal PD activity is seen 2–3 days later after which warfarin concentrations have significantly decreased. The reason for this is that it takes time for the clotting factors, already present, to be eliminated once production has been decreased, and this occurs on a time scale of days. Jusko and Ko have described how accounting for both the molecular mechanism of action and biological context through use of indirect-response PKPD models can help estimate the true potency of compounds for which disconnects between maximal exposure and maximal response occur.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Such approaches are absolutely critical in order to properly estimate and translate potency and maximal activity in support of dose predictions.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Approaches to Dose Prediction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45276" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45276" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Once careful consideration has been given to the clinical goal and estimation/translation of key parameters characterizing the primary pharmacology, the next step is to incorporate this information into an approach to predict dose. While the specifics of any given dose prediction will vary greatly according to the nature of the molecular target, molecular mechanism of action, and pharmacological response of interest, dose predictions can commonly be classified as empirical, PK, or PK/PD in nature.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Empirical</h3><div class="NLM_p last">Empirical dose predictions use a simple scaling such as body surface area to scale the dose showing efficacy in an animal species to a dose that should be effective in man. While such approaches are largely nonexistent today, in the past many drugs relied on this simple empirical approach to gain confidence in advancing the drugs into development. Such studies were not influential in the design process as will be discussed later and cannot be related to drug properties.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> PK Approach</h3><div class="NLM_p">Dose predictions are based on achieving a certain drug exposure given the pharmacological properties of the molecule. Most commonly, this is based on achieving some ratio of unbound drug concentration at the site of action relative to the most relevant measure of potency or explicitly calculating the level of pharmacological activity from the drug concentration, potency, and intrinsic activity. The target value (exposure/potency ratio or calculated % activity) can be based on any of the aforementioned approaches to setting the clinical goal. For example, by use of inhibitory potency for the sake of discussion, there may be enough information to define a certain IC<sub><i>xx</i></sub> (e.g., IC<sub>25</sub>, IC<sub>50</sub>, IC<sub>90</sub>, etc.) as necessary to achieve a clinically relevant end point in a POC trial. In other cases, it might be known that a certain IC<sub><i>xx</i></sub> would normalize a difference in the activity of the molecular target or pathway between healthy and disease conditions. Finally, in the absence of any information, one may choose to target a high degree of pharmacological coverage (e.g., IC<sub>90</sub>) as a no-regrets approach. With these approaches, dose predictions can be generated by an appropriate estimate of the expected clinical pharmacological properties (e.g., potency and maximal activity) which define the target concentration and standard PK prediction methods (CL, <i>V</i><sub>ss</sub>, <i>F</i>, etc.). With these parameters defined, PK models like the one compartment PK model with absorption can be used to provide early predictions of dose in support of design (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). While this type of dose prediction is attractive due to its apparent simplicity, there are challenges and limitations that need to be considered in the appropriate application of this approach. One of the key challenges, which transcends all prediction approaches, is ensuring that the predicted exposure represents that at the site of action and that the measure of potency used in this exercise is translationally relevant. This has been discussed in detail above. A unique challenge to PK-based approaches derives from the fact that exposure profiles (in plasma or other sites of action) are dynamic over the dosing interval, rising with absorption and then declining with metabolism and elimination. As such, doses predicted in this manner are commonly anchored against a discrete point or descriptor of the concentration–time curve. The most common descriptors are steady-state maximum concentration (<i>C</i><sub>max</sub>), minimum concentration (<i>C</i><sub>min</sub>), or average concentration (C<sub>avg</sub> = AUC/dose interval). As such, this approach requires an understanding of the PK driver of the intended pharmacology. This is often not obvious with novel mechanisms encountered in the drug design process. One approach to elucidating the PK driver is dose fractionation, where dose regimens (typically in an animal model) are employed that cause a disconnect between the parameters of <i>C</i><sub>max</sub>, <i>C</i><sub>min</sub>, and <i>C</i><sub>avg</sub> in order to determine the best correlate to the pharmacological response of interest.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> This approach is typically labor intensive, and the validity ultimately depends on a similarity in the PK driver between animals and humans. For this reason, it is most commonly employed for animal models of bacterial infection. For anti-infectives, where in vitro experiments should have a close link to in vivo values such as minimum inhibitory concentration and minimum bactericidal concentration (MIC and MBC), direct extrapolation can take place, particularly where time above these values in terms of plasma concentration can be linked to the clinical goal described earlier. In some cases, general scientific or practical considerations may help identify the most translationally useful PK driver to guide design. For example, dose predictions for <i>C</i><sub>max</sub> may be appropriate for acute PD effects of interest. This helps bring elements of risk assessment into early drug discovery around off-target pharmacology. Perhaps the most common examples are in the area of acute adverse effects, such as the risk of QT prolongation due to hERG inhibition.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In some cases, the PD effect of interest may require a sustained engagement of the molecular target such that a <i>C</i><sub>min</sub> (or its related metric, time above a threshold concentration) is most appropriate. Perhaps the most common examples here are the antivirals, where high and sustained inhibition of replication based on in vitro assays is required due to the lack of appropriate animal models.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Using <i>C</i><sub>min</sub> and drug potency as a simple guide may be appropriate for molecular targets for which maximal engagement is needed to provide clinical efficacy and wide safety margins. Such was the case in the development of the newest class of therapeutics for type 2 diabetes mellitus (T2DM), namely, SGLT2 antagonists that lower blood glucose by decreasing reuptake of filtered glucose in the urine. All of the compounds requiring commercially inviable dose regimens to reach maximal effects on urinary glucose excretion (e.g., >1000 mg TID) failed to progress past phase II (sergliflozin, AVE2268), while all of the currently marketed compounds produce near maximal effects on urinary glucose excretion at low–moderate, once daily doses (dapagliflozin, canagliflozin, empagliflozin, ipragliflozin, ertugliflozin). One key consideration for <i>C</i><sub>min</sub> approaches is the sensitivity to error in the PK parameters, particularly for compounds in which the half-life is short relative to the dose interval. This is particularly important since most PK predictions methods are assessed as being adequate if within 2-fold of reality. To illustrate the impact of a 2-fold error in clearance prediction on dose requirements with this approach, a set of simulations (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) were performed using the <i>C</i><sub>min</sub> equation in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. For the sake of simulations, we assumed a <i>V</i><sub>ss</sub> (steady state volume of distribution) and <i>k</i><sub>a</sub> (absorption rate) of 1.4 L/kg and 1.8/h, respectively. Consistent with an orally administered, hepatically cleared drug, <i>F</i> (bioavailability) was assumed to be a function of clearance (<i>F</i> = 1 – CL/Qh), where Qh represents human hepatic blood flow (20 mL min<sup>–1</sup> kg<sup>–1</sup>). Doses were calculated based on a goal of achieving a <i>C</i><sub>min</sub> of 10 ng/mL for a range of clearance values (0.7–8 mL min<sup>–1</sup> kg<sup>–1</sup>) corresponding to a range of half-lives (2–24 h). The impact of a 2-fold uncertainty in the clearance prediction on the dose projection was simulated across the range of assumed clearance values. Here, it can be seen that uncertainty in the PK profile of the short half-life compound is much greater than for the long half-life compound, particularly at the <i>C</i><sub>min</sub> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). This results from the fact that clearance is typically a first-order process producing an exponential (or log–linear) decline in concentration with time according to the elimination rate (<i>k</i><sub>el</sub>). As such, the errors in CL (as simulated) or <i>V</i><sub>ss</sub> (not shown) have a disproportionate (exponential) effect on <i>C</i><sub>min</sub>, particularly as the half-life becomes small relative to the dose interval (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). Because the dose prediction is proportional to the <i>C</i><sub>min</sub> target, the uncertainty in dose predictions is disproportionately affected by errors in clearance and <i>V</i><sub>ss</sub> in a similar manner (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C and <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. One-Compartment Model Equations To Support a Pharmacokinetic-Based Approach to Dose Prediction</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">equation</th></tr></thead><tbody><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" align="left" valign="middle">dose for <i>C</i><sub>max</sub></td><td class="colsep0 rowsep0" align="left" valign="middle"><span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_m005.gif" alt="" id="_i12" /></img></span></td></tr><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" align="left" valign="middle">dose for <i>C</i><sub>min</sub></td><td class="colsep0 rowsep0" align="left" valign="middle"><span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_m006.gif" alt="" id="_i13" /></img></span></td></tr><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" align="left" valign="middle">dose for <i>C</i><sub>avg</sub></td><td class="colsep0 rowsep0" align="left" valign="middle"><span class="NLM_disp-formula" id="ueq3"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_m007.gif" alt="" id="_i14" /></img></span></td></tr><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" align="left" valign="middle"><i>T</i><sub>max,ss</sub></td><td class="colsep0 rowsep0" align="left" valign="middle"><span class="NLM_disp-formula" id="ueq4"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_m008.gif" alt="" id="_i15" /></img></span></td></tr><tr valign="middle" class="colsep0"><td class="colsep0 rowsep0" align="left" valign="middle"><i>k</i><sub>el</sub></td><td class="colsep0 rowsep0" align="left" valign="middle"><span class="NLM_disp-formula" id="ueq5"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_m009.gif" alt="" id="_i16" /></img></span></td></tr></tbody></table></div></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Sensitivity of <i>C</i><sub>min</sub>-based dose predictions to a 2-fold error in clearance predictions. Solid lines represent the predicted CL, and dashed lines represent the impact of a 2-fold under- and overprediction of clearance. (A) Uncertainty in concentration–time profile for a short half-life (1 h, solid black line) versus a long half-life (24 h, solid gray line) compound dosed once daily to achieve a 10 ng/mL <i>C</i><sub>min</sub>. (B) Uncertainty in <i>C</i><sub>min</sub> as a function of half-life expressed as fold error from the estimate. (C) Effect of half-life on dose prediction and associated uncertainty in dose. (D) Uncertainty in dose as a function of half-life expressed as fold error from the estimate. All simulations were performed with a one compartment pharmacokinetic model with first order absorption.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In other cases, the average concentration at steady-state (<i>C</i><sub>avg,ss</sub>, calculated as AUC/dose interval at steady-state) may be most predictive of efficacy, such as has been reported for the JAK inhibitor tofacitinib and a number of antimicrobials.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a><i>Even in the absence of direct evidence in support of C</i><sub><i>avg,ss</i></sub>, <i>this approach is perhaps the most generally relevant and applicable to design so long as half-life is also carefully considered.</i> One very attractive aspect of this approach in supporting design is that the factors governing <i>C</i><sub>avg,ss</sub> are intuitive and map well to the type of data typically generated during lead optimization. <a class="ref internalNav" href="#eq1" aria-label="Equation 1">Equation 1</a> (taken from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) represents this relationship.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a><span class="NLM_disp-formula" id="eq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_m001.gif" alt="" id="_i17" /></img><span class="labelSpan">(1)</span></span>where <i>C</i><sub>avg,ss</sub>, CL, tau, and <i>F</i> represent the total concentration to achieve the desired effect, the rate of clearance, the dose interval, and bioavailability, respectively. Of course, these parameters represent a composite of drug and biological properties (blood flows, hepatic extraction, absorption, protein binding). However, assuming oral administration and hepatic clearance (i.e., the most common scenario for small molecules), these terms can be expanded as shown below in keeping with the well-stirred model of drug clearance and free drug hypothesis (<a class="ref internalNav" href="#eq2" aria-label="eq 2">eq 2</a>):<span class="NLM_disp-formula" id="eq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_m002.gif" alt="" id="_i18" /></img><span class="labelSpan">(2)</span></span><a class="ref internalNav" href="#eq2" aria-label="Equation 2">Equation 2</a> can be further simplified to properties that are intrinsically related to chemical structure (<a class="ref internalNav" href="#eq3" aria-label="eq 3">eq 3</a>):<span class="NLM_disp-formula" id="eq3"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_m003.gif" alt="" id="_i19" /></img><span class="labelSpan">(3)</span></span></div><div class="NLM_p">In <a class="ref internalNav" href="#eq3" aria-label="eq 3">eq 3</a>, dose is shown to be proportional to the average steady-state unbound concentration (<i>C</i><sub>avg,ss,unbound</sub>, defined based on potency), intrinsic clearance (CL<sub>int,</sub> which is commonly provided by high-throughput assays using liver microsomes and/or hepatocytes, scaled to units of mL min<sup>–1</sup> kg<sup>–1</sup>), and dose interval (tau). Dose is also inversely proportional to fraction absorbed (<i>f</i><sub>a</sub>), which is intrinsically related to the solubility and permeability of a molecule. It is worth noting that fraction unbound in the blood (<i>f</i><sub>u</sub>) drops out of <a class="ref internalNav" href="#eq3" aria-label="eq 3">eq 3</a>, illustrating an important PK principle that <i>C</i><sub>avg,ss,unbound</sub> and therefore doses targeting this value are independent of unbound fraction. When informing <i>C</i><sub>ss,avg,unbound</sub> based on an in vitro measure of potency (e.g., IC<sub><i>xx</i></sub> or EC<sub><i>xx</i></sub>), it is important to correct apparent potencies for nonspecific binding in the incubation (e.g., nontarget proteins, lipid partitioning, plate binding, etc.). Likewise, when informing CL<sub>int</sub> based on measurements in liver microsomes or hepatocytes, it is important to correct apparent values for nonspecific binding. This relationship to the properties of the molecule makes this a particularly attractive approach to provide dose predictions in support of drug design at the very early stages of drug discovery where information is often limited. For example, as conceptually illustrated in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, predicted dose requirements can be visualized for many compounds in lead optimization by informing <a class="ref internalNav" href="#eq3" aria-label="eq 3">eq 3</a> with high throughput data on primary pharmacology (e.g., <i>C</i><sub>ss,avg</sub> = IC<sub>80</sub> in a functional assay of relevance) and metabolic clearance (CL<sub>int</sub> estimated from liver microsomes or hepatocytes). As such, this approach is also attractive in that it can provide a line of sight to the clinical goal consistent with the pace of design cycles. Although the absolute accuracy of such dose predictions will depend on the validity of underlying assumptions (e.g., <i>C</i><sub>ss,avg,unbound</sub> is the appropriate exposure metric; the IC<sub>80</sub> from the pharmacology assay can be translated in this manner), even a sense of relative dose requirements can be very useful at the early stages of design. Additional insight and data generated in the course of a project will invariably support continuous refinement in the approach and yield predictions with a greater degree of accuracy. That said, one universally important caution in the use of this approach is that the average effect over the dosing interval does not necessarily correspond to the effect at the average concentration. For example, a PK profile providing a <i>C</i><sub>ss,avg,unbound</sub> at the IC<sub>80</sub> may provide much less than 80% average inhibition over the dosing interval. The fundamental reason for this is that although <i>C</i><sub>ss,avg,unbound</sub> is independent of half-life, the associated time course of effect is not. To illustrate this issue, we have provided a set of simulations using a simple steady-state one compartment PK model with absorption and a standard inhibitory pharmacological response curve (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). In this hypothetical scenario, we calculate a dose to provide a <i>C</i><sub>ss,avg,unbound</sub> equivalent to a theoretical IC<sub>80</sub>. In the simulations, clearance, bioavailability, and absorption rate were kept constant and volume was allowed to vary in order to examine the effect of half-life in isolation. Consistent with <a class="ref internalNav" href="#eq1" aria-label="eq 1">eq 1</a>, although the peak-to-trough ratios of exposure increase with decreasing half-life (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A), the average concentrations are kept constant across the profiles (IC<sub>80</sub>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). In contrast, the time course of inhibition is very different across the simulated half-lives (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). Notably, as the half-life becomes very short, it is expected that there will be near complete inhibition early in the dose interval and a complete lack of inhibition later in the dose interval. Further, after calculation of the average inhibition over the dosing interval (AUC of inhibition/dose interval), it becomes clear that the average inhibition decreases as half-life is reduced (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D). The disconnect between IC<sub>80</sub> (as a <i>C</i><sub>ss,avg,unbound</sub>) and average percent inhibition becomes pronounced as the dosing interval exceeds the half-life by approximately 3-fold. As such, as general rule of thumb, <i>C</i><sub>ss,avg,unbound</sub> approaches to dose prediction should also come with a design goal of having a drug half-life within 2- to 3-fold of the dose interval. The additional benefit of this goal is that it ensures relatively shallow <i>C</i><sub>max</sub>-to-<i>C</i><sub>min</sub> ratios. For example, an 8 h half-life provides <i>C</i><sub>max</sub> and <i>C</i><sub>min</sub> values that are within 2- to 3-fold of <i>C</i><sub>avg</sub> in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. With this strategy, errors in the dose prediction will be minimized even in the event that <i>C</i><sub>max</sub> or <i>C</i><sub>min</sub> turns out to be the more appropriate PK driver.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Illustration of relative dose visualization based on a <i>C</i><sub>ss,avg</sub> approach in a lead optimization program. Lower and upper red dashed lines correspond to potency and Cl<sub>int</sub> combinations that provide a predicted dose of 20 and 100 mg QD according to <a class="ref internalNav" href="#eq3" aria-label="eq 3">eq 3</a>. Fraction absorbed has been assumed to be 100%, and 50 theoretical compounds (open symbols) have been generated to illustrate how this approach can be used to consider the relative merits of compounds early in lead optimization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Influence of half-life on the time course of pharmacological effect (% inhibition) at a fixed average concentration using a one compartment pharmacokinetic model with first order absorption. (A) Simulations of a time course of steady-state exposure under a fixed bioavailability, absorption rate, and clearance rate but variable volumes to create different half-lives. (B) Relationship between half-life and the average steady-state concentration (IC<sub>80</sub>) over the dosing interval as calculated by AUC/tau. (C) Time course of effect calculated from the simulated exposure profiles assuming a common IC<sub>50</sub> of 10 (units not specified). % inhibition was calculated as 100 × <i>C</i>/(<i>C</i> + IC<sub>50</sub>). (D) Relationship between half-life and average inhibition over the dosing interval at steady-state. Average inhibition was calculated as AUC/tau.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> PK/PD Approach</h3><div class="NLM_p last">In cases where the time-course of exposure and effect can be explicitly understood and expressed mathematically, a PK/PD approach to dose prediction is likely the most useful and accurate approach. This approach avoids the need to identify one aspect of the concentration–time profile (i.e., <i>C</i><sub>max</sub>, <i>C</i><sub>min</sub>, <i>C</i><sub>avg</sub>) as the most relevant and also provides a framework within which to consider the important aforementioned aspects of interpretation and translation of preclinical data. This approach can also be tailored to the particular details of a program, including the molecular mechanism of action, PK profile, biological context, and clinical goal. The value to drug design is in the potential to provide perhaps the clearest line of sight between drug properties and the specific pharmacological outcome of interest. To illustrate this approach, three brief case studies in dose prediction are provided below. These case examples were selected to cover a diversity of indications (diabetes, osteoporosis, and schizophrenia), target types (SLC, enzyme, and GPCR), molecular mechanisms of action (competitive inhibitor, negative allosteric modulator, and irreversible inactivator), and relevant biological context which lead to diverse implications for design.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Competitive SGLT2 Inhibitors for T2DM</h3><div class="NLM_p">Inhibitors of the solute transporter SGLT2 (SLC5A2) represent the newest class of therapeutics for the treatment of T2DM. These compounds work by inhibiting the reabsorption of renally filtered glucose in the proximal tubule of the nephron. This creates a pathway to lower blood glucose levels (and HbA1c) via urinary glucose excretion. Between the years of 2008 and 2016, this was one of the most heavily pursued targets for T2DM in the pharmaceutical industry.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The most desirable agent would be one that produces near maximal effects in urinary glucose excretion (UGE) at a low once daily dose. To support this goal, a simple PKPD model for urinary glucose was developed that accounts for key aspects of the biology (plasma glucose, glomerular filtration rate, reabsorption in normal conditions) and molecular mechanism of action (reversible competitive inhibition). Prior to the availability of literature data on the clinical pharmacology, the model was used to develop an in vitro–in vivo correlation of preclinical pharmacology in rats. At that stage, human predictions were achieved by simply using readily available values for human biology (e.g., plasma glucose, GFR) combined with in vitro measures of the human SGLT2 inhibitory potency. As clinical data with competitors became available, these predictions were further qualified against that data.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> As described in our previous communication, the model was useful in lead optimization by providing an understanding of the need to increase the predicted human half-life of lead material and identifying clearance optimization as the most sensitive means in design (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Ultimately, nomination and early clinical development of the final clinical candidate, ertugliflozin, were supported by prospective predictions of clinical PKPD and dose–UGE response in healthy subjects<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a>which were ultimately shown to be accurate in early clinical studies.<a onclick="showRef(event, 'ref44 ref46 ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref44 ref46 ref47 ref48 ref49">(44,46−49)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Design implications supported by early application of PKPD model-based dose predictions. (A) Relationship between dose and half-life of a lead SGLT2 inhibitor (open symbol), with dashed and solid lines representing the predicted relationship upon changes in volume and clearance, respectively. The implication is that optimization of half-life via clearance is preferred due to greater effect on dose relative to volume (figure reproduced with permission from ref <a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a>. Copyright 2011 American Chemical Society). (B) PKPD model-based predictions of cumulating and sustained suppression of KYNA upon once daily dosing of a short half-life KAT2 inhibitor. The implication is that a short half-life compound is acceptable (figure reproduced with permission from <i>Molecular Pharmacology</i>,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Copyright 2018 The American Society for Pharmacology and Experimental Therapeutics). (C) Acceptable clearance ranges (in green) for negative allosteric CaR modulators given typical volumes of various physiochemical classes. The implication is that a neutral lead series would be the most favorable starting place in design.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Irreversible KAT2 Inactivators for Cognitive Impairment in Schizophrenia</h3><div class="NLM_p last">The therapeutic hypothesis supporting the development of KAT2 inhibitors for this indication is based, in part, on literature reports that the product of this enzyme, kynurenic acid (KYNA), is elevated approximately 2-fold in the brain of schizophrenic patients and is known to have potentially untoward pharmacological activity at several receptors associated with cognitive function. This information was available in the literature years before the initiation of a lead optimization effort. In fact, many such observations implicating a target or pathway in disease are available in the literature and frequently serve to underwrite the initial confidence in rationale for program initiation. In this case, these data were used to set a clinical goal of normalizing KYNA tone (i.e., decreasing baseline concentrations 50% via inhibition of KAT2). The molecular mechanism of action (MMOA) of lead material was irreversible, time-dependent KAT2 inactivation via covalent modification. Accordingly, lead material was screened by standard assays necessary to generate parameters of kinetic inactivation (e.g., <i>K</i><sub>I</sub>, <i>k</i><sub>inact</sub>). As discussed above, general biological factors affecting the duration, magnitude, and potency of inhibition associated with parameters of enzyme inactivation are well-known. Perhaps the most significant biological factor for this MMOA is the half-life of the protein being inactivated, with longer half-lives conferring a greater magnitude, potency, and duration of effect for a given set of <i>K</i><sub>I</sub> and <i>k</i><sub>inact</sub> values. This knowledge was used to rationalize an early estimation of human KAT2 half-life via relatively straightforward inactivation and washout experiments in human astrocytes in vitro. The results of these studies provided a relatively long KAT2 half-life estimate (44 h), corresponding to a recovery time of 5–10 days (i.e., 3–5 half-lives) and suggesting that sustained inhibition would not require a long half-life for the inhibitor. As described previously, this allowed for greater flexibility in design by removing the typical design criteria of achieving a half-life within 2- to 3-fold of the intended dose interval. Subsequent studies were performed as the program progressed to gain additional confidence and precision in this implication and addressed other biological factors of potential relevance to translation within the final PKPD model. Ultimately, a candidate quality compound with a short half-life life (∼3 h) was identified and formal dose predictions were made supporting sustained KAT2 inhibition when dosed once daily (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B).</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Negative Allosteric Modulators of CaR for Osteoporosis</h3><div class="NLM_p last">Parathyroid hormone (PTH1–84) and analogues thereof (PTH1–34, abaloparatide) are the only anabolic agents available for the treatment of osteoporosis. While efficacious, the need for daily subcutaneous administration is not ideal. In theory, small molecule calcilytics with oral bioavailability could recapitulate the efficacy of these agents by taking advantage of the body’s own mechanism for regulating extracellular Ca<sup>2+</sup>. More specifically, such agents were designed to decrease calcium binding to the calcium sensing receptor (CaR) through negative allosteric modulation (NAM), thereby causing a release of PTH from the parathyroid gland (the main endocrine factor for maintaining calcium homeostasis through its actions on bone and kidney). One serious constraint to this approach is related to the fact that PTH has paradoxical effects on bone depending on the profile of elevation. Pulsatile elevations (as achieved with subcutaneous administration) have an anabolic effect, while sustained elevation (as occurs with hyperparathyroidism) has a catabolic effect on bone. This information and literature reports on the biological relationship between calcium receptor occupancy and PTH levels were available in the literature years before any lead optimization effort on small molecule calcilytics. As described previously, this information taken together in the context of a PKPD model served to set atypical and unusually stringent design criteria. Most notable among the design criteria was the need for a half-life of ≤1 h with rapid and complete absorption. <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C shows a simple calculation of the requisite combination of steady-state distribution volume (<i>V</i><sub>ss</sub>) and clearance rate (CL) necessary to achieve this 1 h half-life goal. Three sets of calculations are provided, tracking to the typical <i>V</i><sub>ss</sub> of anionic (0.2 L/kg), cationic (3 L/kg), and neutral molecules (1 L/kg).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Combinations of <i>V</i><sub>ss</sub> and CL within 2-fold of the target half-life are color coded green, while those outside this boundary are color coded red. These results strongly suggested that the neutral molecule space<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> had the highest likelihood of success in recapitulating the desired PTH profile, and as such, the ideal profile was determined to be a <i>V</i><sub>ss</sub> of approximately 1 L/kg and a CL of approximately 10 mL min<sup>–1</sup> kg<sup>–1</sup>. While the tendency for small volumes with anionic compounds can help drive half-life down, the viable CL space is quite narrow and restricted to a region of low clearance that can be problematic to predict. In addition, the tendency for lower permeability in this space provides additional challenges for meeting the goal of rapid absorption. For cationic compounds, the requisite clearance is very high, approaching hepatic blood flow. In this space, the high hepatic extraction provided additional challenges of requiring a higher degree of potency and the potential for a high degree of variability in the clinical pharmacokinetics. Ultimately, a series of 5-(trifluoromethyl)pyrido[4,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one derivatives were identified that met the design goals.<a onclick="showRef(event, 'ref51 ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53 ref54">(51−54)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Future Opportunities and Challenges</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48603" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48603" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Drug design requires a holistic approach to balancing all the necessary properties for clinical success. In recognition of this fact, the design community has developed a number of rules-of-thumb and metrics that empirically represent balance, a number of which have become mainstays in drug design (e.g., Ro5 (rule of 5),<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Ro3 (rule of 3),<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> LipE (lipophilic efficiency),<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> LipMetE (lipophilic metabolism efficiency),<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> etc.). In many ways, dose predictions provide the opportunity to support such efforts to achieve balance with a clearer line of sight into what’s necessary for clinical success. Whether clinical success is defined as adequately testing the therapeutic hypothesis or the achievement of a therapeutic outcome, the requisite dose regimen is perhaps one of two metrics that best reflect the degree to which this balance has been achieved (the other being therapeutic index). As such, the provision of dose predictions into drug design has the potential to enable design through the definition of laboratory objectives for design and the recognition of success once achieved. With increasingly accurate in silico predictions of drug properties, there is further opportunity for virtual dose predictions to help prioritize and even generate design ideas. The combination of in silico prediction of <i>V</i><sub>ss</sub> and in vitro systems utilizing <a class="ref internalNav" href="#eq3" aria-label="eq 3">eq 3</a> (PK approach) provides methods that provide very early dose regimen prediction. Strategies to reduce dose size and dosing frequency are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. However, there are a number of challenges in realizing even the near-term opportunities.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Strategies To Reduce Dose Size and Dosing Frequency</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><u class="uu">strategies to reduce dose size</u></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">· Increase potency (affinity) against target</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">· Decrease intrinsic clearance to increase AUC<sub>u</sub>/dose (see <a class="ref internalNav" href="#eq3" aria-label="eq 3">eq 3</a>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">· Ensure efficient oral absorption</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">· Increase solubility</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">· Increase dissolution by particle size reduction, etc.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">· Increase lipoidal permeability</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">· Decrease efflux</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><u class="uu">strategies to reduce doping frequency</u></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">· Decrease intrinsic clearance to lengthen half-life</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">· Increase <i>V</i><sub>ss</sub> to increase half-life</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><u class="uu">important caveats</u></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">· Solubility is a major limiting factor in drug absorption. Often ignored is that the real solubility declines through kinetic, thermodynamic, crystalline forms, polymorphs, etc.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">· Free drug concentration governed by intrinsic clearance not <i>f</i><sub>u</sub>. Reducing plasma protein binding will have no effect on AUC<sub>u</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">· Reducing intrinsic clearance will reduce dose size and frequency if <i>V</i><sub>ss</sub> maintained.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">· Increasing <i>V</i><sub>ss</sub> will not chage AUC<sub>u</sub>/dose. Amlodipine and nifedipine have similar intrinsic clearance and potency and have similar daily dose sizes despite large differences in <i>V</i><sub>ss</sub></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">· Increasing <i>V</i><sub>ss</sub> strategies often involve incorporation of a basic functional group to increase tissue (membrane) affinity. Increases the probability of off-target pharmacology (e.g., hERG) liability.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">· For intrinsically low <i>V</i><sub>ss</sub> compounds (<TBW, total body water) lowering <i>f</i><sub>u</sub> (increasing plasma protein binding) will increase half-life but not AUC<sub>u</sub>. This strategy is employed with biologicals.</td></tr></tbody></table></div></div><div class="NLM_p">Perhaps the biggest challenge is the pervasive belief that dose predictions are done near the end of the design process to support nomination and early clinical development. This is reflected in the fact that most of the PKPD and QSP (quantitative systems pharmacology) resources across the pharmaceutical industry are aligned to clinical applications and the majority of preclinical resources aligned to the later stages of lead optimization.<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> In order to impact design, efforts to predict dose should begin well before lead optimization. While lead material is often limited at these early stages, much of the work to simulate doses for the sake of defining laboratory objectives can be done without preclinical PKPD studies (e.g., defining the clinical goal, defining the PK driver, qualifying assays for translation, building models of the biological context and molecular mechanism of action from literature data). In addition, those doing dose predictions in support of design must adopt a design mindset, balancing the need for accuracy and precision with the need to provide insight on a relevant time-scale to design. This can be an unusual situation for many PKPD experts that were trained in a traditional clinical and/or academic environment where timelines are longer and the demand for accuracy and precision is much higher. Teams also need to recognize that certain studies may be necessary to fill gaps of critical relevance to design (through implications for dose) but which may sit outside the typical process of screening compounds. For example, the measurement of KAT2 turnover between species provided a critical piece of information into the conclusion that a short-half-life irreversible compound would be suitable to meet the clinical goal. Finally, PKPD scientists need to recognize the value proposition in influencing design (over more traditional applications), seek to better understand this aspect of preclinical research, and see medicinal chemistry as key stakeholders in dose prediction.</div><div class="NLM_p">Another related, but more technical, challenge is to ensure that dose predictions utilize appropriate data. As discussed under key considerations, there are many potential artifacts and theoretical issues related to scaling which can confound the appropriate use of preclinical pharmacology data in dose predictions. Layered on this complexity is the need for the dose prediction approach itself to be useful in design. An extreme example is direct scaling of doses from animals based on allometric principles. In this approach, a human equivalent dose is estimated from a dose producing an effect of interest in an animal. Most commonly, an exponent of 0.33 is used to calculate a human equivalent dose (HED) on the basis of body surface area scaling (<a class="ref internalNav" href="#eq5" aria-label="eq 4">eq 4</a>).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a><span class="NLM_disp-formula" id="eq5"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_m004.gif" alt="" id="_i26" /></img><span class="labelSpan">(4)</span></span></div><div class="NLM_p last">While such approaches have some theoretical basis<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> and are supported by regulatory agencies to calculate starting doses in humans from animal toxicology studies,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> the heavy reliance on animal models and black-box nature makes it of limited value in design. Needing a high dose in an animal to elicit effects (and thus the suggestion of a high dose in human) does not provide any clues as to what needs to be improved. Likewise, PKPD approaches that seek to simply statistically characterize preclinical pharmacology without linkage back to drug properties are not likely to provide the insight necessary to meaningfully support design. In contrast, the aforementioned PK-based approach based on <i>C</i><sub>avg</sub> distills dose down to parameters that make intuitive sense (intrinsic clearance, fraction absorbed, potency) and can be informed by data generated in concert with design cycles for the sake of optimization (human liver microsomes/hepatocytes, solubility, permeability, target potency). However, to be truly successful in application of this type of work requires a team with different skill sets. In addition to high quality medicinal chemistry, DMPK colleagues are often skilled in translation of PK from the preclinical to the clinical situation. More complicated PKPD modeling requires input from modeling and simulation colleagues to provide the additional benefit of explicitly accounting for biological factors affecting dose regimen. The authors believe strongly that such support should be garnered at a very early stage in a project to help the design process. Their belief is that such modeling may not only facilitate success but also identify approaches where the clinical dose requirements are likely to be unacceptable to provide a timely no go decision.</div></div><div class="NLM_back"><div class="NLM_notes" id="NOTES-d7e2017-autogenerated"><p class="first last">The authors declare no competing financial interest.</p></div><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01365" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17148" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17148" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Di</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Worldwide Research and Development, Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6117-9022" title="Orcid link">http://orcid.org/0000-0001-6117-9022</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#337f5a1d775a7363555a4956411d505c5e"><span class="__cf_email__" data-cfemail="ace0c582e8c5ecfccac5d6c9de82cfc3c1">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tristan S. Maurer</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dennis Smith</span> - <span class="hlFld-Affiliation affiliation">4
The Maltings, Walmer, Kent CT14 7AR, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Beaumont</span> - <span class="hlFld-Affiliation affiliation">Medicine
Design, Pfizer Worldwide Research and Development, Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05237" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05237" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Tristan S. Maurer</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=BIO-d7e2401-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tristan S. Maurer</b> received his PharmD from the University of Georgia in 1993 and his Ph.D. from the University of Buffalo, State University of New York in 1999. During his 20 year tenure with Pfizer, his work has focused on the development and application of quantitatively rigorous, biologically based methods to predict human pharmacokinetics and pharmacodynamics from preclinical data. He has coauthored over 70 manuscripts illustrating the utility of these methods to drug design and early clinical development. Currently, Dr. Maurer sits on the Medicine Design leadership team responsible for scientific and operational strategies spanning from idea to loss of exclusivity. He also leads a modeling and simulation group responsible for both computational chemistry and quantitative translational pharmacology across Pfizer’s small molecule portfolio.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Dennis Smith</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=BIO-d7e2406-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dennis Smith</b> worked in the pharmaceutical industry for 32 years after gaining his Ph.D from the University of Manchester. During this period he directly helped in the Discovery and Development of eight marketed NCEs. More recently his roles include advisory boards or expert panels with many drug research based organizations, both industrial and academic, including Medicines for Malaria Venture and Cancer Research UK. He continues to work directly with many drug discovery project teams. His research interests and publications span all aspects of Drug Discovery and Development particularly where drug metabolism knowledge can impact on the design of more efficacious and safer drugs.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Kevin Beaumont</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=BIO-d7e2411-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Kevin Beaumont</b> has worked extensively in the discovery and development drug metabolism field throughout his 36 years in the pharmaceutical industry. His major area of expertise is in the modulation of physicochemistry to affect drug disposition and prediction of human PK. He is author on over 50 peer reviewed publications. Overall, Kevin has worked on many drug discovery and development projects throughout his career. He has been responsible for the DMPK input to at least 30 FIH studies as well as 10 phase II compounds, including one marketed agent. Kevin now provides DMPK input to the Inflammation and Immunology and Rare Disease Research Units, based in Cambridge, Massachusetts.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Li Di</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=BIO-d7e2416-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Li Di</b> has about 25 years of experience in the pharmaceutical industry including Pfizer, Wyeth, and Syntex. She is currently a Research Fellow at Medicine Design Department, Pfizer Global Research and Development, Groton, CT. Her research interests include the areas of drug metabolism, absorption, transporters, pharmacokinetics, blood–brain barrier, and drug–drug interactions. She has over 145 publications including two books and presented more than 90 invited lectures. She is a recipient of the Thomas Alva Edison Patent Award, the New Jersey Association for Biomedical Research Outstanding Woman in Science Award, the Wyeth President’s Award, Peer Award for Excellence, and Publication Award.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63315" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63315" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors greatly appreciate the technical assistance from David Tess.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">5HT</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine receptor</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, excretion</p></td></tr><tr><td class="NLM_term">API</td><td class="NLM_def"><p class="first last">active pharmaceutical ingredient</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">AUC<sub>u</sub></td><td class="NLM_def"><p class="first last">unbound area under the curve</p></td></tr><tr><td class="NLM_term">CaR</td><td class="NLM_def"><p class="first last">calcium sensing receptor</p></td></tr><tr><td class="NLM_term">CatD</td><td class="NLM_def"><p class="first last">cathepsin D</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>avg</sub></td><td class="NLM_def"><p class="first last">average concentration</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CL<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">COG</td><td class="NLM_def"><p class="first last">cost of goods</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>min</sub></td><td class="NLM_def"><p class="first last">minimum concentration</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DMPK</td><td class="NLM_def"><p class="first last">drug metabolism pharmacokinetics</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal response concentration</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term"><i>f</i><sub>a</sub></td><td class="NLM_def"><p class="first last">fraction absorbed</p></td></tr><tr><td class="NLM_term"><i>f</i><sub>u</sub></td><td class="NLM_def"><p class="first last">fraction unbound</p></td></tr><tr><td class="NLM_term">GFR</td><td class="NLM_def"><p class="first last">glomerular filtration rate</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">HbA1c</td><td class="NLM_def"><p class="first last">hemoglobin A1c</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">the human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term"><i>k</i><sub>a</sub></td><td class="NLM_def"><p class="first last">absorption rate constant</p></td></tr><tr><td class="NLM_term">KAT2</td><td class="NLM_def"><p class="first last">kynurenic aminotransferase 2</p></td></tr><tr><td class="NLM_term"><i>k</i><sub>el</sub></td><td class="NLM_def"><p class="first last">elimination rate</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>I</sub></td><td class="NLM_def"><p class="first last">the concentration at which half of the maximal inactivation rate is observed</p></td></tr><tr><td class="NLM_term"><i>k</i><sub>inact</sub></td><td class="NLM_def"><p class="first last">maximal inactivation rate</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>m</sub></td><td class="NLM_def"><p class="first last">Michaelis constant, substrate concentration at half the maximum velocity</p></td></tr><tr><td class="NLM_term">KYNA</td><td class="NLM_def"><p class="first last">kynurenic acid</p></td></tr><tr><td class="NLM_term">LipE</td><td class="NLM_def"><p class="first last">lipophilic efficiency</p></td></tr><tr><td class="NLM_term">LipMetE</td><td class="NLM_def"><p class="first last">lipophilic metabolism efficiency</p></td></tr><tr><td class="NLM_term">MBC</td><td class="NLM_def"><p class="first last">minimum bactericidal concentration</p></td></tr><tr><td class="NLM_term">MIC</td><td class="NLM_def"><p class="first last">minimal inhibitory concentration</p></td></tr><tr><td class="NLM_term">mRNA</td><td class="NLM_def"><p class="first last">messenger ribonucleic acid</p></td></tr><tr><td class="NLM_term">NAM</td><td class="NLM_def"><p class="first last">negative allosteric modulation</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">PG</td><td class="NLM_def"><p class="first last">plasma glucose concentration</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">POC</td><td class="NLM_def"><p class="first last">proof-of-concept</p></td></tr><tr><td class="NLM_term">PTH1</td><td class="NLM_def"><p class="first last">parathyroid hormone</p></td></tr><tr><td class="NLM_term">Qh</td><td class="NLM_def"><p class="first last">hepatic blood flow</p></td></tr><tr><td class="NLM_term">QSP</td><td class="NLM_def"><p class="first last">quantitative systems pharmacology</p></td></tr><tr><td class="NLM_term">Ro3</td><td class="NLM_def"><p class="first last">rule of three</p></td></tr><tr><td class="NLM_term">Ro5</td><td class="NLM_def"><p class="first last">rule of five</p></td></tr><tr><td class="NLM_term">SGLT2</td><td class="NLM_def"><p class="first last">sodium–glucose co-transporter 2</p></td></tr><tr><td class="NLM_term">SLC</td><td class="NLM_def"><p class="first last">solute carrier</p></td></tr><tr><td class="NLM_term">T2DM</td><td class="NLM_def"><p class="first last">type 2 diabetes mellitus</p></td></tr><tr><td class="NLM_term">tau</td><td class="NLM_def"><p class="first last">dose interval</p></td></tr><tr><td class="NLM_term">TBW</td><td class="NLM_def"><p class="first last">total body water</p></td></tr><tr><td class="NLM_term">TCA</td><td class="NLM_def"><p class="first last">tricarboxylic acid</p></td></tr><tr><td class="NLM_term">UGE</td><td class="NLM_def"><p class="first last">urinary glucose excretion</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">steady state volume of distribution.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62652" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62652" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 62 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Relevance of Half-Life in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4273</span>– <span class="NLM_lpage">4282</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00969</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00969" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOnsrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4273-4282&issue=10&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Relevance+of+Half-Life+in+Drug+Design&doi=10.1021%2Facs.jmedchem.7b00969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Relevance of Half-Life in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4273-4282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state.  A half-life of 12-48 h is generally ideal for once daily dosing of oral drugs.  If the half-life is too short, it may require more frequent dosing in order to maintain desired exposures and avoid unnecessarily high peak concns.  This may pose challenges to achieving optimal efficacy, safety, and patient compliance.  If the half-life is too long, the time over which accumulation and subsequent elimination occur may be prolonged.  This may pose problems with managing adverse effects and the design of efficient clin. trials.  Half-life is a key parameter for optimization in research and development.  Structural modification to affect clearance, and to a lesser extent vol. of distribution, is the preferred means of modulating half-life.  An effective approach to half-life optimization requires an understanding of the many pitfalls assocd. with its estn. and interpretation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7kT9hNLRzb7Vg90H21EOLACvtfcHk0li8wutMaMEZ7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOnsrnN&md5=ff748cbebc765f4fa3c3d7b3831f51c8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00969%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DRelevance%2520of%2520Half-Life%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D10%26spage%3D4273%26epage%3D4282%26doi%3D10.1021%2Facs.jmedchem.7b00969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Clearance in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2245</span>– <span class="NLM_lpage">2255</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVCru7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2245-2255&issue=5&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Clearance+in+Drug+Design&doi=10.1021%2Facs.jmedchem.8b01263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Clearance in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2245-2255</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Due to its implications for both dose level and frequency, clearance rate is one of the most important pharmacokinetic parameters to consider in the design of drug candidates.  Clearance can be classified into three general categories, namely, metabolic transformation, renal excretion, and hepatobiliary excretion.  Within each category, there are a host of biochem. and physiol. mechanisms that ultimately det. the clearance rate.  Physiochem. properties are often indicative of the rate-detg. mechanism, with lipophilic mols. tending toward metab. and hydrophilic, polar mols. tending toward passive or active excretion.  Optimization of clearance requires recognition of the major clearance mechanisms and use of the most relevant in vitro and in vivo tools to develop structure-clearance relationships.  The reliability of methods to detect and predict human clearance varies across mechanisms.  While methods for metabolic and passive renal clearance have proven reasonably robust, there is a clear need for better tools to support the optimization of transporter-mediated clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8nvv_L3pL-LVg90H21EOLACvtfcHk0li8wutMaMEZ7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVCru7fO&md5=e4a4d72056ed9b41842a11934fa4bffc</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01263%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DClearance%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D5%26spage%3D2245%26epage%3D2255%26doi%3D10.1021%2Facs.jmedchem.8b01263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Volume of Distribution in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5691</span>– <span class="NLM_lpage">5698</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&issue=15&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Volume+of+Distribution+in+Drug+Design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0lhijvYgzI8ZDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DVolume%2520of%2520Distribution%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D15%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kataria, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappelleri, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadosky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, A. M.</span></span> <span> </span><span class="NLM_article-title">Impact of Reducing Dosing Frequency on Adherence to Oral Therapies: a Literature Review and Meta-Analysis</span>. <i>Patient Preference Adherence</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.2147/PPA.S44646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.2147%2FPPA.S44646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=23737662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A280%3ADC%252BC3snps12ltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=419-434&author=K.+Srivastavaauthor=A.+Aroraauthor=A.+Katariaauthor=J.+C.+Cappelleriauthor=A.+Sadoskyauthor=A.+M.+Peterson&title=Impact+of+Reducing+Dosing+Frequency+on+Adherence+to+Oral+Therapies%3A+a+Literature+Review+and+Meta-Analysis&doi=10.2147%2FPPA.S44646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis</span></div><div class="casAuthors">Srivastava Kunal; Arora Anamika; Kataria Aditi; Cappelleri Joseph C; Sadosky Alesia; Peterson Andrew M</div><div class="citationInfo"><span class="NLM_cas:title">Patient preference and adherence</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">419-34</span>
        ISSN:<span class="NLM_cas:issn">1177-889X</span>.
    </div><div class="casAbstract">OBJECTIVES:  To assess the impact of reduced frequency of oral therapies from multiple-dosing schedules to a once-daily (OD) dosing schedule on adherence, compliance, persistence, and associated economic impact.  METHODS:  A meta-analysis was performed based on relevant articles identified from a comprehensive literature review using MEDLINE® and Embase®.  The review included studies assessing adherence with OD, twice-daily (BID), thrice-daily (TID), and four-times daily (QID) dosing schedules and costs associated with optimal/suboptimal adherence among patients with acute and chronic diseases.  Effect estimates across studies were pooled and analyzed using the DerSimonian and Laird random-effect model.  RESULTS:  Forty-three studies met inclusion criteria, and meta-analyzable data were available from 13 studies.  The overall results indicated that OD schedules were associated with higher adherence rates (odds ratio [OR] 3.07, 95% confidence interval [CI] 1.80-5.23; P < 0.001 for OD versus > OD dosing) and compliance rates (OR 3.50, 95% CI 1.73-7.08; P < 0.001 for OD versus > OD dosing); persistence rates showed the same direction but were not statistically significant (OR 1.43, 95% CI 0.62-3.29; P = 0.405 for OD versus BID dosing).  Results for each of the conditions were consistent with those observed overall with respect to showing the benefits of less frequent dosing.  From a health economic perspective, higher adherence rates with OD relative to multiple dosing in a number of conditions were consistently associated with corresponding lower costs of health care resources utilization.  CONCLUSION:  Current meta-analyses suggested that across acute and chronic disease states, reducing dosage frequency from multiple dosing to OD dosing may improve adherence to therapies among patients.  Improving adherence may result in subsequent decreases in health care costs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpbb1ykVOfYlw2ofyr07jXfW6udTcc2eYbDKAy7eTwxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snps12ltw%253D%253D&md5=4b027f04ac35bada67ab0a6494a1af9f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2147%2FPPA.S44646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FPPA.S44646%26sid%3Dliteratum%253Aachs%26aulast%3DSrivastava%26aufirst%3DK.%26aulast%3DArora%26aufirst%3DA.%26aulast%3DKataria%26aufirst%3DA.%26aulast%3DCappelleri%26aufirst%3DJ.%2BC.%26aulast%3DSadosky%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DA.%2BM.%26atitle%3DImpact%2520of%2520Reducing%2520Dosing%2520Frequency%2520on%2520Adherence%2520to%2520Oral%2520Therapies%253A%2520a%2520Literature%2520Review%2520and%2520Meta-Analysis%26jtitle%3DPatient%2520Preference%2520Adherence%26date%3D2013%26volume%3D7%26spage%3D419%26epage%3D434%26doi%3D10.2147%2FPPA.S44646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viswanathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golin, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashok, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blalock, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wines, R. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coker-Schwimmer, E. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sista, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohr, K. N.</span></span> <span> </span><span class="NLM_article-title">Interventions to Improve Adherence to Self-Administered Medications for Chronic Diseases in the United States: a Systematic Review</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>157</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">795</span>, <span class="refDoi"> DOI: 10.7326/0003-4819-157-11-201212040-00538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.7326%2F0003-4819-157-11-201212040-00538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=22964778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A280%3ADC%252BC38blslSmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2012&pages=785-795&issue=11&author=M.+Viswanathanauthor=C.+E.+Golinauthor=C.+D.+Jonesauthor=M.+Ashokauthor=S.+J.+Blalockauthor=R.+C.+M.+Winesauthor=E.+J.+L.+Coker-Schwimmerauthor=D.+L.+Rosenauthor=P.+Sistaauthor=K.+N.+Lohr&title=Interventions+to+Improve+Adherence+to+Self-Administered+Medications+for+Chronic+Diseases+in+the+United+States%3A+a+Systematic+Review&doi=10.7326%2F0003-4819-157-11-201212040-00538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review</span></div><div class="casAuthors">Viswanathan Meera; Golin Carol E; Jones Christine D; Ashok Mahima; Blalock Susan J; Wines Roberta C M; Coker-Schwimmer Emmanuel J L; Rosen David L; Sista Priyanka; Lohr Kathleen N</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">785-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Suboptimum medication adherence is common in the United States and leads to serious negative health consequences but may respond to intervention.  PURPOSE:  To assess the comparative effectiveness of patient, provider, systems, and policy interventions that aim to improve medication adherence for chronic health conditions in the United States.  DATA SOURCES:  Eligible peer-reviewed publications from MEDLINE and the Cochrane Library indexed through 4 June 2012 and additional studies from reference lists and technical experts.  STUDY SELECTION:  Randomized, controlled trials of patient, provider, or systems interventions to improve adherence to long-term medications and nonrandomized studies of policy interventions to improve medication adherence.  DATA EXTRACTION:  Two investigators independently selected, extracted data from, and rated the risk of bias of relevant studies.  DATA SYNTHESIS:  The evidence was synthesized separately for each clinical condition; within each condition, the type of intervention was synthesized.  Two reviewers graded the strength of evidence by using established criteria.  From 4124 eligible abstracts, 62 trials of patient-, provider-, or systems-level interventions evaluated 18 types of interventions; another 4 observational studies and 1 trial of policy interventions evaluated the effect of reduced medication copayments or improved prescription drug coverage.  Clinical conditions amenable to multiple approaches to improving adherence include hypertension, heart failure, depression, and asthma.  Interventions that improve adherence across multiple clinical conditions include policy interventions to reduce copayments or improve prescription drug coverage, systems interventions to offer case management, and patient-level educational interventions with behavioral support.  LIMITATIONS:  Studies were limited to adults with chronic conditions (excluding HIV, AIDS, severe mental illness, and substance abuse) in the United States.  Clinical and methodological heterogeneity hindered quantitative data pooling.  CONCLUSION:  Reduced out-of-pocket expenses, case management, and patient education with behavioral support all improved medication adherence for more than 1 condition.  Evidence is limited on whether these approaches are broadly applicable or affect longterm medication adherence and health outcomes.  PRIMARY FUNDING SOURCE:  Agency for Healthcare Research and Quality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQj4cu5Zds5NnO4gDb7JggCfW6udTcc2eYbDKAy7eTwxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38blslSmsw%253D%253D&md5=7ac8654540b0763b98a486a11ab23324</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-157-11-201212040-00538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-157-11-201212040-00538%26sid%3Dliteratum%253Aachs%26aulast%3DViswanathan%26aufirst%3DM.%26aulast%3DGolin%26aufirst%3DC.%2BE.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DAshok%26aufirst%3DM.%26aulast%3DBlalock%26aufirst%3DS.%2BJ.%26aulast%3DWines%26aufirst%3DR.%2BC.%2BM.%26aulast%3DCoker-Schwimmer%26aufirst%3DE.%2BJ.%2BL.%26aulast%3DRosen%26aufirst%3DD.%2BL.%26aulast%3DSista%26aufirst%3DP.%26aulast%3DLohr%26aufirst%3DK.%2BN.%26atitle%3DInterventions%2520to%2520Improve%2520Adherence%2520to%2520Self-Administered%2520Medications%2520for%2520Chronic%2520Diseases%2520in%2520the%2520United%2520States%253A%2520a%2520Systematic%2520Review%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2012%26volume%3D157%26issue%3D11%26spage%3D785%26epage%3D795%26doi%3D10.7326%2F0003-4819-157-11-201212040-00538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span> <span> </span><span class="NLM_article-title">Acute Liver Failure Including Acetaminophen Overdose</span>. <i>Med. Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.1016/j.mcna.2008.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.mcna.2008.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=18570942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslWqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2008&pages=761-794&issue=4&author=R.+J.+Fontana&title=Acute+Liver+Failure+Including+Acetaminophen+Overdose&doi=10.1016%2Fj.mcna.2008.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Acute liver failure including acetaminophen overdose</span></div><div class="casAuthors">Fontana, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Medical Clinics of North America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">761-794</span>CODEN:
                <span class="NLM_cas:coden">MCNAA9</span>;
        ISSN:<span class="NLM_cas:issn">0025-7125</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Acute liver failure (ALF) is a dramatic, highly unpredictable clin. syndrome defined by the sudden onset of coagulopathy and encephalopathy.  Acetaminophen overdose, the leading cause of ALF in the United States, has a 66% chance of recovery with early N-acetylcysteine treatment and supportive care.  Cerebral edema and infectious complications are difficult to detect and treat in these patients and may cause irreversible brain damage and multiorgan failure.  One-year survival after emergency liver transplantation is 70%, but 20% of listed patients die, highlighting the importance of early referral of patients who have ALF with a poor prognosis to a transplant center.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGrf38C6bEUrVg90H21EOLACvtfcHk0lgkm3KBbfz4Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslWqtr8%253D&md5=8464a31e2d976a417edce26c45ece8c5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.mcna.2008.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mcna.2008.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26atitle%3DAcute%2520Liver%2520Failure%2520Including%2520Acetaminophen%2520Overdose%26jtitle%3DMed.%2520Clin.%2520North%2520Am.%26date%3D2008%26volume%3D92%26issue%3D4%26spage%3D761%26epage%3D794%26doi%3D10.1016%2Fj.mcna.2008.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyrsopoulos, N.</span></span> <span> </span><span class="NLM_article-title">Acetaminophen-Induced Hepatotoxicity: A Comprehensive Update</span>. <i>J. Clin. Transl. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.14218/JCTH.2015.00052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.14218%2FJCTH.2015.00052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=27350943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A280%3ADC%252BC2s7ktl2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=131-142&issue=2&author=E.+Yoonauthor=A.+Babarauthor=M.+Choudharyauthor=M.+Kutnerauthor=N.+Pyrsopoulos&title=Acetaminophen-Induced+Hepatotoxicity%3A+A+Comprehensive+Update&doi=10.14218%2FJCTH.2015.00052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update</span></div><div class="casAuthors">Yoon Eric; Babar Arooj; Choudhary Moaz; Kutner Matthew; Pyrsopoulos Nikolaos</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical and translational hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-42</span>
        ISSN:<span class="NLM_cas:issn">2225-0719</span>.
    </div><div class="casAbstract">Hepatic injury and subsequent hepatic failure due to both intentional and non-intentional overdose of acetaminophen (APAP) has affected patients for decades, and involves the cornerstone metabolic pathways which take place in the microsomes within hepatocytes.  APAP hepatotoxicity remains a global issue; in the United States, in particular, it accounts for more than 50% of overdose-related acute liver failure and approximately 20% of the liver transplant cases.  The pathophysiology, disease course and management of acute liver failure secondary to APAP toxicity remain to be precisely elucidated, and adverse patient outcomes with increased morbidity and mortality continue to occur.  Although APAP hepatotoxicity follows a predictable timeline of hepatic failure, its clinical presentation might vary.  N-acetylcysteine (NAC) therapy is considered as the mainstay therapy, but liver transplantation might represent a life-saving procedure for selected patients.  Future research focus in this field may benefit from shifting towards obtaining antidotal knowledge at the molecular level, with focus on the underlying molecular signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSx4BXZ2FeKIP9pSBfyDvp7fW6udTcc2ebBppsHfHqetrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7ktl2rsA%253D%253D&md5=d32e4195dfc733b28b7d9b7de07fdd22</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.14218%2FJCTH.2015.00052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14218%252FJCTH.2015.00052%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DE.%26aulast%3DBabar%26aufirst%3DA.%26aulast%3DChoudhary%26aufirst%3DM.%26aulast%3DKutner%26aufirst%3DM.%26aulast%3DPyrsopoulos%26aufirst%3DN.%26atitle%3DAcetaminophen-Induced%2520Hepatotoxicity%253A%2520A%2520Comprehensive%2520Update%26jtitle%3DJ.%2520Clin.%2520Transl.%2520Hepatol.%26date%3D2016%26volume%3D4%26issue%3D2%26spage%3D131%26epage%3D142%26doi%3D10.14218%2FJCTH.2015.00052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><a href="https://www.fda.gov/consumers/consumer-updates/acetaminophen-avoiding-liver-injury" class="extLink">https://www.fda.gov/consumers/consumer-updates/acetaminophen-avoiding-liver-injury</a> (accessed Dec 17, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fconsumers%2Fconsumer-updates%2Facetaminophen-avoiding-liver-injury+%28accessed+Dec+17%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">Evaluation of DILI Predictive Hypotheses in Early Drug Development</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1029</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.7b00025</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.7b00025" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Knu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=1017-1029&issue=4&author=R.+Chanauthor=L.+Z.+Benet&title=Evaluation+of+DILI+Predictive+Hypotheses+in+Early+Drug+Development&doi=10.1021%2Facs.chemrestox.7b00025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of DILI Predictive Hypotheses in Early Drug Development</span></div><div class="casAuthors">Chan, Rosa; Benet, Leslie Z.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1017-1029</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of drug failure in clin. trials and a major reason for drug withdrawals.  DILI has been shown to be dependent on both daily dose and extent of hepatic metab.  Yet, early in drug development daily dose is unknown.  Here, we perform a comprehensive anal. of the published hypotheses that attempt to predict DILI, including a new anal. of the Biopharmaceutics Drug Disposition Classification System (BDDCS) in evaluating the severity of DILI warnings in drug labels approved by the FDA and the withdrawal status due to adverse drug reactions (ADRs).  Our anal. confirms that higher doses ≥50 mg/day lead to increased DILI potential, but this property alone is not sufficient to predict the DILI potential.  We evaluate prior attempts to categorize DILI such as Rule of 2, BSEP inhibition, and measures of key mechanisms of toxicity compared to BDDCS classification.  Our results show that BDDCS Class 2 drugs exhibit the highest DILI severity and that all of the published methodologies evaluated here, except when daily dose is known, do not yield markedly better predictions than BDDCS.  The assertion that extensive metabolized compds. are at higher risk of developing DILI is confirmed but can be enhanced by differentiating BDDCS Class 2 from Class 1 drugs.  We do not propose that the BDDCS classification, which does not require knowledge of the clin. dose, is sufficiently predictive/accurate of DILI potential for new mol. entities but suggest that comparison of proposed DILI prediction methodologies with BDDCS classification is a useful tool to evaluate the potential reliability of newly proposed algorithms.  Conclusion: The most successful approaches to predict DILI potential all include a measure of dose, yet there is a quantifiable uncertainty assocd. with the predicted dose early in drug development.  Here, we compare the possibility of predicting DILI potential using the BDDCS classification vs. previously published methods and note that many hypothesized predictive DILI metrics do no better than just avoiding BDDCS Class 2 drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwMFj2kgoGErVg90H21EOLACvtfcHk0lgkm3KBbfz4Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Knu7s%253D&md5=27c6448357f8e7c862a7d8cfc7d033aa</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.7b00025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.7b00025%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DR.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DEvaluation%2520of%2520DILI%2520Predictive%2520Hypotheses%2520in%2520Early%2520Drug%2520Development%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2017%26volume%3D30%26issue%3D4%26spage%3D1017%26epage%3D1029%26doi%3D10.1021%2Facs.chemrestox.7b00025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">High Lipophilicity and High Daily Dose of Oral Medications are Associated with Significant Risk for Drug-Induced Liver Injury</span>. <i>Hepatology (Hoboken, NJ, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1002/hep.26208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2Fhep.26208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=23258593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=388-396&issue=1&author=M.+Chenauthor=J.+Borlakauthor=W.+Tong&title=High+Lipophilicity+and+High+Daily+Dose+of+Oral+Medications+are+Associated+with+Significant+Risk+for+Drug-Induced+Liver+Injury&doi=10.1002%2Fhep.26208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury</span></div><div class="casAuthors">Chen, Minjun; Borlak, Juergen; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">388-396</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of drug failure in clin. trials and a major reason for drug withdrawals from the market.  Although there is evidence that dosages of ≥100 mg/day are assocd. with increased risk for hepatotoxicity, many drugs are safe at such dosages.  There is an unmet need to predict risk for DILI more reliably, and lipophilicity might be a contributing factor.  We analyzed the combined factors of daily dose and lipophilicity for 164 US Food and Drug Administration-approved oral medications and obsd. high risk for hepatotoxicity (odds ratio [OR], 14.05; P < 0.001) for drugs given at dosages ≥100 mg/day and octanol-water partition coeff. (logP) ≥3.  This defined the "rule-of-two.".  Similar results were obtained for an independent set of 179 oral medications with 85% of the rule-of-two positives being assocd. with hepatotoxicity (OR, 3.89; P < 0.01).  Using the World Health Organization's Anatomical Therapeutic Chem. classification system, the rule-of-two performed best in predicting DILI in seven therapeutic categories.  Among 15 rule-of-two positives, 14 were withdrawn from hepatotoxic drugs, and one was over-the-counter medication labeled for liver injury.  We addnl. examd. drug pairs that have similar chem. structures and act on the same mol. target but differ in their potential for DILI.  Again, the rule-of-two predicted hepatotoxicity reliably.  Finally, the rule-of-two was applied to clin. case studies to identify hepatotoxic drugs in complex comedication regimes to further demonstrate its use.  Conclusion: Apart from dose, lipophilicity contributes significantly to risk for hepatotoxicity.  Applying the rule-of-two is an appropriate means of estg. risk for DILI compared with dose alone. (HEPATOl. 2013).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1EE02L_JCdLVg90H21EOLACvtfcHk0lhoPOzAYZ4Pmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM&md5=a88e02ff29653bdeee53b59a4da46d06</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fhep.26208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26208%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DHigh%2520Lipophilicity%2520and%2520High%2520Daily%2520Dose%2520of%2520Oral%2520Medications%2520are%2520Associated%2520with%2520Significant%2520Risk%2520for%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DHepatology%2520%2528Hoboken%252C%2520NJ%252C%2520U.%2520S.%2529%26date%3D2013%26volume%3D58%26issue%3D1%26spage%3D388%26epage%3D396%26doi%3D10.1002%2Fhep.26208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lammert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einarsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niklasson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span> <span> </span><span class="NLM_article-title">Relationship between Daily Dose of Oral Medications and Idiosyncratic Drug-Induced Liver Injury: Search for Signals</span>. <i>Hepatology (Hoboken, NJ, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2003</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1002/hep.22272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2Fhep.22272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=18454504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=2003-2009&issue=6&author=C.+Lammertauthor=S.+Einarssonauthor=C.+Sahaauthor=A.+Niklassonauthor=E.+Bjornssonauthor=N.+Chalasani&title=Relationship+between+Daily+Dose+of+Oral+Medications+and+Idiosyncratic+Drug-Induced+Liver+Injury%3A+Search+for+Signals&doi=10.1002%2Fhep.22272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals</span></div><div class="casAuthors">Lammert, Craig; Einarsson, Stefan; Saha, Chandan; Niklasson, Anna; Bjornsson, Einar; Chalasani, Naga</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2003-2009</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (DILI) is traditionally thought not to be dose-related.  However, it has been pointed out that most medicines that were withdrawn from marketing or received a black-box warning because of hepatotoxicity were prescribed at daily doses greater than 50 mg/day.  To examine the relationship between daily dose of medications and idiosyncratic DILI, we conducted a study with two aims.  First, using two pharmaceutical databases, we examd. the relationship between daily dose of commonly prescribed medicines in the United States and reported frequency of their selected hepatic adverse events.  Second, we examd. serious DILI cases reported to the Swedish Adverse Drug Reactions Advisory Committee (1970-2004) for any signals supporting the relationship between daily dose and idiosyncratic DILI.  Medications were categorized into ≤10 mg/day, 11-49 mg/day, and ≥50 mg/day groups.  Among US prescription medicines, a statistically significant relationship was obsd. between daily dose of oral medicines and reports of liver failure (P = 0.009), liver transplantation (P < 0.001), and death caused by DILI (P = 0.004) but not alanine aminotransferase (ALT) > 3 × upper limit of normal (P = 0.10) or jaundice (P = 0.16).  Of 598 eligible Swedish DILI cases, 9% belonged to the ≤10 mg/day group, 14.2% to the 11-49 mg/day group, and 77% of cases were caused by medications given at dose ≥50 mg/day.  A statistically significant relationship was noted between daily dose and poor outcome (death or liver transplantation) of Swedish DILI cases (2%, 9.4%, and 13.2% in ≤10, 11-49, and ≥50 mg/day groups, resp., P = 0.03).  Conclusion: These data suggest a relationship between daily doses of oral prescription medications and idiosyncratic DILI.  More studies are needed to validate these observations and to explore their implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-pByO6X3Hk7Vg90H21EOLACvtfcHk0lhoPOzAYZ4Pmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D&md5=f497d61a5253cc653c2d955232471d65</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fhep.22272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22272%26sid%3Dliteratum%253Aachs%26aulast%3DLammert%26aufirst%3DC.%26aulast%3DEinarsson%26aufirst%3DS.%26aulast%3DSaha%26aufirst%3DC.%26aulast%3DNiklasson%26aufirst%3DA.%26aulast%3DBjornsson%26aufirst%3DE.%26aulast%3DChalasani%26aufirst%3DN.%26atitle%3DRelationship%2520between%2520Daily%2520Dose%2520of%2520Oral%2520Medications%2520and%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%253A%2520Search%2520for%2520Signals%26jtitle%3DHepatology%2520%2528Hoboken%252C%2520NJ%252C%2520U.%2520S.%2529%26date%3D2008%26volume%3D47%26issue%3D6%26spage%3D2003%26epage%3D2009%26doi%3D10.1002%2Fhep.22272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergstroem, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, B.</span></span> <span> </span><span class="NLM_article-title">Accelerated Drug Discovery by Rapid Candidate Drug Identification</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1237</span>– <span class="NLM_lpage">1241</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2019.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.drudis.2019.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=30946980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1OnsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1237-1241&issue=6&author=F.+Bergstroemauthor=B.+Lindmark&title=Accelerated+Drug+Discovery+by+Rapid+Candidate+Drug+Identification&doi=10.1016%2Fj.drudis.2019.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Accelerated drug discovery by rapid candidate drug identification</span></div><div class="casAuthors">Bergstroem, Fredrik; Lindmark, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1237-1241</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The eventual candidate drug (CD) is often already synthesized during early drug discovery but not nominated until much later.  To facilitate the rapid identification of a potential CD, a thoroughly worked-out CD target profile (CDTP) with criteria acceptable for the disease target product profile (TPP) is required at the start of lead generation (LG).  In addn. to driving the compd. property optimization, the preclin. project team has to understand the ultimate goal to be able to rapidly identify and progress a potential CD.  A screening cascade with meaningful and well-balanced progression criteria based on the CDTP is required to rapidly filter out unwanted compds. and to progress a potential CD through the cascade to candidate selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPal0J6pugkLVg90H21EOLACvtfcHk0lhoPOzAYZ4Pmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1OnsrY%253D&md5=49a74b6bcf5a932bc51003ef5534fcbe</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2019.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2019.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DBergstroem%26aufirst%3DF.%26aulast%3DLindmark%26aufirst%3DB.%26atitle%3DAccelerated%2520Drug%2520Discovery%2520by%2520Rapid%2520Candidate%2520Drug%2520Identification%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2019%26volume%3D24%26issue%3D6%26spage%3D1237%26epage%3D1241%26doi%3D10.1016%2Fj.drudis.2019.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kola, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landis, J.</span></span> <span> </span><span class="NLM_article-title">Opinion: Can the Pharmaceutical Industry Reduce Attrition Rates?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1038/nrd1470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1038%2Fnrd1470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=15286737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-716&issue=8&author=I.+Kolaauthor=J.+Landis&title=Opinion%3A+Can+the+Pharmaceutical+Industry+Reduce+Attrition+Rates%3F&doi=10.1038%2Fnrd1470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Opinion: Can the pharmaceutical industry reduce attrition rates?</span></div><div class="casAuthors">Kola, Ismail; Landis, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-716</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry faces considerable challenges, both politically and fiscally.  Politically, governments around the world are trying to contain costs and, as health care budgets constitute a very significant part of governmental spending, these costs are the subject of intense scrutiny.  In the United States, drug costs are also the subject of intense political discourse.  This article deals with the fiscal pressures that face the industry from the perspective of R&D.  What impinges on productivity How can we improve current reduced R&D productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruAlrpFPFmiLVg90H21EOLACvtfcHk0ljLZJ0WrNwUMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D&md5=f9025c13a1506f607aaf68415570ed01</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrd1470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1470%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DOpinion%253A%2520Can%2520the%2520Pharmaceutical%2520Industry%2520Reduce%2520Attrition%2520Rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D8%26spage%3D711%26epage%3D716%26doi%3D10.1038%2Fnrd1470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mytelka, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwiddie, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persinger, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munos, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindborg, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schacht, A. L.</span></span> <span> </span><span class="NLM_article-title">How to Improve R&D Productivity: the Pharmaceutical Industry’s Grand Challenge</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1038/nrd3078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1038%2Fnrd3078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=20168317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFemsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=203-214&issue=3&author=S.+M.+Paulauthor=D.+S.+Mytelkaauthor=C.+T.+Dunwiddieauthor=C.+C.+Persingerauthor=B.+H.+Munosauthor=S.+R.+Lindborgauthor=A.+L.+Schacht&title=How+to+Improve+R%26D+Productivity%3A+the+Pharmaceutical+Industry%E2%80%99s+Grand+Challenge&doi=10.1038%2Fnrd3078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">How to improve R&D productivity: the pharmaceutical industry's grand challenge</span></div><div class="casAuthors">Paul, Steven M.; Mytelka, Daniel S.; Dunwiddie, Christopher T.; Persinger, Charles C.; Munos, Bernard H.; Lindborg, Stacy R.; Schacht, Aaron L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-214</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The pharmaceutical industry is under growing pressure from a range of environmental issues, including major losses of revenue owing to patent expirations, increasingly cost-constrained healthcare systems and more demanding regulatory requirements.  In our view, the key to tackling the challenges such issues pose to both the future viability of the pharmaceutical industry and advances in healthcare is to substantially increase the no. and quality of innovative, cost-effective new medicines, without incurring unsustainable R&D costs.  However, it is widely acknowledged that trends in industry R&D productivity have been moving in the opposite direction for a no. of years.  Here, we present a detailed anal. based on comprehensive, recent, industry-wide data to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity.  We then propose specific strategies that could have the most substantial impact in improving R&D productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY67PCIhaBVLVg90H21EOLACvtfcHk0ljLZJ0WrNwUMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFemsbg%253D&md5=2f32bcc48c869290eef18ff9400afcc5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd3078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3078%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DS.%2BM.%26aulast%3DMytelka%26aufirst%3DD.%2BS.%26aulast%3DDunwiddie%26aufirst%3DC.%2BT.%26aulast%3DPersinger%26aufirst%3DC.%2BC.%26aulast%3DMunos%26aufirst%3DB.%2BH.%26aulast%3DLindborg%26aufirst%3DS.%2BR.%26aulast%3DSchacht%26aufirst%3DA.%2BL.%26atitle%3DHow%2520to%2520Improve%2520R%2526D%2520Productivity%253A%2520the%2520Pharmaceutical%2520Industry%25E2%2580%2599s%2520Grand%2520Challenge%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26issue%3D3%26spage%3D203%26epage%3D214%26doi%3D10.1038%2Fnrd3078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Graaf, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegner, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, S. D. A.</span></span> <span> </span><span class="NLM_article-title">Can the Flow of Medicines be Improved? Fundamental Pharmacokinetic and Pharmacological Principles toward Improving Phase II Survival</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9–10</span>),  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.12.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.drudis.2011.12.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=22227532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslymurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=419-424&issue=9%E2%80%9310&author=P.+Morganauthor=P.+H.+Van+Der+Graafauthor=J.+Arrowsmithauthor=D.+E.+Feltnerauthor=K.+S.+Drummondauthor=C.+D.+Wegnerauthor=S.+D.+A.+Street&title=Can+the+Flow+of+Medicines+be+Improved%3F+Fundamental+Pharmacokinetic+and+Pharmacological+Principles+toward+Improving+Phase+II+Survival&doi=10.1016%2Fj.drudis.2011.12.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival</span></div><div class="casAuthors">Morgan, Paul; Van Der Graaf, Piet H.; Arrowsmith, John; Feltner, Doug E.; Drummond, Kira S.; Wegner, Craig D.; Street, Steve D. A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">419-424</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In an effort to uncover systematic learnings that can be applied to improve compd. survival, an anal. was performed on data from Phase II decisions for 44 programs at Pfizer.  It was found that not only were the majority of failures caused by lack of efficacy but also that, in a large no. of cases (43%), it was not possible to conclude whether the mechanism had been tested adequately.  A key finding was that an integrated understanding of the fundamental pharmacokinetic/pharmacodynamic principles of exposure at the site of action, target binding and expression of functional pharmacol. activity (termed together as the three Pillars of survival') all det. the likelihood of candidate survival in Phase II trials and improve the chance of progression to Phase III.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFyWWmU_ARMLVg90H21EOLACvtfcHk0ljLZJ0WrNwUMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslymurk%253D&md5=18816036124edb3d50c4e063fdc40614</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.12.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.12.020%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DVan%2BDer%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DFeltner%26aufirst%3DD.%2BE.%26aulast%3DDrummond%26aufirst%3DK.%2BS.%26aulast%3DWegner%26aufirst%3DC.%2BD.%26aulast%3DStreet%26aufirst%3DS.%2BD.%2BA.%26atitle%3DCan%2520the%2520Flow%2520of%2520Medicines%2520be%2520Improved%253F%2520Fundamental%2520Pharmacokinetic%2520and%2520Pharmacological%2520Principles%2520toward%2520Improving%2520Phase%2520II%2520Survival%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D9%25E2%2580%259310%26spage%3D419%26epage%3D424%26doi%3D10.1016%2Fj.drudis.2011.12.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span> <span> </span><span class="NLM_article-title">Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.085951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1124%2Fdmd.118.085951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=30910784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFeksbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=665-672&issue=6&author=D.+A.+Smithauthor=M.+Rowland&title=Intracellular+and+Intraorgan+Concentrations+of+Small+Molecule+Drugs%3A+Theory%2C+Uncertainties+in+Infectious+Diseases+and+Oncology%2C+and+Promise&doi=10.1124%2Fdmd.118.085951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular and intraorgan concentrations of small molecule drugs: theory, uncertainties in infectious diseases and oncology, and promise</span></div><div class="casAuthors">Smith, Dennis A.; Rowland, Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">665-672</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The distribution of a drug within the body should be considered as involving movement of unbound drug between the various aq. spaces of the body.  At true steady state, even for a compd. of restricted lipoidal permeability, unbound concns. in all aq. compartments (blood, extracellular, and intracellular) are considered identical, unless a compartment has a clearance/transport process.  In contrast, total drug concns. may differ greatly, reflecting binding or partitioning into constituents of each compartment.  For most highly lipid permeable drugs, this uniform unbound concn. is expected to apply.  However, many compds. have restricted lipoidal permeability and are subjected to transport/ clearance processes causing a gradient between intracellular and extracellular unbound concns. even at steady state.  Addnl. concerns arise where the drug target resides in a site of limited vascularity.  Many misleading assumptions about drug concns. and access to drug targets are based on total drug.  Correction, if made, is usually by measuring tissue binding, but this is limited by the lack of homogenicity of the organ or compartment.  Rather than looking for technol. to measure the unbound concn. it may be better to focus on designing high lipoidal permeable mols. with a high chance of achieving a uniform unbound drug concn.  It is hoped this paper will stimulate greater understanding of the path from circulation to cell interior, and thereby in part avoid or minimize the need to provide the exptl. very detg., and sometimes still questionable, answer to this problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovprJD-kOajrVg90H21EOLACvtfcHk0lgotHNmfULirw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFeksbbK&md5=d292c56b795d8d06fcd2abe1aeac1def</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.085951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.085951%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DRowland%26aufirst%3DM.%26atitle%3DIntracellular%2520and%2520Intraorgan%2520Concentrations%2520of%2520Small%2520Molecule%2520Drugs%253A%2520Theory%252C%2520Uncertainties%2520in%2520Infectious%2520Diseases%2520and%2520Oncology%252C%2520and%2520Promise%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2019%26volume%3D47%26issue%3D6%26spage%3D665%26epage%3D672%26doi%3D10.1124%2Fdmd.118.085951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mager, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jusko, W. J.</span></span> <span> </span><span class="NLM_article-title">Scaling Pharmacodynamics from in Vitro and Preclinical Animal Studies to Humans</span>. <i>Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.2133/dmpk.24.16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.2133%2Fdmpk.24.16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=19252333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1Whu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2009&pages=16-24&issue=1&author=D.+E.+Magerauthor=S.+Wooauthor=W.+J.+Jusko&title=Scaling+Pharmacodynamics+from+in+Vitro+and+Preclinical+Animal+Studies+to+Humans&doi=10.2133%2Fdmpk.24.16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Scaling pharmacodynamics from in vitro and preclinical animal studies to humans</span></div><div class="casAuthors">Mager, Donald E.; Woo, Sukyung; Jusko, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-24</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">A review.  An important feature of mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) models is the identification of drug- and system-specific factors that det. the intensity and time-course of pharmacol. effects.  This provides an opportunity to integrate information obtained from in vitro bioassays and preclin. pharmacol. studies in animals to anticipate the clin. and adverse responses to drugs in humans.  The fact that contemporary PK/PD modeling continues to evolve and seeks to emulate systems level properties should provide enhanced capabilities to scale-up pharmacodynamic data.  Crit. steps in drug discovery and development, such as lead compd. and first in human dose selection, may become more efficient with the implementation and further refinement of translational PK/PD modeling.  In this review, we highlight fundamental principles in pharmacodynamics and the basis expectations for in vitro bioassays and traditional allometric scaling in PK/PD modeling.  Discussion of PK/PD modeling efforts for recombinant human erythropoietin is also included as a case study showing the potential for advanced systems anal. to facilitate extrapolations and improve understanding of inter-species differences in drug responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjLp1-6RzUZrVg90H21EOLACvtfcHk0lgotHNmfULirw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1Whu78%253D&md5=2c8fbbe53b9cdc61bc88e392195cabdd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.24.16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.24.16%26sid%3Dliteratum%253Aachs%26aulast%3DMager%26aufirst%3DD.%2BE.%26aulast%3DWoo%26aufirst%3DS.%26aulast%3DJusko%26aufirst%3DW.%2BJ.%26atitle%3DScaling%2520Pharmacodynamics%2520from%2520in%2520Vitro%2520and%2520Preclinical%2520Animal%2520Studies%2520to%2520Humans%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2009%26volume%3D24%26issue%3D1%26spage%3D16%26epage%3D24%26doi%3D10.2133%2Fdmpk.24.16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalvass, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selley, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, G. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Pharmacodynamics of Seven Opioids in P-Glycoprotein-Competent Mice: Assessment of Unbound Brain EC50,u and Correlation of in Vitro, Preclinical, and Clinical data</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>323</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">346</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.119560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1124%2Fjpet.107.119560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=17646430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFahsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2007&pages=346-355&issue=1&author=J.+C.+Kalvassauthor=E.+R.+Olsonauthor=M.+P.+Cassidyauthor=D.+E.+Selleyauthor=G.+M.+Pollack&title=Pharmacokinetics+and+Pharmacodynamics+of+Seven+Opioids+in+P-Glycoprotein-Competent+Mice%3A+Assessment+of+Unbound+Brain+EC50%2Cu+and+Correlation+of+in+Vitro%2C+Preclinical%2C+and+Clinical+data&doi=10.1124%2Fjpet.107.119560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data</span></div><div class="casAuthors">Kalvass, J. Cory; Olson, Emily R.; Cassidy, Michael P.; Selley, Dana E.; Pollack, Gary M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">346-355</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study was conducted to assess the utility of unbound brain EC50 (EC50,u) as a measure of in vivo potency for centrally active drugs.  Seven μ-opioid agonists (alfentanil, fentanyl, loperamide, methadone, meperidine, morphine, and sufentanil) were selected as model central nervous system drugs because they elicit a readily measurable central effect (antinociception) and their clin. pharmacokinetics/pharmacodynamics are well understood.  Mice received an equipotent s.c. dose of one of the model opioids.  The time course of antinociception and the serum and brain concns. were detd.  A pharmacokinetic/pharmacodynamic model was used to est. relevant parameters.  In vitro measures of opioid binding affinity (Ki) and functional activity [EC50 for agonist stimulated guanosine 5'-O-(3-[35S]thio)triphosphate binding] and relevant clin. parameters were obtained to construct in vitro-to-preclin. and preclin.-to-clin. correlations.  The strongest in vitro-to-in vivo correlation was obsd. between Ki and unbound brain EC50,u (r2 ∼ 0.8).  A strong correlation between mouse serum and human plasma EC50 was obsd. (r2 = 0.949); the correlation was improved when cor. for protein binding (r2 = 0.995).  Clin. equipotent i.v. dose was only moderately related to Ki.  However, ests. of ED50 and EC50 (total serum, unbound serum, total brain, and unbound brain) were significant predictors of clin. equipotent i.v. dose; the best correlation was obsd. for brain EC50,u (r2 = 0.982).  For each opioid, brain equilibration half-life in mice was almost identical to the plasma effect-site equilibration half-life measured clin.  These results indicate that the mouse is a good model for opioid human brain disposition and clin. pharmacol. and that superior in vitro-to-preclin. and preclin.-to-clin. correlations can be achieved with relevant unbound concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_E2A6_UTPA7Vg90H21EOLACvtfcHk0lgotHNmfULirw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFahsb%252FN&md5=589fda7ce9d453d14f428c599a3640e5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.119560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.119560%26sid%3Dliteratum%253Aachs%26aulast%3DKalvass%26aufirst%3DJ.%2BC.%26aulast%3DOlson%26aufirst%3DE.%2BR.%26aulast%3DCassidy%26aufirst%3DM.%2BP.%26aulast%3DSelley%26aufirst%3DD.%2BE.%26aulast%3DPollack%26aufirst%3DG.%2BM.%26atitle%3DPharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520Seven%2520Opioids%2520in%2520P-Glycoprotein-Competent%2520Mice%253A%2520Assessment%2520of%2520Unbound%2520Brain%2520EC50%252Cu%2520and%2520Correlation%2520of%2520in%2520Vitro%252C%2520Preclinical%252C%2520and%2520Clinical%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D323%26issue%3D1%26spage%3D346%26epage%3D355%26doi%3D10.1124%2Fjpet.107.119560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vage, C.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Orally-Active and Selective Azaindane 5HT2c Agonist for the Treatment of Obesity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">266</span>– <span class="NLM_lpage">271</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.bmcl.2009.10.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=19914063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=266-271&issue=1&author=K.+K.+C.+Liuauthor=P.+Corneliusauthor=T.+A.+Pattersonauthor=Y.+Zengauthor=S.+Santucciauthor=E.+Tomlinsonauthor=C.+Gibbonsauthor=T.+S.+Maurerauthor=R.+Maralaauthor=J.+Brownauthor=J.+X.+Kongauthor=E.+Leeauthor=W.+Wernerauthor=Z.+Wenzelauthor=C.+Vage&title=Design+and+Synthesis+of+Orally-Active+and+Selective+Azaindane+5HT2c+Agonist+for+the+Treatment+of+Obesity&doi=10.1016%2Fj.bmcl.2009.10.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity</span></div><div class="casAuthors">Liu, Kevin K.-C.; Cornelius, Peter; Patterson, Terrell A.; Zeng, Yuan; Santucci, Stephanie; Tomlinson, Elizabeth; Gibbons, Colleen; Maurer, Tristan S.; Marala, Ravi; Brown, Janice; Kong, Jimmy X.; Lee, Eunsun; Werner, Wendy; Wenzel, Zane; Vage, Chandra</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">266-271</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Based on the original pyrazine hit, CP-0809101, novel conformationally-restricted 5HT2c receptor agonists with 2-piperazin-azaindane scaffold were designed.  Synthesis and structure-activity relationship (SAR) studies are described with emphasis on optimization of the selectivity against 5HT2a and 5HT2b receptors with excellent 2c potency.  Orally-active and selective compds., e.g. I, were identified with dose-responsive in vivo efficacy in the pre-clin. food intake model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqyfkKxRsyzbVg90H21EOLACvtfcHk0lhTupARoKzXiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsb%252FK&md5=823ef6ce05e7a7b5471fd66d645ec818</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.112%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DCornelius%26aufirst%3DP.%26aulast%3DPatterson%26aufirst%3DT.%2BA.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DSantucci%26aufirst%3DS.%26aulast%3DTomlinson%26aufirst%3DE.%26aulast%3DGibbons%26aufirst%3DC.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DMarala%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DJ.%2BX.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DWerner%26aufirst%3DW.%26aulast%3DWenzel%26aufirst%3DZ.%26aulast%3DVage%26aufirst%3DC.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Orally-Active%2520and%2520Selective%2520Azaindane%25205HT2c%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Obesity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D1%26spage%3D266%26epage%3D271%26doi%3D10.1016%2Fj.bmcl.2009.10.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuhl, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atchison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanian, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambroise, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brulet, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">am Ende, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judkins, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span> <span> </span><span class="NLM_article-title">Chemoproteomic Profiling Reveals that Cathepsin D Off-Target Activity Drives Ocular Toxicity of β-Secretase Inhibitors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13042</span>, <span class="refDoi"> DOI: 10.1038/ncomms13042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1038%2Fncomms13042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=27727204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13042&author=A.+M.+Zuhlauthor=C.+E.+Nolanauthor=M.+A.+Brodneyauthor=S.+Niessenauthor=K.+Atchisonauthor=C.+Houleauthor=D.+A.+Karanianauthor=C.+Ambroiseauthor=J.+W.+Bruletauthor=E.+M.+Beckauthor=S.+D.+Doranauthor=B.+T.+O%E2%80%99Neillauthor=C.+W.+am+Endeauthor=C.+Changauthor=K.+F.+Geogheganauthor=G.+M.+Westauthor=J.+C.+Judkinsauthor=X.+Houauthor=D.+R.+Riddellauthor=D.+S.+Johnson&title=Chemoproteomic+Profiling+Reveals+that+Cathepsin+D+Off-Target+Activity+Drives+Ocular+Toxicity+of+%CE%B2-Secretase+Inhibitors&doi=10.1038%2Fncomms13042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors</span></div><div class="casAuthors">Zuhl, Andrea M.; Nolan, Charles E.; Brodney, Michael A.; Niessen, Sherry; Atchison, Kevin; Houle, Christopher; Karanian, David A.; Ambroise, Claude; Brulet, Jeffrey W.; Beck, Elizabeth M.; Doran, Shawn D.; O'Neill, Brian T.; am Ende, Christopher W.; Chang, Cheng; Geoghegan, Kieran F.; West, Graham M.; Judkins, Joshua C.; Hou, Xinjun; Riddell, David R.; Johnson, Douglas S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13042</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of β-secretase BACE1 is considered one of the most promising approaches for treating Alzheimer's disease.  Several structurally distinct BACE1 inhibitors have been withdrawn from development after inducing ocular toxicity in animal models, but the target mediating this toxicity has not been identified.  Here we use a clickable photoaffinity probe to identify cathepsin D (CatD) as a principal off-target of BACE1 inhibitors in human cells.  We find that several BACE1 inhibitors blocked CatD activity in cells with much greater potency than that displayed in cell-free assays with purified protein.  Through a series of exploratory toxicol. studies, we show that quantifying CatD target engagement in cells with the probe is predictive of ocular toxicity in vivo.  Taken together, our findings designate off-target inhibition of CatD as a principal driver of ocular toxicity for BACE1 inhibitors and more generally underscore the power of chem. proteomics for discerning mechanisms of drug action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-LulGVRdJLVg90H21EOLACvtfcHk0lhTupARoKzXiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL&md5=5e2c31195f4f03babec561a5824ccb0d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fncomms13042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13042%26sid%3Dliteratum%253Aachs%26aulast%3DZuhl%26aufirst%3DA.%2BM.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DAtchison%26aufirst%3DK.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DKaranian%26aufirst%3DD.%2BA.%26aulast%3DAmbroise%26aufirst%3DC.%26aulast%3DBrulet%26aufirst%3DJ.%2BW.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BT.%26aulast%3Dam%2BEnde%26aufirst%3DC.%2BW.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DWest%26aufirst%3DG.%2BM.%26aulast%3DJudkins%26aufirst%3DJ.%2BC.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DRiddell%26aufirst%3DD.%2BR.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26atitle%3DChemoproteomic%2520Profiling%2520Reveals%2520that%2520Cathepsin%2520D%2520Off-Target%2520Activity%2520Drives%2520Ocular%2520Toxicity%2520of%2520%25CE%25B2-Secretase%2520Inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13042%26doi%3D10.1038%2Fncomms13042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relation between the Inhibition Constant (K1) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I50) of an Enzymic Reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&issue=23&author=Y.-C.+Chengauthor=W.+H.+Prusoff&title=Relation+between+the+Inhibition+Constant+%28K1%29+and+the+Concentration+of+Inhibitor+Which+Causes+50+Per+Cent+Inhibition+%28I50%29+of+an+Enzymic+Reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0lhTupARoKzXiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.-C.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelation%2520between%2520the%2520Inhibition%2520Constant%2520%2528K1%2529%2520and%2520the%2520Concentration%2520of%2520Inhibitor%2520Which%2520Causes%252050%2520Per%2520Cent%2520Inhibition%2520%2528I50%2529%2520of%2520an%2520Enzymic%2520Reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26issue%3D23%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Features of Selective Kinase Inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2005.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.chembiol.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=15975507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=621-637&issue=6&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Features+of+Selective+Kinase+Inhibitors&doi=10.1016%2Fj.chembiol.2005.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Features of Selective Kinase Inhibitors</span></div><div class="casAuthors">Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">621-637</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Summary: Small-mol. inhibitors of protein and lipid kinases have emerged as indispensable tools for studying signal transduction.  Despite the widespread use of these reagents, there is little consensus about the biochem. criteria that define their potency and selectivity in cells.  We discuss some of the features that det. the cellular activity of kinase inhibitors and propose a framework for interpreting inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAJWhVxtSrCLVg90H21EOLACvtfcHk0lggZx_zB1tzxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D&md5=ce5b3505a0326b04479172ec05573152</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DFeatures%2520of%2520Selective%2520Kinase%2520Inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26issue%3D6%26spage%3D621%26epage%3D637%26doi%3D10.1016%2Fj.chembiol.2005.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Black, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leff, P.</span></span> <span> </span><span class="NLM_article-title">Operational Models of Pharmacological Agonism</span>. <i>Proc. R. Soc. London, B</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>220</i></span> (<span class="NLM_issue">1219</span>),  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1098/rspb.1983.0093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1098%2Frspb.1983.0093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=6141562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaL2cXmtFaqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=220&publication_year=1983&pages=141-162&issue=1219&author=J.+W.+Blackauthor=P.+Leff&title=Operational+Models+of+Pharmacological+Agonism&doi=10.1098%2Frspb.1983.0093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Operational models of pharmacological agonism</span></div><div class="casAuthors">Black, J. W.; Leff, P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Royal Society of London, Series B:  Biological Sciences</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">220</span>
        (<span class="NLM_cas:issue">1219</span>),
    <span class="NLM_cas:pages">141-62</span>CODEN:
                <span class="NLM_cas:coden">PRLBA4</span>;
        ISSN:<span class="NLM_cas:issn">0080-4649</span>.
    </div><div class="casAbstract">A general, operational model is presented which explicitly describes pharmacol. agonism in terms of 3 parameters: an agonist-receptor dissocn. const., the total receptor concn. [Ro], and a parameter (KE) which defines the transduction of the agonist-receptor complex into pharmacol. effect.  The ratio RO/KE, the transducer ratio (τ), is a logical definition for the efficacy of an agonist in a system.  The model provides a chem. definition of intrinsic efficacy, making this parameter exptl. accessible in principle.  Alternate models are compared and contrasted with regard to their practical and conceptual utilities in exptl. pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonpXVldFQ_nbVg90H21EOLACvtfcHk0lggZx_zB1tzxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmtFaqtA%253D%253D&md5=a0421df9c56495d48d076010acf44b65</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1098%2Frspb.1983.0093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frspb.1983.0093%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DJ.%2BW.%26aulast%3DLeff%26aufirst%3DP.%26atitle%3DOperational%2520Models%2520of%2520Pharmacological%2520Agonism%26jtitle%3DProc.%2520R.%2520Soc.%2520London%252C%2520B%26date%3D1983%26volume%3D220%26issue%3D1219%26spage%3D141%26epage%3D162%26doi%3D10.1098%2Frspb.1983.0093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boddeke, H. W. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymonde, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoeffter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span> <span> </span><span class="NLM_article-title">Agonist/Antagonist Interactions with Cloned Human 5-HT1A Receptors: Variations in Intrinsic Activity Studied in Transfected HeLa Cells</span>. <i>Naunyn-Schmiedeberg’s Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>345</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1007/BF00168684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1007%2FBF00168684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1535691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaK38XisV2itL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=1992&pages=257-263&issue=3&author=H.+W.+G.+M.+Boddekeauthor=A.+Farginauthor=J.+R.+Raymondeauthor=P.+Schoeffterauthor=D.+Hoyer&title=Agonist%2FAntagonist+Interactions+with+Cloned+Human+5-HT1A+Receptors%3A+Variations+in+Intrinsic+Activity+Studied+in+Transfected+HeLa+Cells&doi=10.1007%2FBF00168684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist/antagonist interactions with cloned human 5-HT1A receptors:  variations in intrinsic activity studied in transfected HeLa cells</span></div><div class="casAuthors">Boddeke, Hendrikus W. G. M.; Fargin, Annick; Raymond, John R.; Schoeffter, Philippe; Hoyer, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">257-63</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    </div><div class="casAbstract">The characteristics of 5-HT1A-recognition sites and receptor-mediated release of intracellular calcium were established in 2 transfected HeLa cell lines (HA 6 and HA 7) expressing different levels of human 5-HT1A receptors (∼3000 and 500 fmol/mg protein).  The pharmacol. profiles of the binding (detd. with [3H]8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT)] and the calcium response (measured using Fura 2) were clearly of the 5-HT1A type.  Compds. such as 5-HT, 5-carboxamidotryptamine (5-CT), and 8-OH-DPAT acted as full agonists on the calcium response in both HeLa cell lines.  In addn., methiothepin, pindolol, NAN 190 and SDZ 216-525 (Seiler, M. P.; et al., 1991) acted as silent and potent antagonists.  Marked differences were obsd. in the responses mediated in the 2 cell lines.  EC50 values of agonists (particularly 5-HT, 5-CT, flesinoxan, and 8-OH-DPAT) were higher in HA 7 cells (≤80-fold) than in other 5-HT1A receptor models (e.g. inhibition of adenylate cyclase in calf hippocampus).  Further, a variety of compds. (ipsapirone, buspirone, spiroxatrine, MDL 73005) acted as agonists in HA 6 cells, whereas they behaved as silent antagonists in HA 7 cells (which express fewer receptors).  By contrast, KB values for antagonists were comparable in HA 6 and HA 7 cells.  Thus, EC50 values and intrinsic activity for a given drug are subject to large variations depending on the no. of receptors expressed in the target tissue.  The results obtained in HA 6 cells are comparable with respect to both potency and efficacy to those obsd. in calf or mouse hippocampus (inhibition of forskolin stimulated adenylate cyclase), whereas the results obtained in HA 7 cells are similar to those reported in mouse cortex (which was suggested to represent an atypical subtype of the 5-HT1A receptor).  Since the agonist activity of a given compd. at the same receptor can vary markedly, the present data show that intrinsic activity is not only ligand-dependent but also varies with the receptor-effector system studied.  In addn., there seems to be no simple way to make predictions about intrinsic activity, since that feature is model-dependent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbq9_UGwosprVg90H21EOLACvtfcHk0lggZx_zB1tzxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisV2itL4%253D&md5=e71b59284f86b4743e076aebee5b3fb0</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2FBF00168684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00168684%26sid%3Dliteratum%253Aachs%26aulast%3DBoddeke%26aufirst%3DH.%2BW.%2BG.%2BM.%26aulast%3DFargin%26aufirst%3DA.%26aulast%3DRaymonde%26aufirst%3DJ.%2BR.%26aulast%3DSchoeffter%26aufirst%3DP.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DAgonist%252FAntagonist%2520Interactions%2520with%2520Cloned%2520Human%25205-HT1A%2520Receptors%253A%2520Variations%2520in%2520Intrinsic%2520Activity%2520Studied%2520in%2520Transfected%2520HeLa%2520Cells%26jtitle%3DNaunyn-Schmiedeberg%25E2%2580%2599s%2520Arch.%2520Pharmacol.%26date%3D1992%26volume%3D345%26issue%3D3%26spage%3D257%26epage%3D263%26doi%3D10.1007%2FBF00168684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roeske, W. R.</span></span> <span> </span><span class="NLM_article-title">The Relationship between Agonist States of the M1 Muscarinic Receptor and the Hydrolysis of Inositol Lipids in Transfected Murine Fibroblast Cells (B82) Expressing Different Receptor Densities</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>251</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">97</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=2795474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaL1MXmtV2mu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=251&publication_year=1989&pages=90-97&issue=1&author=L.+Meiauthor=J.+Laiauthor=H.+I.+Yamamuraauthor=W.+R.+Roeske&title=The+Relationship+between+Agonist+States+of+the+M1+Muscarinic+Receptor+and+the+Hydrolysis+of+Inositol+Lipids+in+Transfected+Murine+Fibroblast+Cells+%28B82%29+Expressing+Different+Receptor+Densities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The relationship between agonist states of the M1 muscarinic receptor and the hydrolysis of inositol lipids in transfected murine fibroblast cells (B82) expressing different receptor densities</span></div><div class="casAuthors">Mei, Lin; Lai, Josephine; Yamamura, Henry I.; Roeske, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">251</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-7</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The relationship between the M1 muscarinic receptor d. and the receptor-mediated hydrolysis of inositol lipids was studied in cloned murine fibroblast B82 cells which were transfected with the m1 muscarinic receptor gene.  Of the 7 clones examd., the M1 muscarinic receptor densities in these cells characterized by (-)[3H]methyl-3-quinuclidinylbenzilate [(-)-[3H]MQNB] binding ranged from 12 fmol/106 cells in LK3-1 cells to 260 fmol/106 cells in the LK3-8 cells.  Carbachol/(-)[3H]MQNB competition curves for the LK3-1 cells (with low receptor d.) had a Hill coeff. close to unity.  The competition curves for carbachol in the clones with higher receptor densities had Hill coeffs. <1 and were best fitted by a computerized nonlinear least-squares regression program for the 2-site model.  The percentage of the M1 muscarinic receptors which had high affinity for carbachol decreased as the receptor d. increased, suggesting that the presence of endogenous factors in these cells may be important for the agonist affinity state of the receptor.  Concn.-response curves for carbachol-stimulated [3H]inositol monophosphate ([3H]IP1) accumulation were also obtained.  A correlation was obsd. between the d. of M1 muscarinic receptor with high affinity for carbachol and the max. [3H]IP1 accumulation in these cells.  There is no difference among the EC50 values and the dissocn. const. of high-affinity state values of the carbachol/(-)[3H]MQNB competition curves.  Thus, the high-affinity state for carbachol may be the functional state of the M1 muscarinic receptors in these transfected B82 cells.  Although a linear correlation between the total M1 muscarinic receptor d. and the max. [3H]IP1 accumulation was obsd., there was evidence for the existence of spare M1 receptors in the clones with high receptor densities but not in those with low receptor densities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4S_GP0Qcgd7Vg90H21EOLACvtfcHk0liOciGDzF6Rcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmtV2mu78%253D&md5=0ed0651d9cc57fe8a56023a367400c09</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMei%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DJ.%26aulast%3DYamamura%26aufirst%3DH.%2BI.%26aulast%3DRoeske%26aufirst%3DW.%2BR.%26atitle%3DThe%2520Relationship%2520between%2520Agonist%2520States%2520of%2520the%2520M1%2520Muscarinic%2520Receptor%2520and%2520the%2520Hydrolysis%2520of%2520Inositol%2520Lipids%2520in%2520Transfected%2520Murine%2520Fibroblast%2520Cells%2520%2528B82%2529%2520Expressing%2520Different%2520Receptor%2520Densities%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1989%26volume%3D251%26issue%3D1%26spage%3D90%26epage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilardaga, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciccarelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubeaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Neef, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robberecht, P.</span></span> <span> </span><span class="NLM_article-title">Properties and Regulation of the Coupling to Adenylate Cyclase of Secretin Receptors Stably Transfected in Chinese Hamster Ovary Cells</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1022</span>– <span class="NLM_lpage">1028</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=8190092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaK2cXktVWmsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1994&pages=1022-1028&issue=5&author=J.+P.+Vilardagaauthor=E.+Ciccarelliauthor=C.+Dubeauxauthor=P.+De+Neefauthor=A.+Bollenauthor=P.+Robberecht&title=Properties+and+Regulation+of+the+Coupling+to+Adenylate+Cyclase+of+Secretin+Receptors+Stably+Transfected+in+Chinese+Hamster+Ovary+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Properties and regulation of the coupling to adenylate cyclase of secretin receptors stably transfected in Chinese hamster ovary cells</span></div><div class="casAuthors">Vilardaga, J. P.; Ciccarelli, E.; Dubeaux, C.; De Neef, P.; Bollen, A.; Robberecht, P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1022-8</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">The binding properties, coupling to adenylate cyclase, and desensitization of secretin receptors stably expressed in transfected Chinese hamster ovary (CHO) cells were compared in two clones expressing high (CHO-SnR-c5, 450 fmol/mg of protein) and low (CHO-SnR-c1, 40 fmol/mg of protein) receptor densities.  The Kd values for receptor occupancy by secretin, selected analogs, and fragments were identical in CHO-SnR-c1 and -c5 cells and identical to those described for native receptors from NG 108-15 cells.  The Kact values for adenylate cyclase stimulation were identical to the Kd values in CHO-SnR-c1 cells but 5-10-fold higher than those in CHO-SnR-c5 cells.  The Kact values in both CHO-SnR-c1 and -c5 cell lines were reduced in the presence of the nonhydrolyzable GTP deriv. guanosine-5'-(β,γ-imido)triphosphate and after pretreatment of the cells with cholera toxin.  Preincubation of both CHO-SnR-c1 and -c5 cell lines with secretin for 24 h reduced their binding capacity and reduced secretin efficacy in CHO-SnR-c1 cells and secretin potency in CHO-SnR-c5 cells.  These results suggest efficient coupling of the secretin receptor to the adenylate cyclase machinery and the existence of spare receptors in the clone expressing higher receptor d.  Pretreatment of the two cell lines with the reducing agent dithiothreitol reduced the binding capacity and induced the appearance of a low affinity binding component.  In both cell lines, dithiothreitol pretreatment decreased secretin potency but not secretin efficacy, suggesting the necessity of integrity of the disulfide bridges for optimal receptor recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwspuuyO6wirVg90H21EOLACvtfcHk0liOciGDzF6Rcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktVWmsL0%253D&md5=33b3da332935ecf58928215f9b977cb7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVilardaga%26aufirst%3DJ.%2BP.%26aulast%3DCiccarelli%26aufirst%3DE.%26aulast%3DDubeaux%26aufirst%3DC.%26aulast%3DDe%2BNeef%26aufirst%3DP.%26aulast%3DBollen%26aufirst%3DA.%26aulast%3DRobberecht%26aufirst%3DP.%26atitle%3DProperties%2520and%2520Regulation%2520of%2520the%2520Coupling%2520to%2520Adenylate%2520Cyclase%2520of%2520Secretin%2520Receptors%2520Stably%2520Transfected%2520in%2520Chinese%2520Hamster%2520Ovary%2520Cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D1994%26volume%3D45%26issue%3D5%26spage%3D1022%26epage%3D1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladurner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronk, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallender, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. W.</span></span> <span> </span><span class="NLM_article-title">Agonist Potency at the Cloned Human beta-3-Adrenoceptor Depends on Receptor Expression Level and Nature of Assay</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>279</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=8858996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaK28Xmtlemurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1996&pages=214-221&issue=1&author=S.+Wilsonauthor=J.+K.+Chambersauthor=J.+E.+Parkauthor=A.+Ladurnerauthor=D.+W.+Cronkauthor=C.+G.+Chapmanauthor=H.+Kallenderauthor=M.+J.+Browneauthor=G.+J.+Murphyauthor=P.+W.+Young&title=Agonist+Potency+at+the+Cloned+Human+beta-3-Adrenoceptor+Depends+on+Receptor+Expression+Level+and+Nature+of+Assay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist potency at the cloned human beta-3-adrenoceptor depends on receptor expression level and nature of assay</span></div><div class="casAuthors">Wilson, Shelagh; Chambers, Jon K.; Park, Janet E.; Ladurner, Andreas; Cronk, David W.; Chapman, Conrad G.; Kallender, Howard; Browne, Michael J.; Murphy, Gregory J.; Young, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">214-221</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The cloned human β3-adrenoceptor was expressed in Chinese hamster ovary cells at three different levels (130, 400 and 3000 fmol/mg).  The potency and intrinsic activity of a range of agonists in functional assays with these cell lines rose as a function of increasing receptor d.  Operational anal. of concn.-response data allowed calcn. of functional affinity and efficacy of agonists at the human β3-adrenoceptor.  The data highlighted the low efficacy of BRL 37344 for the human β3-adrenoceptor, which may explain its lower potency at the human receptor despite its higher affinity relative to isoprenaline.  The potency of catecholamines at the human β3-adrenoceptor was 1 to 2 orders of magnitude higher when detd. in an intact cell cAMP accumulation assay compared with a membrane-based adenylyl cyclase activation assay.  The reason for this enhanced sensitivity is not clear, but the result is that the potency of the natural agonist noradrenaline in the intact cell is considerably higher than predicted either from its ligand binding affinity, or from its potency in membrane-based assays.  Much smaller enhancements in sensitivity were obsd. for compds. of the aryloxypropanolamine class such as CGP 12177, with the result that the rank order of potency of such agonists at the β3-adrenoceptor was altered.  In particular, CGP 12177 exhibited high relative potency in the cyclase assay, but low relative potency in intact cell assays.  These findings highlight the importance of selecting appropriate expression levels and appropriate assay methodol. when cloned receptors are used to characterize agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrE1drf0Q7l7Vg90H21EOLACvtfcHk0liOciGDzF6Rcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xmtlemurs%253D&md5=a798adedd58dd0057c3293a27a413150</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DChambers%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DLadurner%26aufirst%3DA.%26aulast%3DCronk%26aufirst%3DD.%2BW.%26aulast%3DChapman%26aufirst%3DC.%2BG.%26aulast%3DKallender%26aufirst%3DH.%26aulast%3DBrowne%26aufirst%3DM.%2BJ.%26aulast%3DMurphy%26aufirst%3DG.%2BJ.%26aulast%3DYoung%26aufirst%3DP.%2BW.%26atitle%3DAgonist%2520Potency%2520at%2520the%2520Cloned%2520Human%2520beta-3-Adrenoceptor%2520Depends%2520on%2520Receptor%2520Expression%2520Level%2520and%2520Nature%2520of%2520Assay%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1996%26volume%3D279%26issue%3D1%26spage%3D214%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ploeger, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Graaf, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danhof, M.</span></span> <span> </span><span class="NLM_article-title">Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling</span>. <i>Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.2133/dmpk.24.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.2133%2Fdmpk.24.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=19252332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1Whu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2009&pages=3-15&issue=1&author=B.+A.+Ploegerauthor=P.+H.+van+der+Graafauthor=M.+Danhof&title=Incorporating+Receptor+Theory+in+Mechanism-Based+Pharmacokinetic-Pharmacodynamic+%28PK-PD%29+Modeling&doi=10.2133%2Fdmpk.24.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling</span></div><div class="casAuthors">Ploeger, Bart A.; van der Graaf, Piet H.; Danhof, Meindert</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-15</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">A review.  Pharmacokinetic-Pharmacodynamic (PK-PD) modeling helps to better understand drug efficacy and safety and has, therefore, become a powerful tool in the learning-confirming cycles of drug-development.  In translational drug research, mechanism-based PK-PD modeling has been recognized as a tool for bringing forward early insights in drug efficacy and safety into the clin. development.  These models differ from descriptive PK-PD models in that they quant. characterize specific processes in the causal chain between drug administration and effect.  This includes target site distribution, binding and activation, pharmacodynamic interactions, transduction and homeostatic feedback mechanisms.  Compared to descriptive models mechanism-based PK-PD models that utilize receptor theory concepts for characterization of target binding and target activation processes have improved properties for extrapolation and prediction.  In this respect, receptor theory constitutes the basis for (1) prediction of in vivo drug concn.-effect relationships and (2) characterization of target assocn.-dissocn. kinetics as determinants of hysteresis in the time course of the drug effect.  This approach intrinsically distinguishes drug- and system specific parameters explicitly, allowing accurate extrapolation from in vitro to in vivo and across species.  This review provides an overview of recent developments in incorporating receptor theory in PK-PD modeling with a specific focus on the identifiability of these models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiEoxCJr7FxLVg90H21EOLACvtfcHk0ljY1tMWZZsNBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1Whu74%253D&md5=1a7546e40bee16441d6ae69a73b679e8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.24.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.24.3%26sid%3Dliteratum%253Aachs%26aulast%3DPloeger%26aufirst%3DB.%2BA.%26aulast%3Dvan%2Bder%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3DDanhof%26aufirst%3DM.%26atitle%3DIncorporating%2520Receptor%2520Theory%2520in%2520Mechanism-Based%2520Pharmacokinetic-Pharmacodynamic%2520%2528PK-PD%2529%2520Modeling%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2009%26volume%3D24%26issue%3D1%26spage%3D3%26epage%3D15%26doi%3D10.2133%2Fdmpk.24.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span> <span> </span><span class="NLM_article-title">Analytical Pharmacology: How Numbers Can Guide Drug Discovery</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1021/acsptsci.8b00057</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.8b00057" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivFWrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&pages=9-17&issue=1&author=T.+Kenakin&title=Analytical+Pharmacology%3A+How+Numbers+Can+Guide+Drug+Discovery&doi=10.1021%2Facsptsci.8b00057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Analytical Pharmacology: How Numbers Can Guide Drug Discovery</span></div><div class="casAuthors">Kenakin, Terry</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-17</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The unique ways in which pharmacol. data compares to math. models are described.  Examples show that insights into agonist action (prediction of agonism in vivo) and antagonist mechanism of action (orthosteric vs allosteric) can be gained that assist in the candidate selection process for new drugs in drug discovery and development efforts.  In addn., the impact of component processes on complex physiol. systems can be delineated, such as the effects of the hepatic system on whole body clearance in pharmacokinetics and prediction of drug-drug interactions.  Finally, models are instrumental in the procurement of universal drug parameters that can be used in medicinal chem.-based structure-activity relationships.  The revitalization of these ideas under the banner of "Anal. Pharmacol." may serve to re-emphasize these concepts over qual. description and lead to a better foundation for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRrI1PZfWIUrVg90H21EOLACvtfcHk0ljY1tMWZZsNBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivFWrsA%253D%253D&md5=b1979716d723efe9c19c117301caf564</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.8b00057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.8b00057%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26atitle%3DAnalytical%2520Pharmacology%253A%2520How%2520Numbers%2520Can%2520Guide%2520Drug%2520Discovery%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2019%26volume%3D2%26issue%3D1%26spage%3D9%26epage%3D17%26doi%3D10.1021%2Facsptsci.8b00057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizi-Fard, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, H.-L.</span></span> <span> </span><span class="NLM_article-title">Impact of Mechanism-Based Enzyme Inactivation on Inhibitor Potency: Implications for Rational Drug Discovery</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1414</span>, <span class="refDoi"> DOI: 10.1002/1520-6017(200011)89:11<1404::AID-JPS4>3.0.CO;2-#</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=11015686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVygsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2000&pages=1404-1414&issue=11&author=T.+S.+Maurerauthor=M.+A.+Tabrizi-Fardauthor=H.-L.+Fung&title=Impact+of+Mechanism-Based+Enzyme+Inactivation+on+Inhibitor+Potency%3A+Implications+for+Rational+Drug+Discovery&doi=10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of mechanism-based enzyme inactivation on inhibitor potency: implications for rational drug discovery</span></div><div class="casAuthors">Maurer, Tristan S.; Tabrizi-Fard, Mohammad A.; Fung, Ho-Leung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1404-1414</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Mechanism-based enzyme inactivators (MBEIs) have unique kinetic actions that make predictions of potency, selectivity, and potential for metabolic drug interactions more complex than for competitive antagonists.  We have derived a math. relationship that links the influence of substrate concn. and binding const. ([S] and Km, resp.), inhibitor concn. and binding const. ([I] and KI, resp.), and inactivation rate const. (kinact) to enzyme activity (v) and maximal activity (Vmax) at any time (t).  The kinetic behavior of this relationship was validated in murine-macrophage cell cultures using MBEIs of nitric oxide synthase (NOS).  This initial equation was also used in the derivation of a new relationship that directly links the kinetic parameters of mechanism-based inactivation to inhibitory potency at a particular time (IC50(t)).  Using this direct relationship, we obsd. that the predicted rank inhibitory potency of a series of MBEIs was improved over that predicted by the KI parameter alone.  These relationships offer a fundamental understanding of the kinetics of MBEI action and may be useful in the evaluation of these compds. during the discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpORTg5_VClm7Vg90H21EOLACvtfcHk0liXXHE-WT-EAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVygsbY%253D&md5=9cfdede7312035ea0971247595106a9e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1520-6017%2528200011%252989%253A11%253C1404%253A%253AAID-JPS4%253E3.0.CO%253B2-%2523%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DTabrizi-Fard%26aufirst%3DM.%2BA.%26aulast%3DFung%26aufirst%3DH.-L.%26atitle%3DImpact%2520of%2520Mechanism-Based%2520Enzyme%2520Inactivation%2520on%2520Inhibitor%2520Potency%253A%2520Implications%2520for%2520Rational%2520Drug%2520Discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2000%26volume%3D89%26issue%3D11%26spage%3D1404%26epage%3D1414%26doi%3D10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowland
Yeo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsky, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostami-Hodjegan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, G. T.</span></span> <span> </span><span class="NLM_article-title">Prediction of Time-Dependent CYP3A4 Drug-Drug Interactions by Physiologically Based Pharmacokinetic Modelling: Impact of Inactivation Parameters and Enzyme Turnover</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2011.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.ejps.2011.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=21540107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFSkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=160-173&issue=3&author=K.+Rowland%0AYeoauthor=R.+L.+Walskyauthor=M.+Jameiauthor=A.+Rostami-Hodjeganauthor=G.+T.+Tucker&title=Prediction+of+Time-Dependent+CYP3A4+Drug-Drug+Interactions+by+Physiologically+Based+Pharmacokinetic+Modelling%3A+Impact+of+Inactivation+Parameters+and+Enzyme+Turnover&doi=10.1016%2Fj.ejps.2011.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover</span></div><div class="casAuthors">Rowland Yeo, K.; Walsky, R. L.; Jamei, M.; Rostami-Hodjegan, A.; Tucker, G. T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">160-173</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Predicting the magnitude of time-dependent metabolic drug-drug (mDDIs) interactions involving cytochrome P 450 3A4 (CYP3A4) from in vitro data requires accurate knowledge of the inactivation parameters of the inhibitor (K I, k inact) and of the turnover of the enzyme (k deg) in both the gut and the liver.  We have predicted the magnitude of mDDIs obsd. in 29 in vivo studies involving six CYP3A4 probe substrates and five mechanism based inhibitors of CYP3A4 of variable potency (azithromycin, clarithromycin, diltiazem, erythromycin and verapamil).  Inactivation parameters detd. anew in a single lab. under standardised conditions together with data from substrate and inhibitor files within the Simcyp Simulator (Version 9.3) were used to det. a value of the hepatic k deg (0.0193 or 0.0077 h-1) most appropriate for the prediction of mDDIs involving time-dependent inhibition of CYP3A4.  The higher value resulted in decreased bias (geometric mean fold error - 1.05 vs. 1.30) and increased precision (root mean squared error - 1.29 vs. 2.30) of predictions of mean ratios of AUC in the absence and presence of inhibitor.  Depending on the k deg value used (0.0193 vs. 0.0077 h-1), predicted mean ratios of AUC were within 2-fold of the obsd. values for all (100%) and 27 (93%) of the 29 studies, resp. and within 1.5-fold for 24 (83%) and 17 (59%) of the 29 studies, resp.  Comprehensive PBPK models were applied for accurate assessment of the potential for mDDIs involving time-dependent inhibition of CYP3A4 using a hepatic k deg value of 0.0193 h-1 in conjunction with inactivation parameters detd. by the conventional exptl. approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Smu_gOTvVbVg90H21EOLACvtfcHk0liXXHE-WT-EAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFSkt7Y%253D&md5=ab242e3e6c530c220ca3d73340d6ac00</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2011.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2011.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DRowland%2BYeo%26aufirst%3DK.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DJamei%26aufirst%3DM.%26aulast%3DRostami-Hodjegan%26aufirst%3DA.%26aulast%3DTucker%26aufirst%3DG.%2BT.%26atitle%3DPrediction%2520of%2520Time-Dependent%2520CYP3A4%2520Drug-Drug%2520Interactions%2520by%2520Physiologically%2520Based%2520Pharmacokinetic%2520Modelling%253A%2520Impact%2520of%2520Inactivation%2520Parameters%2520and%2520Enzyme%2520Turnover%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D43%26issue%3D3%26spage%3D160%26epage%3D173%26doi%3D10.1016%2Fj.ejps.2011.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayhew, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. D.</span></span> <span> </span><span class="NLM_article-title">An in Vitro Model for Predicting in Vivo Inhibition of Cytochrome P450 3A4 by Metabolic Intermediate Complex Formation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1037</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10950845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtFCrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=1031-1037&issue=9&author=B.+S.+Mayhewauthor=D.+R.+Jonesauthor=S.+D.+Hall&title=An+in+Vitro+Model+for+Predicting+in+Vivo+Inhibition+of+Cytochrome+P450+3A4+by+Metabolic+Intermediate+Complex+Formation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation</span></div><div class="casAuthors">Mayhew, Bradley S.; Jones, David R.; Hall, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1031-1037</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">An in vitro model is proposed to account for the clin. obsd. inhibition of cytochrome P 450 (CYP) 3A that results from administration of clarithromycin, fluoxetine, or diltiazem.  Rates for loss of CYP3A4 enzymic activity resulting from metabolic intermediate complex formation and the concn. dependencies thereof were detd. in vitro for clarithromycin, fluoxetine, and N-desmethyl diltiazem, which is the primary metabolite of diltiazem.  Using the in vitro concn.-dependent rates for loss of activity, in vivo rates of CYP3A4 inactivation were predicted for these compds. at a clin. relevant unbound plasma concn. of 0.1 μM.  Based on the predicted rates combined with published rates for in vivo CYP3A degrdn., our model predicts that fluoxetine, clarithromycin, and the primary metabolite of diltiazem reduce the steady-state concn. of liver CYP3A4 to approx. 72, 39, or 21% of initial levels, resp.  These redns. correspond to 1.4-, 2.6-, or 4.7-fold increases, resp., in the area under the plasma concn.-time curve of a coadministered drug that is eliminated exclusively by hepatic CYP3A4 metab.  These predicted results are in good agreement with reported clin. data.  The major implication of this work is that fluoxetine, clarithromycin, and the primary metabolite of diltiazem, at clin. relevant concns., inactivate CYP3A4 enzymic activity at rates sufficient to affect in vivo concns. of CYP3A4 and thereby affect the clearance of compds. eliminated by this pathway.  We speculate that mechanisms involving substrate-mediated mechanistic inactivation of CYPs play a major role in many clin. obsd. drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEd5oxG2WwlrVg90H21EOLACvtfcHk0liXXHE-WT-EAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtFCrtbg%253D&md5=1b36235981bcebd86376586d2dedace7</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMayhew%26aufirst%3DB.%2BS.%26aulast%3DJones%26aufirst%3DD.%2BR.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DAn%2520in%2520Vitro%2520Model%2520for%2520Predicting%2520in%2520Vivo%2520Inhibition%2520of%2520Cytochrome%2520P450%25203A4%2520by%2520Metabolic%2520Intermediate%2520Complex%2520Formation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2000%26volume%3D28%26issue%3D9%26spage%3D1031%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erion, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T.</span></span> <span> </span><span class="NLM_article-title">Model-Based Assessment of Plasma Citrate Flux Into the Liver: Implications for NaCT as a Therapeutic Target</span>. <i>CPT: Pharmacometrics Syst. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">132</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1002/psp4.12062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2Fpsp4.12062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=27069776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1Gnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=132-139&issue=3&author=Z.+Liauthor=D.+Erionauthor=T.+Maurer&title=Model-Based+Assessment+of+Plasma+Citrate+Flux+Into+the+Liver%3A+Implications+for+NaCT+as+a+Therapeutic+Target&doi=10.1002%2Fpsp4.12062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Model-Based Assessment of Plasma Citrate Flux Into the Liver: Implications for NaCT as a Therapeutic Target</span></div><div class="casAuthors">Li, Z.; Erion, Dm; Maurer, Ts</div><div class="citationInfo"><span class="NLM_cas:title">CPT: Pharmacometrics & Systems Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">132-139</span>CODEN:
                <span class="NLM_cas:coden">CPSPBR</span>;
        ISSN:<span class="NLM_cas:issn">2163-8306</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cytoplasmic citrate serves as an important regulator of gluconeogenesis and carbon source for de novo lipogenesis in the liver.  For this reason, the sodium-coupled citrate transporter (NaCT), a plasma membrane transporter that governs hepatic influx of plasma citrate in human, is being explored as a potential therapeutic target for metabolic disorders.  As cytoplasmic citrate also originates from intracellular mitochondria, the relative contribution of these two pathways represents crit. information necessary to underwrite confidence in this target.  In this work, hepatic influx of plasma citrate was quantified via pharmacokinetic modeling of published clin. data.  The influx was then compared to independent literature ests. of intracellular citrate flux in human liver.  The results indicate that, under normal conditions, <10% of hepatic citrate originates from plasma.  Similar ests. were detd. exptl. in mice and rats.  This suggests that NaCT inhibition will have a limited impact on hepatic citrate concns. across species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEqnnsuh1zvrVg90H21EOLACvtfcHk0lgqs_h0MsN0Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1Gnt7c%253D&md5=d9055275904abd411b300f03e979450a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fpsp4.12062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsp4.12062%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DErion%26aufirst%3DD.%26aulast%3DMaurer%26aufirst%3DT.%26atitle%3DModel-Based%2520Assessment%2520of%2520Plasma%2520Citrate%2520Flux%2520Into%2520the%2520Liver%253A%2520Implications%2520for%2520NaCT%2520as%2520a%2520Therapeutic%2520Target%26jtitle%3DCPT%253A%2520Pharmacometrics%2520Syst.%2520Pharmacol.%26date%3D2016%26volume%3D5%26issue%3D3%26spage%3D132%26epage%3D139%26doi%3D10.1002%2Fpsp4.12062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jusko, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H. C.</span></span> <span> </span><span class="NLM_article-title">Physiologic Indirect Response Models Characterize Diverse Types of Pharmacodynamic Effects</span>. <i>Clin. Pharmacol. Ther. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">406</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1038/clpt.1994.155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1038%2Fclpt.1994.155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=7955802" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1994&pages=406-419&issue=4&author=W.+J.+Juskoauthor=H.+C.+Ko&title=Physiologic+Indirect+Response+Models+Characterize+Diverse+Types+of+Pharmacodynamic+Effects&doi=10.1038%2Fclpt.1994.155"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fclpt.1994.155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.1994.155%26sid%3Dliteratum%253Aachs%26aulast%3DJusko%26aufirst%3DW.%2BJ.%26aulast%3DKo%26aufirst%3DH.%2BC.%26atitle%3DPhysiologic%2520Indirect%2520Response%2520Models%2520Characterize%2520Diverse%2520Types%2520of%2520Pharmacodynamic%2520Effects%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D1994%26volume%3D56%26issue%3D4%26spage%3D406%26epage%3D419%26doi%3D10.1038%2Fclpt.1994.155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craig, W. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1086/516284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1086%2F516284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=9455502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaK1cXltVaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1998&pages=1-10&issue=1&author=W.+A.+Craig&title=Pharmacokinetic%2FPharmacodynamic+Parameters%3A+Rationale+for+Antibacterial+Dosing+of+Mice+and+Men&doi=10.1086%2F516284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men</span></div><div class="casAuthors">Craig, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">A review with 64 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzV5ls_EvnebVg90H21EOLACvtfcHk0lgqs_h0MsN0Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltVaqtw%253D%253D&md5=c4277a411e8d24789c3bff279c0ef569</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1086%2F516284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F516284%26sid%3Dliteratum%253Aachs%26aulast%3DCraig%26aufirst%3DW.%2BA.%26atitle%3DPharmacokinetic%252FPharmacodynamic%2520Parameters%253A%2520Rationale%2520for%2520Antibacterial%2520Dosing%2520of%2520Mice%2520and%2520Men%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D1998%26volume%3D26%26issue%3D1%26spage%3D1%26epage%3D10%26doi%3D10.1086%2F516284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggleston, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span> <span> </span><span class="NLM_article-title">Validation and Clinical Utility of the hERG IC50:Cmax Ratio to Determine the Risk of Drug-Induced Torsades de Pointes: A Meta-Analysis</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1002/phar.2087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2Fphar.2087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=29380488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmt1Wksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=341-348&issue=3&author=D.+F.+Lehmannauthor=W.+D.+Egglestonauthor=D.+Wang&title=Validation+and+Clinical+Utility+of+the+hERG+IC50%3ACmax+Ratio+to+Determine+the+Risk+of+Drug-Induced+Torsades+de+Pointes%3A+A+Meta-Analysis&doi=10.1002%2Fphar.2087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Validation and Clinical Utility of the hERG IC50:Cmax Ratio to Determine the Risk of Drug-Induced Torsades de Pointes: A Meta-Analysis</span></div><div class="casAuthors">Lehmann, David F.; Eggleston, William D.; Wang, Dongliang</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-348</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-9114</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Use of the QT interval cor. for heart rate (QTc) on the ECG (ECG) to predict torsades de pointes (TdP) risk from culprit drugs is neither sensitive nor specific.  The ratio of the half-max. inhibitory concn. of the hERG channel (hERG IC50) to the peak serum concn. of unbound drug (Cmax) is used during drug development to screen out chem. entities likely to cause TdP.  To validate the use of the hERG IC50:Cmax ratio to predict TdP risk from a culprit drug by its correlation with TdP incidence.  Medline (between 1966 and March 2017) was accessed for hERG IC50 and Cmax values from the antihistamine, fluoroquinolone, and antipsychotic classes to identify cases of drug-induced TdP.  Exposure to a culprit drug was estd. from annual revenues reported by the manufacturer.  Inclusion criteria for TdP cases were provision of an ECG tracing that demonstrated QTc prolongation with TdP and normal serum values of potassium, calcium, and magnesium.  Cases reported in patients with a prior rhythm disturbance and those involving a drug interaction were excluded.  The Meta-Anal. of Observational Studies in Epidemiol. checklist was used for epidemiol. data extn. by two authors.  Negligible risk drugs were defined by an hERG IC50:Cmax ratio that correlated with less than a 5% chance of one TdP event for every 100 million exposures (relative risk [RR] 1.0).  The hERG IC50:Cmax ratio correlated with TdP risk (0.312; 95% confidence interval 0.205-0.476, p<0.0001), a ratio of 80 (RR 1.0).  The RR from olanzapine is on par with loratadine; ziprasidone is comparable with ciprofloxacin.  Drugs with an RR greater than 50 include astemizole, risperidone, haloperidol, and thioridazine.  The hERG IC50:Cmax ratio was correlated with TdP incidence for culprit drugs.  This validation provides support for the potential use of the hERG IC50:Cmax ratio for clin. decision making in instances of drug selection where TdP risk is a concern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvHw4uCL_aUbVg90H21EOLACvtfcHk0lgEv1kCk9e7cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmt1Wksbc%253D&md5=a15869af1fb0e9a522f2155700249517</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fphar.2087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.2087%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DD.%2BF.%26aulast%3DEggleston%26aufirst%3DW.%2BD.%26aulast%3DWang%26aufirst%3DD.%26atitle%3DValidation%2520and%2520Clinical%2520Utility%2520of%2520the%2520hERG%2520IC50%253ACmax%2520Ratio%2520to%2520Determine%2520the%2520Risk%2520of%2520Drug-Induced%2520Torsades%2520de%2520Pointes%253A%2520A%2520Meta-Analysis%26jtitle%3DPharmacotherapy%26date%3D2018%26volume%3D38%26issue%3D3%26spage%3D341%26epage%3D348%26doi%3D10.1002%2Fphar.2087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goutelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baudry, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagnieu, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boibieux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livrozet, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyramond, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chidiac, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tod, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferry, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic-Pharmacodynamic Modeling of Unboosted Atazanavir in a Cohort of Stable HIV-Infected Patients</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1128/AAC.01822-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1128%2FAAC.01822-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=23147727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1SrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=517-523&issue=1&author=S.+Goutelleauthor=T.+Baudryauthor=M.-C.+Gagnieuauthor=A.+Boibieuxauthor=J.-M.+Livrozetauthor=D.+Peyramondauthor=C.+Chidiacauthor=M.+Todauthor=T.+Ferry&title=Pharmacokinetic-Pharmacodynamic+Modeling+of+Unboosted+Atazanavir+in+a+Cohort+of+Stable+HIV-Infected+Patients&doi=10.1128%2FAAC.01822-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic-pharmacodynamic modeling of unboosted atazanavir in a cohort of stable HIV-infected patients</span></div><div class="casAuthors">Goutelle, Sylvain; Baudry, Thomas; Gagnieu, Marie-Claude; Boibieux, Andre; Livrozet, Jean-Michel; Peyramond, Dominique; Chidiac, Christian; Tod, Michel; Ferry, Tristan</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">517-523</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Limited data on the pharmacokinetics and pharmacodynamics (PK/PD) of unboosted atazanavir (uATV) in treatment-experienced patients are available.  The aim of this work was to study the PK/PD of unboosted atazanavir in a cohort of HIV-infected patients.  Data were available for 58 HIV-infected patients (69 uATV-based regimens).  Atazanavir concns. were analyzed by using a population approach, and the relationship between atazanavir PK and clin. outcome was examd. using logistic regression.  The final PK model was a linear one-compartment model with a mixt. absorption model to account for two subgroups of absorbers.  The mean (interindividual variability) of population PK parameters were as follows: clearance, 13.4 L/h (40.7%), vol. of distribution, 71.1 L (29.7%), and fraction of regular absorbers, 0.49.  Seven subjects experienced virol. failure after switch to uATV.  All of them were identified as low absorbers in the PK modeling.  The absorption rate const. (0.38 ± 0.20 vs. 0.75 ± 0.28 h-1; P = 0.002) and ATV exposure (area under the concn.-time curve from 0 to 24 h [AUC0-24], 10.3 ± 2.1 vs. 22.4 ± 11.2 mg · h · liter-1; P = 0.001) were significantly lower in patients with virol. failure than in patients without failure.  In the logistic regression anal., both the absorption rate const. and ATV trough concn. significantly influenced the probability of virol. failure.  A significant relationship between ATV pharmacokinetics and virol. response was obsd. in a cohort of HIV patients who were administered unboosted atazanavir.  This study also suggests that twice-daily administration of uATV may optimize drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFEi5Wb0W_7bVg90H21EOLACvtfcHk0lgEv1kCk9e7cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1SrtLg%253D&md5=2a9621e97286aa55d4564b5a4b097e40</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FAAC.01822-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01822-12%26sid%3Dliteratum%253Aachs%26aulast%3DGoutelle%26aufirst%3DS.%26aulast%3DBaudry%26aufirst%3DT.%26aulast%3DGagnieu%26aufirst%3DM.-C.%26aulast%3DBoibieux%26aufirst%3DA.%26aulast%3DLivrozet%26aufirst%3DJ.-M.%26aulast%3DPeyramond%26aufirst%3DD.%26aulast%3DChidiac%26aufirst%3DC.%26aulast%3DTod%26aufirst%3DM.%26aulast%3DFerry%26aufirst%3DT.%26atitle%3DPharmacokinetic-Pharmacodynamic%2520Modeling%2520of%2520Unboosted%2520Atazanavir%2520in%2520a%2520Cohort%2520of%2520Stable%2520HIV-Infected%2520Patients%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26issue%3D1%26spage%3D517%26epage%3D523%26doi%3D10.1128%2FAAC.01822-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutmacher, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furst, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikranian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduaka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span> <span> </span><span class="NLM_article-title">Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib</span>. <i>Clin. Pharmacol. Ther. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1002/cpt.576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2Fcpt.576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=27859030" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2017&pages=745-753&issue=6&author=M.+Lambaauthor=M.+M.+Hutmacherauthor=D.+E.+Furstauthor=A.+Dikranianauthor=M.+E.+Dowtyauthor=D.+Conradoauthor=T.+Stockauthor=C.+Nduakaauthor=J.+Cookauthor=S.+Krishnaswami&title=Model-Informed+Development+and+Registration+of+a+Once-Daily+Regimen+of+Extended-Release+Tofacitinib&doi=10.1002%2Fcpt.576"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fcpt.576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.576%26sid%3Dliteratum%253Aachs%26aulast%3DLamba%26aufirst%3DM.%26aulast%3DHutmacher%26aufirst%3DM.%2BM.%26aulast%3DFurst%26aufirst%3DD.%2BE.%26aulast%3DDikranian%26aufirst%3DA.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DConrado%26aufirst%3DD.%26aulast%3DStock%26aufirst%3DT.%26aulast%3DNduaka%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DKrishnaswami%26aufirst%3DS.%26atitle%3DModel-Informed%2520Development%2520and%2520Registration%2520of%2520a%2520Once-Daily%2520Regimen%2520of%2520Extended-Release%2520Tofacitinib%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2017%26volume%3D101%26issue%3D6%26spage%3D745%26epage%3D753%26doi%3D10.1002%2Fcpt.576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, N.</span></span> <span> </span><span class="NLM_article-title">Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.209304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1124%2Fjpet.113.209304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=24218541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=165-173&issue=1&author=M.+E.+Dowtyauthor=M.+I.+Jessonauthor=S.+Ghoshauthor=J.+Leeauthor=D.+M.+Meyerauthor=S.+Krishnaswamiauthor=N.+Kishore&title=Preclinical+to+Clinical+Translation+of+Tofacitinib%2C+a+Janus+Kinase+Inhibitor%2C+in+Rheumatoid+Arthritis&doi=10.1124%2Fjpet.113.209304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis</span></div><div class="casAuthors">Dowty, Martin E.; Jesson, Michael I.; Ghosh, Sarbani; Lee, Jamie; Meyer, Debra M.; Krishnaswami, Sriram; Kishore, Nandini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-173, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A crit. piece in the translation of preclin. studies to clin. trials is the detn. of dosing regimens that allow max. therapeutic benefit with min. toxicity.  The preclin. pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib, an oral Janus kinase (JAK) inhibitor, in a mouse collagen-induced arthritis (mCIA) model was compared with clin. PK/PD data from patients with rheumatoid arthritis (RA).  Preclin. evaluations included target modulation and PK/PD modeling based on continuous s.c. infusion or oral once- or twice-daily (BID) dosing paradigms in mice.  The human PK/PD profile was obtained from pooled data from four phase 2 studies in patients with RA, and maximal effect models were used to evaluate efficacy after 12 wk of tofacitinib treatment (1-15 mg BID).  In mCIA, the main driver of efficacy was inhibition of cytokine receptor signaling mediated by JAK1 heterodimers, but not JAK2 homodimers, and continuous daily inhibition was not required to maintain efficacy.  Projected efficacy could be predicted from total daily exposure irresp. of the oral dosing paradigm, with a total steady-state plasma concn. achieving 50% of the maximal response (Cave50) of ∼100 nM.  Tofacitinib potency (ED50) in clin. studies was ∼3.5 mg BID (90% confidence interval: 2.3, 5.5) or total Cave50 of ∼40 nM, derived using Disease Activity Scores from patients with RA.  The collective clin. and preclin. data indicated the importance of Cave as a driver of efficacy, rather than max. or min. plasma concn. (Cmax or Cmin), where Cave50 values were within ∼2-fold of each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDs-lnT0HFF7Vg90H21EOLACvtfcHk0lgEv1kCk9e7cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D&md5=faed45ef8eabb5e1bde0819702f26ffa</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.209304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.209304%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DKishore%26aufirst%3DN.%26atitle%3DPreclinical%2520to%2520Clinical%2520Translation%2520of%2520Tofacitinib%252C%2520a%2520Janus%2520Kinase%2520Inhibitor%252C%2520in%2520Rheumatoid%2520Arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26issue%3D1%26spage%3D165%26epage%3D173%26doi%3D10.1124%2Fjpet.113.209304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northam, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alway, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, O. S.</span></span> <span> </span><span class="NLM_article-title">Blood Levels of Drug at the Equilibrium State after Multiple Dosing</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>207</i></span> (<span class="NLM_issue">5003</span>),  <span class="NLM_fpage">1301</span>– <span class="NLM_lpage">1302</span>, <span class="refDoi"> DOI: 10.1038/2071301a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1038%2F2071301a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=5884654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A280%3ADyaF287ksVSntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=1965&pages=1301-1302&issue=5003&author=J.+G.+Wagnerauthor=J.+I.+Northamauthor=C.+D.+Alwayauthor=O.+S.+Carpenter&title=Blood+Levels+of+Drug+at+the+Equilibrium+State+after+Multiple+Dosing&doi=10.1038%2F2071301a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Blood levels of drug at the equilibrium state after multiple dosing</span></div><div class="casAuthors">Wagner J G; Northam J I; Alway C D; Carpenter O S</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">207</span>
        (<span class="NLM_cas:issue">5003</span>),
    <span class="NLM_cas:pages">1301-2</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkXM4pbz4uL8uCWE5mhx1RfW6udTcc2ea5YuA_7CI4Urntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaF287ksVSntQ%253D%253D&md5=de878fcb3ee5b632be74a12d50dfcfa7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2F2071301a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F2071301a0%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DJ.%2BG.%26aulast%3DNortham%26aufirst%3DJ.%2BI.%26aulast%3DAlway%26aufirst%3DC.%2BD.%26aulast%3DCarpenter%26aufirst%3DO.%2BS.%26atitle%3DBlood%2520Levels%2520of%2520Drug%2520at%2520the%2520Equilibrium%2520State%2520after%2520Multiple%2520Dosing%26jtitle%3DNature%26date%3D1965%26volume%3D207%26issue%3D5003%26spage%3D1301%26epage%3D1302%26doi%3D10.1038%2F2071301a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moscovitz, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpino, P. A.</span></span> <span> </span><span class="NLM_article-title">Diabetes Area Patent Participation Analysis - Part II: Years 2011–2016</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1406477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1080%2F13543776.2018.1406477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=29140125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2lu7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=111-122&issue=2&author=M.+Boehmauthor=M.+Crawfordauthor=J.+E.+Moscovitzauthor=P.+A.+Carpino&title=Diabetes+Area+Patent+Participation+Analysis+-+Part+II%3A+Years+2011%E2%80%932016&doi=10.1080%2F13543776.2018.1406477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetes area patent participation analysis - part II: years 2011-2016</span></div><div class="casAuthors">Boehm, Markus; Crawford, Matthew; Moscovitz, Jamie E.; Carpino, Philip A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-122</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Diabetes is a metabolic disease characterized by elevated levels of plasma glucose.  When untreated, diabetes increases the risk of developing co-morbidities such as cardiovascular disease.  Several drugs, often used as part of combination therapies, have been approved to treat the disease, but these drugs will eventually fail to effectively control blood glucose levels, at which point insulin replacement therapy is required.  A medical need exists for new antidiabetic drugs that exhibit good efficacy with improved safety/toleration profiles and can be added on top of existing therapies, or that can provide addnl. benefits beyond glucose lowering such as pancreatic beta (β)-cell protection.  This review analyzes drug targets and applicants of patents that published between 2011-2016 claiming novel small or large mols. for the treatment of diabetes, and compares the results to the 2008-2010 time period.  A majority of patent activity around the discovery of new antidiabetic drugs in 2011-2016 was directed against 15 targets, most of which were also the focus of drug discovery efforts in the 2008-2010 time period.  Few targets were identified that promote pancreatic β-cell regeneration and β-cell health, areas where future opportunities may exist for developing transformative drug therapies that may potentially lead to cures for diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTaNt6C867rbVg90H21EOLACvtfcHk0lj5z0N8Nsu2tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2lu7fO&md5=ef2cc0d3242e6d639e56ba69bbd7a843</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1406477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1406477%26sid%3Dliteratum%253Aachs%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DCrawford%26aufirst%3DM.%26aulast%3DMoscovitz%26aufirst%3DJ.%2BE.%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26atitle%3DDiabetes%2520Area%2520Patent%2520Participation%2520Analysis%2520-%2520Part%2520II%253A%2520Years%25202011%25E2%2580%25932016%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26issue%3D2%26spage%3D111%26epage%3D122%26doi%3D10.1080%2F13543776.2018.1406477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddish-Berhane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant-Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boustany-Kari, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leininger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tugnait, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascitti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamic Model of Sodium-Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">576</span>– <span class="NLM_lpage">584</span>, <span class="refDoi"> DOI: 10.1208/s12248-011-9297-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1208%2Fs12248-011-9297-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=21870203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFamtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=576-584&issue=4&author=T.+S.+Maurerauthor=A.+Ghoshauthor=N.+Haddish-Berhaneauthor=A.+Sawant-Basakauthor=C.+M.+Boustany-Kariauthor=L.+Sheauthor=M.+T.+Leiningerauthor=T.+Zhuauthor=M.+Tugnaitauthor=X.+Yangauthor=E.+Kimotoauthor=V.+Mascittiauthor=R.+P.+Robinson&title=Pharmacodynamic+Model+of+Sodium-Glucose+Transporter+2+%28SGLT2%29+Inhibition%3A+Implications+for+Quantitative+Translational+Pharmacology&doi=10.1208%2Fs12248-011-9297-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamic Model of Sodium-Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology</span></div><div class="casAuthors">Maurer, Tristan S.; Ghosh, Avijit; Haddish-Berhane, Nahor; Sawant-Basak, Aarti; Boustany-Kari, Carine M.; She, Li; Leininger, Michael T.; Zhu, Tong; Tugnait, Meera; Yang, Xin; Kimoto, Emi; Mascitti, Vincent; Robinson, Ralph P.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">576-584</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Sodium-glucose co-transporter-2 (SGLT2) inhibitors are an emerging class of agents for use in the treatment of type 2 diabetes mellitus (T2DM).  Inhibition of SGLT2 leads to improved glycemic control through increased urinary glucose excretion (UGE).  In this study, a biol. based pharmacokinetic/pharmacodynamic (PK/PD) model of SGLT2 inhibitor-mediated UGE was developed.  The derived model was used to characterize the acute PK/PD relationship of the SGLT2 inhibitor, dapagliflozin, in rats.  The quant. translational pharmacol. of dapagliflozin was examd. through both prospective simulation and direct modeling of mean literature data obtained for dapagliflozin in healthy subjects.  Prospective simulations provided time courses of UGE that were of consistent shape to clin. observations, but were modestly biased toward under prediction.  Direct modeling provided an improved characterization of the data and precise parameter ests. which were reasonably consistent with those predicted from preclin. data.  Overall, these results indicate that the acute clin. pharmacol. of SGLT2 inhibitors in healthy subjects can be reasonably well predicted from preclin. data through rational accounting of species differences in pharmacokinetics, physiol., and SGLT2 pharmacol.  Because these data can be generated at the earliest stages of drug discovery, the proposed model is useful in the design and development of novel SGLT2 inhibitors.  In addn., this model is expected to serve as a useful foundation for future efforts to understand and predict the effects of SGLT2 inhibition under chronic administration and in other patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAM6fgz9MxjrVg90H21EOLACvtfcHk0lj5z0N8Nsu2tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFamtr7I&md5=ad9427ceb6c723ff27f5b8d5c85ff0fa</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1208%2Fs12248-011-9297-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-011-9297-2%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DHaddish-Berhane%26aufirst%3DN.%26aulast%3DSawant-Basak%26aufirst%3DA.%26aulast%3DBoustany-Kari%26aufirst%3DC.%2BM.%26aulast%3DShe%26aufirst%3DL.%26aulast%3DLeininger%26aufirst%3DM.%2BT.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DTugnait%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DKimoto%26aufirst%3DE.%26aulast%3DMascitti%26aufirst%3DV.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26atitle%3DPharmacodynamic%2520Model%2520of%2520Sodium-Glucose%2520Transporter%25202%2520%2528SGLT2%2529%2520Inhibition%253A%2520Implications%2520for%2520Quantitative%2520Translational%2520Pharmacology%26jtitle%3DAAPS%2520J.%26date%3D2011%26volume%3D13%26issue%3D4%26spage%3D576%26epage%3D584%26doi%3D10.1208%2Fs12248-011-9297-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascitti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boustany-Kari, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klenotic, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leininger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukaiyama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preville, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobol, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steppan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuma, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tugnait, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2952</span>– <span class="NLM_lpage">2960</span>, <span class="refDoi"> DOI: 10.1021/jm200049r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200049r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVCntrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2952-2960&issue=8&author=V.+Mascittiauthor=T.+S.+Maurerauthor=R.+P.+Robinsonauthor=J.+Bianauthor=C.+M.+Boustany-Kariauthor=T.+Brandtauthor=B.+M.+Collmanauthor=A.+S.+Kalgutkarauthor=M.+K.+Klenoticauthor=M.+T.+Leiningerauthor=A.+Loweauthor=R.+J.+Maguireauthor=V.+M.+Mastersonauthor=Z.+Miaoauthor=E.+Mukaiyamaauthor=J.+D.+Patelauthor=J.+C.+Pettersenauthor=C.+Previlleauthor=B.+Samasauthor=L.+Sheauthor=Z.+Sobolauthor=C.+M.+Steppanauthor=B.+D.+Stevensauthor=B.+A.+Thumaauthor=M.+Tugnaitauthor=D.+Zengauthor=T.+Zhu&title=Discovery+of+a+Clinical+Candidate+from+the+Structurally+Unique+Dioxa-bicyclo%5B3.2.1%5Doctane+Class+of+Sodium-Dependent+Glucose+Cotransporter+2+Inhibitors&doi=10.1021%2Fjm200049r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors</span></div><div class="casAuthors">Mascitti, Vincent; Maurer, Tristan S.; Robinson, Ralph P.; Bian, Jianwei; Boustany-Kari, Carine M.; Brandt, Thomas; Collman, Benjamin M.; Kalgutkar, Amit S.; Klenotic, Michelle K.; Leininger, Michael T.; Lowe, Andre; Maguire, Robert J.; Masterson, Victoria M.; Miao, Zhuang; Mukaiyama, Emi; Patel, Jigna D.; Pettersen, John C.; Preville, Cathy; Samas, Brian; She, Li; Sobol, Zhanna; Steppan, Claire M.; Stevens, Benjamin D.; Thuma, Benjamin A.; Tugnait, Meera; Zeng, Dongxiang; Zhu, Tong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2952-2960</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PF-04971729 (I) belongs to a new class of potent and selective sodium-dependent glucose cotransporter 2 inhibitors incorporating a unique dioxa-bicyclo[3.2.1]octane (bridged ketal) ring system.  In this paper we present the design, synthesis, preclin. evaluation, and human dose predictions related to I.  This compd. demonstrated robust urinary glucose excretion in rats and an excellent preclin. safety profile.  It is currently in phase 2 clin. trials and is being evaluated for the treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoytwz0hHDVmrVg90H21EOLACvtfcHk0lhnvyFalyX_tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVCntrY%253D&md5=80e156d19d3a6a87a61dca59cc1a0e99</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm200049r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200049r%26sid%3Dliteratum%253Aachs%26aulast%3DMascitti%26aufirst%3DV.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DBian%26aufirst%3DJ.%26aulast%3DBoustany-Kari%26aufirst%3DC.%2BM.%26aulast%3DBrandt%26aufirst%3DT.%26aulast%3DCollman%26aufirst%3DB.%2BM.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DKlenotic%26aufirst%3DM.%2BK.%26aulast%3DLeininger%26aufirst%3DM.%2BT.%26aulast%3DLowe%26aufirst%3DA.%26aulast%3DMaguire%26aufirst%3DR.%2BJ.%26aulast%3DMasterson%26aufirst%3DV.%2BM.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DMukaiyama%26aufirst%3DE.%26aulast%3DPatel%26aufirst%3DJ.%2BD.%26aulast%3DPettersen%26aufirst%3DJ.%2BC.%26aulast%3DPreville%26aufirst%3DC.%26aulast%3DSamas%26aufirst%3DB.%26aulast%3DShe%26aufirst%3DL.%26aulast%3DSobol%26aufirst%3DZ.%26aulast%3DSteppan%26aufirst%3DC.%2BM.%26aulast%3DStevens%26aufirst%3DB.%2BD.%26aulast%3DThuma%26aufirst%3DB.%2BA.%26aulast%3DTugnait%26aufirst%3DM.%26aulast%3DZeng%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520Clinical%2520Candidate%2520from%2520the%2520Structurally%2520Unique%2520Dioxa-bicyclo%255B3.2.1%255Doctane%2520Class%2520of%2520Sodium-Dependent%2520Glucose%2520Cotransporter%25202%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D8%26spage%3D2952%26epage%3D2960%26doi%3D10.1021%2Fjm200049r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Graaf, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandema, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anziano, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, R. L.</span></span> <span> </span><span class="NLM_article-title">Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development</span>. <i>Clin. Pharmacol. Ther. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">502</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1038/clpt.2013.54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1038%2Fclpt.2013.54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=23588322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1arsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=502-514&issue=6&author=P.+A.+Milliganauthor=M.+J.+Brownauthor=B.+Marchantauthor=S.+W.+Martinauthor=P.+H.+van+der%0AGraafauthor=N.+Bensonauthor=G.+Nucciauthor=D.+J.+Nicholsauthor=R.+A.+Boydauthor=J.+W.+Mandemaauthor=S.+Krishnaswamiauthor=S.+Zwillichauthor=D.+Grubenauthor=R.+J.+Anzianoauthor=T.+C.+Stockauthor=R.+L.+Lalonde&title=Model-Based+Drug+Development%3A+A+Rational+Approach+to+Efficiently+Accelerate+Drug+Development&doi=10.1038%2Fclpt.2013.54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development</span></div><div class="casAuthors">Milligan, P. A.; Brown, M. J.; Marchant, B.; Martin, S. W.; van der Graaf, P. H.; Benson, N.; Nucci, G.; Nichols, D. J.; Boyd, R. A.; Mandema, J. W.; Krishnaswami, S.; Zwillich, S.; Gruben, D.; Anziano, R. J.; Stock, T. C.; Lalonde, R. L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">502-514</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The pharmaceutical industry continues to face significant challenges.  Very few compds. that enter development reach the marketplace, and the investment required for each success can surpass 1.8 billion.  Despite attempts to improve efficiency and increase productivity, total investment continues to rise whereas the output of new medicines declines.  With costs increasing exponentially through each development phase, it is failure in phase II and phase III that is most wasteful.  In today's development paradigm, late-stage failure is principally a result of insufficient efficacy.  This is manifested as either a failure to differentiate sufficiently from placebo (shown for both novel and precedented mechanisms) or a failure to demonstrate sufficient differentiation from existing compds.  Set in this context, this article will discuss the role model-based drug development (MBDD) approaches can and do play in accelerating and optimizing compd. development strategies through a series of illustrative examples.  Clin. Pharmacol. & Therapeutics (2013); 93 6, 502-514. doi:10.1038/clpt.2013.54.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcq-yl0EkXMLVg90H21EOLACvtfcHk0lhnvyFalyX_tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1arsbs%253D&md5=89db09d5e3ea787abd2a7a610b496ea8</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2013.54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2013.54%26sid%3Dliteratum%253Aachs%26aulast%3DMilligan%26aufirst%3DP.%2BA.%26aulast%3DBrown%26aufirst%3DM.%2BJ.%26aulast%3DMarchant%26aufirst%3DB.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3Dvan%2Bder%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3DBenson%26aufirst%3DN.%26aulast%3DNucci%26aufirst%3DG.%26aulast%3DNichols%26aufirst%3DD.%2BJ.%26aulast%3DBoyd%26aufirst%3DR.%2BA.%26aulast%3DMandema%26aufirst%3DJ.%2BW.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DZwillich%26aufirst%3DS.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DAnziano%26aufirst%3DR.%2BJ.%26aulast%3DStock%26aufirst%3DT.%2BC.%26aulast%3DLalonde%26aufirst%3DR.%2BL.%26atitle%3DModel-Based%2520Drug%2520Development%253A%2520A%2520Rational%2520Approach%2520to%2520Efficiently%2520Accelerate%2520Drug%2520Development%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2013%26volume%3D93%26issue%3D6%26spage%3D502%26epage%3D514%26doi%3D10.1038%2Fclpt.2013.54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawadzke, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salafia, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strick, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gernhardt, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant-Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dounay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuttle, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span> <span> </span><span class="NLM_article-title">Quantitative Translational Analysis of Brain Kynurenic Acid Modulation via Irreversible Kynurenine Aminotransferase II Inhibition</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">833</span>, <span class="refDoi"> DOI: 10.1124/mol.118.111625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1124%2Fmol.118.111625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=29853495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2018&pages=823-833&issue=2&author=C.+Changauthor=K.+R.+Fonsecaauthor=C.+Liauthor=W.+Hornerauthor=L.+E.+Zawadzkeauthor=M.+A.+Salafiaauthor=K.+A.+Welchauthor=C.+A.+Strickauthor=B.+M.+Campbellauthor=S.+S.+Gernhardtauthor=H.+Rongauthor=A.+Sawant-Basakauthor=J.+Lirasauthor=A.+Dounayauthor=J.+B.+Tuttleauthor=P.+Verhoestauthor=T.+S.+Maurer&title=Quantitative+Translational+Analysis+of+Brain+Kynurenic+Acid+Modulation+via+Irreversible+Kynurenine+Aminotransferase+II+Inhibition&doi=10.1124%2Fmol.118.111625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative translational analysis of brain kynurenic acid modulation via irreversible kynurenine aminotransferase II inhibition</span></div><div class="casAuthors">Chang, Cheng; Fonseca, Kari R.; Li, Cheryl; Horner, Weldon; Zawadzke, Laura E.; Salafia, Michelle A.; Welch, Kathryn A.; Strick, Christine A.; Campbell, Brian M.; Gernhardt, Steve S.; Rong, Haojing; Sawant-Basak, Aarti; Liras, Jennifer; Dounay, Amy; Tuttle, Jamison B.; Verhoest, Patrick; Maurer, Tristan S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">823-833</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Kynurenic acid (KYNA) plays a significant role in maintaining normal brain function, and abnormalities in KYNA levels have been assocd. with various central nervous system disorders.  Confirmation of its causality in human diseases requires safe and effective modulation of central KYNA levels in the clinic.  The kynurenine aminotransferases (KAT) II enzyme represents an attractive target for pharmacol. modulation of central KYNA levels; however, KAT II and KYNA turnover kinetics, which could contribute to the duration of pharmacol. effect, have not been reported.  In this study, the kinetics of central KYNA-lowering effect in rats and nonhuman primates (NHPs, Cynomolgus macaques) was investigated using multiple KAT II irreversible inhibitors as pharmacol. probes.  Mechanistic pharmacokinetic-pharmacodynamic anal. of in vivo responses to irreversible inhibition quant. revealed that 1) KAT II turnover is relatively slow [16-76 h' half-life (t1/2)], whereas KYNA is cleared more rapidly from the brain (<1 h t1/2) in both rats and NHPs, 2) KAT II turnover is slower in NHPs than in rats (76 h vs. 16 h t1/2, resp.), and 3) the percent contribution of KAT II to KYNA formation is const. (∼80%) across rats and NHPs.  Addnl., modeling results enabled establishment of in vitro-in vivo correlation for both enzyme turnover rates and drug potencies.  In summary, quant. translational anal. confirmed the feasibility of central KYNA modulation in humans.  Model-based anal., where system-specific properties and drug-specific properties are mechanistically sepd. from in vivo responses, enabled quant. understanding of the KAT II-KYNA pathway, as well as assisted development of promising candidates to test KYNA hypothesis in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgp257SYyEYbVg90H21EOLACvtfcHk0lg2el5ywsoG9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgsrrL&md5=edd11481237e8fc780cad2a0528b1623</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1124%2Fmol.118.111625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.118.111625%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DC.%26aulast%3DFonseca%26aufirst%3DK.%2BR.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DHorner%26aufirst%3DW.%26aulast%3DZawadzke%26aufirst%3DL.%2BE.%26aulast%3DSalafia%26aufirst%3DM.%2BA.%26aulast%3DWelch%26aufirst%3DK.%2BA.%26aulast%3DStrick%26aufirst%3DC.%2BA.%26aulast%3DCampbell%26aufirst%3DB.%2BM.%26aulast%3DGernhardt%26aufirst%3DS.%2BS.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DSawant-Basak%26aufirst%3DA.%26aulast%3DLiras%26aufirst%3DJ.%26aulast%3DDounay%26aufirst%3DA.%26aulast%3DTuttle%26aufirst%3DJ.%2BB.%26aulast%3DVerhoest%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26atitle%3DQuantitative%2520Translational%2520Analysis%2520of%2520Brain%2520Kynurenic%2520Acid%2520Modulation%2520via%2520Irreversible%2520Kynurenine%2520Aminotransferase%2520II%2520Inhibition%26jtitle%3DMol.%2520Pharmacol.%26date%3D2018%26volume%3D94%26issue%3D2%26spage%3D823%26epage%3D833%26doi%3D10.1124%2Fmol.118.111625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sikjaer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amstrup, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolighed, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjaer, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosekilde, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rejnmark, L.</span></span> <span> </span><span class="NLM_article-title">PTH(1–84) Replacement Therapy in Hypoparathyroidism: A Randomized Controlled Trial on Pharmacokinetic and Dynamic Effects after 6 Months of Treatment</span>. <i>J. Bone Miner. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2232</span>– <span class="NLM_lpage">2243</span>, <span class="refDoi"> DOI: 10.1002/jbmr.1964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2Fjbmr.1964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=23649554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyrurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2013&pages=2232-2243&issue=10&author=T.+Sikjaerauthor=A.+K.+Amstrupauthor=L.+Rolighedauthor=S.+G.+Kjaerauthor=L.+Mosekildeauthor=L.+Rejnmark&title=PTH%281%E2%80%9384%29+Replacement+Therapy+in+Hypoparathyroidism%3A+A+Randomized+Controlled+Trial+on+Pharmacokinetic+and+Dynamic+Effects+after+6+Months+of+Treatment&doi=10.1002%2Fjbmr.1964"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">PTH(1-84) replacement therapy in hypoparathyroidism: A randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment</span></div><div class="casAuthors">Sikjaer, Tanja; Amstrup, Anne Kristine; Rolighed, Lars; Kjaer, Soren Geill; Mosekilde, Leif; Rejnmark, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bone and Mineral Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2232-2243</span>CODEN:
                <span class="NLM_cas:coden">JBMREJ</span>;
        ISSN:<span class="NLM_cas:issn">0884-0431</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Untreated, hypoparathyroidism (hypoPT) is a state of hypocalcemia with inappropriately low plasma parathyroid hormone (PTH) levels and hyperphosphatemia.  PTH administration normalizes plasma calcium and phosphate levels and reduces the doses of calcium and active vitamin D analogs needed.  To develop an evidence-based clin. algorithm to monitor hypoPT patients treated with recombinant human PTH (rhPTH[1-84]) injected s.c. in the thigh, we performed a 24-h monitoring study of pharmacokinetic and pharmacodynamic effects in a group of 38 patients who had completed a 6-mo randomized study on effects of treatment with a fixed rhPTH(1-84) dose of 100 μg/d or similar placebo as an add-on to conventional treatment.  PTH levels rose immediately, reaching a median peak level of 26.5 (interquartile range [IQR], 20.1-42.5) pmol/L 15 min following injection.  Thereafter, levels gradually decreased until reaching predosing levels after 16 h, with a plasma half-life of 2.2 (1.7-2.5) hours.  RhPTH(1-84) changed the diurnal rhythms of ionized calcium levels and 1,25-dihydroxyvitamin D (1,25[OH]2D) levels, with rising levels following injection.  Ionized calcium peaked after 7.0 (5.0-10.0) hours.  Asymptomatic hypercalcemia was present in 71% of the rhPTH(1-84)-treated patients.  Compared with placebo, 24-h urinary calcium, phosphate, and magnesium did not change, although the diurnal variation in renal excretion rates changed significantly in response to treatment.  In conclusion, as a safety precaution, we recommend occasionally measuring calcium levels at approx. 7 h after administration in order to reveal episodes of hypercalcemia.  A 100-μg daily dose of rhPTH(1-84) appears to be too high in some patients, suggesting a need for a device allowing for individual dose adjustments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYJqwQqu4qvbVg90H21EOLACvtfcHk0lg2el5ywsoG9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyrurbP&md5=7a67e22d33dfadb0527a034cdbdff2a2</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fjbmr.1964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjbmr.1964%26sid%3Dliteratum%253Aachs%26aulast%3DSikjaer%26aufirst%3DT.%26aulast%3DAmstrup%26aufirst%3DA.%2BK.%26aulast%3DRolighed%26aufirst%3DL.%26aulast%3DKjaer%26aufirst%3DS.%2BG.%26aulast%3DMosekilde%26aufirst%3DL.%26aulast%3DRejnmark%26aufirst%3DL.%26atitle%3DPTH%25281%25E2%2580%259384%2529%2520Replacement%2520Therapy%2520in%2520Hypoparathyroidism%253A%2520A%2520Randomized%2520Controlled%2520Trial%2520on%2520Pharmacokinetic%2520and%2520Dynamic%2520Effects%2520after%25206%2520Months%2520of%2520Treatment%26jtitle%3DJ.%2520Bone%2520Miner.%2520Res.%26date%3D2013%26volume%3D28%26issue%3D10%26spage%3D2232%26epage%3D2243%26doi%3D10.1002%2Fjbmr.1964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henneman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosman, F.</span></span> <span> </span><span class="NLM_article-title">Subcutaneous Administration of the Amino-Terminal Fragment of Human Parathyroid Hormone-(1–34): Kinetics and Biochemical Response in Estrogenized Osteoporotic Patients</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1535</span>– <span class="NLM_lpage">1539</span>, <span class="refDoi"> DOI: 10.1210/jcem.77.6.8263137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1210%2Fjcem.77.6.8263137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=8263137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A280%3ADyaK2c%252Fos1Onsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1993&pages=1535-1539&issue=6&author=R.+Lindsayauthor=J.+Nievesauthor=E.+Hennemanauthor=V.+Shenauthor=F.+Cosman&title=Subcutaneous+Administration+of+the+Amino-Terminal+Fragment+of+Human+Parathyroid+Hormone-%281%E2%80%9334%29%3A+Kinetics+and+Biochemical+Response+in+Estrogenized+Osteoporotic+Patients&doi=10.1210%2Fjcem.77.6.8263137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients</span></div><div class="casAuthors">Lindsay R; Nieves J; Henneman E; Shen V; Cosman F</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical endocrinology and metabolism</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1535-9</span>
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    </div><div class="casAbstract">A standard dose (400 U or 25 micrograms) of human (h) PTH-(1-34) was administered sc in 11 estrogen-treated patients with postmenopausal osteoporosis.  Increments in circulating hPTH-(1-34) were brisk, peaking at 30 min, with variable peak levels averaging 10 times normal.  Clearance of the peptide from the circulation followed an expontential pattern, with a mean t1/2 of 75 min.  Peptide administration was followed by an immediate decline in serum concentrations of PTH-(1-84), which remained suppressed at about 65% of the basal value for the duration of the study (4 h).  Serum calcium did not increase until 120 min, thus occurring after the diminution in PTH-(1-84).  Serum phosphorus declined promptly as urinary phosphate excretion increased.  There were no clear changes in urinary calcium excretion, but urinary cAMP excretion increased within 120 min.  In 9 of 11 patients, the serum concentration of 1,25-dihydroxyvitamin D increased, with mean levels increasing progressively after 90 min to approximately 30% above baseline (P < 0.05).  In conclusion, sc administration of 25 micrograms hPTH-(1-34) produces significant short term changes in mineral homeostasis that appear to be mediated by the kidney, parathyroid gland, and skeleton, with the latter displaying the most delayed response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeD-Xfhv2p9MkU0YCbOU3EfW6udTcc2eb2-xrUIO63I7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c%252Fos1Onsw%253D%253D&md5=52513e76e683184ecb3a2ad762097b89</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1210%2Fjcem.77.6.8263137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem.77.6.8263137%26sid%3Dliteratum%253Aachs%26aulast%3DLindsay%26aufirst%3DR.%26aulast%3DNieves%26aufirst%3DJ.%26aulast%3DHenneman%26aufirst%3DE.%26aulast%3DShen%26aufirst%3DV.%26aulast%3DCosman%26aufirst%3DF.%26atitle%3DSubcutaneous%2520Administration%2520of%2520the%2520Amino-Terminal%2520Fragment%2520of%2520Human%2520Parathyroid%2520Hormone-%25281%25E2%2580%259334%2529%253A%2520Kinetics%2520and%2520Biochemical%2520Response%2520in%2520Estrogenized%2520Osteoporotic%2520Patients%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D1993%26volume%3D77%26issue%3D6%26spage%3D1535%26epage%3D1539%26doi%3D10.1210%2Fjcem.77.6.8263137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mager, D. E.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamic Model of Parathyroid Hormone Modulation by a Negative Allosteric Modulator of the Calcium-Sensing Receptor</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1208/s12248-011-9266-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1208%2Fs12248-011-9266-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=21437757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsFans70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=265-273&issue=2&author=A.+K.+Abrahamauthor=T.+S.+Maurerauthor=A.+S.+Kalgutkarauthor=X.+Gaoauthor=M.+Liauthor=D.+R.+Healyauthor=D.+N.+Petersenauthor=D.+A.+Griffithauthor=D.+E.+Mager&title=Pharmacodynamic+Model+of+Parathyroid+Hormone+Modulation+by+a+Negative+Allosteric+Modulator+of+the+Calcium-Sensing+Receptor&doi=10.1208%2Fs12248-011-9266-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamic Model of Parathyroid Hormone Modulation by a Negative Allosteric Modulator of the Calcium-Sensing Receptor</span></div><div class="casAuthors">Abraham, Anson K.; Maurer, Tristan S.; Kalgutkar, Amit S.; Gao, Xiang; Li, Mei; Healy, David R.; Petersen, Donna N.; Griffith, David A.; Mager, Donald E.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-273</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In this study, a pharmacodynamic model is developed, based on calcium-parathyroid hormone (PTH) homeostasis, which describes the concn.-effect relationship of a neg. allosteric modulator of the calcium-sensing receptor (CaR) in rats.  Plasma concns. of drug and PTH were detd. from plasma samples obtained via serial jugular vein sampling following single s.c. doses of 1, 5, 45, and 150 mg/kg to male Sprague-Dawley rats (n = 5/dose).  Drug pharmacokinetics was described by a one-compartment model with first-order absorption and linear elimination.  Concn.-time profiles of PTH were characterized using a model in which the compd. allosterically modulates Ca+2 binding to the CaR that, in turn, modulates PTH through a precursor-pool indirect response model.  Addnl., neg. feedback was incorporated to account for tolerance obsd. at higher dose levels.  Model fitting and parameter estn. were conducted using the max. likelihood algorithm.  The proposed model well characterized the data and provided compd. specific ests. of the Ki and cooperativity const. (α) of 1.47 ng/mL and 0.406, resp.  In addn., the estd. model parameters for PTH turnover were comparable to that previously reported.  The final generalized model is capable of characterizing both PTH-Ca+2 homeostasis and the pharmacokinetics and pharmacodynamics assocd. with the neg. allosteric CaR modulator.  As such, the model provides a simple platform for anal. of drugs targeting the PTH-Ca+2 system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT8yNEn8I8t7Vg90H21EOLACvtfcHk0ljiFjAnFHE7Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsFans70%253D&md5=15abf5d8bcc508fc87717a02ef4afe01</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1208%2Fs12248-011-9266-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-011-9266-9%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DA.%2BK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHealy%26aufirst%3DD.%2BR.%26aulast%3DPetersen%26aufirst%3DD.%2BN.%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DMager%26aufirst%3DD.%2BE.%26atitle%3DPharmacodynamic%2520Model%2520of%2520Parathyroid%2520Hormone%2520Modulation%2520by%2520a%2520Negative%2520Allosteric%2520Modulator%2520of%2520the%2520Calcium-Sensing%2520Receptor%26jtitle%3DAAPS%2520J.%26date%3D2011%26volume%3D13%26issue%3D2%26spage%3D265%26epage%3D273%26doi%3D10.1208%2Fs12248-011-9266-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mager, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span> <span> </span><span class="NLM_article-title">Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Parathyroid Hormone-Calcium Homeostasis in Rats and Humans</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>330</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.152033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1124%2Fjpet.109.152033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=19386792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFeltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=169-178&issue=1&author=A.+K.+Abrahamauthor=D.+E.+Magerauthor=X.+Gaoauthor=M.+Liauthor=D.+R.+Healyauthor=T.+S.+Maurer&title=Mechanism-Based+Pharmacokinetic%2FPharmacodynamic+Model+of+Parathyroid+Hormone-Calcium+Homeostasis+in+Rats+and+Humans&doi=10.1124%2Fjpet.109.152033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based pharmacokinetic/pharmacodynamic model of parathyroid hormone-calcium homeostasis in rats and humans</span></div><div class="casAuthors">Abraham, Anson K.; Mager, Donald E.; Gao, Xiang; Li, Mei; Healy, David R.; Maurer, Tristan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The purpose of this study was to develop a mechanism-based pharmacokinetic/pharmacodynamic model that describes the regulation of the parathyroid hormone (PTH)-Ca2+ system in rats and humans.  Temporal concn. data for endogenous PTH and Ca2+ were extd. from literature for rats (normal adult males) and humans.  In addn., exogenous PTH was administered s.c. to male Sprague-Dawley rats with jugular vein catheters, and plasma concns. were measured over time.  A math. model was developed and fitted simultaneously to endogenous PTH, Ca2+, and exogenous PTH concns. in rats.  Ca2+ concns. were described using a turnover model, with its depletion being induced by a chelating agent, and PTH concns. were characterized using a precursor-dependent indirect response model.  The same structural model was used for fitting data obtained in humans.  PTH stimulation was driven by occupancy of the Ca2+ sensing receptor, and lowering of physiol. Ca2+ concns. increased PTH secretion, with PTH profiles being adequately described by the model.  PTH stimulatory capacity was baseline-dependent in rats [Smax_rats = 34.8 × PTHo] and humans [Smax_humans = 392/PTHo].  Modeling results suggest that normal rats are twice as sensitive to Ca2+-induced PTH stimulation compared with humans.  In conclusion, the developed model adequately characterizes the PTH-Ca2+ regulation across species and may be useful in the development of therapeutic drugs targeting this system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkOcKZQyMyBrVg90H21EOLACvtfcHk0ljiFjAnFHE7Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFeltb4%253D&md5=0948f58abc3ed432e49c6de7d54b6c2a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.152033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.152033%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DA.%2BK.%26aulast%3DMager%26aufirst%3DD.%2BE.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHealy%26aufirst%3DD.%2BR.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26atitle%3DMechanism-Based%2520Pharmacokinetic%252FPharmacodynamic%2520Model%2520of%2520Parathyroid%2520Hormone-Calcium%2520Homeostasis%2520in%2520Rats%2520and%2520Humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26issue%3D1%26spage%3D169%26epage%3D178%26doi%3D10.1124%2Fjpet.109.152033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berellini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1466</span>– <span class="NLM_lpage">1477</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.082966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1124%2Fdmd.118.082966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=30115648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVeiurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1466-1477&issue=11&author=F.+Lombardoauthor=G.+Berelliniauthor=R.+S.+Obach&title=Trend+Analysis+of+a+Database+of+Intravenous+Pharmacokinetic+Parameters+in+Humans+for+1352+Drug+Compounds&doi=10.1124%2Fdmd.118.082966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 1352 drug compounds</span></div><div class="casAuthors">Lombardo, Franco; Berellini, Giuliano; Scott Obach, R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1466-1477</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We report a trend anal. of human i.v. pharmacokinetic data on a data set of 1352 drugs.  The aim in building this data set and its detailed anal. was to provide, as in the previous case published in 2008, an extended, robust, and accurate resource that could be applied by drug metab., clin. pharmacol., and medicinal chem. scientists to a variety of scaling approaches.  All in vivo data were obtained or derived from original refs., either through the literature or regulatory agency reports, exclusively from studies utilizing i.v. administration.  Plasma protein binding data were collected from other available sources to supplement these pharmacokinetic data.  These parameters were analyzed concurrently with a range of physicochem. properties, and resultant trends and patterns within the data are presented.  In addn., the date of first disclosure of each mol. was reported and the potential "temporal" impact on data trends was analyzed.  The findings reported here are consistent with earlier described trends between pharmacokinetic behavior and physicochem. properties.  Furthermore, the availability of a large data set of pharmacokinetic data in humans will be important to further pursue analyses of physicochem. properties, trends, and modeling efforts and should propel our deeper understanding (esp. in terms of clearance) of the absorption, distribution, metab., and excretion behavior of drug compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8uXJIZzHD-LVg90H21EOLACvtfcHk0lgoz0Ag6mANeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVeiurzL&md5=21311cdf07ac151e5e29da4afbd87448</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.082966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.082966%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DBerellini%26aufirst%3DG.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DTrend%2520Analysis%2520of%2520a%2520Database%2520of%2520Intravenous%2520Pharmacokinetic%2520Parameters%2520in%2520Humans%2520for%25201352%2520Drug%2520Compounds%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26issue%3D11%26spage%3D1466%26epage%3D1477%26doi%3D10.1124%2Fdmd.118.082966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Didiuk, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benbow, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechle, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirico, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungerford, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Brinno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawistoski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagley, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, K. S.</span></span> <span> </span><span class="NLM_article-title">Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one Derivatives as Orally-Active Calcium-Sensing Receptor Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4555</span>– <span class="NLM_lpage">4559</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.bmcl.2009.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=19625189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptVCktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4555-4559&issue=16&author=M.+T.+Didiukauthor=D.+A.+Griffithauthor=J.+W.+Benbowauthor=K.+K.+C.+Liuauthor=D.+P.+Walkerauthor=F.+C.+Biauthor=J.+Morrisauthor=A.+Guzman-Perezauthor=H.+Gaoauthor=B.+M.+Bechleauthor=R.+M.+Kelleyauthor=X.+Yangauthor=K.+Diricoauthor=S.+Ahmedauthor=W.+Hungerfordauthor=J.+Di+Brinnoauthor=M.+P.+Zawistoskiauthor=S.+W.+Bagleyauthor=J.+Liauthor=Y.+Zengauthor=S.+Santucciauthor=R.+Oliverauthor=M.+Corbettauthor=T.+Olsonauthor=C.+Chenauthor=M.+Liauthor=V.+M.+Paralkarauthor=K.+A.+Riccardiauthor=D.+R.+Healyauthor=A.+S.+Kalgutkarauthor=T.+S.+Maurerauthor=H.+T.+Nguyenauthor=K.+S.+Frederick&title=Short-acting+5-%28trifluoromethyl%29pyrido%5B4%2C3-d%5Dpyrimidin-4%283H%29-one+Derivatives+as+Orally-Active+Calcium-Sensing+Receptor+Antagonists&doi=10.1016%2Fj.bmcl.2009.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists</span></div><div class="casAuthors">Didiuk, Mary T.; Griffith, David A.; Benbow, John W.; Liu, Kevin K. C.; Walker, Daniel P.; Bi, F. Christopher; Morris, Joel; Guzman-Perez, Angel; Gao, Hua; Bechle, Bruce M.; Kelley, Ryan M.; Yang, Xiaojing; Dirico, Kenneth; Ahmed, Syed; Hungerford, William; Di Brinno, Joseph; Zawistoski, Michael P.; Bagley, Scott W.; Li, Jianke; Zeng, Yuan; Santucci, Stephanie; Oliver, Robert; Corbett, Matthew; Olson, Thanh; Chen, Chiliu; Li, Mei; Paralkar, Vishwas M.; Riccardi, Keith A.; Healy, David R.; Kalgutkar, Amit S.; Maurer, Tristan S.; Nguyen, Hang T.; Frederick, Kosea S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4555-4559</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthesis and structure-activity relationship (SAR) studies on 5-trifluoromethylpyrido[4,3-d]pyrimidin-4(3H)-ones, a novel class of calcium receptor antagonists is described with particular emphasis on optimization of the pharmacokinetic/pharmacodynamic parameters required for a short duration of action compd.  Orally-active compds. were identified which displayed the desired animal pharmacol. (rapid and transient stimulation of parathyroid hormone) essential for bone anabolic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraYBYzEAb7mrVg90H21EOLACvtfcHk0lgoz0Ag6mANeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptVCktbs%253D&md5=b3d69f8b4c212feb2cbc93187ea5a85f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DDidiuk%26aufirst%3DM.%2BT.%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DBenbow%26aufirst%3DJ.%2BW.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBi%26aufirst%3DF.%2BC.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DBechle%26aufirst%3DB.%2BM.%26aulast%3DKelley%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DDirico%26aufirst%3DK.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DHungerford%26aufirst%3DW.%26aulast%3DDi%2BBrinno%26aufirst%3DJ.%26aulast%3DZawistoski%26aufirst%3DM.%2BP.%26aulast%3DBagley%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DSantucci%26aufirst%3DS.%26aulast%3DOliver%26aufirst%3DR.%26aulast%3DCorbett%26aufirst%3DM.%26aulast%3DOlson%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DParalkar%26aufirst%3DV.%2BM.%26aulast%3DRiccardi%26aufirst%3DK.%2BA.%26aulast%3DHealy%26aufirst%3DD.%2BR.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DNguyen%26aufirst%3DH.%2BT.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26atitle%3DShort-acting%25205-%2528trifluoromethyl%2529pyrido%255B4%252C3-d%255Dpyrimidin-4%25283H%2529-one%2520Derivatives%2520as%2520Orally-Active%2520Calcium-Sensing%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D16%26spage%3D4555%26epage%3D4559%26doi%3D10.1016%2Fj.bmcl.2009.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">John, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harfst, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeffler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belleli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruin, G. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seuwen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klickstein, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mindeholm, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kneissel, M.</span></span> <span> </span><span class="NLM_article-title">AXT914 a Novel, Orally-Active Parathyroid Hormone-Releasing Drug in Two Early Studies of Healthy Volunteers and Postmenopausal Women</span>. <i>Bone (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1016/j.bone.2014.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.bone.2014.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=24769332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVaksL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2014&pages=204-210&author=M.+R.+Johnauthor=E.+Harfstauthor=J.+Loefflerauthor=R.+Belleliauthor=J.+Masonauthor=G.+J.+M.+Bruinauthor=K.+Seuwenauthor=L.+B.+Klicksteinauthor=L.+Mindeholmauthor=L.+Widlerauthor=M.+Kneissel&title=AXT914+a+Novel%2C+Orally-Active+Parathyroid+Hormone-Releasing+Drug+in+Two+Early+Studies+of+Healthy+Volunteers+and+Postmenopausal+Women&doi=10.1016%2Fj.bone.2014.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women</span></div><div class="casAuthors">John, Markus R.; Harfst, Evita; Loeffler, Juergen; Belleli, Rossella; Mason, June; Bruin, Gerard J. M.; Seuwen, Klaus; Klickstein, Lloyd B.; Mindeholm, Linda; Widler, Leo; Kneissel, Michaela</div><div class="citationInfo"><span class="NLM_cas:title">Bone (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">204-210</span>CODEN:
                <span class="NLM_cas:coden">BONEDL</span>;
        ISSN:<span class="NLM_cas:issn">1873-2763</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Antagonism of the calcium-sensing receptor in the parathyroid gland leads to parathyroid hormone (PTH) release.  Calcilytics are a new class of mols. designed to exploit this mechanism.  In order to mimic the known bone-anabolic pharmacokinetic (PK) profile of s.c. administered PTH, such mols. must trigger sharp, transient and robust release of PTH.  The results of two early clin. studies with the orally-active calcilytic AXT914, a quinazolin-2ne deriv. are reported.  These were GCP-compliant, single and multiple dose studies of PK/PD and tolerability in healthy volunteers and postmenopausal women.  The first study, examd. single ascending doses (4 to 120 mg) and limited multiple doses (60 or 120 mg q.d. for 12 days) of AXT914.  The second study was a randomized, double-blind, active- and placebo-controlled, 4-wk repeat-dose parallel group study of healthy postmenopausal women (45 and 60 mg AXT914, placebo, 20 μg Forteo/teriparatide/PTH(1-34) fragment).  AXT914 was well tolerated at all doses and reproducibly induced the desired PTH-release profiles.  Yet, 4 wk of 45 or 60 mg AXT914 did not result in the expected changes in circulating bone biomarkers seen with teriparatide.  However total serum calcium levels increased above baseline in the 45 and 60 mg AXT914 treatment groups (8.0 % and 10.7%, resp.), compared to that in the teriparatide and placebo groups (1.3% and 1.0%, resp.).  Thus the trial was terminated after a planned interim anal. due to lack of effect on bone formation biomarkers and dose-limiting effects on serum calcium.  In conclusion, AXT914 was well tolerated but the obsd. transient and reproducible PTH-release after repeat oral administration of AXT914 which showed an exposure profile close to that of s c.  PTH, did not translate into a bone anabolic response and was assocd. with a persistent dose-related increase in serum calcium concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohmNkNHtJty7Vg90H21EOLACvtfcHk0lhNp42THXj4bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVaksL3I&md5=f1c441b85df5390f98c7dad4de3f09e4</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bone.2014.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bone.2014.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DJohn%26aufirst%3DM.%2BR.%26aulast%3DHarfst%26aufirst%3DE.%26aulast%3DLoeffler%26aufirst%3DJ.%26aulast%3DBelleli%26aufirst%3DR.%26aulast%3DMason%26aufirst%3DJ.%26aulast%3DBruin%26aufirst%3DG.%2BJ.%2BM.%26aulast%3DSeuwen%26aufirst%3DK.%26aulast%3DKlickstein%26aufirst%3DL.%2BB.%26aulast%3DMindeholm%26aufirst%3DL.%26aulast%3DWidler%26aufirst%3DL.%26aulast%3DKneissel%26aufirst%3DM.%26atitle%3DAXT914%2520a%2520Novel%252C%2520Orally-Active%2520Parathyroid%2520Hormone-Releasing%2520Drug%2520in%2520Two%2520Early%2520Studies%2520of%2520Healthy%2520Volunteers%2520and%2520Postmenopausal%2520Women%26jtitle%3DBone%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2014%26volume%3D64%26spage%3D204%26epage%3D210%26doi%3D10.1016%2Fj.bone.2014.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cosman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilchrist, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foldes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Villiers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyden, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinnis, I. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denker, A. E.</span></span> <span> </span><span class="NLM_article-title">A Phase 2 Study of MK-5442, a Calcium-Sensing Receptor Antagonist, in Postmenopausal Women with Osteoporosis after Long-Term Use of Oral Bisphosphonates</span>. <i>Osteoporosis Int.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1007/s00198-015-3392-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1007%2Fs00198-015-3392-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=26556736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVKqtrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=377-386&issue=1&author=F.+Cosmanauthor=N.+Gilchristauthor=M.+McClungauthor=J.+Foldesauthor=T.+de+Villiersauthor=A.+Santoraauthor=A.+Leungauthor=S.+Samantaauthor=N.+Heydenauthor=I.+J.+P.+McGinnisauthor=E.+Rosenbergauthor=A.+E.+Denker&title=A+Phase+2+Study+of+MK-5442%2C+a+Calcium-Sensing+Receptor+Antagonist%2C+in+Postmenopausal+Women+with+Osteoporosis+after+Long-Term+Use+of+Oral+Bisphosphonates&doi=10.1007%2Fs00198-015-3392-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates</span></div><div class="casAuthors">Cosman, F.; Gilchrist, N.; McClung, M.; Foldes, J.; de Villiers, T.; Santora, A.; Leung, A.; Samanta, S.; Heyden, N.; McGinnis, II, J. P.; Rosenberg, E.; Denker, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Osteoporosis International</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">377-386</span>CODEN:
                <span class="NLM_cas:coden">OSINEP</span>;
        ISSN:<span class="NLM_cas:issn">0937-941X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag London Ltd.</span>)
        </div><div class="casAbstract">Summary: In women with osteoporosis treated with alendronate for >12 mo and oral bisphosphonates for >3 of the last 4 years, switching to MK-5442, a calcium receptor antagonist, stimulated endogenous parathyroid hormone (PTH) secretion and increased bone turnover marker levels, but produced a decline in bone mineral d. (BMD) at all sites.  Introduction: This study assessed the effects of switching from long-term oral bisphosphonate therapy to the calcium-sensing receptor antagonist MK-5442 on BMD and bone turnover markers (BTMs) in post-menopausal women with osteoporosis.  Methods: This randomized, active and placebo-controlled, dose-ranging study enrolled 526 postmenopausal women, who had taken alendronate (ALN) for ≥12 mo preceding the trial and any oral bisphosphonate for ≥3 of the preceding 4 years and had spine or hip BMD T-scores ≤-2.5 or ≤-1.5 with ≥1 prior fragility fracture.  Women were randomized to continue ALN 70 mg weekly or switch to MK-5442 (5, 7.5, 10, or 15 mg daily) or placebo.  Results: Switching from ALN to MK-5442 produced a dose-dependent parathyroid hormone (PTH) pulse of threefold to sixfold above baseline at 1 h, with PTH levels that remained twofold to threefold above baseline at 4 h and returned to baseline by 24 h.  Switching to MK-5442 or placebo increased BTM levels compared to baseline within 3 mo and MK-5442 10 mg increased BTM levels compared to placebo by 6 mo.  With all MK-5442 doses and placebo, spine and hip BMD declined from baseline, and at 12 mo, BMD levels were below those who continued ALN (all groups P < 0.05 vs ALN).  There was also a dose-dependent increase in the incidence of hypercalcemia with MK-5442.  Conclusion: Switching from ALN to MK-5442 resulted in a pulsatile increase in PTH and increases in BTMs, but a decline in BMD compared with continued ALN.  MK-5442 is not a viable option for the treatment of osteoporosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0gFq8pwhPdrVg90H21EOLACvtfcHk0lhNp42THXj4bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVKqtrrK&md5=06afd60cf458794104da186d04d4200a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs00198-015-3392-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00198-015-3392-7%26sid%3Dliteratum%253Aachs%26aulast%3DCosman%26aufirst%3DF.%26aulast%3DGilchrist%26aufirst%3DN.%26aulast%3DMcClung%26aufirst%3DM.%26aulast%3DFoldes%26aufirst%3DJ.%26aulast%3Dde%2BVilliers%26aufirst%3DT.%26aulast%3DSantora%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DA.%26aulast%3DSamanta%26aufirst%3DS.%26aulast%3DHeyden%26aufirst%3DN.%26aulast%3DMcGinnis%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DRosenberg%26aufirst%3DE.%26aulast%3DDenker%26aufirst%3DA.%2BE.%26atitle%3DA%2520Phase%25202%2520Study%2520of%2520MK-5442%252C%2520a%2520Calcium-Sensing%2520Receptor%2520Antagonist%252C%2520in%2520Postmenopausal%2520Women%2520with%2520Osteoporosis%2520after%2520Long-Term%2520Use%2520of%2520Oral%2520Bisphosphonates%26jtitle%3DOsteoporosis%2520Int.%26date%3D2016%26volume%3D27%26issue%3D1%26spage%3D377%26epage%3D386%26doi%3D10.1007%2Fs00198-015-3392-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nemeth, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, W. G.</span></span> <span> </span><span class="NLM_article-title">Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures</span>. <i>Calcif. Tissue Int.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>98</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1007/s00223-015-0052-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1007%2Fs00223-015-0052-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=26319799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVajs7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2016&pages=341-358&issue=4&author=E.+F.+Nemethauthor=W.+G.+Goodman&title=Calcimimetic+and+Calcilytic+Drugs%3A+Feats%2C+Flops%2C+and+Futures&doi=10.1007%2Fs00223-015-0052-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures</span></div><div class="casAuthors">Nemeth, E. F.; Goodman, W. G.</div><div class="citationInfo"><span class="NLM_cas:title">Calcified Tissue International</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">341-358</span>CODEN:
                <span class="NLM_cas:coden">CTINDZ</span>;
        ISSN:<span class="NLM_cas:issn">0171-967X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The actions of extracellular Ca2+ in regulating parathyroid gland and kidney functions are mediated by the extracellular calcium receptor (CaR), a G protein-coupled receptor.  The CaR is one of the essential mols. maintaining systemic Ca2+ homeostasis and is a mol. target for drugs useful in treating bone and mineral disorders.  Ligands that activate the CaR are termed calcimimetics and are classified as either agonists (type I) or pos. allosteric modulators (type II); calcimimetics inhibit the secretion of parathyroid hormone (PTH).  Cinacalcet is a type II calcimimetic that is used to treat secondary hyperparathyroidism in patients receiving dialysis and to treat hypercalcemia in some forms of primary hyperparathyroidism.  The use of cinacalcet among patients with secondary hyperparathyroidism who are managed with dialysis effectively lowers circulating PTH levels, reduces serum phosphorus and FGF23 concns., improves bone histopathol., and may diminish skeletal fracture rates and the need for parathyroidectomy.  A second generation type II calcimimetic (AMG 416) is currently under regulatory review.  Calcilytics are CaR antagonists that stimulate the secretion of PTH.  Several calcilytic compds. have been evaluated as orally active anabolic therapies for postmenopausal osteoporosis but clin. development of all of them has been abandoned because they lacked clin. efficacy.  Calcilytics might be repurposed for new indications like autosomal dominant hypocalcemia or other disorders beyond those involving systemic Ca2+ homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlbRJGITOUL7Vg90H21EOLACvtfcHk0lhNp42THXj4bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVajs7bI&md5=2aa48effc3f94f1c61e9e25877ee0cb1</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs00223-015-0052-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00223-015-0052-z%26sid%3Dliteratum%253Aachs%26aulast%3DNemeth%26aufirst%3DE.%2BF.%26aulast%3DGoodman%26aufirst%3DW.%2BG.%26atitle%3DCalcimimetic%2520and%2520Calcilytic%2520Drugs%253A%2520Feats%252C%2520Flops%252C%2520and%2520Futures%26jtitle%3DCalcif.%2520Tissue%2520Int.%26date%3D2016%26volume%3D98%26issue%3D4%26spage%3D341%26epage%3D358%26doi%3D10.1007%2Fs00223-015-0052-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&issue=1%E2%80%933&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0lj3dEwxhOklAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26issue%3D1%25E2%2580%25933%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">A “Rule of Three” for Fragment-Based Lead Discovery?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(03)02831-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2FS1359-6446%2803%2902831-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=14554012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A280%3ADC%252BD3svns1Cnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=876-877&issue=19&author=M.+Congreveauthor=R.+Carrauthor=C.+Murrayauthor=H.+Jhoti&title=A+%E2%80%9CRule+of+Three%E2%80%9D+for+Fragment-Based+Lead+Discovery%3F&doi=10.1016%2FS1359-6446%2803%2902831-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A 'rule of three' for fragment-based lead discovery?</span></div><div class="casAuthors">Congreve Miles; Carr Robin; Murray Chris; Jhoti Harren</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">876-7</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfFswFSn5vb43yKPtYViAGfW6udTcc2ebwE-tt0W7ddLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svns1Cnsw%253D%253D&md5=137886dbb2062f7a3ad39277dd888df3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2803%2902831-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252803%252902831-9%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCarr%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DA%2520%25E2%2580%259CRule%2520of%2520Three%25E2%2580%259D%2520for%2520Fragment-Based%2520Lead%2520Discovery%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2003%26volume%3D8%26issue%3D19%26spage%3D876%26epage%3D877%26doi%3D10.1016%2FS1359-6446%2803%2902831-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T.</span></span> <span> </span><span class="NLM_article-title">Rapid Assessment of a Novel Series of Selective CB(2) Agonists Using Parallel Synthesis Protocols: A Lipophilic Efficiency (LipE) Analysis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4406</span>– <span class="NLM_lpage">4409</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.05.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&issue=15&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneauthor=A.+M.+Correiaauthor=D.+R.+Owenauthor=L.+R.+Thompsonauthor=I.+Tranauthor=M.+F.+Tuttauthor=T.+Young&title=Rapid+Assessment+of+a+Novel+Series+of+Selective+CB%282%29+Agonists+Using+Parallel+Synthesis+Protocols%3A+A+Lipophilic+Efficiency+%28LipE%29+Analysis&doi=10.1016%2Fj.bmcl.2009.05.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0lj3dEwxhOklAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DCorreia%26aufirst%3DA.%2BM.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26aulast%3DTran%26aufirst%3DI.%26aulast%3DTutt%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DRapid%2520Assessment%2520of%2520a%2520Novel%2520Series%2520of%2520Selective%2520CB%25282%2529%2520Agonists%2520Using%2520Parallel%2520Synthesis%2520Protocols%253A%2520A%2520Lipophilic%2520Efficiency%2520%2528LipE%2529%2520Analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D15%26spage%3D4406%26epage%3D4409%26doi%3D10.1016%2Fj.bmcl.2009.05.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keefer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span> <span> </span><span class="NLM_article-title">Evaluating the Differences in Cycloalkyl Ether Metabolism Using the Design Parameter “Lipophilic Metabolism Efficiency” (LipMetE) and a Matched Molecular Pairs Analysis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">6985</span>– <span class="NLM_lpage">6990</span>, <span class="refDoi"> DOI: 10.1021/jm4008642</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4008642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6985-6990&issue=17&author=A.+F.+Stepanauthor=G.+W.+Kauffmanauthor=C.+E.+Keeferauthor=P.+R.+Verhoestauthor=M.+Edwards&title=Evaluating+the+Differences+in+Cycloalkyl+Ether+Metabolism+Using+the+Design+Parameter+%E2%80%9CLipophilic+Metabolism+Efficiency%E2%80%9D+%28LipMetE%29+and+a+Matched+Molecular+Pairs+Analysis&doi=10.1021%2Fjm4008642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluating the Differences in Cycloalkyl Ether Metabolism Using the Design Parameter "Lipophilic Metabolism Efficiency" (LipMetE) and a Matched Molecular Pairs Analysis</span></div><div class="casAuthors">Stepan, Antonia F.; Kauffman, Gregory W.; Keefer, Christopher E.; Verhoest, Patrick R.; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6985-6990</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have obsd. previously that modification of ring size and substitution pattern may be used as a strategy to mitigate the metabolic instability of cycloalkyl ethers.  In this article, we introduce a medicinal chem. design parameter named "lipophilic metab. efficiency" (LipMetE) that indicates that these changes in metabolic stability can be largely ascribed to changes in lipophilicity.  Our matched mol. pair anal. also indicates that this finding is a general phenomenon, widely obsd. across different chemotypes.  It is our hope that both the LipMetE design parameter and the results from our pairwise anal. will be useful tools for medicinal chemists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpiFJ_fPxurbVg90H21EOLACvtfcHk0lh1TYHgbvN68A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurvJ&md5=596673d35831b979b8daf5a4ccb8a218</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm4008642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4008642%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DKeefer%26aufirst%3DC.%2BE.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DEvaluating%2520the%2520Differences%2520in%2520Cycloalkyl%2520Ether%2520Metabolism%2520Using%2520the%2520Design%2520Parameter%2520%25E2%2580%259CLipophilic%2520Metabolism%2520Efficiency%25E2%2580%259D%2520%2528LipMetE%2529%2520and%2520a%2520Matched%2520Molecular%2520Pairs%2520Analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D17%26spage%3D6985%26epage%3D6990%26doi%3D10.1021%2Fjm4008642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuck, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damian-Iordache, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimbach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnatry, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liederer, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettetal, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudra, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijsen, M. J. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raybon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuck, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suryawanshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakilynejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span> <span> </span><span class="NLM_article-title">Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1208/s12248-014-9716-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1208%2Fs12248-014-9716-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=25630504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslehsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=462-473&issue=2&author=E.+Schuckauthor=T.+Bohnertauthor=A.+Chakravartyauthor=V.+Damian-Iordacheauthor=C.+Gibsonauthor=C.-P.+Hsuauthor=T.+Heimbachauthor=A.+S.+Krishnatryauthor=B.+M.+Liedererauthor=J.+Linauthor=T.+Maurerauthor=J.+T.+Mettetalauthor=D.+R.+Mudraauthor=M.+J.+M.+A.+Nijsenauthor=J.+Raybonauthor=P.+Schroederauthor=V.+Schuckauthor=S.+Suryawanshiauthor=Y.+Suauthor=P.+Trapaauthor=A.+Tsaiauthor=M.+Vakilynejadauthor=S.+Wangauthor=H.+Wong&title=Preclinical+Pharmacokinetic%2FPharmacodynamic+Modeling+and+Simulation+in+the+Pharmaceutical+Industry%3A+An+IQ+Consortium+Survey+Examining+the+Current+Landscape&doi=10.1208%2Fs12248-014-9716-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape</span></div><div class="casAuthors">Schuck, Edgar; Bohnert, Tonika; Chakravarty, Arijit; Damian-Iordache, Valeriu; Gibson, Christopher; Hsu, Cheng-Pang; Heimbach, Tycho; Krishnatry, Anu Shilpa; Liederer, Bianca M.; Lin, Jing; Maurer, Tristan; Mettetal, Jerome T.; Mudra, Daniel R.; Nijsen, Marjoleen J. M. A.; Raybon, Joseph; Schroeder, Patricia; Schuck, Virna; Suryawanshi, Satyendra; Su, Yaming; Trapa, Patrick; Tsai, Alice; Vakilynejad, Majid; Wang, Shining; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">462-473</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The application of modeling and simulation techniques is increasingly common in preclin. stages of the drug discovery and development process.  A survey focusing on preclin. pharmacokinetic/pharmacodynamics (PK/PD) anal. was conducted across pharmaceutical companies that are members of the International Consortium for Quality and Innovation in Pharmaceutical Development.  Based on survey responses, ∼68% of companies use preclin. PK/PD anal. in all therapeutic areas indicating its broad application.  An important goal of preclin. PK/PD anal. in all pharmaceutical companies is for the selection/optimization of doses and/or dose regimens, including prediction of human efficacious doses.  Oncol. was the therapeutic area with the most PK/PD anal. support and where it showed the most impact.  Consistent use of more complex systems pharmacol. models and hybrid physiol. based pharmacokinetic models with PK/PD components was less common compared to traditional PK/PD models.  Preclin. PK/PD anal. is increasingly being included in regulatory submissions with ∼73% of companies including these data to some degree.  Most companies (∼86%) have seen impact of preclin. PK/PD analyses in drug development.  Finally, ∼59% of pharmaceutical companies have plans to expand their PK/PD modeling groups over the next 2 years indicating continued growth.  The growth of preclin. PK/PD modeling groups in pharmaceutical industry is necessary to establish required resources and skills to further expand use of preclin. PK/PD modeling in a meaningful and impactful manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcipAzVX5DQ7Vg90H21EOLACvtfcHk0lh1TYHgbvN68A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslehsrw%253D&md5=a8156f55850d64d1a560512c21cf895f</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1208%2Fs12248-014-9716-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-014-9716-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchuck%26aufirst%3DE.%26aulast%3DBohnert%26aufirst%3DT.%26aulast%3DChakravarty%26aufirst%3DA.%26aulast%3DDamian-Iordache%26aufirst%3DV.%26aulast%3DGibson%26aufirst%3DC.%26aulast%3DHsu%26aufirst%3DC.-P.%26aulast%3DHeimbach%26aufirst%3DT.%26aulast%3DKrishnatry%26aufirst%3DA.%2BS.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMaurer%26aufirst%3DT.%26aulast%3DMettetal%26aufirst%3DJ.%2BT.%26aulast%3DMudra%26aufirst%3DD.%2BR.%26aulast%3DNijsen%26aufirst%3DM.%2BJ.%2BM.%2BA.%26aulast%3DRaybon%26aufirst%3DJ.%26aulast%3DSchroeder%26aufirst%3DP.%26aulast%3DSchuck%26aufirst%3DV.%26aulast%3DSuryawanshi%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DTrapa%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DA.%26aulast%3DVakilynejad%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DPreclinical%2520Pharmacokinetic%252FPharmacodynamic%2520Modeling%2520and%2520Simulation%2520in%2520the%2520Pharmaceutical%2520Industry%253A%2520An%2520IQ%2520Consortium%2520Survey%2520Examining%2520the%2520Current%2520Landscape%26jtitle%3DAAPS%2520J.%26date%3D2015%26volume%3D17%26issue%3D2%26spage%3D462%26epage%3D473%26doi%3D10.1208%2Fs12248-014-9716-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nijsen, M. J. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw-Pierce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liederer, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettetal, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuck, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spilker, M. E.</span></span> <span> </span><span class="NLM_article-title">Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape</span>. <i>CPT: Pharmacometrics Syst. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1002/psp4.12282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2Fpsp4.12282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=29349875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=135-146&issue=3&author=M.+J.+M.+A.+Nijsenauthor=F.+Wuauthor=L.+Bansalauthor=E.+Bradshaw-Pierceauthor=J.+R.+Chanauthor=B.+M.+Liedererauthor=J.+T.+Mettetalauthor=P.+Schroederauthor=E.+Schuckauthor=A.+Tsaiauthor=C.+Xuauthor=A.+Chimalakondaauthor=K.+Leauthor=M.+Penneyauthor=B.+Toppauthor=A.+Yamadaauthor=M.+E.+Spilker&title=Preclinical+QSP+Modeling+in+the+Pharmaceutical+Industry%3A+An+IQ+Consortium+Survey+Examining+the+Current+Landscape&doi=10.1002%2Fpsp4.12282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape</span></div><div class="casAuthors">Nijsen, Marjoleen J. M. A.; Wu, Fan; Bansal, Loveleena; Bradshaw-Pierce, Erica; Chan, Jason R.; Liederer, Bianca M.; Mettetal, Jerome T.; Schroeder, Patricia; Schuck, Edgar; Tsai, Alice; Xu, Christine; Chimalakonda, Anjaneya; Le, Kha; Penney, Mark; Topp, Brian; Yamada, Akihiro; Spilker, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">CPT: Pharmacometrics & Systems Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">135-146</span>CODEN:
                <span class="NLM_cas:coden">CPSPBR</span>;
        ISSN:<span class="NLM_cas:issn">2163-8306</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A cross-industry survey was conducted to assess the landscape of preclin. quant. systems pharmacol. (QSP) modeling within pharmaceutical companies.  This article presents the survey results, which provide insights on the current state of preclin. QSP modeling in addn. to future opportunities.  Our results call attention to the need for an aligned definition and consistent terminol. around QSP, yet highlight the broad applicability and benefits preclin. QSP modeling is currently delivering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2yDgos1LCibVg90H21EOLACvtfcHk0lj_433R30D8PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGhs7s%253D&md5=f8007901081fedb9763b89782917ba37</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1002%2Fpsp4.12282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsp4.12282%26sid%3Dliteratum%253Aachs%26aulast%3DNijsen%26aufirst%3DM.%2BJ.%2BM.%2BA.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DBansal%26aufirst%3DL.%26aulast%3DBradshaw-Pierce%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DJ.%2BR.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DMettetal%26aufirst%3DJ.%2BT.%26aulast%3DSchroeder%26aufirst%3DP.%26aulast%3DSchuck%26aufirst%3DE.%26aulast%3DTsai%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DK.%26aulast%3DPenney%26aufirst%3DM.%26aulast%3DTopp%26aufirst%3DB.%26aulast%3DYamada%26aufirst%3DA.%26aulast%3DSpilker%26aufirst%3DM.%2BE.%26atitle%3DPreclinical%2520QSP%2520Modeling%2520in%2520the%2520Pharmaceutical%2520Industry%253A%2520An%2520IQ%2520Consortium%2520Survey%2520Examining%2520the%2520Current%2520Landscape%26jtitle%3DCPT%253A%2520Pharmacometrics%2520Syst.%2520Pharmacol.%26date%3D2018%26volume%3D7%26issue%3D3%26spage%3D135%26epage%3D146%26doi%3D10.1002%2Fpsp4.12282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, S.</span></span> <span> </span><span class="NLM_article-title">A Simple Practice Guide for Dose Conversion between Animals and Human</span>. <i>J. Basic Clin Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.4103/0976-0105.177703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.4103%2F0976-0105.177703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=27057123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A280%3ADC%252BC28fotV2hsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=27-31&issue=2&author=A.+B.+Nairauthor=S.+Jacob&title=A+Simple+Practice+Guide+for+Dose+Conversion+between+Animals+and+Human&doi=10.4103%2F0976-0105.177703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">A simple practice guide for dose conversion between animals and human</span></div><div class="casAuthors">Nair Anroop B; Jacob Shery</div><div class="citationInfo"><span class="NLM_cas:title">Journal of basic and clinical pharmacy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">27-31</span>
        ISSN:<span class="NLM_cas:issn">0976-0105</span>.
    </div><div class="casAbstract">Understanding the concept of extrapolation of dose between species is important for pharmaceutical researchers when initiating new animal or human experiments.  Interspecies allometric scaling for dose conversion from animal to human studies is one of the most controversial areas in clinical pharmacology.  Allometric approach considers the differences in body surface area, which is associated with animal weight while extrapolating the doses of therapeutic agents among the species.  This review provides basic information about translation of doses between species and estimation of starting dose for clinical trials using allometric scaling.  The method of calculation of injection volume for parenteral formulation based on human equivalent dose is also briefed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDuPq7lwLZ_xwLZxei1HN8fW6udTcc2eYeIh2IUJ9j_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fotV2hsQ%253D%253D&md5=527e4c74daabcb030b1e475cc22d8404</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.4103%2F0976-0105.177703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-0105.177703%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DA.%2BB.%26aulast%3DJacob%26aufirst%3DS.%26atitle%3DA%2520Simple%2520Practice%2520Guide%2520for%2520Dose%2520Conversion%2520between%2520Animals%2520and%2520Human%26jtitle%3DJ.%2520Basic%2520Clin%2520Pharm.%26date%3D2016%26volume%3D7%26issue%3D2%26spage%3D27%26epage%3D31%26doi%3D10.4103%2F0976-0105.177703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">West, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enquist, B. J.</span></span> <span> </span><span class="NLM_article-title">A General Model for the Origin of Allometric Scaling Laws in Biology</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>276</i></span> (<span class="NLM_issue">5309</span>),  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1126/science.276.5309.122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1126%2Fscience.276.5309.122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=9082983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaK2sXitl2jtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=122-126&issue=5309&author=G.+B.+Westauthor=J.+H.+Brownauthor=B.+J.+Enquist&title=A+General+Model+for+the+Origin+of+Allometric+Scaling+Laws+in+Biology&doi=10.1126%2Fscience.276.5309.122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A general model for the origin of allometric scaling laws in biology</span></div><div class="casAuthors">West, Geoffrey B.; Brown, James H.; Enquist, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">5309</span>),
    <span class="NLM_cas:pages">122-126</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Allometric scaling relations, including the 3/4 power law for metabolic rates, are characteristic of all organisms and are here derived from a general model that describes how essential materials are transported through space-filling fractal networks of branching tubes.  The model assumes that the energy dissipated is minimized and that the terminal tubes do not vary with body size.  It provides a complete anal. of scaling relations for mammalian circulatory systems that are in agreement with data.  More generally, the model predicts structural and functional properties of vertebrate cardiovascular and respiratory systems, plant vascular systems, insect tracheal tubes, and other distribution networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNkdfXXHt1P7Vg90H21EOLACvtfcHk0lj_433R30D8PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXitl2jtro%253D&md5=bb88c8dacfd9183a76c441d593b52ac7</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1126%2Fscience.276.5309.122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.276.5309.122%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DG.%2BB.%26aulast%3DBrown%26aufirst%3DJ.%2BH.%26aulast%3DEnquist%26aufirst%3DB.%2BJ.%26atitle%3DA%2520General%2520Model%2520for%2520the%2520Origin%2520of%2520Allometric%2520Scaling%2520Laws%2520in%2520Biology%26jtitle%3DScience%26date%3D1997%26volume%3D276%26issue%3D5309%26spage%3D122%26epage%3D126%26doi%3D10.1126%2Fscience.276.5309.122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 9 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Emile P. Chen, Robert W. Bondi, <span class="NLM_string-name hlFld-ContribAuthor">Paul J. Michalski</span>. </span><span class="cited-content_cbyCitation_article-title">Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 3185-3196. <a href="https://doi.org/10.1021/acs.jmedchem.0c02033" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02033%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DModel-based%252BTarget%252BPharmacology%252BAssessment%252B%252528mTPA%252529%25253A%252BAn%252BApproach%252BUsing%252BPBPK%25252FPD%252BModeling%252Band%252BMachine%252BLearning%252Bto%252BDesign%252BMedicinal%252BChemistry%252Band%252BDMPK%252BStrategies%252Bin%252BEarly%252BDrug%252BDiscovery%26aulast%3DChen%26aufirst%3DEmile%2BP.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D23112020%26date%3D15032021%26volume%3D64%26issue%3D6%26spage%3D3185%26epage%3D3196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Richard S. Hong, Alessandra Mattei, Ahmad Y. Sheikh, Rajni Miglani Bhardwaj, Michael A. Bellucci, Keith F. McDaniel, M. Olivia Pierce, Guangxu Sun, Sizhu Li, Lingle Wang, Sayan Mondal, Jianguo Ji, <span class="NLM_string-name hlFld-ContribAuthor">Thomas B. Borchardt</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Physics-Based Ensemble Modeling Approach That Utilizes 3D Molecular Conformation and Packing to Access Aqueous Thermodynamic Solubility: A Case Study of Orally Available Bromodomain and Extraterminal Domain Inhibitor Lead Optimization Series. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2021,</strong> <em>61 </em>
                                    (3)
                                     , 1412-1426. <a href="https://doi.org/10.1021/acs.jcim.0c01410" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c01410</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c01410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c01410%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DNovel%252BPhysics-Based%252BEnsemble%252BModeling%252BApproach%252BThat%252BUtilizes%252B3D%252BMolecular%252BConformation%252Band%252BPacking%252Bto%252BAccess%252BAqueous%252BThermodynamic%252BSolubility%25253A%252BA%252BCase%252BStudy%252Bof%252BOrally%252BAvailable%252BBromodomain%252Band%252BExtraterminal%252BDomain%252BInhibitor%252BLead%252BOptimization%252BSeries%26aulast%3DHong%26aufirst%3DRichard%2BS.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D07122020%26date%3D04032021%26volume%3D61%26issue%3D3%26spage%3D1412%26epage%3D1426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leslie Z.  Benet</span>, <span class="hlFld-ContribAuthor ">Jasleen K.  Sodhi</span>, <span class="hlFld-ContribAuthor ">George  Makrygiorgos</span>, <span class="hlFld-ContribAuthor ">Ali  Mesbah</span>. </span><span class="cited-content_cbyCitation_article-title">There is Only One Valid Definition of Clearance: Critical Examination of Clearance Concepts Reveals the Potential for Errors in Clinical Drug Dosing Decisions. </span><span class="cited-content_cbyCitation_journal-name">The AAPS Journal</span><span> <strong>2021,</strong> <em>23 </em>
                                    (3)
                                     <a href="https://doi.org/10.1208/s12248-021-00591-z" title="DOI URL">https://doi.org/10.1208/s12248-021-00591-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1208/s12248-021-00591-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1208%2Fs12248-021-00591-z%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520AAPS%2520Journal%26atitle%3DThere%252Bis%252BOnly%252BOne%252BValid%252BDefinition%252Bof%252BClearance%25253A%252BCritical%252BExamination%252Bof%252BClearance%252BConcepts%252BReveals%252Bthe%252BPotential%252Bfor%252BErrors%252Bin%252BClinical%252BDrug%252BDosing%252BDecisions%26aulast%3DBenet%26aufirst%3DLeslie%2BZ.%26date%3D2021%26date%3D2021%26volume%3D23%26issue%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas A.  Baillie</span>. </span><span class="cited-content_cbyCitation_article-title">Approaches to mitigate the risk of serious adverse reactions in covalent drug design. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (3)
                                     , 275-287. <a href="https://doi.org/10.1080/17460441.2021.1832079" title="DOI URL">https://doi.org/10.1080/17460441.2021.1832079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1832079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1832079%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DApproaches%252Bto%252Bmitigate%252Bthe%252Brisk%252Bof%252Bserious%252Badverse%252Breactions%252Bin%252Bcovalent%252Bdrug%252Bdesign%26aulast%3DBaillie%26aufirst%3DThomas%2BA.%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D3%26spage%3D275%26epage%3D287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lewis D.  Pennington</span>, <span class="hlFld-ContribAuthor ">Ingo  Muegge</span>. </span><span class="cited-content_cbyCitation_article-title">Holistic Drug Design for Multiparameter Optimization in Modern Small Molecule Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>10 </em>, 128003. <a href="https://doi.org/10.1016/j.bmcl.2021.128003" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128003%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DHolistic%252BDrug%252BDesign%252Bfor%252BMultiparameter%252BOptimization%252Bin%252BModern%252BSmall%252BMolecule%252BDrug%252BDiscovery%26aulast%3DPennington%26aufirst%3DLewis%2BD.%26date%3D2021%26volume%3D10%26spage%3D128003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tristan S.  Maurer</span>. </span><span class="cited-content_cbyCitation_article-title">Nonspecific Binding Considerations in the Rational Design and Development of Small Molecule COVID‐19 Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacology & Therapeutics</span><span> <strong>2021,</strong> <em>323 </em><a href="https://doi.org/10.1002/cpt.2159" title="DOI URL">https://doi.org/10.1002/cpt.2159</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpt.2159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpt.2159%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacology%2520%2526%2520Therapeutics%26atitle%3DNonspecific%252BBinding%252BConsiderations%252Bin%252Bthe%252BRational%252BDesign%252Band%252BDevelopment%252Bof%252BSmall%252BMolecule%252BCOVID%2525E2%252580%25259019%252BTherapeutics%26aulast%3DMaurer%26aufirst%3DTristan%2BS.%26date%3D2021%26date%3D2021%26volume%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anmol  Gulati</span>, <span class="hlFld-ContribAuthor ">Charles S.  Yeung</span>, <span class="hlFld-ContribAuthor ">Blair  Lapointe</span>, <span class="hlFld-ContribAuthor ">Solomon D.  Kattar</span>, <span class="hlFld-ContribAuthor ">Hakan  Gunaydin</span>, <span class="hlFld-ContribAuthor ">Jack D.  Scott</span>, <span class="hlFld-ContribAuthor ">Kaleen K.  Childers</span>, <span class="hlFld-ContribAuthor ">Joey L.  Methot</span>, <span class="hlFld-ContribAuthor ">Vladimir  Simov</span>, <span class="hlFld-ContribAuthor ">Ravi  Kurukulasuriya</span>, <span class="hlFld-ContribAuthor ">Barbara  Pio</span>, <span class="hlFld-ContribAuthor ">Greg J.  Morriello</span>, <span class="hlFld-ContribAuthor ">Ping  Liu</span>, <span class="hlFld-ContribAuthor ">Haiqun  Tang</span>, <span class="hlFld-ContribAuthor ">Santhosh  Neelamkavil</span>, <span class="hlFld-ContribAuthor ">Harold B.  Wood</span>, <span class="hlFld-ContribAuthor ">Vanessa L.  Rada</span>, <span class="hlFld-ContribAuthor ">Michael J.  Ardolino</span>, <span class="hlFld-ContribAuthor ">Xin Cindy  Yan</span>, <span class="hlFld-ContribAuthor ">Rachel  Palte</span>, <span class="hlFld-ContribAuthor ">Karin  Otte</span>, <span class="hlFld-ContribAuthor ">Robert  Faltus</span>, <span class="hlFld-ContribAuthor ">Janice  Woodhouse</span>, <span class="hlFld-ContribAuthor ">Laxminarayan G.  Hegde</span>, <span class="hlFld-ContribAuthor ">Paul  Ciaccio</span>, <span class="hlFld-ContribAuthor ">Ellen C.  Minnihan</span>, <span class="hlFld-ContribAuthor ">Erin F.  DiMauro</span>, <span class="hlFld-ContribAuthor ">Matthew J.  Fell</span>, <span class="hlFld-ContribAuthor ">Peter H.  Fuller</span>, <span class="hlFld-ContribAuthor ">J. Michael  Ellis</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>20 </em><a href="https://doi.org/10.1039/D1MD00097G" title="DOI URL">https://doi.org/10.1039/D1MD00097G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00097G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00097G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DOptimization%252Bof%252Bbrain-penetrant%252Bpicolinamide%252Bderived%252Bleucine-rich%252Brepeat%252Bkinase%252B2%252B%252528LRRK2%252529%252Binhibitors%26aulast%3DGulati%26aufirst%3DAnmol%26date%3D2021%26date%3D2021%26volume%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenying Angela  Liu</span>, <span class="hlFld-ContribAuthor ">Li  Yu</span>, <span class="hlFld-ContribAuthor ">Peter N.  Morcos</span>, <span class="hlFld-ContribAuthor ">Francois  Mercier</span>, <span class="hlFld-ContribAuthor ">Barbara J.  Brennan</span>. </span><span class="cited-content_cbyCitation_article-title">Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs. </span><span class="cited-content_cbyCitation_journal-name">Cancer Chemotherapy and Pharmacology</span><span> <strong>2020,</strong> <em>85 </em>
                                    (6)
                                     , 1015-1027. <a href="https://doi.org/10.1007/s00280-020-04076-2" title="DOI URL">https://doi.org/10.1007/s00280-020-04076-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00280-020-04076-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00280-020-04076-2%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Chemotherapy%2520and%2520Pharmacology%26atitle%3DAssessing%252Bthe%252Btranslational%252Bvalue%252Bof%252Bpre-clinical%252Bstudies%252Bfor%252Bclinical%252Bresponse%252Brate%252Bin%252Boncology%25253A%252Ban%252Bexploratory%252Binvestigation%252Bof%252B42%252BFDA-approved%252Bsmall-molecule%252Btargeted%252Banticancer%252Bdrugs%26aulast%3DLiu%26aufirst%3DWenying%2BAngela%26date%3D2020%26date%3D2020%26volume%3D85%26issue%3D6%26spage%3D1015%26epage%3D1027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sheila Annie  Peters</span>, <span class="hlFld-ContribAuthor ">Carl  Petersson</span>, <span class="hlFld-ContribAuthor ">Andree  Blaukat</span>, <span class="hlFld-ContribAuthor ">Joern-Peter  Halle</span>, <span class="hlFld-ContribAuthor ">Hugues  Dolgos</span>. </span><span class="cited-content_cbyCitation_article-title">Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (5)
                                     , 909-919. <a href="https://doi.org/10.1016/j.drudis.2020.01.002" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.01.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.01.002%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DPrediction%252Bof%252Bactive%252Bhuman%252Bdose%25253A%252Blearnings%252Bfrom%252B20%252Byears%252Bof%252BMerck%252BKGaA%252Bexperience%25252C%252Billustrated%252Bby%252Bcase%252Bstudies%26aulast%3DPeters%26aufirst%3DSheila%2BAnnie%26date%3D2020%26volume%3D25%26issue%3D5%26spage%3D909%26epage%3D919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_0006.gif" alt="" id="_i2" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Conceptual illustration of three approaches to a quantitative clinical objective in support of design. (A) 80% target modulation is targeted based on an understanding of the relationship between target activity and disease. (B) 80% target modulation is targeted based on a “no-regrets” approach to ensuring that the mechanism will be tested in the clinic. (C) 80% target modulation is rationalized on the basis of data indicating that this is what’s required to restore target activity to healthy levels.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Sensitivity of <i>C</i><sub>min</sub>-based dose predictions to a 2-fold error in clearance predictions. Solid lines represent the predicted CL, and dashed lines represent the impact of a 2-fold under- and overprediction of clearance. (A) Uncertainty in concentration–time profile for a short half-life (1 h, solid black line) versus a long half-life (24 h, solid gray line) compound dosed once daily to achieve a 10 ng/mL <i>C</i><sub>min</sub>. (B) Uncertainty in <i>C</i><sub>min</sub> as a function of half-life expressed as fold error from the estimate. (C) Effect of half-life on dose prediction and associated uncertainty in dose. (D) Uncertainty in dose as a function of half-life expressed as fold error from the estimate. All simulations were performed with a one compartment pharmacokinetic model with first order absorption.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Illustration of relative dose visualization based on a <i>C</i><sub>ss,avg</sub> approach in a lead optimization program. Lower and upper red dashed lines correspond to potency and Cl<sub>int</sub> combinations that provide a predicted dose of 20 and 100 mg QD according to <a class="ref internalNav" href="#eq3" aria-label="eq 3">eq 3</a>. Fraction absorbed has been assumed to be 100%, and 50 theoretical compounds (open symbols) have been generated to illustrate how this approach can be used to consider the relative merits of compounds early in lead optimization.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Influence of half-life on the time course of pharmacological effect (% inhibition) at a fixed average concentration using a one compartment pharmacokinetic model with first order absorption. (A) Simulations of a time course of steady-state exposure under a fixed bioavailability, absorption rate, and clearance rate but variable volumes to create different half-lives. (B) Relationship between half-life and the average steady-state concentration (IC<sub>80</sub>) over the dosing interval as calculated by AUC/tau. (C) Time course of effect calculated from the simulated exposure profiles assuming a common IC<sub>50</sub> of 10 (units not specified). % inhibition was calculated as 100 × <i>C</i>/(<i>C</i> + IC<sub>50</sub>). (D) Relationship between half-life and average inhibition over the dosing interval at steady-state. Average inhibition was calculated as AUC/tau.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/medium/jm9b01365_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Design implications supported by early application of PKPD model-based dose predictions. (A) Relationship between dose and half-life of a lead SGLT2 inhibitor (open symbol), with dashed and solid lines representing the predicted relationship upon changes in volume and clearance, respectively. The implication is that optimization of half-life via clearance is preferred due to greater effect on dose relative to volume (figure reproduced with permission from ref <a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a>. Copyright 2011 American Chemical Society). (B) PKPD model-based predictions of cumulating and sustained suppression of KYNA upon once daily dosing of a short half-life KAT2 inhibitor. The implication is that a short half-life compound is acceptable (figure reproduced with permission from <i>Molecular Pharmacology</i>,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Copyright 2018 The American Society for Pharmacology and Experimental Therapeutics). (C) Acceptable clearance ranges (in green) for negative allosteric CaR modulators given typical volumes of various physiochemical classes. The implication is that a neutral lead series would be the most favorable starting place in design.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01365/20200618/images/large/jm9b01365_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01365&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i33">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50523" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50523" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 62 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Relevance of Half-Life in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4273</span>– <span class="NLM_lpage">4282</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00969</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00969" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOnsrnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4273-4282&issue=10&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Relevance+of+Half-Life+in+Drug+Design&doi=10.1021%2Facs.jmedchem.7b00969"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Relevance of Half-Life in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4273-4282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state.  A half-life of 12-48 h is generally ideal for once daily dosing of oral drugs.  If the half-life is too short, it may require more frequent dosing in order to maintain desired exposures and avoid unnecessarily high peak concns.  This may pose challenges to achieving optimal efficacy, safety, and patient compliance.  If the half-life is too long, the time over which accumulation and subsequent elimination occur may be prolonged.  This may pose problems with managing adverse effects and the design of efficient clin. trials.  Half-life is a key parameter for optimization in research and development.  Structural modification to affect clearance, and to a lesser extent vol. of distribution, is the preferred means of modulating half-life.  An effective approach to half-life optimization requires an understanding of the many pitfalls assocd. with its estn. and interpretation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7kT9hNLRzb7Vg90H21EOLACvtfcHk0lhyR5fdyhmV9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOnsrnN&md5=ff748cbebc765f4fa3c3d7b3831f51c8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00969%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DRelevance%2520of%2520Half-Life%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D10%26spage%3D4273%26epage%3D4282%26doi%3D10.1021%2Facs.jmedchem.7b00969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Clearance in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">2245</span>– <span class="NLM_lpage">2255</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVCru7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2245-2255&issue=5&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Clearance+in+Drug+Design&doi=10.1021%2Facs.jmedchem.8b01263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Clearance in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2245-2255</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Due to its implications for both dose level and frequency, clearance rate is one of the most important pharmacokinetic parameters to consider in the design of drug candidates.  Clearance can be classified into three general categories, namely, metabolic transformation, renal excretion, and hepatobiliary excretion.  Within each category, there are a host of biochem. and physiol. mechanisms that ultimately det. the clearance rate.  Physiochem. properties are often indicative of the rate-detg. mechanism, with lipophilic mols. tending toward metab. and hydrophilic, polar mols. tending toward passive or active excretion.  Optimization of clearance requires recognition of the major clearance mechanisms and use of the most relevant in vitro and in vivo tools to develop structure-clearance relationships.  The reliability of methods to detect and predict human clearance varies across mechanisms.  While methods for metabolic and passive renal clearance have proven reasonably robust, there is a clear need for better tools to support the optimization of transporter-mediated clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8nvv_L3pL-LVg90H21EOLACvtfcHk0lhyR5fdyhmV9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVCru7fO&md5=e4a4d72056ed9b41842a11934fa4bffc</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01263%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DClearance%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D5%26spage%3D2245%26epage%3D2255%26doi%3D10.1021%2Facs.jmedchem.8b01263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span> <span> </span><span class="NLM_article-title">Volume of Distribution in Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">5691</span>– <span class="NLM_lpage">5698</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00201</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00201" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5691-5698&issue=15&author=D.+A.+Smithauthor=K.+Beaumontauthor=T.+S.+Maurerauthor=L.+Di&title=Volume+of+Distribution+in+Drug+Design&doi=10.1021%2Facs.jmedchem.5b00201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Volume of Distribution in Drug Design</span></div><div class="casAuthors">Smith, Dennis A.; Beaumont, Kevin; Maurer, Tristan S.; Di, Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5691-5698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Vol. of distribution is one of the most important pharmacokinetic properties of a drug candidate.  It is a major determinant of half-life and dosing frequency of a drug.  For a similar log P, a basic mol. will tend to exhibit higher vol. of distribution than a neutral mol.  Acids often exhibit low vols. of distribution.  Although a design strategy against vol. of distribution can be advantageous in achieving desirable dosing regimen, it must be well-directed in order to avoid detrimental effects to other important properties.  Strategies to increase vol. of distribution include adding lipophilicity and introducing basic functional groups in a way that does not increase metabolic clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP7QwgPahf4bVg90H21EOLACvtfcHk0ljmGa2mPqh-vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSlsb0%253D&md5=2c7289b3602a8edef2d9ef0e6a82e483</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00201%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDi%26aufirst%3DL.%26atitle%3DVolume%2520of%2520Distribution%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D15%26spage%3D5691%26epage%3D5698%26doi%3D10.1021%2Facs.jmedchem.5b00201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kataria, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappelleri, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadosky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, A. M.</span></span> <span> </span><span class="NLM_article-title">Impact of Reducing Dosing Frequency on Adherence to Oral Therapies: a Literature Review and Meta-Analysis</span>. <i>Patient Preference Adherence</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">434</span>, <span class="refDoi"> DOI: 10.2147/PPA.S44646</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.2147%2FPPA.S44646" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=23737662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A280%3ADC%252BC3snps12ltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=419-434&author=K.+Srivastavaauthor=A.+Aroraauthor=A.+Katariaauthor=J.+C.+Cappelleriauthor=A.+Sadoskyauthor=A.+M.+Peterson&title=Impact+of+Reducing+Dosing+Frequency+on+Adherence+to+Oral+Therapies%3A+a+Literature+Review+and+Meta-Analysis&doi=10.2147%2FPPA.S44646"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis</span></div><div class="casAuthors">Srivastava Kunal; Arora Anamika; Kataria Aditi; Cappelleri Joseph C; Sadosky Alesia; Peterson Andrew M</div><div class="citationInfo"><span class="NLM_cas:title">Patient preference and adherence</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">419-34</span>
        ISSN:<span class="NLM_cas:issn">1177-889X</span>.
    </div><div class="casAbstract">OBJECTIVES:  To assess the impact of reduced frequency of oral therapies from multiple-dosing schedules to a once-daily (OD) dosing schedule on adherence, compliance, persistence, and associated economic impact.  METHODS:  A meta-analysis was performed based on relevant articles identified from a comprehensive literature review using MEDLINE® and Embase®.  The review included studies assessing adherence with OD, twice-daily (BID), thrice-daily (TID), and four-times daily (QID) dosing schedules and costs associated with optimal/suboptimal adherence among patients with acute and chronic diseases.  Effect estimates across studies were pooled and analyzed using the DerSimonian and Laird random-effect model.  RESULTS:  Forty-three studies met inclusion criteria, and meta-analyzable data were available from 13 studies.  The overall results indicated that OD schedules were associated with higher adherence rates (odds ratio [OR] 3.07, 95% confidence interval [CI] 1.80-5.23; P < 0.001 for OD versus > OD dosing) and compliance rates (OR 3.50, 95% CI 1.73-7.08; P < 0.001 for OD versus > OD dosing); persistence rates showed the same direction but were not statistically significant (OR 1.43, 95% CI 0.62-3.29; P = 0.405 for OD versus BID dosing).  Results for each of the conditions were consistent with those observed overall with respect to showing the benefits of less frequent dosing.  From a health economic perspective, higher adherence rates with OD relative to multiple dosing in a number of conditions were consistently associated with corresponding lower costs of health care resources utilization.  CONCLUSION:  Current meta-analyses suggested that across acute and chronic disease states, reducing dosage frequency from multiple dosing to OD dosing may improve adherence to therapies among patients.  Improving adherence may result in subsequent decreases in health care costs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpbb1ykVOfYlw2ofyr07jXfW6udTcc2ebjtTVfhtI5Tbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snps12ltw%253D%253D&md5=4b027f04ac35bada67ab0a6494a1af9f</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2147%2FPPA.S44646&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FPPA.S44646%26sid%3Dliteratum%253Aachs%26aulast%3DSrivastava%26aufirst%3DK.%26aulast%3DArora%26aufirst%3DA.%26aulast%3DKataria%26aufirst%3DA.%26aulast%3DCappelleri%26aufirst%3DJ.%2BC.%26aulast%3DSadosky%26aufirst%3DA.%26aulast%3DPeterson%26aufirst%3DA.%2BM.%26atitle%3DImpact%2520of%2520Reducing%2520Dosing%2520Frequency%2520on%2520Adherence%2520to%2520Oral%2520Therapies%253A%2520a%2520Literature%2520Review%2520and%2520Meta-Analysis%26jtitle%3DPatient%2520Preference%2520Adherence%26date%3D2013%26volume%3D7%26spage%3D419%26epage%3D434%26doi%3D10.2147%2FPPA.S44646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Viswanathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golin, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashok, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blalock, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wines, R. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coker-Schwimmer, E. J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sista, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohr, K. N.</span></span> <span> </span><span class="NLM_article-title">Interventions to Improve Adherence to Self-Administered Medications for Chronic Diseases in the United States: a Systematic Review</span>. <i>Ann. Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>157</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">795</span>, <span class="refDoi"> DOI: 10.7326/0003-4819-157-11-201212040-00538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.7326%2F0003-4819-157-11-201212040-00538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=22964778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A280%3ADC%252BC38blslSmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2012&pages=785-795&issue=11&author=M.+Viswanathanauthor=C.+E.+Golinauthor=C.+D.+Jonesauthor=M.+Ashokauthor=S.+J.+Blalockauthor=R.+C.+M.+Winesauthor=E.+J.+L.+Coker-Schwimmerauthor=D.+L.+Rosenauthor=P.+Sistaauthor=K.+N.+Lohr&title=Interventions+to+Improve+Adherence+to+Self-Administered+Medications+for+Chronic+Diseases+in+the+United+States%3A+a+Systematic+Review&doi=10.7326%2F0003-4819-157-11-201212040-00538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review</span></div><div class="casAuthors">Viswanathan Meera; Golin Carol E; Jones Christine D; Ashok Mahima; Blalock Susan J; Wines Roberta C M; Coker-Schwimmer Emmanuel J L; Rosen David L; Sista Priyanka; Lohr Kathleen N</div><div class="citationInfo"><span class="NLM_cas:title">Annals of internal medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">785-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Suboptimum medication adherence is common in the United States and leads to serious negative health consequences but may respond to intervention.  PURPOSE:  To assess the comparative effectiveness of patient, provider, systems, and policy interventions that aim to improve medication adherence for chronic health conditions in the United States.  DATA SOURCES:  Eligible peer-reviewed publications from MEDLINE and the Cochrane Library indexed through 4 June 2012 and additional studies from reference lists and technical experts.  STUDY SELECTION:  Randomized, controlled trials of patient, provider, or systems interventions to improve adherence to long-term medications and nonrandomized studies of policy interventions to improve medication adherence.  DATA EXTRACTION:  Two investigators independently selected, extracted data from, and rated the risk of bias of relevant studies.  DATA SYNTHESIS:  The evidence was synthesized separately for each clinical condition; within each condition, the type of intervention was synthesized.  Two reviewers graded the strength of evidence by using established criteria.  From 4124 eligible abstracts, 62 trials of patient-, provider-, or systems-level interventions evaluated 18 types of interventions; another 4 observational studies and 1 trial of policy interventions evaluated the effect of reduced medication copayments or improved prescription drug coverage.  Clinical conditions amenable to multiple approaches to improving adherence include hypertension, heart failure, depression, and asthma.  Interventions that improve adherence across multiple clinical conditions include policy interventions to reduce copayments or improve prescription drug coverage, systems interventions to offer case management, and patient-level educational interventions with behavioral support.  LIMITATIONS:  Studies were limited to adults with chronic conditions (excluding HIV, AIDS, severe mental illness, and substance abuse) in the United States.  Clinical and methodological heterogeneity hindered quantitative data pooling.  CONCLUSION:  Reduced out-of-pocket expenses, case management, and patient education with behavioral support all improved medication adherence for more than 1 condition.  Evidence is limited on whether these approaches are broadly applicable or affect longterm medication adherence and health outcomes.  PRIMARY FUNDING SOURCE:  Agency for Healthcare Research and Quality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQj4cu5Zds5NnO4gDb7JggCfW6udTcc2ebjtTVfhtI5Tbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38blslSmsw%253D%253D&md5=7ac8654540b0763b98a486a11ab23324</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.7326%2F0003-4819-157-11-201212040-00538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7326%252F0003-4819-157-11-201212040-00538%26sid%3Dliteratum%253Aachs%26aulast%3DViswanathan%26aufirst%3DM.%26aulast%3DGolin%26aufirst%3DC.%2BE.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DAshok%26aufirst%3DM.%26aulast%3DBlalock%26aufirst%3DS.%2BJ.%26aulast%3DWines%26aufirst%3DR.%2BC.%2BM.%26aulast%3DCoker-Schwimmer%26aufirst%3DE.%2BJ.%2BL.%26aulast%3DRosen%26aufirst%3DD.%2BL.%26aulast%3DSista%26aufirst%3DP.%26aulast%3DLohr%26aufirst%3DK.%2BN.%26atitle%3DInterventions%2520to%2520Improve%2520Adherence%2520to%2520Self-Administered%2520Medications%2520for%2520Chronic%2520Diseases%2520in%2520the%2520United%2520States%253A%2520a%2520Systematic%2520Review%26jtitle%3DAnn.%2520Intern.%2520Med.%26date%3D2012%26volume%3D157%26issue%3D11%26spage%3D785%26epage%3D795%26doi%3D10.7326%2F0003-4819-157-11-201212040-00538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, R. J.</span></span> <span> </span><span class="NLM_article-title">Acute Liver Failure Including Acetaminophen Overdose</span>. <i>Med. Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.1016/j.mcna.2008.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.mcna.2008.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=18570942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpslWqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2008&pages=761-794&issue=4&author=R.+J.+Fontana&title=Acute+Liver+Failure+Including+Acetaminophen+Overdose&doi=10.1016%2Fj.mcna.2008.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Acute liver failure including acetaminophen overdose</span></div><div class="casAuthors">Fontana, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Medical Clinics of North America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">761-794</span>CODEN:
                <span class="NLM_cas:coden">MCNAA9</span>;
        ISSN:<span class="NLM_cas:issn">0025-7125</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Acute liver failure (ALF) is a dramatic, highly unpredictable clin. syndrome defined by the sudden onset of coagulopathy and encephalopathy.  Acetaminophen overdose, the leading cause of ALF in the United States, has a 66% chance of recovery with early N-acetylcysteine treatment and supportive care.  Cerebral edema and infectious complications are difficult to detect and treat in these patients and may cause irreversible brain damage and multiorgan failure.  One-year survival after emergency liver transplantation is 70%, but 20% of listed patients die, highlighting the importance of early referral of patients who have ALF with a poor prognosis to a transplant center.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGrf38C6bEUrVg90H21EOLACvtfcHk0lgDBMpL1mSgRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpslWqtr8%253D&md5=8464a31e2d976a417edce26c45ece8c5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.mcna.2008.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mcna.2008.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26atitle%3DAcute%2520Liver%2520Failure%2520Including%2520Acetaminophen%2520Overdose%26jtitle%3DMed.%2520Clin.%2520North%2520Am.%26date%3D2008%26volume%3D92%26issue%3D4%26spage%3D761%26epage%3D794%26doi%3D10.1016%2Fj.mcna.2008.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhary, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyrsopoulos, N.</span></span> <span> </span><span class="NLM_article-title">Acetaminophen-Induced Hepatotoxicity: A Comprehensive Update</span>. <i>J. Clin. Transl. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.14218/JCTH.2015.00052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.14218%2FJCTH.2015.00052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=27350943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A280%3ADC%252BC2s7ktl2rsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=131-142&issue=2&author=E.+Yoonauthor=A.+Babarauthor=M.+Choudharyauthor=M.+Kutnerauthor=N.+Pyrsopoulos&title=Acetaminophen-Induced+Hepatotoxicity%3A+A+Comprehensive+Update&doi=10.14218%2FJCTH.2015.00052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update</span></div><div class="casAuthors">Yoon Eric; Babar Arooj; Choudhary Moaz; Kutner Matthew; Pyrsopoulos Nikolaos</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical and translational hepatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-42</span>
        ISSN:<span class="NLM_cas:issn">2225-0719</span>.
    </div><div class="casAbstract">Hepatic injury and subsequent hepatic failure due to both intentional and non-intentional overdose of acetaminophen (APAP) has affected patients for decades, and involves the cornerstone metabolic pathways which take place in the microsomes within hepatocytes.  APAP hepatotoxicity remains a global issue; in the United States, in particular, it accounts for more than 50% of overdose-related acute liver failure and approximately 20% of the liver transplant cases.  The pathophysiology, disease course and management of acute liver failure secondary to APAP toxicity remain to be precisely elucidated, and adverse patient outcomes with increased morbidity and mortality continue to occur.  Although APAP hepatotoxicity follows a predictable timeline of hepatic failure, its clinical presentation might vary.  N-acetylcysteine (NAC) therapy is considered as the mainstay therapy, but liver transplantation might represent a life-saving procedure for selected patients.  Future research focus in this field may benefit from shifting towards obtaining antidotal knowledge at the molecular level, with focus on the underlying molecular signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSx4BXZ2FeKIP9pSBfyDvp7fW6udTcc2ebaqv2Z9P2rbLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7ktl2rsA%253D%253D&md5=d32e4195dfc733b28b7d9b7de07fdd22</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.14218%2FJCTH.2015.00052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14218%252FJCTH.2015.00052%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DE.%26aulast%3DBabar%26aufirst%3DA.%26aulast%3DChoudhary%26aufirst%3DM.%26aulast%3DKutner%26aufirst%3DM.%26aulast%3DPyrsopoulos%26aufirst%3DN.%26atitle%3DAcetaminophen-Induced%2520Hepatotoxicity%253A%2520A%2520Comprehensive%2520Update%26jtitle%3DJ.%2520Clin.%2520Transl.%2520Hepatol.%26date%3D2016%26volume%3D4%26issue%3D2%26spage%3D131%26epage%3D142%26doi%3D10.14218%2FJCTH.2015.00052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><a href="https://www.fda.gov/consumers/consumer-updates/acetaminophen-avoiding-liver-injury" class="extLink">https://www.fda.gov/consumers/consumer-updates/acetaminophen-avoiding-liver-injury</a> (accessed Dec 17, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fconsumers%2Fconsumer-updates%2Facetaminophen-avoiding-liver-injury+%28accessed+Dec+17%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span> <span> </span><span class="NLM_article-title">Evaluation of DILI Predictive Hypotheses in Early Drug Development</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1017</span>– <span class="NLM_lpage">1029</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.7b00025</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.7b00025" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Knu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2017&pages=1017-1029&issue=4&author=R.+Chanauthor=L.+Z.+Benet&title=Evaluation+of+DILI+Predictive+Hypotheses+in+Early+Drug+Development&doi=10.1021%2Facs.chemrestox.7b00025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of DILI Predictive Hypotheses in Early Drug Development</span></div><div class="casAuthors">Chan, Rosa; Benet, Leslie Z.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1017-1029</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of drug failure in clin. trials and a major reason for drug withdrawals.  DILI has been shown to be dependent on both daily dose and extent of hepatic metab.  Yet, early in drug development daily dose is unknown.  Here, we perform a comprehensive anal. of the published hypotheses that attempt to predict DILI, including a new anal. of the Biopharmaceutics Drug Disposition Classification System (BDDCS) in evaluating the severity of DILI warnings in drug labels approved by the FDA and the withdrawal status due to adverse drug reactions (ADRs).  Our anal. confirms that higher doses ≥50 mg/day lead to increased DILI potential, but this property alone is not sufficient to predict the DILI potential.  We evaluate prior attempts to categorize DILI such as Rule of 2, BSEP inhibition, and measures of key mechanisms of toxicity compared to BDDCS classification.  Our results show that BDDCS Class 2 drugs exhibit the highest DILI severity and that all of the published methodologies evaluated here, except when daily dose is known, do not yield markedly better predictions than BDDCS.  The assertion that extensive metabolized compds. are at higher risk of developing DILI is confirmed but can be enhanced by differentiating BDDCS Class 2 from Class 1 drugs.  We do not propose that the BDDCS classification, which does not require knowledge of the clin. dose, is sufficiently predictive/accurate of DILI potential for new mol. entities but suggest that comparison of proposed DILI prediction methodologies with BDDCS classification is a useful tool to evaluate the potential reliability of newly proposed algorithms.  Conclusion: The most successful approaches to predict DILI potential all include a measure of dose, yet there is a quantifiable uncertainty assocd. with the predicted dose early in drug development.  Here, we compare the possibility of predicting DILI potential using the BDDCS classification vs. previously published methods and note that many hypothesized predictive DILI metrics do no better than just avoiding BDDCS Class 2 drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwMFj2kgoGErVg90H21EOLACvtfcHk0lgDBMpL1mSgRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Knu7s%253D&md5=27c6448357f8e7c862a7d8cfc7d033aa</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.7b00025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.7b00025%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DR.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26atitle%3DEvaluation%2520of%2520DILI%2520Predictive%2520Hypotheses%2520in%2520Early%2520Drug%2520Development%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2017%26volume%3D30%26issue%3D4%26spage%3D1017%26epage%3D1029%26doi%3D10.1021%2Facs.chemrestox.7b00025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borlak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, W.</span></span> <span> </span><span class="NLM_article-title">High Lipophilicity and High Daily Dose of Oral Medications are Associated with Significant Risk for Drug-Induced Liver Injury</span>. <i>Hepatology (Hoboken, NJ, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">388</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1002/hep.26208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2Fhep.26208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=23258593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=388-396&issue=1&author=M.+Chenauthor=J.+Borlakauthor=W.+Tong&title=High+Lipophilicity+and+High+Daily+Dose+of+Oral+Medications+are+Associated+with+Significant+Risk+for+Drug-Induced+Liver+Injury&doi=10.1002%2Fhep.26208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury</span></div><div class="casAuthors">Chen, Minjun; Borlak, Juergen; Tong, Weida</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">388-396</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Drug-induced liver injury (DILI) is a leading cause of drug failure in clin. trials and a major reason for drug withdrawals from the market.  Although there is evidence that dosages of ≥100 mg/day are assocd. with increased risk for hepatotoxicity, many drugs are safe at such dosages.  There is an unmet need to predict risk for DILI more reliably, and lipophilicity might be a contributing factor.  We analyzed the combined factors of daily dose and lipophilicity for 164 US Food and Drug Administration-approved oral medications and obsd. high risk for hepatotoxicity (odds ratio [OR], 14.05; P < 0.001) for drugs given at dosages ≥100 mg/day and octanol-water partition coeff. (logP) ≥3.  This defined the "rule-of-two.".  Similar results were obtained for an independent set of 179 oral medications with 85% of the rule-of-two positives being assocd. with hepatotoxicity (OR, 3.89; P < 0.01).  Using the World Health Organization's Anatomical Therapeutic Chem. classification system, the rule-of-two performed best in predicting DILI in seven therapeutic categories.  Among 15 rule-of-two positives, 14 were withdrawn from hepatotoxic drugs, and one was over-the-counter medication labeled for liver injury.  We addnl. examd. drug pairs that have similar chem. structures and act on the same mol. target but differ in their potential for DILI.  Again, the rule-of-two predicted hepatotoxicity reliably.  Finally, the rule-of-two was applied to clin. case studies to identify hepatotoxic drugs in complex comedication regimes to further demonstrate its use.  Conclusion: Apart from dose, lipophilicity contributes significantly to risk for hepatotoxicity.  Applying the rule-of-two is an appropriate means of estg. risk for DILI compared with dose alone. (HEPATOl. 2013).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1EE02L_JCdLVg90H21EOLACvtfcHk0lgJHgpHaUhuHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVaisrrM&md5=a88e02ff29653bdeee53b59a4da46d06</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fhep.26208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.26208%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBorlak%26aufirst%3DJ.%26aulast%3DTong%26aufirst%3DW.%26atitle%3DHigh%2520Lipophilicity%2520and%2520High%2520Daily%2520Dose%2520of%2520Oral%2520Medications%2520are%2520Associated%2520with%2520Significant%2520Risk%2520for%2520Drug-Induced%2520Liver%2520Injury%26jtitle%3DHepatology%2520%2528Hoboken%252C%2520NJ%252C%2520U.%2520S.%2529%26date%3D2013%26volume%3D58%26issue%3D1%26spage%3D388%26epage%3D396%26doi%3D10.1002%2Fhep.26208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lammert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einarsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niklasson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalasani, N.</span></span> <span> </span><span class="NLM_article-title">Relationship between Daily Dose of Oral Medications and Idiosyncratic Drug-Induced Liver Injury: Search for Signals</span>. <i>Hepatology (Hoboken, NJ, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2003</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.1002/hep.22272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2Fhep.22272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=18454504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=2003-2009&issue=6&author=C.+Lammertauthor=S.+Einarssonauthor=C.+Sahaauthor=A.+Niklassonauthor=E.+Bjornssonauthor=N.+Chalasani&title=Relationship+between+Daily+Dose+of+Oral+Medications+and+Idiosyncratic+Drug-Induced+Liver+Injury%3A+Search+for+Signals&doi=10.1002%2Fhep.22272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals</span></div><div class="casAuthors">Lammert, Craig; Einarsson, Stefan; Saha, Chandan; Niklasson, Anna; Bjornsson, Einar; Chalasani, Naga</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2003-2009</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Idiosyncratic drug-induced liver injury (DILI) is traditionally thought not to be dose-related.  However, it has been pointed out that most medicines that were withdrawn from marketing or received a black-box warning because of hepatotoxicity were prescribed at daily doses greater than 50 mg/day.  To examine the relationship between daily dose of medications and idiosyncratic DILI, we conducted a study with two aims.  First, using two pharmaceutical databases, we examd. the relationship between daily dose of commonly prescribed medicines in the United States and reported frequency of their selected hepatic adverse events.  Second, we examd. serious DILI cases reported to the Swedish Adverse Drug Reactions Advisory Committee (1970-2004) for any signals supporting the relationship between daily dose and idiosyncratic DILI.  Medications were categorized into ≤10 mg/day, 11-49 mg/day, and ≥50 mg/day groups.  Among US prescription medicines, a statistically significant relationship was obsd. between daily dose of oral medicines and reports of liver failure (P = 0.009), liver transplantation (P < 0.001), and death caused by DILI (P = 0.004) but not alanine aminotransferase (ALT) > 3 × upper limit of normal (P = 0.10) or jaundice (P = 0.16).  Of 598 eligible Swedish DILI cases, 9% belonged to the ≤10 mg/day group, 14.2% to the 11-49 mg/day group, and 77% of cases were caused by medications given at dose ≥50 mg/day.  A statistically significant relationship was noted between daily dose and poor outcome (death or liver transplantation) of Swedish DILI cases (2%, 9.4%, and 13.2% in ≤10, 11-49, and ≥50 mg/day groups, resp., P = 0.03).  Conclusion: These data suggest a relationship between daily doses of oral prescription medications and idiosyncratic DILI.  More studies are needed to validate these observations and to explore their implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-pByO6X3Hk7Vg90H21EOLACvtfcHk0lgJHgpHaUhuHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVagt7w%253D&md5=f497d61a5253cc653c2d955232471d65</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fhep.22272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22272%26sid%3Dliteratum%253Aachs%26aulast%3DLammert%26aufirst%3DC.%26aulast%3DEinarsson%26aufirst%3DS.%26aulast%3DSaha%26aufirst%3DC.%26aulast%3DNiklasson%26aufirst%3DA.%26aulast%3DBjornsson%26aufirst%3DE.%26aulast%3DChalasani%26aufirst%3DN.%26atitle%3DRelationship%2520between%2520Daily%2520Dose%2520of%2520Oral%2520Medications%2520and%2520Idiosyncratic%2520Drug-Induced%2520Liver%2520Injury%253A%2520Search%2520for%2520Signals%26jtitle%3DHepatology%2520%2528Hoboken%252C%2520NJ%252C%2520U.%2520S.%2529%26date%3D2008%26volume%3D47%26issue%3D6%26spage%3D2003%26epage%3D2009%26doi%3D10.1002%2Fhep.22272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergstroem, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindmark, B.</span></span> <span> </span><span class="NLM_article-title">Accelerated Drug Discovery by Rapid Candidate Drug Identification</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1237</span>– <span class="NLM_lpage">1241</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2019.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.drudis.2019.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=30946980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1OnsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1237-1241&issue=6&author=F.+Bergstroemauthor=B.+Lindmark&title=Accelerated+Drug+Discovery+by+Rapid+Candidate+Drug+Identification&doi=10.1016%2Fj.drudis.2019.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Accelerated drug discovery by rapid candidate drug identification</span></div><div class="casAuthors">Bergstroem, Fredrik; Lindmark, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1237-1241</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The eventual candidate drug (CD) is often already synthesized during early drug discovery but not nominated until much later.  To facilitate the rapid identification of a potential CD, a thoroughly worked-out CD target profile (CDTP) with criteria acceptable for the disease target product profile (TPP) is required at the start of lead generation (LG).  In addn. to driving the compd. property optimization, the preclin. project team has to understand the ultimate goal to be able to rapidly identify and progress a potential CD.  A screening cascade with meaningful and well-balanced progression criteria based on the CDTP is required to rapidly filter out unwanted compds. and to progress a potential CD through the cascade to candidate selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPal0J6pugkLVg90H21EOLACvtfcHk0lgJHgpHaUhuHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1OnsrY%253D&md5=49a74b6bcf5a932bc51003ef5534fcbe</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2019.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2019.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DBergstroem%26aufirst%3DF.%26aulast%3DLindmark%26aufirst%3DB.%26atitle%3DAccelerated%2520Drug%2520Discovery%2520by%2520Rapid%2520Candidate%2520Drug%2520Identification%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2019%26volume%3D24%26issue%3D6%26spage%3D1237%26epage%3D1241%26doi%3D10.1016%2Fj.drudis.2019.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kola, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landis, J.</span></span> <span> </span><span class="NLM_article-title">Opinion: Can the Pharmaceutical Industry Reduce Attrition Rates?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1038/nrd1470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1038%2Fnrd1470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=15286737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-716&issue=8&author=I.+Kolaauthor=J.+Landis&title=Opinion%3A+Can+the+Pharmaceutical+Industry+Reduce+Attrition+Rates%3F&doi=10.1038%2Fnrd1470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Opinion: Can the pharmaceutical industry reduce attrition rates?</span></div><div class="casAuthors">Kola, Ismail; Landis, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-716</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry faces considerable challenges, both politically and fiscally.  Politically, governments around the world are trying to contain costs and, as health care budgets constitute a very significant part of governmental spending, these costs are the subject of intense scrutiny.  In the United States, drug costs are also the subject of intense political discourse.  This article deals with the fiscal pressures that face the industry from the perspective of R&D.  What impinges on productivity How can we improve current reduced R&D productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruAlrpFPFmiLVg90H21EOLACvtfcHk0lgJHgpHaUhuHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D&md5=f9025c13a1506f607aaf68415570ed01</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrd1470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1470%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DOpinion%253A%2520Can%2520the%2520Pharmaceutical%2520Industry%2520Reduce%2520Attrition%2520Rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26issue%3D8%26spage%3D711%26epage%3D716%26doi%3D10.1038%2Fnrd1470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mytelka, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunwiddie, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persinger, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munos, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindborg, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schacht, A. L.</span></span> <span> </span><span class="NLM_article-title">How to Improve R&D Productivity: the Pharmaceutical Industry’s Grand Challenge</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1038/nrd3078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1038%2Fnrd3078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=20168317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFemsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=203-214&issue=3&author=S.+M.+Paulauthor=D.+S.+Mytelkaauthor=C.+T.+Dunwiddieauthor=C.+C.+Persingerauthor=B.+H.+Munosauthor=S.+R.+Lindborgauthor=A.+L.+Schacht&title=How+to+Improve+R%26D+Productivity%3A+the+Pharmaceutical+Industry%E2%80%99s+Grand+Challenge&doi=10.1038%2Fnrd3078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">How to improve R&D productivity: the pharmaceutical industry's grand challenge</span></div><div class="casAuthors">Paul, Steven M.; Mytelka, Daniel S.; Dunwiddie, Christopher T.; Persinger, Charles C.; Munos, Bernard H.; Lindborg, Stacy R.; Schacht, Aaron L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">203-214</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The pharmaceutical industry is under growing pressure from a range of environmental issues, including major losses of revenue owing to patent expirations, increasingly cost-constrained healthcare systems and more demanding regulatory requirements.  In our view, the key to tackling the challenges such issues pose to both the future viability of the pharmaceutical industry and advances in healthcare is to substantially increase the no. and quality of innovative, cost-effective new medicines, without incurring unsustainable R&D costs.  However, it is widely acknowledged that trends in industry R&D productivity have been moving in the opposite direction for a no. of years.  Here, we present a detailed anal. based on comprehensive, recent, industry-wide data to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity.  We then propose specific strategies that could have the most substantial impact in improving R&D productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY67PCIhaBVLVg90H21EOLACvtfcHk0lgMPPGdcjzCJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFemsbg%253D&md5=2f32bcc48c869290eef18ff9400afcc5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrd3078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3078%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DS.%2BM.%26aulast%3DMytelka%26aufirst%3DD.%2BS.%26aulast%3DDunwiddie%26aufirst%3DC.%2BT.%26aulast%3DPersinger%26aufirst%3DC.%2BC.%26aulast%3DMunos%26aufirst%3DB.%2BH.%26aulast%3DLindborg%26aufirst%3DS.%2BR.%26aulast%3DSchacht%26aufirst%3DA.%2BL.%26atitle%3DHow%2520to%2520Improve%2520R%2526D%2520Productivity%253A%2520the%2520Pharmaceutical%2520Industry%25E2%2580%2599s%2520Grand%2520Challenge%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26issue%3D3%26spage%3D203%26epage%3D214%26doi%3D10.1038%2Fnrd3078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Graaf, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegner, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Street, S. D. A.</span></span> <span> </span><span class="NLM_article-title">Can the Flow of Medicines be Improved? Fundamental Pharmacokinetic and Pharmacological Principles toward Improving Phase II Survival</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">9–10</span>),  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2011.12.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.drudis.2011.12.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=22227532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslymurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=419-424&issue=9%E2%80%9310&author=P.+Morganauthor=P.+H.+Van+Der+Graafauthor=J.+Arrowsmithauthor=D.+E.+Feltnerauthor=K.+S.+Drummondauthor=C.+D.+Wegnerauthor=S.+D.+A.+Street&title=Can+the+Flow+of+Medicines+be+Improved%3F+Fundamental+Pharmacokinetic+and+Pharmacological+Principles+toward+Improving+Phase+II+Survival&doi=10.1016%2Fj.drudis.2011.12.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival</span></div><div class="casAuthors">Morgan, Paul; Van Der Graaf, Piet H.; Arrowsmith, John; Feltner, Doug E.; Drummond, Kira S.; Wegner, Craig D.; Street, Steve D. A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">419-424</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In an effort to uncover systematic learnings that can be applied to improve compd. survival, an anal. was performed on data from Phase II decisions for 44 programs at Pfizer.  It was found that not only were the majority of failures caused by lack of efficacy but also that, in a large no. of cases (43%), it was not possible to conclude whether the mechanism had been tested adequately.  A key finding was that an integrated understanding of the fundamental pharmacokinetic/pharmacodynamic principles of exposure at the site of action, target binding and expression of functional pharmacol. activity (termed together as the three Pillars of survival') all det. the likelihood of candidate survival in Phase II trials and improve the chance of progression to Phase III.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFyWWmU_ARMLVg90H21EOLACvtfcHk0lgMPPGdcjzCJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslymurk%253D&md5=18816036124edb3d50c4e063fdc40614</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.12.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.12.020%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DVan%2BDer%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DFeltner%26aufirst%3DD.%2BE.%26aulast%3DDrummond%26aufirst%3DK.%2BS.%26aulast%3DWegner%26aufirst%3DC.%2BD.%26aulast%3DStreet%26aufirst%3DS.%2BD.%2BA.%26atitle%3DCan%2520the%2520Flow%2520of%2520Medicines%2520be%2520Improved%253F%2520Fundamental%2520Pharmacokinetic%2520and%2520Pharmacological%2520Principles%2520toward%2520Improving%2520Phase%2520II%2520Survival%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D9%25E2%2580%259310%26spage%3D419%26epage%3D424%26doi%3D10.1016%2Fj.drudis.2011.12.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, M.</span></span> <span> </span><span class="NLM_article-title">Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>47</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.085951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1124%2Fdmd.118.085951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=30910784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFeksbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2019&pages=665-672&issue=6&author=D.+A.+Smithauthor=M.+Rowland&title=Intracellular+and+Intraorgan+Concentrations+of+Small+Molecule+Drugs%3A+Theory%2C+Uncertainties+in+Infectious+Diseases+and+Oncology%2C+and+Promise&doi=10.1124%2Fdmd.118.085951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Intracellular and intraorgan concentrations of small molecule drugs: theory, uncertainties in infectious diseases and oncology, and promise</span></div><div class="casAuthors">Smith, Dennis A.; Rowland, Malcolm</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">665-672</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The distribution of a drug within the body should be considered as involving movement of unbound drug between the various aq. spaces of the body.  At true steady state, even for a compd. of restricted lipoidal permeability, unbound concns. in all aq. compartments (blood, extracellular, and intracellular) are considered identical, unless a compartment has a clearance/transport process.  In contrast, total drug concns. may differ greatly, reflecting binding or partitioning into constituents of each compartment.  For most highly lipid permeable drugs, this uniform unbound concn. is expected to apply.  However, many compds. have restricted lipoidal permeability and are subjected to transport/ clearance processes causing a gradient between intracellular and extracellular unbound concns. even at steady state.  Addnl. concerns arise where the drug target resides in a site of limited vascularity.  Many misleading assumptions about drug concns. and access to drug targets are based on total drug.  Correction, if made, is usually by measuring tissue binding, but this is limited by the lack of homogenicity of the organ or compartment.  Rather than looking for technol. to measure the unbound concn. it may be better to focus on designing high lipoidal permeable mols. with a high chance of achieving a uniform unbound drug concn.  It is hoped this paper will stimulate greater understanding of the path from circulation to cell interior, and thereby in part avoid or minimize the need to provide the exptl. very detg., and sometimes still questionable, answer to this problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovprJD-kOajrVg90H21EOLACvtfcHk0lgMPPGdcjzCJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFeksbbK&md5=d292c56b795d8d06fcd2abe1aeac1def</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.085951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.085951%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DRowland%26aufirst%3DM.%26atitle%3DIntracellular%2520and%2520Intraorgan%2520Concentrations%2520of%2520Small%2520Molecule%2520Drugs%253A%2520Theory%252C%2520Uncertainties%2520in%2520Infectious%2520Diseases%2520and%2520Oncology%252C%2520and%2520Promise%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2019%26volume%3D47%26issue%3D6%26spage%3D665%26epage%3D672%26doi%3D10.1124%2Fdmd.118.085951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mager, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jusko, W. J.</span></span> <span> </span><span class="NLM_article-title">Scaling Pharmacodynamics from in Vitro and Preclinical Animal Studies to Humans</span>. <i>Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.2133/dmpk.24.16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.2133%2Fdmpk.24.16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=19252333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1Whu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2009&pages=16-24&issue=1&author=D.+E.+Magerauthor=S.+Wooauthor=W.+J.+Jusko&title=Scaling+Pharmacodynamics+from+in+Vitro+and+Preclinical+Animal+Studies+to+Humans&doi=10.2133%2Fdmpk.24.16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Scaling pharmacodynamics from in vitro and preclinical animal studies to humans</span></div><div class="casAuthors">Mager, Donald E.; Woo, Sukyung; Jusko, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-24</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">A review.  An important feature of mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) models is the identification of drug- and system-specific factors that det. the intensity and time-course of pharmacol. effects.  This provides an opportunity to integrate information obtained from in vitro bioassays and preclin. pharmacol. studies in animals to anticipate the clin. and adverse responses to drugs in humans.  The fact that contemporary PK/PD modeling continues to evolve and seeks to emulate systems level properties should provide enhanced capabilities to scale-up pharmacodynamic data.  Crit. steps in drug discovery and development, such as lead compd. and first in human dose selection, may become more efficient with the implementation and further refinement of translational PK/PD modeling.  In this review, we highlight fundamental principles in pharmacodynamics and the basis expectations for in vitro bioassays and traditional allometric scaling in PK/PD modeling.  Discussion of PK/PD modeling efforts for recombinant human erythropoietin is also included as a case study showing the potential for advanced systems anal. to facilitate extrapolations and improve understanding of inter-species differences in drug responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjLp1-6RzUZrVg90H21EOLACvtfcHk0ljB74lUl30wYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1Whu78%253D&md5=2c8fbbe53b9cdc61bc88e392195cabdd</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.24.16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.24.16%26sid%3Dliteratum%253Aachs%26aulast%3DMager%26aufirst%3DD.%2BE.%26aulast%3DWoo%26aufirst%3DS.%26aulast%3DJusko%26aufirst%3DW.%2BJ.%26atitle%3DScaling%2520Pharmacodynamics%2520from%2520in%2520Vitro%2520and%2520Preclinical%2520Animal%2520Studies%2520to%2520Humans%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2009%26volume%3D24%26issue%3D1%26spage%3D16%26epage%3D24%26doi%3D10.2133%2Fdmpk.24.16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalvass, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassidy, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selley, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, G. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Pharmacodynamics of Seven Opioids in P-Glycoprotein-Competent Mice: Assessment of Unbound Brain EC50,u and Correlation of in Vitro, Preclinical, and Clinical data</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>323</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">346</span>– <span class="NLM_lpage">355</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.119560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1124%2Fjpet.107.119560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=17646430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFahsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2007&pages=346-355&issue=1&author=J.+C.+Kalvassauthor=E.+R.+Olsonauthor=M.+P.+Cassidyauthor=D.+E.+Selleyauthor=G.+M.+Pollack&title=Pharmacokinetics+and+Pharmacodynamics+of+Seven+Opioids+in+P-Glycoprotein-Competent+Mice%3A+Assessment+of+Unbound+Brain+EC50%2Cu+and+Correlation+of+in+Vitro%2C+Preclinical%2C+and+Clinical+data&doi=10.1124%2Fjpet.107.119560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data</span></div><div class="casAuthors">Kalvass, J. Cory; Olson, Emily R.; Cassidy, Michael P.; Selley, Dana E.; Pollack, Gary M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">346-355</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study was conducted to assess the utility of unbound brain EC50 (EC50,u) as a measure of in vivo potency for centrally active drugs.  Seven μ-opioid agonists (alfentanil, fentanyl, loperamide, methadone, meperidine, morphine, and sufentanil) were selected as model central nervous system drugs because they elicit a readily measurable central effect (antinociception) and their clin. pharmacokinetics/pharmacodynamics are well understood.  Mice received an equipotent s.c. dose of one of the model opioids.  The time course of antinociception and the serum and brain concns. were detd.  A pharmacokinetic/pharmacodynamic model was used to est. relevant parameters.  In vitro measures of opioid binding affinity (Ki) and functional activity [EC50 for agonist stimulated guanosine 5'-O-(3-[35S]thio)triphosphate binding] and relevant clin. parameters were obtained to construct in vitro-to-preclin. and preclin.-to-clin. correlations.  The strongest in vitro-to-in vivo correlation was obsd. between Ki and unbound brain EC50,u (r2 ∼ 0.8).  A strong correlation between mouse serum and human plasma EC50 was obsd. (r2 = 0.949); the correlation was improved when cor. for protein binding (r2 = 0.995).  Clin. equipotent i.v. dose was only moderately related to Ki.  However, ests. of ED50 and EC50 (total serum, unbound serum, total brain, and unbound brain) were significant predictors of clin. equipotent i.v. dose; the best correlation was obsd. for brain EC50,u (r2 = 0.982).  For each opioid, brain equilibration half-life in mice was almost identical to the plasma effect-site equilibration half-life measured clin.  These results indicate that the mouse is a good model for opioid human brain disposition and clin. pharmacol. and that superior in vitro-to-preclin. and preclin.-to-clin. correlations can be achieved with relevant unbound concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_E2A6_UTPA7Vg90H21EOLACvtfcHk0ljB74lUl30wYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFahsb%252FN&md5=589fda7ce9d453d14f428c599a3640e5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.119560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.119560%26sid%3Dliteratum%253Aachs%26aulast%3DKalvass%26aufirst%3DJ.%2BC.%26aulast%3DOlson%26aufirst%3DE.%2BR.%26aulast%3DCassidy%26aufirst%3DM.%2BP.%26aulast%3DSelley%26aufirst%3DD.%2BE.%26aulast%3DPollack%26aufirst%3DG.%2BM.%26atitle%3DPharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520Seven%2520Opioids%2520in%2520P-Glycoprotein-Competent%2520Mice%253A%2520Assessment%2520of%2520Unbound%2520Brain%2520EC50%252Cu%2520and%2520Correlation%2520of%2520in%2520Vitro%252C%2520Preclinical%252C%2520and%2520Clinical%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D323%26issue%3D1%26spage%3D346%26epage%3D355%26doi%3D10.1124%2Fjpet.107.119560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzel, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vage, C.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Orally-Active and Selective Azaindane 5HT2c Agonist for the Treatment of Obesity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">266</span>– <span class="NLM_lpage">271</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.bmcl.2009.10.112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=19914063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsb%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=266-271&issue=1&author=K.+K.+C.+Liuauthor=P.+Corneliusauthor=T.+A.+Pattersonauthor=Y.+Zengauthor=S.+Santucciauthor=E.+Tomlinsonauthor=C.+Gibbonsauthor=T.+S.+Maurerauthor=R.+Maralaauthor=J.+Brownauthor=J.+X.+Kongauthor=E.+Leeauthor=W.+Wernerauthor=Z.+Wenzelauthor=C.+Vage&title=Design+and+Synthesis+of+Orally-Active+and+Selective+Azaindane+5HT2c+Agonist+for+the+Treatment+of+Obesity&doi=10.1016%2Fj.bmcl.2009.10.112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity</span></div><div class="casAuthors">Liu, Kevin K.-C.; Cornelius, Peter; Patterson, Terrell A.; Zeng, Yuan; Santucci, Stephanie; Tomlinson, Elizabeth; Gibbons, Colleen; Maurer, Tristan S.; Marala, Ravi; Brown, Janice; Kong, Jimmy X.; Lee, Eunsun; Werner, Wendy; Wenzel, Zane; Vage, Chandra</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">266-271</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Based on the original pyrazine hit, CP-0809101, novel conformationally-restricted 5HT2c receptor agonists with 2-piperazin-azaindane scaffold were designed.  Synthesis and structure-activity relationship (SAR) studies are described with emphasis on optimization of the selectivity against 5HT2a and 5HT2b receptors with excellent 2c potency.  Orally-active and selective compds., e.g. I, were identified with dose-responsive in vivo efficacy in the pre-clin. food intake model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqyfkKxRsyzbVg90H21EOLACvtfcHk0ljB74lUl30wYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsF2jsb%252FK&md5=823ef6ce05e7a7b5471fd66d645ec818</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.112%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DCornelius%26aufirst%3DP.%26aulast%3DPatterson%26aufirst%3DT.%2BA.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DSantucci%26aufirst%3DS.%26aulast%3DTomlinson%26aufirst%3DE.%26aulast%3DGibbons%26aufirst%3DC.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DMarala%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DJ.%2BX.%26aulast%3DLee%26aufirst%3DE.%26aulast%3DWerner%26aufirst%3DW.%26aulast%3DWenzel%26aufirst%3DZ.%26aulast%3DVage%26aufirst%3DC.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Orally-Active%2520and%2520Selective%2520Azaindane%25205HT2c%2520Agonist%2520for%2520the%2520Treatment%2520of%2520Obesity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26issue%3D1%26spage%3D266%26epage%3D271%26doi%3D10.1016%2Fj.bmcl.2009.10.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuhl, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atchison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanian, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambroise, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brulet, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">am Ende, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judkins, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span> <span> </span><span class="NLM_article-title">Chemoproteomic Profiling Reveals that Cathepsin D Off-Target Activity Drives Ocular Toxicity of β-Secretase Inhibitors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13042</span>, <span class="refDoi"> DOI: 10.1038/ncomms13042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1038%2Fncomms13042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=27727204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13042&author=A.+M.+Zuhlauthor=C.+E.+Nolanauthor=M.+A.+Brodneyauthor=S.+Niessenauthor=K.+Atchisonauthor=C.+Houleauthor=D.+A.+Karanianauthor=C.+Ambroiseauthor=J.+W.+Bruletauthor=E.+M.+Beckauthor=S.+D.+Doranauthor=B.+T.+O%E2%80%99Neillauthor=C.+W.+am+Endeauthor=C.+Changauthor=K.+F.+Geogheganauthor=G.+M.+Westauthor=J.+C.+Judkinsauthor=X.+Houauthor=D.+R.+Riddellauthor=D.+S.+Johnson&title=Chemoproteomic+Profiling+Reveals+that+Cathepsin+D+Off-Target+Activity+Drives+Ocular+Toxicity+of+%CE%B2-Secretase+Inhibitors&doi=10.1038%2Fncomms13042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors</span></div><div class="casAuthors">Zuhl, Andrea M.; Nolan, Charles E.; Brodney, Michael A.; Niessen, Sherry; Atchison, Kevin; Houle, Christopher; Karanian, David A.; Ambroise, Claude; Brulet, Jeffrey W.; Beck, Elizabeth M.; Doran, Shawn D.; O'Neill, Brian T.; am Ende, Christopher W.; Chang, Cheng; Geoghegan, Kieran F.; West, Graham M.; Judkins, Joshua C.; Hou, Xinjun; Riddell, David R.; Johnson, Douglas S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13042</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of β-secretase BACE1 is considered one of the most promising approaches for treating Alzheimer's disease.  Several structurally distinct BACE1 inhibitors have been withdrawn from development after inducing ocular toxicity in animal models, but the target mediating this toxicity has not been identified.  Here we use a clickable photoaffinity probe to identify cathepsin D (CatD) as a principal off-target of BACE1 inhibitors in human cells.  We find that several BACE1 inhibitors blocked CatD activity in cells with much greater potency than that displayed in cell-free assays with purified protein.  Through a series of exploratory toxicol. studies, we show that quantifying CatD target engagement in cells with the probe is predictive of ocular toxicity in vivo.  Taken together, our findings designate off-target inhibition of CatD as a principal driver of ocular toxicity for BACE1 inhibitors and more generally underscore the power of chem. proteomics for discerning mechanisms of drug action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-LulGVRdJLVg90H21EOLACvtfcHk0lhg6fNE7srD1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL&md5=5e2c31195f4f03babec561a5824ccb0d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fncomms13042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13042%26sid%3Dliteratum%253Aachs%26aulast%3DZuhl%26aufirst%3DA.%2BM.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DAtchison%26aufirst%3DK.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DKaranian%26aufirst%3DD.%2BA.%26aulast%3DAmbroise%26aufirst%3DC.%26aulast%3DBrulet%26aufirst%3DJ.%2BW.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BT.%26aulast%3Dam%2BEnde%26aufirst%3DC.%2BW.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DWest%26aufirst%3DG.%2BM.%26aulast%3DJudkins%26aufirst%3DJ.%2BC.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DRiddell%26aufirst%3DD.%2BR.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26atitle%3DChemoproteomic%2520Profiling%2520Reveals%2520that%2520Cathepsin%2520D%2520Off-Target%2520Activity%2520Drives%2520Ocular%2520Toxicity%2520of%2520%25CE%25B2-Secretase%2520Inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13042%26doi%3D10.1038%2Fncomms13042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusoff, W. H.</span></span> <span> </span><span class="NLM_article-title">Relation between the Inhibition Constant (K1) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I50) of an Enzymic Reaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">3099</span>– <span class="NLM_lpage">3108</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=4202581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&issue=23&author=Y.-C.+Chengauthor=W.+H.+Prusoff&title=Relation+between+the+Inhibition+Constant+%28K1%29+and+the+Concentration+of+Inhibitor+Which+Causes+50+Per+Cent+Inhibition+%28I50%29+of+an+Enzymic+Reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction</span></div><div class="casAuthors">Cheng, Yung-Chi; Prusoff, William H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3099-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">The Ki and I50 values are equal where the kinetics are non- or uncompetitive, but not where they are competitive.  The relation between the 2 values was analyzed for non- and uncompetitive bi- and monosubstrate reactions and for competitive bisubstrate reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqodFY_8msz57Vg90H21EOLACvtfcHk0lhg6fNE7srD1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXhtVGgs7c%253D&md5=fe7175ca300d8f4085df87af37f8656c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.-C.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelation%2520between%2520the%2520Inhibition%2520Constant%2520%2528K1%2529%2520and%2520the%2520Concentration%2520of%2520Inhibitor%2520Which%2520Causes%252050%2520Per%2520Cent%2520Inhibition%2520%2528I50%2529%2520of%2520an%2520Enzymic%2520Reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26issue%3D23%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Features of Selective Kinase Inhibitors</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2005.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.chembiol.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=15975507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=621-637&issue=6&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Features+of+Selective+Kinase+Inhibitors&doi=10.1016%2Fj.chembiol.2005.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Features of Selective Kinase Inhibitors</span></div><div class="casAuthors">Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">621-637</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Summary: Small-mol. inhibitors of protein and lipid kinases have emerged as indispensable tools for studying signal transduction.  Despite the widespread use of these reagents, there is little consensus about the biochem. criteria that define their potency and selectivity in cells.  We discuss some of the features that det. the cellular activity of kinase inhibitors and propose a framework for interpreting inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAJWhVxtSrCLVg90H21EOLACvtfcHk0lhg6fNE7srD1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D&md5=ce5b3505a0326b04479172ec05573152</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DFeatures%2520of%2520Selective%2520Kinase%2520Inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26issue%3D6%26spage%3D621%26epage%3D637%26doi%3D10.1016%2Fj.chembiol.2005.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Black, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leff, P.</span></span> <span> </span><span class="NLM_article-title">Operational Models of Pharmacological Agonism</span>. <i>Proc. R. Soc. London, B</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>220</i></span> (<span class="NLM_issue">1219</span>),  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1098/rspb.1983.0093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1098%2Frspb.1983.0093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=6141562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaL2cXmtFaqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=220&publication_year=1983&pages=141-162&issue=1219&author=J.+W.+Blackauthor=P.+Leff&title=Operational+Models+of+Pharmacological+Agonism&doi=10.1098%2Frspb.1983.0093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Operational models of pharmacological agonism</span></div><div class="casAuthors">Black, J. W.; Leff, P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Royal Society of London, Series B:  Biological Sciences</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">220</span>
        (<span class="NLM_cas:issue">1219</span>),
    <span class="NLM_cas:pages">141-62</span>CODEN:
                <span class="NLM_cas:coden">PRLBA4</span>;
        ISSN:<span class="NLM_cas:issn">0080-4649</span>.
    </div><div class="casAbstract">A general, operational model is presented which explicitly describes pharmacol. agonism in terms of 3 parameters: an agonist-receptor dissocn. const., the total receptor concn. [Ro], and a parameter (KE) which defines the transduction of the agonist-receptor complex into pharmacol. effect.  The ratio RO/KE, the transducer ratio (τ), is a logical definition for the efficacy of an agonist in a system.  The model provides a chem. definition of intrinsic efficacy, making this parameter exptl. accessible in principle.  Alternate models are compared and contrasted with regard to their practical and conceptual utilities in exptl. pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonpXVldFQ_nbVg90H21EOLACvtfcHk0ljMEaIsXtYyYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmtFaqtA%253D%253D&md5=a0421df9c56495d48d076010acf44b65</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1098%2Frspb.1983.0093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frspb.1983.0093%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DJ.%2BW.%26aulast%3DLeff%26aufirst%3DP.%26atitle%3DOperational%2520Models%2520of%2520Pharmacological%2520Agonism%26jtitle%3DProc.%2520R.%2520Soc.%2520London%252C%2520B%26date%3D1983%26volume%3D220%26issue%3D1219%26spage%3D141%26epage%3D162%26doi%3D10.1098%2Frspb.1983.0093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boddeke, H. W. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymonde, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoeffter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyer, D.</span></span> <span> </span><span class="NLM_article-title">Agonist/Antagonist Interactions with Cloned Human 5-HT1A Receptors: Variations in Intrinsic Activity Studied in Transfected HeLa Cells</span>. <i>Naunyn-Schmiedeberg’s Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>345</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1007/BF00168684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1007%2FBF00168684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1535691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaK38XisV2itL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=1992&pages=257-263&issue=3&author=H.+W.+G.+M.+Boddekeauthor=A.+Farginauthor=J.+R.+Raymondeauthor=P.+Schoeffterauthor=D.+Hoyer&title=Agonist%2FAntagonist+Interactions+with+Cloned+Human+5-HT1A+Receptors%3A+Variations+in+Intrinsic+Activity+Studied+in+Transfected+HeLa+Cells&doi=10.1007%2FBF00168684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist/antagonist interactions with cloned human 5-HT1A receptors:  variations in intrinsic activity studied in transfected HeLa cells</span></div><div class="casAuthors">Boddeke, Hendrikus W. G. M.; Fargin, Annick; Raymond, John R.; Schoeffter, Philippe; Hoyer, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">257-63</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    </div><div class="casAbstract">The characteristics of 5-HT1A-recognition sites and receptor-mediated release of intracellular calcium were established in 2 transfected HeLa cell lines (HA 6 and HA 7) expressing different levels of human 5-HT1A receptors (∼3000 and 500 fmol/mg protein).  The pharmacol. profiles of the binding (detd. with [3H]8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT)] and the calcium response (measured using Fura 2) were clearly of the 5-HT1A type.  Compds. such as 5-HT, 5-carboxamidotryptamine (5-CT), and 8-OH-DPAT acted as full agonists on the calcium response in both HeLa cell lines.  In addn., methiothepin, pindolol, NAN 190 and SDZ 216-525 (Seiler, M. P.; et al., 1991) acted as silent and potent antagonists.  Marked differences were obsd. in the responses mediated in the 2 cell lines.  EC50 values of agonists (particularly 5-HT, 5-CT, flesinoxan, and 8-OH-DPAT) were higher in HA 7 cells (≤80-fold) than in other 5-HT1A receptor models (e.g. inhibition of adenylate cyclase in calf hippocampus).  Further, a variety of compds. (ipsapirone, buspirone, spiroxatrine, MDL 73005) acted as agonists in HA 6 cells, whereas they behaved as silent antagonists in HA 7 cells (which express fewer receptors).  By contrast, KB values for antagonists were comparable in HA 6 and HA 7 cells.  Thus, EC50 values and intrinsic activity for a given drug are subject to large variations depending on the no. of receptors expressed in the target tissue.  The results obtained in HA 6 cells are comparable with respect to both potency and efficacy to those obsd. in calf or mouse hippocampus (inhibition of forskolin stimulated adenylate cyclase), whereas the results obtained in HA 7 cells are similar to those reported in mouse cortex (which was suggested to represent an atypical subtype of the 5-HT1A receptor).  Since the agonist activity of a given compd. at the same receptor can vary markedly, the present data show that intrinsic activity is not only ligand-dependent but also varies with the receptor-effector system studied.  In addn., there seems to be no simple way to make predictions about intrinsic activity, since that feature is model-dependent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbq9_UGwosprVg90H21EOLACvtfcHk0ljMEaIsXtYyYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisV2itL4%253D&md5=e71b59284f86b4743e076aebee5b3fb0</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2FBF00168684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00168684%26sid%3Dliteratum%253Aachs%26aulast%3DBoddeke%26aufirst%3DH.%2BW.%2BG.%2BM.%26aulast%3DFargin%26aufirst%3DA.%26aulast%3DRaymonde%26aufirst%3DJ.%2BR.%26aulast%3DSchoeffter%26aufirst%3DP.%26aulast%3DHoyer%26aufirst%3DD.%26atitle%3DAgonist%252FAntagonist%2520Interactions%2520with%2520Cloned%2520Human%25205-HT1A%2520Receptors%253A%2520Variations%2520in%2520Intrinsic%2520Activity%2520Studied%2520in%2520Transfected%2520HeLa%2520Cells%26jtitle%3DNaunyn-Schmiedeberg%25E2%2580%2599s%2520Arch.%2520Pharmacol.%26date%3D1992%26volume%3D345%26issue%3D3%26spage%3D257%26epage%3D263%26doi%3D10.1007%2FBF00168684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roeske, W. R.</span></span> <span> </span><span class="NLM_article-title">The Relationship between Agonist States of the M1 Muscarinic Receptor and the Hydrolysis of Inositol Lipids in Transfected Murine Fibroblast Cells (B82) Expressing Different Receptor Densities</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>251</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">97</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=2795474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaL1MXmtV2mu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=251&publication_year=1989&pages=90-97&issue=1&author=L.+Meiauthor=J.+Laiauthor=H.+I.+Yamamuraauthor=W.+R.+Roeske&title=The+Relationship+between+Agonist+States+of+the+M1+Muscarinic+Receptor+and+the+Hydrolysis+of+Inositol+Lipids+in+Transfected+Murine+Fibroblast+Cells+%28B82%29+Expressing+Different+Receptor+Densities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The relationship between agonist states of the M1 muscarinic receptor and the hydrolysis of inositol lipids in transfected murine fibroblast cells (B82) expressing different receptor densities</span></div><div class="casAuthors">Mei, Lin; Lai, Josephine; Yamamura, Henry I.; Roeske, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">251</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-7</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">The relationship between the M1 muscarinic receptor d. and the receptor-mediated hydrolysis of inositol lipids was studied in cloned murine fibroblast B82 cells which were transfected with the m1 muscarinic receptor gene.  Of the 7 clones examd., the M1 muscarinic receptor densities in these cells characterized by (-)[3H]methyl-3-quinuclidinylbenzilate [(-)-[3H]MQNB] binding ranged from 12 fmol/106 cells in LK3-1 cells to 260 fmol/106 cells in the LK3-8 cells.  Carbachol/(-)[3H]MQNB competition curves for the LK3-1 cells (with low receptor d.) had a Hill coeff. close to unity.  The competition curves for carbachol in the clones with higher receptor densities had Hill coeffs. <1 and were best fitted by a computerized nonlinear least-squares regression program for the 2-site model.  The percentage of the M1 muscarinic receptors which had high affinity for carbachol decreased as the receptor d. increased, suggesting that the presence of endogenous factors in these cells may be important for the agonist affinity state of the receptor.  Concn.-response curves for carbachol-stimulated [3H]inositol monophosphate ([3H]IP1) accumulation were also obtained.  A correlation was obsd. between the d. of M1 muscarinic receptor with high affinity for carbachol and the max. [3H]IP1 accumulation in these cells.  There is no difference among the EC50 values and the dissocn. const. of high-affinity state values of the carbachol/(-)[3H]MQNB competition curves.  Thus, the high-affinity state for carbachol may be the functional state of the M1 muscarinic receptors in these transfected B82 cells.  Although a linear correlation between the total M1 muscarinic receptor d. and the max. [3H]IP1 accumulation was obsd., there was evidence for the existence of spare M1 receptors in the clones with high receptor densities but not in those with low receptor densities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4S_GP0Qcgd7Vg90H21EOLACvtfcHk0ljMEaIsXtYyYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXmtV2mu78%253D&md5=0ed0651d9cc57fe8a56023a367400c09</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMei%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DJ.%26aulast%3DYamamura%26aufirst%3DH.%2BI.%26aulast%3DRoeske%26aufirst%3DW.%2BR.%26atitle%3DThe%2520Relationship%2520between%2520Agonist%2520States%2520of%2520the%2520M1%2520Muscarinic%2520Receptor%2520and%2520the%2520Hydrolysis%2520of%2520Inositol%2520Lipids%2520in%2520Transfected%2520Murine%2520Fibroblast%2520Cells%2520%2528B82%2529%2520Expressing%2520Different%2520Receptor%2520Densities%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1989%26volume%3D251%26issue%3D1%26spage%3D90%26epage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilardaga, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciccarelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubeaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Neef, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robberecht, P.</span></span> <span> </span><span class="NLM_article-title">Properties and Regulation of the Coupling to Adenylate Cyclase of Secretin Receptors Stably Transfected in Chinese Hamster Ovary Cells</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1022</span>– <span class="NLM_lpage">1028</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=8190092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaK2cXktVWmsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1994&pages=1022-1028&issue=5&author=J.+P.+Vilardagaauthor=E.+Ciccarelliauthor=C.+Dubeauxauthor=P.+De+Neefauthor=A.+Bollenauthor=P.+Robberecht&title=Properties+and+Regulation+of+the+Coupling+to+Adenylate+Cyclase+of+Secretin+Receptors+Stably+Transfected+in+Chinese+Hamster+Ovary+Cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Properties and regulation of the coupling to adenylate cyclase of secretin receptors stably transfected in Chinese hamster ovary cells</span></div><div class="casAuthors">Vilardaga, J. P.; Ciccarelli, E.; Dubeaux, C.; De Neef, P.; Bollen, A.; Robberecht, P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1022-8</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">The binding properties, coupling to adenylate cyclase, and desensitization of secretin receptors stably expressed in transfected Chinese hamster ovary (CHO) cells were compared in two clones expressing high (CHO-SnR-c5, 450 fmol/mg of protein) and low (CHO-SnR-c1, 40 fmol/mg of protein) receptor densities.  The Kd values for receptor occupancy by secretin, selected analogs, and fragments were identical in CHO-SnR-c1 and -c5 cells and identical to those described for native receptors from NG 108-15 cells.  The Kact values for adenylate cyclase stimulation were identical to the Kd values in CHO-SnR-c1 cells but 5-10-fold higher than those in CHO-SnR-c5 cells.  The Kact values in both CHO-SnR-c1 and -c5 cell lines were reduced in the presence of the nonhydrolyzable GTP deriv. guanosine-5'-(β,γ-imido)triphosphate and after pretreatment of the cells with cholera toxin.  Preincubation of both CHO-SnR-c1 and -c5 cell lines with secretin for 24 h reduced their binding capacity and reduced secretin efficacy in CHO-SnR-c1 cells and secretin potency in CHO-SnR-c5 cells.  These results suggest efficient coupling of the secretin receptor to the adenylate cyclase machinery and the existence of spare receptors in the clone expressing higher receptor d.  Pretreatment of the two cell lines with the reducing agent dithiothreitol reduced the binding capacity and induced the appearance of a low affinity binding component.  In both cell lines, dithiothreitol pretreatment decreased secretin potency but not secretin efficacy, suggesting the necessity of integrity of the disulfide bridges for optimal receptor recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwspuuyO6wirVg90H21EOLACvtfcHk0liT7s3DRBPf8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktVWmsL0%253D&md5=33b3da332935ecf58928215f9b977cb7</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVilardaga%26aufirst%3DJ.%2BP.%26aulast%3DCiccarelli%26aufirst%3DE.%26aulast%3DDubeaux%26aufirst%3DC.%26aulast%3DDe%2BNeef%26aufirst%3DP.%26aulast%3DBollen%26aufirst%3DA.%26aulast%3DRobberecht%26aufirst%3DP.%26atitle%3DProperties%2520and%2520Regulation%2520of%2520the%2520Coupling%2520to%2520Adenylate%2520Cyclase%2520of%2520Secretin%2520Receptors%2520Stably%2520Transfected%2520in%2520Chinese%2520Hamster%2520Ovary%2520Cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D1994%26volume%3D45%26issue%3D5%26spage%3D1022%26epage%3D1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladurner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronk, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallender, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Browne, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. W.</span></span> <span> </span><span class="NLM_article-title">Agonist Potency at the Cloned Human beta-3-Adrenoceptor Depends on Receptor Expression Level and Nature of Assay</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>279</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">214</span>– <span class="NLM_lpage">221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=8858996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaK28Xmtlemurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1996&pages=214-221&issue=1&author=S.+Wilsonauthor=J.+K.+Chambersauthor=J.+E.+Parkauthor=A.+Ladurnerauthor=D.+W.+Cronkauthor=C.+G.+Chapmanauthor=H.+Kallenderauthor=M.+J.+Browneauthor=G.+J.+Murphyauthor=P.+W.+Young&title=Agonist+Potency+at+the+Cloned+Human+beta-3-Adrenoceptor+Depends+on+Receptor+Expression+Level+and+Nature+of+Assay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist potency at the cloned human beta-3-adrenoceptor depends on receptor expression level and nature of assay</span></div><div class="casAuthors">Wilson, Shelagh; Chambers, Jon K.; Park, Janet E.; Ladurner, Andreas; Cronk, David W.; Chapman, Conrad G.; Kallender, Howard; Browne, Michael J.; Murphy, Gregory J.; Young, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">214-221</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The cloned human β3-adrenoceptor was expressed in Chinese hamster ovary cells at three different levels (130, 400 and 3000 fmol/mg).  The potency and intrinsic activity of a range of agonists in functional assays with these cell lines rose as a function of increasing receptor d.  Operational anal. of concn.-response data allowed calcn. of functional affinity and efficacy of agonists at the human β3-adrenoceptor.  The data highlighted the low efficacy of BRL 37344 for the human β3-adrenoceptor, which may explain its lower potency at the human receptor despite its higher affinity relative to isoprenaline.  The potency of catecholamines at the human β3-adrenoceptor was 1 to 2 orders of magnitude higher when detd. in an intact cell cAMP accumulation assay compared with a membrane-based adenylyl cyclase activation assay.  The reason for this enhanced sensitivity is not clear, but the result is that the potency of the natural agonist noradrenaline in the intact cell is considerably higher than predicted either from its ligand binding affinity, or from its potency in membrane-based assays.  Much smaller enhancements in sensitivity were obsd. for compds. of the aryloxypropanolamine class such as CGP 12177, with the result that the rank order of potency of such agonists at the β3-adrenoceptor was altered.  In particular, CGP 12177 exhibited high relative potency in the cyclase assay, but low relative potency in intact cell assays.  These findings highlight the importance of selecting appropriate expression levels and appropriate assay methodol. when cloned receptors are used to characterize agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrE1drf0Q7l7Vg90H21EOLACvtfcHk0liT7s3DRBPf8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xmtlemurs%253D&md5=a798adedd58dd0057c3293a27a413150</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DChambers%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DLadurner%26aufirst%3DA.%26aulast%3DCronk%26aufirst%3DD.%2BW.%26aulast%3DChapman%26aufirst%3DC.%2BG.%26aulast%3DKallender%26aufirst%3DH.%26aulast%3DBrowne%26aufirst%3DM.%2BJ.%26aulast%3DMurphy%26aufirst%3DG.%2BJ.%26aulast%3DYoung%26aufirst%3DP.%2BW.%26atitle%3DAgonist%2520Potency%2520at%2520the%2520Cloned%2520Human%2520beta-3-Adrenoceptor%2520Depends%2520on%2520Receptor%2520Expression%2520Level%2520and%2520Nature%2520of%2520Assay%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1996%26volume%3D279%26issue%3D1%26spage%3D214%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ploeger, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Graaf, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danhof, M.</span></span> <span> </span><span class="NLM_article-title">Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling</span>. <i>Drug Metab. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.2133/dmpk.24.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.2133%2Fdmpk.24.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=19252332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1Whu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2009&pages=3-15&issue=1&author=B.+A.+Ploegerauthor=P.+H.+van+der+Graafauthor=M.+Danhof&title=Incorporating+Receptor+Theory+in+Mechanism-Based+Pharmacokinetic-Pharmacodynamic+%28PK-PD%29+Modeling&doi=10.2133%2Fdmpk.24.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling</span></div><div class="casAuthors">Ploeger, Bart A.; van der Graaf, Piet H.; Danhof, Meindert</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Pharmacokinetics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-15</span>CODEN:
                <span class="NLM_cas:coden">DMPRB8</span>;
        ISSN:<span class="NLM_cas:issn">1347-4367</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society for the Study of Xenobiotics</span>)
        </div><div class="casAbstract">A review.  Pharmacokinetic-Pharmacodynamic (PK-PD) modeling helps to better understand drug efficacy and safety and has, therefore, become a powerful tool in the learning-confirming cycles of drug-development.  In translational drug research, mechanism-based PK-PD modeling has been recognized as a tool for bringing forward early insights in drug efficacy and safety into the clin. development.  These models differ from descriptive PK-PD models in that they quant. characterize specific processes in the causal chain between drug administration and effect.  This includes target site distribution, binding and activation, pharmacodynamic interactions, transduction and homeostatic feedback mechanisms.  Compared to descriptive models mechanism-based PK-PD models that utilize receptor theory concepts for characterization of target binding and target activation processes have improved properties for extrapolation and prediction.  In this respect, receptor theory constitutes the basis for (1) prediction of in vivo drug concn.-effect relationships and (2) characterization of target assocn.-dissocn. kinetics as determinants of hysteresis in the time course of the drug effect.  This approach intrinsically distinguishes drug- and system specific parameters explicitly, allowing accurate extrapolation from in vitro to in vivo and across species.  This review provides an overview of recent developments in incorporating receptor theory in PK-PD modeling with a specific focus on the identifiability of these models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiEoxCJr7FxLVg90H21EOLACvtfcHk0liT7s3DRBPf8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1Whu74%253D&md5=1a7546e40bee16441d6ae69a73b679e8</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.2133%2Fdmpk.24.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2133%252Fdmpk.24.3%26sid%3Dliteratum%253Aachs%26aulast%3DPloeger%26aufirst%3DB.%2BA.%26aulast%3Dvan%2Bder%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3DDanhof%26aufirst%3DM.%26atitle%3DIncorporating%2520Receptor%2520Theory%2520in%2520Mechanism-Based%2520Pharmacokinetic-Pharmacodynamic%2520%2528PK-PD%2529%2520Modeling%26jtitle%3DDrug%2520Metab.%2520Pharmacokinet.%26date%3D2009%26volume%3D24%26issue%3D1%26spage%3D3%26epage%3D15%26doi%3D10.2133%2Fdmpk.24.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span> <span> </span><span class="NLM_article-title">Analytical Pharmacology: How Numbers Can Guide Drug Discovery</span>. <i>ACS Pharmacol. Transl. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1021/acsptsci.8b00057</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsptsci.8b00057" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivFWrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&pages=9-17&issue=1&author=T.+Kenakin&title=Analytical+Pharmacology%3A+How+Numbers+Can+Guide+Drug+Discovery&doi=10.1021%2Facsptsci.8b00057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Analytical Pharmacology: How Numbers Can Guide Drug Discovery</span></div><div class="casAuthors">Kenakin, Terry</div><div class="citationInfo"><span class="NLM_cas:title">ACS Pharmacology & Translational Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-17</span>CODEN:
                <span class="NLM_cas:coden">APTSFN</span>;
        ISSN:<span class="NLM_cas:issn">2575-9108</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The unique ways in which pharmacol. data compares to math. models are described.  Examples show that insights into agonist action (prediction of agonism in vivo) and antagonist mechanism of action (orthosteric vs allosteric) can be gained that assist in the candidate selection process for new drugs in drug discovery and development efforts.  In addn., the impact of component processes on complex physiol. systems can be delineated, such as the effects of the hepatic system on whole body clearance in pharmacokinetics and prediction of drug-drug interactions.  Finally, models are instrumental in the procurement of universal drug parameters that can be used in medicinal chem.-based structure-activity relationships.  The revitalization of these ideas under the banner of "Anal. Pharmacol." may serve to re-emphasize these concepts over qual. description and lead to a better foundation for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRrI1PZfWIUrVg90H21EOLACvtfcHk0lhBXERNnSPBKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivFWrsA%253D%253D&md5=b1979716d723efe9c19c117301caf564</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facsptsci.8b00057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsptsci.8b00057%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26atitle%3DAnalytical%2520Pharmacology%253A%2520How%2520Numbers%2520Can%2520Guide%2520Drug%2520Discovery%26jtitle%3DACS%2520Pharmacol.%2520Transl.%2520Sci.%26date%3D2019%26volume%3D2%26issue%3D1%26spage%3D9%26epage%3D17%26doi%3D10.1021%2Facsptsci.8b00057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabrizi-Fard, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, H.-L.</span></span> <span> </span><span class="NLM_article-title">Impact of Mechanism-Based Enzyme Inactivation on Inhibitor Potency: Implications for Rational Drug Discovery</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1414</span>, <span class="refDoi"> DOI: 10.1002/1520-6017(200011)89:11<1404::AID-JPS4>3.0.CO;2-#</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=11015686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVygsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2000&pages=1404-1414&issue=11&author=T.+S.+Maurerauthor=M.+A.+Tabrizi-Fardauthor=H.-L.+Fung&title=Impact+of+Mechanism-Based+Enzyme+Inactivation+on+Inhibitor+Potency%3A+Implications+for+Rational+Drug+Discovery&doi=10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of mechanism-based enzyme inactivation on inhibitor potency: implications for rational drug discovery</span></div><div class="casAuthors">Maurer, Tristan S.; Tabrizi-Fard, Mohammad A.; Fung, Ho-Leung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1404-1414</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Mechanism-based enzyme inactivators (MBEIs) have unique kinetic actions that make predictions of potency, selectivity, and potential for metabolic drug interactions more complex than for competitive antagonists.  We have derived a math. relationship that links the influence of substrate concn. and binding const. ([S] and Km, resp.), inhibitor concn. and binding const. ([I] and KI, resp.), and inactivation rate const. (kinact) to enzyme activity (v) and maximal activity (Vmax) at any time (t).  The kinetic behavior of this relationship was validated in murine-macrophage cell cultures using MBEIs of nitric oxide synthase (NOS).  This initial equation was also used in the derivation of a new relationship that directly links the kinetic parameters of mechanism-based inactivation to inhibitory potency at a particular time (IC50(t)).  Using this direct relationship, we obsd. that the predicted rank inhibitory potency of a series of MBEIs was improved over that predicted by the KI parameter alone.  These relationships offer a fundamental understanding of the kinetics of MBEI action and may be useful in the evaluation of these compds. during the discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpORTg5_VClm7Vg90H21EOLACvtfcHk0lhBXERNnSPBKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVygsbY%253D&md5=9cfdede7312035ea0971247595106a9e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1520-6017%2528200011%252989%253A11%253C1404%253A%253AAID-JPS4%253E3.0.CO%253B2-%2523%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DTabrizi-Fard%26aufirst%3DM.%2BA.%26aulast%3DFung%26aufirst%3DH.-L.%26atitle%3DImpact%2520of%2520Mechanism-Based%2520Enzyme%2520Inactivation%2520on%2520Inhibitor%2520Potency%253A%2520Implications%2520for%2520Rational%2520Drug%2520Discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2000%26volume%3D89%26issue%3D11%26spage%3D1404%26epage%3D1414%26doi%3D10.1002%2F1520-6017%28200011%2989%3A11%3C1404%3A%3AAID-JPS4%3E3.0.CO%3B2-%23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowland
Yeo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsky, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostami-Hodjegan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, G. T.</span></span> <span> </span><span class="NLM_article-title">Prediction of Time-Dependent CYP3A4 Drug-Drug Interactions by Physiologically Based Pharmacokinetic Modelling: Impact of Inactivation Parameters and Enzyme Turnover</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2011.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.ejps.2011.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=21540107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFSkt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2011&pages=160-173&issue=3&author=K.+Rowland%0AYeoauthor=R.+L.+Walskyauthor=M.+Jameiauthor=A.+Rostami-Hodjeganauthor=G.+T.+Tucker&title=Prediction+of+Time-Dependent+CYP3A4+Drug-Drug+Interactions+by+Physiologically+Based+Pharmacokinetic+Modelling%3A+Impact+of+Inactivation+Parameters+and+Enzyme+Turnover&doi=10.1016%2Fj.ejps.2011.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover</span></div><div class="casAuthors">Rowland Yeo, K.; Walsky, R. L.; Jamei, M.; Rostami-Hodjegan, A.; Tucker, G. T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">160-173</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Predicting the magnitude of time-dependent metabolic drug-drug (mDDIs) interactions involving cytochrome P 450 3A4 (CYP3A4) from in vitro data requires accurate knowledge of the inactivation parameters of the inhibitor (K I, k inact) and of the turnover of the enzyme (k deg) in both the gut and the liver.  We have predicted the magnitude of mDDIs obsd. in 29 in vivo studies involving six CYP3A4 probe substrates and five mechanism based inhibitors of CYP3A4 of variable potency (azithromycin, clarithromycin, diltiazem, erythromycin and verapamil).  Inactivation parameters detd. anew in a single lab. under standardised conditions together with data from substrate and inhibitor files within the Simcyp Simulator (Version 9.3) were used to det. a value of the hepatic k deg (0.0193 or 0.0077 h-1) most appropriate for the prediction of mDDIs involving time-dependent inhibition of CYP3A4.  The higher value resulted in decreased bias (geometric mean fold error - 1.05 vs. 1.30) and increased precision (root mean squared error - 1.29 vs. 2.30) of predictions of mean ratios of AUC in the absence and presence of inhibitor.  Depending on the k deg value used (0.0193 vs. 0.0077 h-1), predicted mean ratios of AUC were within 2-fold of the obsd. values for all (100%) and 27 (93%) of the 29 studies, resp. and within 1.5-fold for 24 (83%) and 17 (59%) of the 29 studies, resp.  Comprehensive PBPK models were applied for accurate assessment of the potential for mDDIs involving time-dependent inhibition of CYP3A4 using a hepatic k deg value of 0.0193 h-1 in conjunction with inactivation parameters detd. by the conventional exptl. approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3Smu_gOTvVbVg90H21EOLACvtfcHk0lhBXERNnSPBKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFSkt7Y%253D&md5=ab242e3e6c530c220ca3d73340d6ac00</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2011.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2011.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DRowland%2BYeo%26aufirst%3DK.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DJamei%26aufirst%3DM.%26aulast%3DRostami-Hodjegan%26aufirst%3DA.%26aulast%3DTucker%26aufirst%3DG.%2BT.%26atitle%3DPrediction%2520of%2520Time-Dependent%2520CYP3A4%2520Drug-Drug%2520Interactions%2520by%2520Physiologically%2520Based%2520Pharmacokinetic%2520Modelling%253A%2520Impact%2520of%2520Inactivation%2520Parameters%2520and%2520Enzyme%2520Turnover%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D43%26issue%3D3%26spage%3D160%26epage%3D173%26doi%3D10.1016%2Fj.ejps.2011.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayhew, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S. D.</span></span> <span> </span><span class="NLM_article-title">An in Vitro Model for Predicting in Vivo Inhibition of Cytochrome P450 3A4 by Metabolic Intermediate Complex Formation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1037</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10950845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtFCrtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=1031-1037&issue=9&author=B.+S.+Mayhewauthor=D.+R.+Jonesauthor=S.+D.+Hall&title=An+in+Vitro+Model+for+Predicting+in+Vivo+Inhibition+of+Cytochrome+P450+3A4+by+Metabolic+Intermediate+Complex+Formation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation</span></div><div class="casAuthors">Mayhew, Bradley S.; Jones, David R.; Hall, Stephen D.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1031-1037</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">An in vitro model is proposed to account for the clin. obsd. inhibition of cytochrome P 450 (CYP) 3A that results from administration of clarithromycin, fluoxetine, or diltiazem.  Rates for loss of CYP3A4 enzymic activity resulting from metabolic intermediate complex formation and the concn. dependencies thereof were detd. in vitro for clarithromycin, fluoxetine, and N-desmethyl diltiazem, which is the primary metabolite of diltiazem.  Using the in vitro concn.-dependent rates for loss of activity, in vivo rates of CYP3A4 inactivation were predicted for these compds. at a clin. relevant unbound plasma concn. of 0.1 μM.  Based on the predicted rates combined with published rates for in vivo CYP3A degrdn., our model predicts that fluoxetine, clarithromycin, and the primary metabolite of diltiazem reduce the steady-state concn. of liver CYP3A4 to approx. 72, 39, or 21% of initial levels, resp.  These redns. correspond to 1.4-, 2.6-, or 4.7-fold increases, resp., in the area under the plasma concn.-time curve of a coadministered drug that is eliminated exclusively by hepatic CYP3A4 metab.  These predicted results are in good agreement with reported clin. data.  The major implication of this work is that fluoxetine, clarithromycin, and the primary metabolite of diltiazem, at clin. relevant concns., inactivate CYP3A4 enzymic activity at rates sufficient to affect in vivo concns. of CYP3A4 and thereby affect the clearance of compds. eliminated by this pathway.  We speculate that mechanisms involving substrate-mediated mechanistic inactivation of CYPs play a major role in many clin. obsd. drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEd5oxG2WwlrVg90H21EOLACvtfcHk0liLm2Pp-t05hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtFCrtbg%253D&md5=1b36235981bcebd86376586d2dedace7</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMayhew%26aufirst%3DB.%2BS.%26aulast%3DJones%26aufirst%3DD.%2BR.%26aulast%3DHall%26aufirst%3DS.%2BD.%26atitle%3DAn%2520in%2520Vitro%2520Model%2520for%2520Predicting%2520in%2520Vivo%2520Inhibition%2520of%2520Cytochrome%2520P450%25203A4%2520by%2520Metabolic%2520Intermediate%2520Complex%2520Formation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2000%26volume%3D28%26issue%3D9%26spage%3D1031%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erion, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T.</span></span> <span> </span><span class="NLM_article-title">Model-Based Assessment of Plasma Citrate Flux Into the Liver: Implications for NaCT as a Therapeutic Target</span>. <i>CPT: Pharmacometrics Syst. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">132</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1002/psp4.12062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2Fpsp4.12062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=27069776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1Gnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=132-139&issue=3&author=Z.+Liauthor=D.+Erionauthor=T.+Maurer&title=Model-Based+Assessment+of+Plasma+Citrate+Flux+Into+the+Liver%3A+Implications+for+NaCT+as+a+Therapeutic+Target&doi=10.1002%2Fpsp4.12062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Model-Based Assessment of Plasma Citrate Flux Into the Liver: Implications for NaCT as a Therapeutic Target</span></div><div class="casAuthors">Li, Z.; Erion, Dm; Maurer, Ts</div><div class="citationInfo"><span class="NLM_cas:title">CPT: Pharmacometrics & Systems Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">132-139</span>CODEN:
                <span class="NLM_cas:coden">CPSPBR</span>;
        ISSN:<span class="NLM_cas:issn">2163-8306</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Cytoplasmic citrate serves as an important regulator of gluconeogenesis and carbon source for de novo lipogenesis in the liver.  For this reason, the sodium-coupled citrate transporter (NaCT), a plasma membrane transporter that governs hepatic influx of plasma citrate in human, is being explored as a potential therapeutic target for metabolic disorders.  As cytoplasmic citrate also originates from intracellular mitochondria, the relative contribution of these two pathways represents crit. information necessary to underwrite confidence in this target.  In this work, hepatic influx of plasma citrate was quantified via pharmacokinetic modeling of published clin. data.  The influx was then compared to independent literature ests. of intracellular citrate flux in human liver.  The results indicate that, under normal conditions, <10% of hepatic citrate originates from plasma.  Similar ests. were detd. exptl. in mice and rats.  This suggests that NaCT inhibition will have a limited impact on hepatic citrate concns. across species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEqnnsuh1zvrVg90H21EOLACvtfcHk0liLm2Pp-t05hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1Gnt7c%253D&md5=d9055275904abd411b300f03e979450a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fpsp4.12062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsp4.12062%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DErion%26aufirst%3DD.%26aulast%3DMaurer%26aufirst%3DT.%26atitle%3DModel-Based%2520Assessment%2520of%2520Plasma%2520Citrate%2520Flux%2520Into%2520the%2520Liver%253A%2520Implications%2520for%2520NaCT%2520as%2520a%2520Therapeutic%2520Target%26jtitle%3DCPT%253A%2520Pharmacometrics%2520Syst.%2520Pharmacol.%26date%3D2016%26volume%3D5%26issue%3D3%26spage%3D132%26epage%3D139%26doi%3D10.1002%2Fpsp4.12062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jusko, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, H. C.</span></span> <span> </span><span class="NLM_article-title">Physiologic Indirect Response Models Characterize Diverse Types of Pharmacodynamic Effects</span>. <i>Clin. Pharmacol. Ther. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">406</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1038/clpt.1994.155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1038%2Fclpt.1994.155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=7955802" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1994&pages=406-419&issue=4&author=W.+J.+Juskoauthor=H.+C.+Ko&title=Physiologic+Indirect+Response+Models+Characterize+Diverse+Types+of+Pharmacodynamic+Effects&doi=10.1038%2Fclpt.1994.155"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fclpt.1994.155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.1994.155%26sid%3Dliteratum%253Aachs%26aulast%3DJusko%26aufirst%3DW.%2BJ.%26aulast%3DKo%26aufirst%3DH.%2BC.%26atitle%3DPhysiologic%2520Indirect%2520Response%2520Models%2520Characterize%2520Diverse%2520Types%2520of%2520Pharmacodynamic%2520Effects%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D1994%26volume%3D56%26issue%3D4%26spage%3D406%26epage%3D419%26doi%3D10.1038%2Fclpt.1994.155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Craig, W. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1086/516284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1086%2F516284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=9455502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaK1cXltVaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1998&pages=1-10&issue=1&author=W.+A.+Craig&title=Pharmacokinetic%2FPharmacodynamic+Parameters%3A+Rationale+for+Antibacterial+Dosing+of+Mice+and+Men&doi=10.1086%2F516284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men</span></div><div class="casAuthors">Craig, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1058-4838</span>.
    
            (<span class="NLM_cas:orgname">University of Chicago Press</span>)
        </div><div class="casAbstract">A review with 64 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzV5ls_EvnebVg90H21EOLACvtfcHk0liLm2Pp-t05hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltVaqtw%253D%253D&md5=c4277a411e8d24789c3bff279c0ef569</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1086%2F516284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F516284%26sid%3Dliteratum%253Aachs%26aulast%3DCraig%26aufirst%3DW.%2BA.%26atitle%3DPharmacokinetic%252FPharmacodynamic%2520Parameters%253A%2520Rationale%2520for%2520Antibacterial%2520Dosing%2520of%2520Mice%2520and%2520Men%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D1998%26volume%3D26%26issue%3D1%26spage%3D1%26epage%3D10%26doi%3D10.1086%2F516284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggleston, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span> <span> </span><span class="NLM_article-title">Validation and Clinical Utility of the hERG IC50:Cmax Ratio to Determine the Risk of Drug-Induced Torsades de Pointes: A Meta-Analysis</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1002/phar.2087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2Fphar.2087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=29380488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmt1Wksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=341-348&issue=3&author=D.+F.+Lehmannauthor=W.+D.+Egglestonauthor=D.+Wang&title=Validation+and+Clinical+Utility+of+the+hERG+IC50%3ACmax+Ratio+to+Determine+the+Risk+of+Drug-Induced+Torsades+de+Pointes%3A+A+Meta-Analysis&doi=10.1002%2Fphar.2087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Validation and Clinical Utility of the hERG IC50:Cmax Ratio to Determine the Risk of Drug-Induced Torsades de Pointes: A Meta-Analysis</span></div><div class="casAuthors">Lehmann, David F.; Eggleston, William D.; Wang, Dongliang</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">341-348</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-9114</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Use of the QT interval cor. for heart rate (QTc) on the ECG (ECG) to predict torsades de pointes (TdP) risk from culprit drugs is neither sensitive nor specific.  The ratio of the half-max. inhibitory concn. of the hERG channel (hERG IC50) to the peak serum concn. of unbound drug (Cmax) is used during drug development to screen out chem. entities likely to cause TdP.  To validate the use of the hERG IC50:Cmax ratio to predict TdP risk from a culprit drug by its correlation with TdP incidence.  Medline (between 1966 and March 2017) was accessed for hERG IC50 and Cmax values from the antihistamine, fluoroquinolone, and antipsychotic classes to identify cases of drug-induced TdP.  Exposure to a culprit drug was estd. from annual revenues reported by the manufacturer.  Inclusion criteria for TdP cases were provision of an ECG tracing that demonstrated QTc prolongation with TdP and normal serum values of potassium, calcium, and magnesium.  Cases reported in patients with a prior rhythm disturbance and those involving a drug interaction were excluded.  The Meta-Anal. of Observational Studies in Epidemiol. checklist was used for epidemiol. data extn. by two authors.  Negligible risk drugs were defined by an hERG IC50:Cmax ratio that correlated with less than a 5% chance of one TdP event for every 100 million exposures (relative risk [RR] 1.0).  The hERG IC50:Cmax ratio correlated with TdP risk (0.312; 95% confidence interval 0.205-0.476, p<0.0001), a ratio of 80 (RR 1.0).  The RR from olanzapine is on par with loratadine; ziprasidone is comparable with ciprofloxacin.  Drugs with an RR greater than 50 include astemizole, risperidone, haloperidol, and thioridazine.  The hERG IC50:Cmax ratio was correlated with TdP incidence for culprit drugs.  This validation provides support for the potential use of the hERG IC50:Cmax ratio for clin. decision making in instances of drug selection where TdP risk is a concern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvHw4uCL_aUbVg90H21EOLACvtfcHk0liVKZf5p3NdRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmt1Wksbc%253D&md5=a15869af1fb0e9a522f2155700249517</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fphar.2087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.2087%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DD.%2BF.%26aulast%3DEggleston%26aufirst%3DW.%2BD.%26aulast%3DWang%26aufirst%3DD.%26atitle%3DValidation%2520and%2520Clinical%2520Utility%2520of%2520the%2520hERG%2520IC50%253ACmax%2520Ratio%2520to%2520Determine%2520the%2520Risk%2520of%2520Drug-Induced%2520Torsades%2520de%2520Pointes%253A%2520A%2520Meta-Analysis%26jtitle%3DPharmacotherapy%26date%3D2018%26volume%3D38%26issue%3D3%26spage%3D341%26epage%3D348%26doi%3D10.1002%2Fphar.2087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goutelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baudry, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagnieu, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boibieux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livrozet, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyramond, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chidiac, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tod, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferry, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic-Pharmacodynamic Modeling of Unboosted Atazanavir in a Cohort of Stable HIV-Infected Patients</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1128/AAC.01822-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1128%2FAAC.01822-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=23147727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1SrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=517-523&issue=1&author=S.+Goutelleauthor=T.+Baudryauthor=M.-C.+Gagnieuauthor=A.+Boibieuxauthor=J.-M.+Livrozetauthor=D.+Peyramondauthor=C.+Chidiacauthor=M.+Todauthor=T.+Ferry&title=Pharmacokinetic-Pharmacodynamic+Modeling+of+Unboosted+Atazanavir+in+a+Cohort+of+Stable+HIV-Infected+Patients&doi=10.1128%2FAAC.01822-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic-pharmacodynamic modeling of unboosted atazanavir in a cohort of stable HIV-infected patients</span></div><div class="casAuthors">Goutelle, Sylvain; Baudry, Thomas; Gagnieu, Marie-Claude; Boibieux, Andre; Livrozet, Jean-Michel; Peyramond, Dominique; Chidiac, Christian; Tod, Michel; Ferry, Tristan</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">517-523</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Limited data on the pharmacokinetics and pharmacodynamics (PK/PD) of unboosted atazanavir (uATV) in treatment-experienced patients are available.  The aim of this work was to study the PK/PD of unboosted atazanavir in a cohort of HIV-infected patients.  Data were available for 58 HIV-infected patients (69 uATV-based regimens).  Atazanavir concns. were analyzed by using a population approach, and the relationship between atazanavir PK and clin. outcome was examd. using logistic regression.  The final PK model was a linear one-compartment model with a mixt. absorption model to account for two subgroups of absorbers.  The mean (interindividual variability) of population PK parameters were as follows: clearance, 13.4 L/h (40.7%), vol. of distribution, 71.1 L (29.7%), and fraction of regular absorbers, 0.49.  Seven subjects experienced virol. failure after switch to uATV.  All of them were identified as low absorbers in the PK modeling.  The absorption rate const. (0.38 ± 0.20 vs. 0.75 ± 0.28 h-1; P = 0.002) and ATV exposure (area under the concn.-time curve from 0 to 24 h [AUC0-24], 10.3 ± 2.1 vs. 22.4 ± 11.2 mg · h · liter-1; P = 0.001) were significantly lower in patients with virol. failure than in patients without failure.  In the logistic regression anal., both the absorption rate const. and ATV trough concn. significantly influenced the probability of virol. failure.  A significant relationship between ATV pharmacokinetics and virol. response was obsd. in a cohort of HIV patients who were administered unboosted atazanavir.  This study also suggests that twice-daily administration of uATV may optimize drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFEi5Wb0W_7bVg90H21EOLACvtfcHk0liVKZf5p3NdRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1SrtLg%253D&md5=2a9621e97286aa55d4564b5a4b097e40</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1128%2FAAC.01822-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01822-12%26sid%3Dliteratum%253Aachs%26aulast%3DGoutelle%26aufirst%3DS.%26aulast%3DBaudry%26aufirst%3DT.%26aulast%3DGagnieu%26aufirst%3DM.-C.%26aulast%3DBoibieux%26aufirst%3DA.%26aulast%3DLivrozet%26aufirst%3DJ.-M.%26aulast%3DPeyramond%26aufirst%3DD.%26aulast%3DChidiac%26aufirst%3DC.%26aulast%3DTod%26aufirst%3DM.%26aulast%3DFerry%26aufirst%3DT.%26atitle%3DPharmacokinetic-Pharmacodynamic%2520Modeling%2520of%2520Unboosted%2520Atazanavir%2520in%2520a%2520Cohort%2520of%2520Stable%2520HIV-Infected%2520Patients%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26issue%3D1%26spage%3D517%26epage%3D523%26doi%3D10.1128%2FAAC.01822-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutmacher, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furst, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikranian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nduaka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span> <span> </span><span class="NLM_article-title">Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib</span>. <i>Clin. Pharmacol. Ther. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">753</span>, <span class="refDoi"> DOI: 10.1002/cpt.576</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2Fcpt.576" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=27859030" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2017&pages=745-753&issue=6&author=M.+Lambaauthor=M.+M.+Hutmacherauthor=D.+E.+Furstauthor=A.+Dikranianauthor=M.+E.+Dowtyauthor=D.+Conradoauthor=T.+Stockauthor=C.+Nduakaauthor=J.+Cookauthor=S.+Krishnaswami&title=Model-Informed+Development+and+Registration+of+a+Once-Daily+Regimen+of+Extended-Release+Tofacitinib&doi=10.1002%2Fcpt.576"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fcpt.576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.576%26sid%3Dliteratum%253Aachs%26aulast%3DLamba%26aufirst%3DM.%26aulast%3DHutmacher%26aufirst%3DM.%2BM.%26aulast%3DFurst%26aufirst%3DD.%2BE.%26aulast%3DDikranian%26aufirst%3DA.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DConrado%26aufirst%3DD.%26aulast%3DStock%26aufirst%3DT.%26aulast%3DNduaka%26aufirst%3DC.%26aulast%3DCook%26aufirst%3DJ.%26aulast%3DKrishnaswami%26aufirst%3DS.%26atitle%3DModel-Informed%2520Development%2520and%2520Registration%2520of%2520a%2520Once-Daily%2520Regimen%2520of%2520Extended-Release%2520Tofacitinib%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2017%26volume%3D101%26issue%3D6%26spage%3D745%26epage%3D753%26doi%3D10.1002%2Fcpt.576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishore, N.</span></span> <span> </span><span class="NLM_article-title">Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>348</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.209304</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1124%2Fjpet.113.209304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=24218541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2014&pages=165-173&issue=1&author=M.+E.+Dowtyauthor=M.+I.+Jessonauthor=S.+Ghoshauthor=J.+Leeauthor=D.+M.+Meyerauthor=S.+Krishnaswamiauthor=N.+Kishore&title=Preclinical+to+Clinical+Translation+of+Tofacitinib%2C+a+Janus+Kinase+Inhibitor%2C+in+Rheumatoid+Arthritis&doi=10.1124%2Fjpet.113.209304"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis</span></div><div class="casAuthors">Dowty, Martin E.; Jesson, Michael I.; Ghosh, Sarbani; Lee, Jamie; Meyer, Debra M.; Krishnaswami, Sriram; Kishore, Nandini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">165-173, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A crit. piece in the translation of preclin. studies to clin. trials is the detn. of dosing regimens that allow max. therapeutic benefit with min. toxicity.  The preclin. pharmacokinetic (PK)/pharmacodynamic (PD) profile of tofacitinib, an oral Janus kinase (JAK) inhibitor, in a mouse collagen-induced arthritis (mCIA) model was compared with clin. PK/PD data from patients with rheumatoid arthritis (RA).  Preclin. evaluations included target modulation and PK/PD modeling based on continuous s.c. infusion or oral once- or twice-daily (BID) dosing paradigms in mice.  The human PK/PD profile was obtained from pooled data from four phase 2 studies in patients with RA, and maximal effect models were used to evaluate efficacy after 12 wk of tofacitinib treatment (1-15 mg BID).  In mCIA, the main driver of efficacy was inhibition of cytokine receptor signaling mediated by JAK1 heterodimers, but not JAK2 homodimers, and continuous daily inhibition was not required to maintain efficacy.  Projected efficacy could be predicted from total daily exposure irresp. of the oral dosing paradigm, with a total steady-state plasma concn. achieving 50% of the maximal response (Cave50) of ∼100 nM.  Tofacitinib potency (ED50) in clin. studies was ∼3.5 mg BID (90% confidence interval: 2.3, 5.5) or total Cave50 of ∼40 nM, derived using Disease Activity Scores from patients with RA.  The collective clin. and preclin. data indicated the importance of Cave as a driver of efficacy, rather than max. or min. plasma concn. (Cmax or Cmin), where Cave50 values were within ∼2-fold of each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDs-lnT0HFF7Vg90H21EOLACvtfcHk0ligjS1nO6Hl9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisVKju78%253D&md5=faed45ef8eabb5e1bde0819702f26ffa</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.209304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.209304%26sid%3Dliteratum%253Aachs%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DKishore%26aufirst%3DN.%26atitle%3DPreclinical%2520to%2520Clinical%2520Translation%2520of%2520Tofacitinib%252C%2520a%2520Janus%2520Kinase%2520Inhibitor%252C%2520in%2520Rheumatoid%2520Arthritis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D348%26issue%3D1%26spage%3D165%26epage%3D173%26doi%3D10.1124%2Fjpet.113.209304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northam, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alway, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, O. S.</span></span> <span> </span><span class="NLM_article-title">Blood Levels of Drug at the Equilibrium State after Multiple Dosing</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>207</i></span> (<span class="NLM_issue">5003</span>),  <span class="NLM_fpage">1301</span>– <span class="NLM_lpage">1302</span>, <span class="refDoi"> DOI: 10.1038/2071301a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1038%2F2071301a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=5884654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A280%3ADyaF287ksVSntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=207&publication_year=1965&pages=1301-1302&issue=5003&author=J.+G.+Wagnerauthor=J.+I.+Northamauthor=C.+D.+Alwayauthor=O.+S.+Carpenter&title=Blood+Levels+of+Drug+at+the+Equilibrium+State+after+Multiple+Dosing&doi=10.1038%2F2071301a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Blood levels of drug at the equilibrium state after multiple dosing</span></div><div class="casAuthors">Wagner J G; Northam J I; Alway C D; Carpenter O S</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">207</span>
        (<span class="NLM_cas:issue">5003</span>),
    <span class="NLM_cas:pages">1301-2</span>
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkXM4pbz4uL8uCWE5mhx1RfW6udTcc2ea5v7R-Fumorrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaF287ksVSntQ%253D%253D&md5=de878fcb3ee5b632be74a12d50dfcfa7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2F2071301a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F2071301a0%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DJ.%2BG.%26aulast%3DNortham%26aufirst%3DJ.%2BI.%26aulast%3DAlway%26aufirst%3DC.%2BD.%26aulast%3DCarpenter%26aufirst%3DO.%2BS.%26atitle%3DBlood%2520Levels%2520of%2520Drug%2520at%2520the%2520Equilibrium%2520State%2520after%2520Multiple%2520Dosing%26jtitle%3DNature%26date%3D1965%26volume%3D207%26issue%3D5003%26spage%3D1301%26epage%3D1302%26doi%3D10.1038%2F2071301a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moscovitz, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpino, P. A.</span></span> <span> </span><span class="NLM_article-title">Diabetes Area Patent Participation Analysis - Part II: Years 2011–2016</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1406477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1080%2F13543776.2018.1406477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=29140125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2lu7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=111-122&issue=2&author=M.+Boehmauthor=M.+Crawfordauthor=J.+E.+Moscovitzauthor=P.+A.+Carpino&title=Diabetes+Area+Patent+Participation+Analysis+-+Part+II%3A+Years+2011%E2%80%932016&doi=10.1080%2F13543776.2018.1406477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Diabetes area patent participation analysis - part II: years 2011-2016</span></div><div class="casAuthors">Boehm, Markus; Crawford, Matthew; Moscovitz, Jamie E.; Carpino, Philip A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-122</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Diabetes is a metabolic disease characterized by elevated levels of plasma glucose.  When untreated, diabetes increases the risk of developing co-morbidities such as cardiovascular disease.  Several drugs, often used as part of combination therapies, have been approved to treat the disease, but these drugs will eventually fail to effectively control blood glucose levels, at which point insulin replacement therapy is required.  A medical need exists for new antidiabetic drugs that exhibit good efficacy with improved safety/toleration profiles and can be added on top of existing therapies, or that can provide addnl. benefits beyond glucose lowering such as pancreatic beta (β)-cell protection.  This review analyzes drug targets and applicants of patents that published between 2011-2016 claiming novel small or large mols. for the treatment of diabetes, and compares the results to the 2008-2010 time period.  A majority of patent activity around the discovery of new antidiabetic drugs in 2011-2016 was directed against 15 targets, most of which were also the focus of drug discovery efforts in the 2008-2010 time period.  Few targets were identified that promote pancreatic β-cell regeneration and β-cell health, areas where future opportunities may exist for developing transformative drug therapies that may potentially lead to cures for diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTaNt6C867rbVg90H21EOLACvtfcHk0ligjS1nO6Hl9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2lu7fO&md5=ef2cc0d3242e6d639e56ba69bbd7a843</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1406477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1406477%26sid%3Dliteratum%253Aachs%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DCrawford%26aufirst%3DM.%26aulast%3DMoscovitz%26aufirst%3DJ.%2BE.%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26atitle%3DDiabetes%2520Area%2520Patent%2520Participation%2520Analysis%2520-%2520Part%2520II%253A%2520Years%25202011%25E2%2580%25932016%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26issue%3D2%26spage%3D111%26epage%3D122%26doi%3D10.1080%2F13543776.2018.1406477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddish-Berhane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant-Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boustany-Kari, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leininger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tugnait, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mascitti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamic Model of Sodium-Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">576</span>– <span class="NLM_lpage">584</span>, <span class="refDoi"> DOI: 10.1208/s12248-011-9297-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1208%2Fs12248-011-9297-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=21870203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFamtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=576-584&issue=4&author=T.+S.+Maurerauthor=A.+Ghoshauthor=N.+Haddish-Berhaneauthor=A.+Sawant-Basakauthor=C.+M.+Boustany-Kariauthor=L.+Sheauthor=M.+T.+Leiningerauthor=T.+Zhuauthor=M.+Tugnaitauthor=X.+Yangauthor=E.+Kimotoauthor=V.+Mascittiauthor=R.+P.+Robinson&title=Pharmacodynamic+Model+of+Sodium-Glucose+Transporter+2+%28SGLT2%29+Inhibition%3A+Implications+for+Quantitative+Translational+Pharmacology&doi=10.1208%2Fs12248-011-9297-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamic Model of Sodium-Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology</span></div><div class="casAuthors">Maurer, Tristan S.; Ghosh, Avijit; Haddish-Berhane, Nahor; Sawant-Basak, Aarti; Boustany-Kari, Carine M.; She, Li; Leininger, Michael T.; Zhu, Tong; Tugnait, Meera; Yang, Xin; Kimoto, Emi; Mascitti, Vincent; Robinson, Ralph P.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">576-584</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Sodium-glucose co-transporter-2 (SGLT2) inhibitors are an emerging class of agents for use in the treatment of type 2 diabetes mellitus (T2DM).  Inhibition of SGLT2 leads to improved glycemic control through increased urinary glucose excretion (UGE).  In this study, a biol. based pharmacokinetic/pharmacodynamic (PK/PD) model of SGLT2 inhibitor-mediated UGE was developed.  The derived model was used to characterize the acute PK/PD relationship of the SGLT2 inhibitor, dapagliflozin, in rats.  The quant. translational pharmacol. of dapagliflozin was examd. through both prospective simulation and direct modeling of mean literature data obtained for dapagliflozin in healthy subjects.  Prospective simulations provided time courses of UGE that were of consistent shape to clin. observations, but were modestly biased toward under prediction.  Direct modeling provided an improved characterization of the data and precise parameter ests. which were reasonably consistent with those predicted from preclin. data.  Overall, these results indicate that the acute clin. pharmacol. of SGLT2 inhibitors in healthy subjects can be reasonably well predicted from preclin. data through rational accounting of species differences in pharmacokinetics, physiol., and SGLT2 pharmacol.  Because these data can be generated at the earliest stages of drug discovery, the proposed model is useful in the design and development of novel SGLT2 inhibitors.  In addn., this model is expected to serve as a useful foundation for future efforts to understand and predict the effects of SGLT2 inhibition under chronic administration and in other patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAM6fgz9MxjrVg90H21EOLACvtfcHk0ligjS1nO6Hl9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFamtr7I&md5=ad9427ceb6c723ff27f5b8d5c85ff0fa</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1208%2Fs12248-011-9297-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-011-9297-2%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DHaddish-Berhane%26aufirst%3DN.%26aulast%3DSawant-Basak%26aufirst%3DA.%26aulast%3DBoustany-Kari%26aufirst%3DC.%2BM.%26aulast%3DShe%26aufirst%3DL.%26aulast%3DLeininger%26aufirst%3DM.%2BT.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DTugnait%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DKimoto%26aufirst%3DE.%26aulast%3DMascitti%26aufirst%3DV.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26atitle%3DPharmacodynamic%2520Model%2520of%2520Sodium-Glucose%2520Transporter%25202%2520%2528SGLT2%2529%2520Inhibition%253A%2520Implications%2520for%2520Quantitative%2520Translational%2520Pharmacology%26jtitle%3DAAPS%2520J.%26date%3D2011%26volume%3D13%26issue%3D4%26spage%3D576%26epage%3D584%26doi%3D10.1208%2Fs12248-011-9297-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mascitti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boustany-Kari, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klenotic, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leininger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masterson, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukaiyama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preville, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobol, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steppan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuma, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tugnait, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2952</span>– <span class="NLM_lpage">2960</span>, <span class="refDoi"> DOI: 10.1021/jm200049r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200049r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVCntrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2952-2960&issue=8&author=V.+Mascittiauthor=T.+S.+Maurerauthor=R.+P.+Robinsonauthor=J.+Bianauthor=C.+M.+Boustany-Kariauthor=T.+Brandtauthor=B.+M.+Collmanauthor=A.+S.+Kalgutkarauthor=M.+K.+Klenoticauthor=M.+T.+Leiningerauthor=A.+Loweauthor=R.+J.+Maguireauthor=V.+M.+Mastersonauthor=Z.+Miaoauthor=E.+Mukaiyamaauthor=J.+D.+Patelauthor=J.+C.+Pettersenauthor=C.+Previlleauthor=B.+Samasauthor=L.+Sheauthor=Z.+Sobolauthor=C.+M.+Steppanauthor=B.+D.+Stevensauthor=B.+A.+Thumaauthor=M.+Tugnaitauthor=D.+Zengauthor=T.+Zhu&title=Discovery+of+a+Clinical+Candidate+from+the+Structurally+Unique+Dioxa-bicyclo%5B3.2.1%5Doctane+Class+of+Sodium-Dependent+Glucose+Cotransporter+2+Inhibitors&doi=10.1021%2Fjm200049r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors</span></div><div class="casAuthors">Mascitti, Vincent; Maurer, Tristan S.; Robinson, Ralph P.; Bian, Jianwei; Boustany-Kari, Carine M.; Brandt, Thomas; Collman, Benjamin M.; Kalgutkar, Amit S.; Klenotic, Michelle K.; Leininger, Michael T.; Lowe, Andre; Maguire, Robert J.; Masterson, Victoria M.; Miao, Zhuang; Mukaiyama, Emi; Patel, Jigna D.; Pettersen, John C.; Preville, Cathy; Samas, Brian; She, Li; Sobol, Zhanna; Steppan, Claire M.; Stevens, Benjamin D.; Thuma, Benjamin A.; Tugnait, Meera; Zeng, Dongxiang; Zhu, Tong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2952-2960</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PF-04971729 (I) belongs to a new class of potent and selective sodium-dependent glucose cotransporter 2 inhibitors incorporating a unique dioxa-bicyclo[3.2.1]octane (bridged ketal) ring system.  In this paper we present the design, synthesis, preclin. evaluation, and human dose predictions related to I.  This compd. demonstrated robust urinary glucose excretion in rats and an excellent preclin. safety profile.  It is currently in phase 2 clin. trials and is being evaluated for the treatment of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoytwz0hHDVmrVg90H21EOLACvtfcHk0lhsB3lnoGHoKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVCntrY%253D&md5=80e156d19d3a6a87a61dca59cc1a0e99</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm200049r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200049r%26sid%3Dliteratum%253Aachs%26aulast%3DMascitti%26aufirst%3DV.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DBian%26aufirst%3DJ.%26aulast%3DBoustany-Kari%26aufirst%3DC.%2BM.%26aulast%3DBrandt%26aufirst%3DT.%26aulast%3DCollman%26aufirst%3DB.%2BM.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DKlenotic%26aufirst%3DM.%2BK.%26aulast%3DLeininger%26aufirst%3DM.%2BT.%26aulast%3DLowe%26aufirst%3DA.%26aulast%3DMaguire%26aufirst%3DR.%2BJ.%26aulast%3DMasterson%26aufirst%3DV.%2BM.%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DMukaiyama%26aufirst%3DE.%26aulast%3DPatel%26aufirst%3DJ.%2BD.%26aulast%3DPettersen%26aufirst%3DJ.%2BC.%26aulast%3DPreville%26aufirst%3DC.%26aulast%3DSamas%26aufirst%3DB.%26aulast%3DShe%26aufirst%3DL.%26aulast%3DSobol%26aufirst%3DZ.%26aulast%3DSteppan%26aufirst%3DC.%2BM.%26aulast%3DStevens%26aufirst%3DB.%2BD.%26aulast%3DThuma%26aufirst%3DB.%2BA.%26aulast%3DTugnait%26aufirst%3DM.%26aulast%3DZeng%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520Clinical%2520Candidate%2520from%2520the%2520Structurally%2520Unique%2520Dioxa-bicyclo%255B3.2.1%255Doctane%2520Class%2520of%2520Sodium-Dependent%2520Glucose%2520Cotransporter%25202%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D8%26spage%3D2952%26epage%3D2960%26doi%3D10.1021%2Fjm200049r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Graaf, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandema, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnaswami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwillich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anziano, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stock, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lalonde, R. L.</span></span> <span> </span><span class="NLM_article-title">Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development</span>. <i>Clin. Pharmacol. Ther. (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">502</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1038/clpt.2013.54</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1038%2Fclpt.2013.54" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=23588322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3sXot1arsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2013&pages=502-514&issue=6&author=P.+A.+Milliganauthor=M.+J.+Brownauthor=B.+Marchantauthor=S.+W.+Martinauthor=P.+H.+van+der%0AGraafauthor=N.+Bensonauthor=G.+Nucciauthor=D.+J.+Nicholsauthor=R.+A.+Boydauthor=J.+W.+Mandemaauthor=S.+Krishnaswamiauthor=S.+Zwillichauthor=D.+Grubenauthor=R.+J.+Anzianoauthor=T.+C.+Stockauthor=R.+L.+Lalonde&title=Model-Based+Drug+Development%3A+A+Rational+Approach+to+Efficiently+Accelerate+Drug+Development&doi=10.1038%2Fclpt.2013.54"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development</span></div><div class="casAuthors">Milligan, P. A.; Brown, M. J.; Marchant, B.; Martin, S. W.; van der Graaf, P. H.; Benson, N.; Nucci, G.; Nichols, D. J.; Boyd, R. A.; Mandema, J. W.; Krishnaswami, S.; Zwillich, S.; Gruben, D.; Anziano, R. J.; Stock, T. C.; Lalonde, R. L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">502-514</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The pharmaceutical industry continues to face significant challenges.  Very few compds. that enter development reach the marketplace, and the investment required for each success can surpass 1.8 billion.  Despite attempts to improve efficiency and increase productivity, total investment continues to rise whereas the output of new medicines declines.  With costs increasing exponentially through each development phase, it is failure in phase II and phase III that is most wasteful.  In today's development paradigm, late-stage failure is principally a result of insufficient efficacy.  This is manifested as either a failure to differentiate sufficiently from placebo (shown for both novel and precedented mechanisms) or a failure to demonstrate sufficient differentiation from existing compds.  Set in this context, this article will discuss the role model-based drug development (MBDD) approaches can and do play in accelerating and optimizing compd. development strategies through a series of illustrative examples.  Clin. Pharmacol. & Therapeutics (2013); 93 6, 502-514. doi:10.1038/clpt.2013.54.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcq-yl0EkXMLVg90H21EOLACvtfcHk0lhsB3lnoGHoKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXot1arsbs%253D&md5=89db09d5e3ea787abd2a7a610b496ea8</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2013.54&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2013.54%26sid%3Dliteratum%253Aachs%26aulast%3DMilligan%26aufirst%3DP.%2BA.%26aulast%3DBrown%26aufirst%3DM.%2BJ.%26aulast%3DMarchant%26aufirst%3DB.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3Dvan%2Bder%2BGraaf%26aufirst%3DP.%2BH.%26aulast%3DBenson%26aufirst%3DN.%26aulast%3DNucci%26aufirst%3DG.%26aulast%3DNichols%26aufirst%3DD.%2BJ.%26aulast%3DBoyd%26aufirst%3DR.%2BA.%26aulast%3DMandema%26aufirst%3DJ.%2BW.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DZwillich%26aufirst%3DS.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DAnziano%26aufirst%3DR.%2BJ.%26aulast%3DStock%26aufirst%3DT.%2BC.%26aulast%3DLalonde%26aufirst%3DR.%2BL.%26atitle%3DModel-Based%2520Drug%2520Development%253A%2520A%2520Rational%2520Approach%2520to%2520Efficiently%2520Accelerate%2520Drug%2520Development%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2013%26volume%3D93%26issue%3D6%26spage%3D502%26epage%3D514%26doi%3D10.1038%2Fclpt.2013.54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonseca, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawadzke, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salafia, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strick, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gernhardt, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant-Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dounay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuttle, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span> <span> </span><span class="NLM_article-title">Quantitative Translational Analysis of Brain Kynurenic Acid Modulation via Irreversible Kynurenine Aminotransferase II Inhibition</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">823</span>– <span class="NLM_lpage">833</span>, <span class="refDoi"> DOI: 10.1124/mol.118.111625</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1124%2Fmol.118.111625" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=29853495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgsrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2018&pages=823-833&issue=2&author=C.+Changauthor=K.+R.+Fonsecaauthor=C.+Liauthor=W.+Hornerauthor=L.+E.+Zawadzkeauthor=M.+A.+Salafiaauthor=K.+A.+Welchauthor=C.+A.+Strickauthor=B.+M.+Campbellauthor=S.+S.+Gernhardtauthor=H.+Rongauthor=A.+Sawant-Basakauthor=J.+Lirasauthor=A.+Dounayauthor=J.+B.+Tuttleauthor=P.+Verhoestauthor=T.+S.+Maurer&title=Quantitative+Translational+Analysis+of+Brain+Kynurenic+Acid+Modulation+via+Irreversible+Kynurenine+Aminotransferase+II+Inhibition&doi=10.1124%2Fmol.118.111625"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative translational analysis of brain kynurenic acid modulation via irreversible kynurenine aminotransferase II inhibition</span></div><div class="casAuthors">Chang, Cheng; Fonseca, Kari R.; Li, Cheryl; Horner, Weldon; Zawadzke, Laura E.; Salafia, Michelle A.; Welch, Kathryn A.; Strick, Christine A.; Campbell, Brian M.; Gernhardt, Steve S.; Rong, Haojing; Sawant-Basak, Aarti; Liras, Jennifer; Dounay, Amy; Tuttle, Jamison B.; Verhoest, Patrick; Maurer, Tristan S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">823-833</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Kynurenic acid (KYNA) plays a significant role in maintaining normal brain function, and abnormalities in KYNA levels have been assocd. with various central nervous system disorders.  Confirmation of its causality in human diseases requires safe and effective modulation of central KYNA levels in the clinic.  The kynurenine aminotransferases (KAT) II enzyme represents an attractive target for pharmacol. modulation of central KYNA levels; however, KAT II and KYNA turnover kinetics, which could contribute to the duration of pharmacol. effect, have not been reported.  In this study, the kinetics of central KYNA-lowering effect in rats and nonhuman primates (NHPs, Cynomolgus macaques) was investigated using multiple KAT II irreversible inhibitors as pharmacol. probes.  Mechanistic pharmacokinetic-pharmacodynamic anal. of in vivo responses to irreversible inhibition quant. revealed that 1) KAT II turnover is relatively slow [16-76 h' half-life (t1/2)], whereas KYNA is cleared more rapidly from the brain (<1 h t1/2) in both rats and NHPs, 2) KAT II turnover is slower in NHPs than in rats (76 h vs. 16 h t1/2, resp.), and 3) the percent contribution of KAT II to KYNA formation is const. (∼80%) across rats and NHPs.  Addnl., modeling results enabled establishment of in vitro-in vivo correlation for both enzyme turnover rates and drug potencies.  In summary, quant. translational anal. confirmed the feasibility of central KYNA modulation in humans.  Model-based anal., where system-specific properties and drug-specific properties are mechanistically sepd. from in vivo responses, enabled quant. understanding of the KAT II-KYNA pathway, as well as assisted development of promising candidates to test KYNA hypothesis in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgp257SYyEYbVg90H21EOLACvtfcHk0liCTiXA1fYJVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgsrrL&md5=edd11481237e8fc780cad2a0528b1623</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1124%2Fmol.118.111625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.118.111625%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DC.%26aulast%3DFonseca%26aufirst%3DK.%2BR.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DHorner%26aufirst%3DW.%26aulast%3DZawadzke%26aufirst%3DL.%2BE.%26aulast%3DSalafia%26aufirst%3DM.%2BA.%26aulast%3DWelch%26aufirst%3DK.%2BA.%26aulast%3DStrick%26aufirst%3DC.%2BA.%26aulast%3DCampbell%26aufirst%3DB.%2BM.%26aulast%3DGernhardt%26aufirst%3DS.%2BS.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DSawant-Basak%26aufirst%3DA.%26aulast%3DLiras%26aufirst%3DJ.%26aulast%3DDounay%26aufirst%3DA.%26aulast%3DTuttle%26aufirst%3DJ.%2BB.%26aulast%3DVerhoest%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26atitle%3DQuantitative%2520Translational%2520Analysis%2520of%2520Brain%2520Kynurenic%2520Acid%2520Modulation%2520via%2520Irreversible%2520Kynurenine%2520Aminotransferase%2520II%2520Inhibition%26jtitle%3DMol.%2520Pharmacol.%26date%3D2018%26volume%3D94%26issue%3D2%26spage%3D823%26epage%3D833%26doi%3D10.1124%2Fmol.118.111625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sikjaer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amstrup, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolighed, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjaer, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosekilde, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rejnmark, L.</span></span> <span> </span><span class="NLM_article-title">PTH(1–84) Replacement Therapy in Hypoparathyroidism: A Randomized Controlled Trial on Pharmacokinetic and Dynamic Effects after 6 Months of Treatment</span>. <i>J. Bone Miner. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2232</span>– <span class="NLM_lpage">2243</span>, <span class="refDoi"> DOI: 10.1002/jbmr.1964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2Fjbmr.1964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=23649554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyrurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2013&pages=2232-2243&issue=10&author=T.+Sikjaerauthor=A.+K.+Amstrupauthor=L.+Rolighedauthor=S.+G.+Kjaerauthor=L.+Mosekildeauthor=L.+Rejnmark&title=PTH%281%E2%80%9384%29+Replacement+Therapy+in+Hypoparathyroidism%3A+A+Randomized+Controlled+Trial+on+Pharmacokinetic+and+Dynamic+Effects+after+6+Months+of+Treatment&doi=10.1002%2Fjbmr.1964"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">PTH(1-84) replacement therapy in hypoparathyroidism: A randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment</span></div><div class="casAuthors">Sikjaer, Tanja; Amstrup, Anne Kristine; Rolighed, Lars; Kjaer, Soren Geill; Mosekilde, Leif; Rejnmark, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Bone and Mineral Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2232-2243</span>CODEN:
                <span class="NLM_cas:coden">JBMREJ</span>;
        ISSN:<span class="NLM_cas:issn">0884-0431</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Untreated, hypoparathyroidism (hypoPT) is a state of hypocalcemia with inappropriately low plasma parathyroid hormone (PTH) levels and hyperphosphatemia.  PTH administration normalizes plasma calcium and phosphate levels and reduces the doses of calcium and active vitamin D analogs needed.  To develop an evidence-based clin. algorithm to monitor hypoPT patients treated with recombinant human PTH (rhPTH[1-84]) injected s.c. in the thigh, we performed a 24-h monitoring study of pharmacokinetic and pharmacodynamic effects in a group of 38 patients who had completed a 6-mo randomized study on effects of treatment with a fixed rhPTH(1-84) dose of 100 μg/d or similar placebo as an add-on to conventional treatment.  PTH levels rose immediately, reaching a median peak level of 26.5 (interquartile range [IQR], 20.1-42.5) pmol/L 15 min following injection.  Thereafter, levels gradually decreased until reaching predosing levels after 16 h, with a plasma half-life of 2.2 (1.7-2.5) hours.  RhPTH(1-84) changed the diurnal rhythms of ionized calcium levels and 1,25-dihydroxyvitamin D (1,25[OH]2D) levels, with rising levels following injection.  Ionized calcium peaked after 7.0 (5.0-10.0) hours.  Asymptomatic hypercalcemia was present in 71% of the rhPTH(1-84)-treated patients.  Compared with placebo, 24-h urinary calcium, phosphate, and magnesium did not change, although the diurnal variation in renal excretion rates changed significantly in response to treatment.  In conclusion, as a safety precaution, we recommend occasionally measuring calcium levels at approx. 7 h after administration in order to reveal episodes of hypercalcemia.  A 100-μg daily dose of rhPTH(1-84) appears to be too high in some patients, suggesting a need for a device allowing for individual dose adjustments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYJqwQqu4qvbVg90H21EOLACvtfcHk0liCTiXA1fYJVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyrurbP&md5=7a67e22d33dfadb0527a034cdbdff2a2</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fjbmr.1964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjbmr.1964%26sid%3Dliteratum%253Aachs%26aulast%3DSikjaer%26aufirst%3DT.%26aulast%3DAmstrup%26aufirst%3DA.%2BK.%26aulast%3DRolighed%26aufirst%3DL.%26aulast%3DKjaer%26aufirst%3DS.%2BG.%26aulast%3DMosekilde%26aufirst%3DL.%26aulast%3DRejnmark%26aufirst%3DL.%26atitle%3DPTH%25281%25E2%2580%259384%2529%2520Replacement%2520Therapy%2520in%2520Hypoparathyroidism%253A%2520A%2520Randomized%2520Controlled%2520Trial%2520on%2520Pharmacokinetic%2520and%2520Dynamic%2520Effects%2520after%25206%2520Months%2520of%2520Treatment%26jtitle%3DJ.%2520Bone%2520Miner.%2520Res.%26date%3D2013%26volume%3D28%26issue%3D10%26spage%3D2232%26epage%3D2243%26doi%3D10.1002%2Fjbmr.1964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindsay, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henneman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cosman, F.</span></span> <span> </span><span class="NLM_article-title">Subcutaneous Administration of the Amino-Terminal Fragment of Human Parathyroid Hormone-(1–34): Kinetics and Biochemical Response in Estrogenized Osteoporotic Patients</span>. <i>J. Clin. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1535</span>– <span class="NLM_lpage">1539</span>, <span class="refDoi"> DOI: 10.1210/jcem.77.6.8263137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1210%2Fjcem.77.6.8263137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=8263137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A280%3ADyaK2c%252Fos1Onsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1993&pages=1535-1539&issue=6&author=R.+Lindsayauthor=J.+Nievesauthor=E.+Hennemanauthor=V.+Shenauthor=F.+Cosman&title=Subcutaneous+Administration+of+the+Amino-Terminal+Fragment+of+Human+Parathyroid+Hormone-%281%E2%80%9334%29%3A+Kinetics+and+Biochemical+Response+in+Estrogenized+Osteoporotic+Patients&doi=10.1210%2Fjcem.77.6.8263137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients</span></div><div class="casAuthors">Lindsay R; Nieves J; Henneman E; Shen V; Cosman F</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical endocrinology and metabolism</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1535-9</span>
        ISSN:<span class="NLM_cas:issn">0021-972X</span>.
    </div><div class="casAbstract">A standard dose (400 U or 25 micrograms) of human (h) PTH-(1-34) was administered sc in 11 estrogen-treated patients with postmenopausal osteoporosis.  Increments in circulating hPTH-(1-34) were brisk, peaking at 30 min, with variable peak levels averaging 10 times normal.  Clearance of the peptide from the circulation followed an expontential pattern, with a mean t1/2 of 75 min.  Peptide administration was followed by an immediate decline in serum concentrations of PTH-(1-84), which remained suppressed at about 65% of the basal value for the duration of the study (4 h).  Serum calcium did not increase until 120 min, thus occurring after the diminution in PTH-(1-84).  Serum phosphorus declined promptly as urinary phosphate excretion increased.  There were no clear changes in urinary calcium excretion, but urinary cAMP excretion increased within 120 min.  In 9 of 11 patients, the serum concentration of 1,25-dihydroxyvitamin D increased, with mean levels increasing progressively after 90 min to approximately 30% above baseline (P < 0.05).  In conclusion, sc administration of 25 micrograms hPTH-(1-34) produces significant short term changes in mineral homeostasis that appear to be mediated by the kidney, parathyroid gland, and skeleton, with the latter displaying the most delayed response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeD-Xfhv2p9MkU0YCbOU3EfW6udTcc2eYjvHp081gAY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c%252Fos1Onsw%253D%253D&md5=52513e76e683184ecb3a2ad762097b89</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1210%2Fjcem.77.6.8263137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fjcem.77.6.8263137%26sid%3Dliteratum%253Aachs%26aulast%3DLindsay%26aufirst%3DR.%26aulast%3DNieves%26aufirst%3DJ.%26aulast%3DHenneman%26aufirst%3DE.%26aulast%3DShen%26aufirst%3DV.%26aulast%3DCosman%26aufirst%3DF.%26atitle%3DSubcutaneous%2520Administration%2520of%2520the%2520Amino-Terminal%2520Fragment%2520of%2520Human%2520Parathyroid%2520Hormone-%25281%25E2%2580%259334%2529%253A%2520Kinetics%2520and%2520Biochemical%2520Response%2520in%2520Estrogenized%2520Osteoporotic%2520Patients%26jtitle%3DJ.%2520Clin.%2520Endocrinol.%2520Metab.%26date%3D1993%26volume%3D77%26issue%3D6%26spage%3D1535%26epage%3D1539%26doi%3D10.1210%2Fjcem.77.6.8263137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mager, D. E.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamic Model of Parathyroid Hormone Modulation by a Negative Allosteric Modulator of the Calcium-Sensing Receptor</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1208/s12248-011-9266-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1208%2Fs12248-011-9266-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=21437757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsFans70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=265-273&issue=2&author=A.+K.+Abrahamauthor=T.+S.+Maurerauthor=A.+S.+Kalgutkarauthor=X.+Gaoauthor=M.+Liauthor=D.+R.+Healyauthor=D.+N.+Petersenauthor=D.+A.+Griffithauthor=D.+E.+Mager&title=Pharmacodynamic+Model+of+Parathyroid+Hormone+Modulation+by+a+Negative+Allosteric+Modulator+of+the+Calcium-Sensing+Receptor&doi=10.1208%2Fs12248-011-9266-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamic Model of Parathyroid Hormone Modulation by a Negative Allosteric Modulator of the Calcium-Sensing Receptor</span></div><div class="casAuthors">Abraham, Anson K.; Maurer, Tristan S.; Kalgutkar, Amit S.; Gao, Xiang; Li, Mei; Healy, David R.; Petersen, Donna N.; Griffith, David A.; Mager, Donald E.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-273</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">In this study, a pharmacodynamic model is developed, based on calcium-parathyroid hormone (PTH) homeostasis, which describes the concn.-effect relationship of a neg. allosteric modulator of the calcium-sensing receptor (CaR) in rats.  Plasma concns. of drug and PTH were detd. from plasma samples obtained via serial jugular vein sampling following single s.c. doses of 1, 5, 45, and 150 mg/kg to male Sprague-Dawley rats (n = 5/dose).  Drug pharmacokinetics was described by a one-compartment model with first-order absorption and linear elimination.  Concn.-time profiles of PTH were characterized using a model in which the compd. allosterically modulates Ca+2 binding to the CaR that, in turn, modulates PTH through a precursor-pool indirect response model.  Addnl., neg. feedback was incorporated to account for tolerance obsd. at higher dose levels.  Model fitting and parameter estn. were conducted using the max. likelihood algorithm.  The proposed model well characterized the data and provided compd. specific ests. of the Ki and cooperativity const. (α) of 1.47 ng/mL and 0.406, resp.  In addn., the estd. model parameters for PTH turnover were comparable to that previously reported.  The final generalized model is capable of characterizing both PTH-Ca+2 homeostasis and the pharmacokinetics and pharmacodynamics assocd. with the neg. allosteric CaR modulator.  As such, the model provides a simple platform for anal. of drugs targeting the PTH-Ca+2 system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT8yNEn8I8t7Vg90H21EOLACvtfcHk0lgjlTizxFv3Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsFans70%253D&md5=15abf5d8bcc508fc87717a02ef4afe01</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1208%2Fs12248-011-9266-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-011-9266-9%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DA.%2BK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHealy%26aufirst%3DD.%2BR.%26aulast%3DPetersen%26aufirst%3DD.%2BN.%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DMager%26aufirst%3DD.%2BE.%26atitle%3DPharmacodynamic%2520Model%2520of%2520Parathyroid%2520Hormone%2520Modulation%2520by%2520a%2520Negative%2520Allosteric%2520Modulator%2520of%2520the%2520Calcium-Sensing%2520Receptor%26jtitle%3DAAPS%2520J.%26date%3D2011%26volume%3D13%26issue%3D2%26spage%3D265%26epage%3D273%26doi%3D10.1208%2Fs12248-011-9266-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mager, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span> <span> </span><span class="NLM_article-title">Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Parathyroid Hormone-Calcium Homeostasis in Rats and Humans</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>330</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">178</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.152033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1124%2Fjpet.109.152033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=19386792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosFeltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=330&publication_year=2009&pages=169-178&issue=1&author=A.+K.+Abrahamauthor=D.+E.+Magerauthor=X.+Gaoauthor=M.+Liauthor=D.+R.+Healyauthor=T.+S.+Maurer&title=Mechanism-Based+Pharmacokinetic%2FPharmacodynamic+Model+of+Parathyroid+Hormone-Calcium+Homeostasis+in+Rats+and+Humans&doi=10.1124%2Fjpet.109.152033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based pharmacokinetic/pharmacodynamic model of parathyroid hormone-calcium homeostasis in rats and humans</span></div><div class="casAuthors">Abraham, Anson K.; Mager, Donald E.; Gao, Xiang; Li, Mei; Healy, David R.; Maurer, Tristan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">330</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">169-178</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The purpose of this study was to develop a mechanism-based pharmacokinetic/pharmacodynamic model that describes the regulation of the parathyroid hormone (PTH)-Ca2+ system in rats and humans.  Temporal concn. data for endogenous PTH and Ca2+ were extd. from literature for rats (normal adult males) and humans.  In addn., exogenous PTH was administered s.c. to male Sprague-Dawley rats with jugular vein catheters, and plasma concns. were measured over time.  A math. model was developed and fitted simultaneously to endogenous PTH, Ca2+, and exogenous PTH concns. in rats.  Ca2+ concns. were described using a turnover model, with its depletion being induced by a chelating agent, and PTH concns. were characterized using a precursor-dependent indirect response model.  The same structural model was used for fitting data obtained in humans.  PTH stimulation was driven by occupancy of the Ca2+ sensing receptor, and lowering of physiol. Ca2+ concns. increased PTH secretion, with PTH profiles being adequately described by the model.  PTH stimulatory capacity was baseline-dependent in rats [Smax_rats = 34.8 × PTHo] and humans [Smax_humans = 392/PTHo].  Modeling results suggest that normal rats are twice as sensitive to Ca2+-induced PTH stimulation compared with humans.  In conclusion, the developed model adequately characterizes the PTH-Ca2+ regulation across species and may be useful in the development of therapeutic drugs targeting this system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkOcKZQyMyBrVg90H21EOLACvtfcHk0lgjlTizxFv3Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosFeltb4%253D&md5=0948f58abc3ed432e49c6de7d54b6c2a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.152033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.152033%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DA.%2BK.%26aulast%3DMager%26aufirst%3DD.%2BE.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHealy%26aufirst%3DD.%2BR.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26atitle%3DMechanism-Based%2520Pharmacokinetic%252FPharmacodynamic%2520Model%2520of%2520Parathyroid%2520Hormone-Calcium%2520Homeostasis%2520in%2520Rats%2520and%2520Humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D330%26issue%3D1%26spage%3D169%26epage%3D178%26doi%3D10.1124%2Fjpet.109.152033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berellini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1466</span>– <span class="NLM_lpage">1477</span>, <span class="refDoi"> DOI: 10.1124/dmd.118.082966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1124%2Fdmd.118.082966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=30115648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVeiurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=1466-1477&issue=11&author=F.+Lombardoauthor=G.+Berelliniauthor=R.+S.+Obach&title=Trend+Analysis+of+a+Database+of+Intravenous+Pharmacokinetic+Parameters+in+Humans+for+1352+Drug+Compounds&doi=10.1124%2Fdmd.118.082966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 1352 drug compounds</span></div><div class="casAuthors">Lombardo, Franco; Berellini, Giuliano; Scott Obach, R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1466-1477</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">We report a trend anal. of human i.v. pharmacokinetic data on a data set of 1352 drugs.  The aim in building this data set and its detailed anal. was to provide, as in the previous case published in 2008, an extended, robust, and accurate resource that could be applied by drug metab., clin. pharmacol., and medicinal chem. scientists to a variety of scaling approaches.  All in vivo data were obtained or derived from original refs., either through the literature or regulatory agency reports, exclusively from studies utilizing i.v. administration.  Plasma protein binding data were collected from other available sources to supplement these pharmacokinetic data.  These parameters were analyzed concurrently with a range of physicochem. properties, and resultant trends and patterns within the data are presented.  In addn., the date of first disclosure of each mol. was reported and the potential "temporal" impact on data trends was analyzed.  The findings reported here are consistent with earlier described trends between pharmacokinetic behavior and physicochem. properties.  Furthermore, the availability of a large data set of pharmacokinetic data in humans will be important to further pursue analyses of physicochem. properties, trends, and modeling efforts and should propel our deeper understanding (esp. in terms of clearance) of the absorption, distribution, metab., and excretion behavior of drug compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8uXJIZzHD-LVg90H21EOLACvtfcHk0lgjlTizxFv3Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVeiurzL&md5=21311cdf07ac151e5e29da4afbd87448</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1124%2Fdmd.118.082966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.118.082966%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DBerellini%26aufirst%3DG.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DTrend%2520Analysis%2520of%2520a%2520Database%2520of%2520Intravenous%2520Pharmacokinetic%2520Parameters%2520in%2520Humans%2520for%25201352%2520Drug%2520Compounds%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2018%26volume%3D46%26issue%3D11%26spage%3D1466%26epage%3D1477%26doi%3D10.1124%2Fdmd.118.082966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Didiuk, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benbow, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman-Perez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechle, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirico, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungerford, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Brinno, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zawistoski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagley, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paralkar, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccardi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, K. S.</span></span> <span> </span><span class="NLM_article-title">Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one Derivatives as Orally-Active Calcium-Sensing Receptor Antagonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">4555</span>– <span class="NLM_lpage">4559</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.bmcl.2009.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=19625189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptVCktbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4555-4559&issue=16&author=M.+T.+Didiukauthor=D.+A.+Griffithauthor=J.+W.+Benbowauthor=K.+K.+C.+Liuauthor=D.+P.+Walkerauthor=F.+C.+Biauthor=J.+Morrisauthor=A.+Guzman-Perezauthor=H.+Gaoauthor=B.+M.+Bechleauthor=R.+M.+Kelleyauthor=X.+Yangauthor=K.+Diricoauthor=S.+Ahmedauthor=W.+Hungerfordauthor=J.+Di+Brinnoauthor=M.+P.+Zawistoskiauthor=S.+W.+Bagleyauthor=J.+Liauthor=Y.+Zengauthor=S.+Santucciauthor=R.+Oliverauthor=M.+Corbettauthor=T.+Olsonauthor=C.+Chenauthor=M.+Liauthor=V.+M.+Paralkarauthor=K.+A.+Riccardiauthor=D.+R.+Healyauthor=A.+S.+Kalgutkarauthor=T.+S.+Maurerauthor=H.+T.+Nguyenauthor=K.+S.+Frederick&title=Short-acting+5-%28trifluoromethyl%29pyrido%5B4%2C3-d%5Dpyrimidin-4%283H%29-one+Derivatives+as+Orally-Active+Calcium-Sensing+Receptor+Antagonists&doi=10.1016%2Fj.bmcl.2009.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists</span></div><div class="casAuthors">Didiuk, Mary T.; Griffith, David A.; Benbow, John W.; Liu, Kevin K. C.; Walker, Daniel P.; Bi, F. Christopher; Morris, Joel; Guzman-Perez, Angel; Gao, Hua; Bechle, Bruce M.; Kelley, Ryan M.; Yang, Xiaojing; Dirico, Kenneth; Ahmed, Syed; Hungerford, William; Di Brinno, Joseph; Zawistoski, Michael P.; Bagley, Scott W.; Li, Jianke; Zeng, Yuan; Santucci, Stephanie; Oliver, Robert; Corbett, Matthew; Olson, Thanh; Chen, Chiliu; Li, Mei; Paralkar, Vishwas M.; Riccardi, Keith A.; Healy, David R.; Kalgutkar, Amit S.; Maurer, Tristan S.; Nguyen, Hang T.; Frederick, Kosea S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4555-4559</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthesis and structure-activity relationship (SAR) studies on 5-trifluoromethylpyrido[4,3-d]pyrimidin-4(3H)-ones, a novel class of calcium receptor antagonists is described with particular emphasis on optimization of the pharmacokinetic/pharmacodynamic parameters required for a short duration of action compd.  Orally-active compds. were identified which displayed the desired animal pharmacol. (rapid and transient stimulation of parathyroid hormone) essential for bone anabolic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraYBYzEAb7mrVg90H21EOLACvtfcHk0lgYpPEmYcnmmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptVCktbs%253D&md5=b3d69f8b4c212feb2cbc93187ea5a85f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DDidiuk%26aufirst%3DM.%2BT.%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DBenbow%26aufirst%3DJ.%2BW.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBi%26aufirst%3DF.%2BC.%26aulast%3DMorris%26aufirst%3DJ.%26aulast%3DGuzman-Perez%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DBechle%26aufirst%3DB.%2BM.%26aulast%3DKelley%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DDirico%26aufirst%3DK.%26aulast%3DAhmed%26aufirst%3DS.%26aulast%3DHungerford%26aufirst%3DW.%26aulast%3DDi%2BBrinno%26aufirst%3DJ.%26aulast%3DZawistoski%26aufirst%3DM.%2BP.%26aulast%3DBagley%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DSantucci%26aufirst%3DS.%26aulast%3DOliver%26aufirst%3DR.%26aulast%3DCorbett%26aufirst%3DM.%26aulast%3DOlson%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DParalkar%26aufirst%3DV.%2BM.%26aulast%3DRiccardi%26aufirst%3DK.%2BA.%26aulast%3DHealy%26aufirst%3DD.%2BR.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DNguyen%26aufirst%3DH.%2BT.%26aulast%3DFrederick%26aufirst%3DK.%2BS.%26atitle%3DShort-acting%25205-%2528trifluoromethyl%2529pyrido%255B4%252C3-d%255Dpyrimidin-4%25283H%2529-one%2520Derivatives%2520as%2520Orally-Active%2520Calcium-Sensing%2520Receptor%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D16%26spage%3D4555%26epage%3D4559%26doi%3D10.1016%2Fj.bmcl.2009.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">John, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harfst, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeffler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belleli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruin, G. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seuwen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klickstein, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mindeholm, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widler, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kneissel, M.</span></span> <span> </span><span class="NLM_article-title">AXT914 a Novel, Orally-Active Parathyroid Hormone-Releasing Drug in Two Early Studies of Healthy Volunteers and Postmenopausal Women</span>. <i>Bone (N. Y., NY, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1016/j.bone.2014.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.bone.2014.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=24769332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVaksL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2014&pages=204-210&author=M.+R.+Johnauthor=E.+Harfstauthor=J.+Loefflerauthor=R.+Belleliauthor=J.+Masonauthor=G.+J.+M.+Bruinauthor=K.+Seuwenauthor=L.+B.+Klicksteinauthor=L.+Mindeholmauthor=L.+Widlerauthor=M.+Kneissel&title=AXT914+a+Novel%2C+Orally-Active+Parathyroid+Hormone-Releasing+Drug+in+Two+Early+Studies+of+Healthy+Volunteers+and+Postmenopausal+Women&doi=10.1016%2Fj.bone.2014.04.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women</span></div><div class="casAuthors">John, Markus R.; Harfst, Evita; Loeffler, Juergen; Belleli, Rossella; Mason, June; Bruin, Gerard J. M.; Seuwen, Klaus; Klickstein, Lloyd B.; Mindeholm, Linda; Widler, Leo; Kneissel, Michaela</div><div class="citationInfo"><span class="NLM_cas:title">Bone (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">204-210</span>CODEN:
                <span class="NLM_cas:coden">BONEDL</span>;
        ISSN:<span class="NLM_cas:issn">1873-2763</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Antagonism of the calcium-sensing receptor in the parathyroid gland leads to parathyroid hormone (PTH) release.  Calcilytics are a new class of mols. designed to exploit this mechanism.  In order to mimic the known bone-anabolic pharmacokinetic (PK) profile of s.c. administered PTH, such mols. must trigger sharp, transient and robust release of PTH.  The results of two early clin. studies with the orally-active calcilytic AXT914, a quinazolin-2ne deriv. are reported.  These were GCP-compliant, single and multiple dose studies of PK/PD and tolerability in healthy volunteers and postmenopausal women.  The first study, examd. single ascending doses (4 to 120 mg) and limited multiple doses (60 or 120 mg q.d. for 12 days) of AXT914.  The second study was a randomized, double-blind, active- and placebo-controlled, 4-wk repeat-dose parallel group study of healthy postmenopausal women (45 and 60 mg AXT914, placebo, 20 μg Forteo/teriparatide/PTH(1-34) fragment).  AXT914 was well tolerated at all doses and reproducibly induced the desired PTH-release profiles.  Yet, 4 wk of 45 or 60 mg AXT914 did not result in the expected changes in circulating bone biomarkers seen with teriparatide.  However total serum calcium levels increased above baseline in the 45 and 60 mg AXT914 treatment groups (8.0 % and 10.7%, resp.), compared to that in the teriparatide and placebo groups (1.3% and 1.0%, resp.).  Thus the trial was terminated after a planned interim anal. due to lack of effect on bone formation biomarkers and dose-limiting effects on serum calcium.  In conclusion, AXT914 was well tolerated but the obsd. transient and reproducible PTH-release after repeat oral administration of AXT914 which showed an exposure profile close to that of s c.  PTH, did not translate into a bone anabolic response and was assocd. with a persistent dose-related increase in serum calcium concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohmNkNHtJty7Vg90H21EOLACvtfcHk0lgYpPEmYcnmmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVaksL3I&md5=f1c441b85df5390f98c7dad4de3f09e4</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bone.2014.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bone.2014.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DJohn%26aufirst%3DM.%2BR.%26aulast%3DHarfst%26aufirst%3DE.%26aulast%3DLoeffler%26aufirst%3DJ.%26aulast%3DBelleli%26aufirst%3DR.%26aulast%3DMason%26aufirst%3DJ.%26aulast%3DBruin%26aufirst%3DG.%2BJ.%2BM.%26aulast%3DSeuwen%26aufirst%3DK.%26aulast%3DKlickstein%26aufirst%3DL.%2BB.%26aulast%3DMindeholm%26aufirst%3DL.%26aulast%3DWidler%26aufirst%3DL.%26aulast%3DKneissel%26aufirst%3DM.%26atitle%3DAXT914%2520a%2520Novel%252C%2520Orally-Active%2520Parathyroid%2520Hormone-Releasing%2520Drug%2520in%2520Two%2520Early%2520Studies%2520of%2520Healthy%2520Volunteers%2520and%2520Postmenopausal%2520Women%26jtitle%3DBone%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D2014%26volume%3D64%26spage%3D204%26epage%3D210%26doi%3D10.1016%2Fj.bone.2014.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cosman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilchrist, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foldes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Villiers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santora, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyden, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGinnis, I. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denker, A. E.</span></span> <span> </span><span class="NLM_article-title">A Phase 2 Study of MK-5442, a Calcium-Sensing Receptor Antagonist, in Postmenopausal Women with Osteoporosis after Long-Term Use of Oral Bisphosphonates</span>. <i>Osteoporosis Int.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1007/s00198-015-3392-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1007%2Fs00198-015-3392-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=26556736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVKqtrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=377-386&issue=1&author=F.+Cosmanauthor=N.+Gilchristauthor=M.+McClungauthor=J.+Foldesauthor=T.+de+Villiersauthor=A.+Santoraauthor=A.+Leungauthor=S.+Samantaauthor=N.+Heydenauthor=I.+J.+P.+McGinnisauthor=E.+Rosenbergauthor=A.+E.+Denker&title=A+Phase+2+Study+of+MK-5442%2C+a+Calcium-Sensing+Receptor+Antagonist%2C+in+Postmenopausal+Women+with+Osteoporosis+after+Long-Term+Use+of+Oral+Bisphosphonates&doi=10.1007%2Fs00198-015-3392-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates</span></div><div class="casAuthors">Cosman, F.; Gilchrist, N.; McClung, M.; Foldes, J.; de Villiers, T.; Santora, A.; Leung, A.; Samanta, S.; Heyden, N.; McGinnis, II, J. P.; Rosenberg, E.; Denker, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Osteoporosis International</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">377-386</span>CODEN:
                <span class="NLM_cas:coden">OSINEP</span>;
        ISSN:<span class="NLM_cas:issn">0937-941X</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag London Ltd.</span>)
        </div><div class="casAbstract">Summary: In women with osteoporosis treated with alendronate for >12 mo and oral bisphosphonates for >3 of the last 4 years, switching to MK-5442, a calcium receptor antagonist, stimulated endogenous parathyroid hormone (PTH) secretion and increased bone turnover marker levels, but produced a decline in bone mineral d. (BMD) at all sites.  Introduction: This study assessed the effects of switching from long-term oral bisphosphonate therapy to the calcium-sensing receptor antagonist MK-5442 on BMD and bone turnover markers (BTMs) in post-menopausal women with osteoporosis.  Methods: This randomized, active and placebo-controlled, dose-ranging study enrolled 526 postmenopausal women, who had taken alendronate (ALN) for ≥12 mo preceding the trial and any oral bisphosphonate for ≥3 of the preceding 4 years and had spine or hip BMD T-scores ≤-2.5 or ≤-1.5 with ≥1 prior fragility fracture.  Women were randomized to continue ALN 70 mg weekly or switch to MK-5442 (5, 7.5, 10, or 15 mg daily) or placebo.  Results: Switching from ALN to MK-5442 produced a dose-dependent parathyroid hormone (PTH) pulse of threefold to sixfold above baseline at 1 h, with PTH levels that remained twofold to threefold above baseline at 4 h and returned to baseline by 24 h.  Switching to MK-5442 or placebo increased BTM levels compared to baseline within 3 mo and MK-5442 10 mg increased BTM levels compared to placebo by 6 mo.  With all MK-5442 doses and placebo, spine and hip BMD declined from baseline, and at 12 mo, BMD levels were below those who continued ALN (all groups P < 0.05 vs ALN).  There was also a dose-dependent increase in the incidence of hypercalcemia with MK-5442.  Conclusion: Switching from ALN to MK-5442 resulted in a pulsatile increase in PTH and increases in BTMs, but a decline in BMD compared with continued ALN.  MK-5442 is not a viable option for the treatment of osteoporosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0gFq8pwhPdrVg90H21EOLACvtfcHk0liYWm5a8cEqWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVKqtrrK&md5=06afd60cf458794104da186d04d4200a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs00198-015-3392-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00198-015-3392-7%26sid%3Dliteratum%253Aachs%26aulast%3DCosman%26aufirst%3DF.%26aulast%3DGilchrist%26aufirst%3DN.%26aulast%3DMcClung%26aufirst%3DM.%26aulast%3DFoldes%26aufirst%3DJ.%26aulast%3Dde%2BVilliers%26aufirst%3DT.%26aulast%3DSantora%26aufirst%3DA.%26aulast%3DLeung%26aufirst%3DA.%26aulast%3DSamanta%26aufirst%3DS.%26aulast%3DHeyden%26aufirst%3DN.%26aulast%3DMcGinnis%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DRosenberg%26aufirst%3DE.%26aulast%3DDenker%26aufirst%3DA.%2BE.%26atitle%3DA%2520Phase%25202%2520Study%2520of%2520MK-5442%252C%2520a%2520Calcium-Sensing%2520Receptor%2520Antagonist%252C%2520in%2520Postmenopausal%2520Women%2520with%2520Osteoporosis%2520after%2520Long-Term%2520Use%2520of%2520Oral%2520Bisphosphonates%26jtitle%3DOsteoporosis%2520Int.%26date%3D2016%26volume%3D27%26issue%3D1%26spage%3D377%26epage%3D386%26doi%3D10.1007%2Fs00198-015-3392-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nemeth, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, W. G.</span></span> <span> </span><span class="NLM_article-title">Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures</span>. <i>Calcif. Tissue Int.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>98</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1007/s00223-015-0052-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1007%2Fs00223-015-0052-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=26319799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVajs7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2016&pages=341-358&issue=4&author=E.+F.+Nemethauthor=W.+G.+Goodman&title=Calcimimetic+and+Calcilytic+Drugs%3A+Feats%2C+Flops%2C+and+Futures&doi=10.1007%2Fs00223-015-0052-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures</span></div><div class="casAuthors">Nemeth, E. F.; Goodman, W. G.</div><div class="citationInfo"><span class="NLM_cas:title">Calcified Tissue International</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">341-358</span>CODEN:
                <span class="NLM_cas:coden">CTINDZ</span>;
        ISSN:<span class="NLM_cas:issn">0171-967X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The actions of extracellular Ca2+ in regulating parathyroid gland and kidney functions are mediated by the extracellular calcium receptor (CaR), a G protein-coupled receptor.  The CaR is one of the essential mols. maintaining systemic Ca2+ homeostasis and is a mol. target for drugs useful in treating bone and mineral disorders.  Ligands that activate the CaR are termed calcimimetics and are classified as either agonists (type I) or pos. allosteric modulators (type II); calcimimetics inhibit the secretion of parathyroid hormone (PTH).  Cinacalcet is a type II calcimimetic that is used to treat secondary hyperparathyroidism in patients receiving dialysis and to treat hypercalcemia in some forms of primary hyperparathyroidism.  The use of cinacalcet among patients with secondary hyperparathyroidism who are managed with dialysis effectively lowers circulating PTH levels, reduces serum phosphorus and FGF23 concns., improves bone histopathol., and may diminish skeletal fracture rates and the need for parathyroidectomy.  A second generation type II calcimimetic (AMG 416) is currently under regulatory review.  Calcilytics are CaR antagonists that stimulate the secretion of PTH.  Several calcilytic compds. have been evaluated as orally active anabolic therapies for postmenopausal osteoporosis but clin. development of all of them has been abandoned because they lacked clin. efficacy.  Calcilytics might be repurposed for new indications like autosomal dominant hypocalcemia or other disorders beyond those involving systemic Ca2+ homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlbRJGITOUL7Vg90H21EOLACvtfcHk0liYWm5a8cEqWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVajs7bI&md5=2aa48effc3f94f1c61e9e25877ee0cb1</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs00223-015-0052-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00223-015-0052-z%26sid%3Dliteratum%253Aachs%26aulast%3DNemeth%26aufirst%3DE.%2BF.%26aulast%3DGoodman%26aufirst%3DW.%2BG.%26atitle%3DCalcimimetic%2520and%2520Calcilytic%2520Drugs%253A%2520Feats%252C%2520Flops%252C%2520and%2520Futures%26jtitle%3DCalcif.%2520Tissue%2520Int.%26date%3D2016%26volume%3D98%26issue%3D4%26spage%3D341%26epage%3D358%26doi%3D10.1007%2Fs00223-015-0052-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">1–3</span>),  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&issue=1%E2%80%933&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+Computational+Approaches+to+Estimate+Solubility+and+Permeability+in+Drug+Discovery+and+Development+Settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0lh1BTCjD9SjiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520Computational%2520Approaches%2520to%2520Estimate%2520Solubility%2520and%2520Permeability%2520in%2520Drug%2520Discovery%2520and%2520Development%2520Settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26issue%3D1%25E2%2580%25933%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Congreve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhoti, H.</span></span> <span> </span><span class="NLM_article-title">A “Rule of Three” for Fragment-Based Lead Discovery?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(03)02831-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2FS1359-6446%2803%2902831-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=14554012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A280%3ADC%252BD3svns1Cnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=876-877&issue=19&author=M.+Congreveauthor=R.+Carrauthor=C.+Murrayauthor=H.+Jhoti&title=A+%E2%80%9CRule+of+Three%E2%80%9D+for+Fragment-Based+Lead+Discovery%3F&doi=10.1016%2FS1359-6446%2803%2902831-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A 'rule of three' for fragment-based lead discovery?</span></div><div class="casAuthors">Congreve Miles; Carr Robin; Murray Chris; Jhoti Harren</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">876-7</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfFswFSn5vb43yKPtYViAGfW6udTcc2eZUvESVc8okcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svns1Cnsw%253D%253D&md5=137886dbb2062f7a3ad39277dd888df3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2803%2902831-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252803%252902831-9%26sid%3Dliteratum%253Aachs%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DCarr%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DC.%26aulast%3DJhoti%26aufirst%3DH.%26atitle%3DA%2520%25E2%2580%259CRule%2520of%2520Three%25E2%2580%259D%2520for%2520Fragment-Based%2520Lead%2520Discovery%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2003%26volume%3D8%26issue%3D19%26spage%3D876%26epage%3D877%26doi%3D10.1016%2FS1359-6446%2803%2902831-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryckmans, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, T.</span></span> <span> </span><span class="NLM_article-title">Rapid Assessment of a Novel Series of Selective CB(2) Agonists Using Parallel Synthesis Protocols: A Lipophilic Efficiency (LipE) Analysis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">4406</span>– <span class="NLM_lpage">4409</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.05.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1016%2Fj.bmcl.2009.05.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=19500981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=4406-4409&issue=15&author=T.+Ryckmansauthor=M.+P.+Edwardsauthor=V.+A.+Horneauthor=A.+M.+Correiaauthor=D.+R.+Owenauthor=L.+R.+Thompsonauthor=I.+Tranauthor=M.+F.+Tuttauthor=T.+Young&title=Rapid+Assessment+of+a+Novel+Series+of+Selective+CB%282%29+Agonists+Using+Parallel+Synthesis+Protocols%3A+A+Lipophilic+Efficiency+%28LipE%29+Analysis&doi=10.1016%2Fj.bmcl.2009.05.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis</span></div><div class="casAuthors">Ryckmans, Thomas; Edwards, Martin P.; Horne, Val A.; Correia, Ana Monica; Owen, Dafydd R.; Thompson, Lisa R.; Tran, Isabelle; Tutt, Michelle F.; Young, Tim</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4406-4409</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of libraries were designed using the 1-(cyclopropylmethyl)-2-alkyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-5-ium templates 2a-b, and Sulfonamide derivs. 11a-n proved to be potent agonists of the CB2 receptor.  Anal. of the Lipophilic Efficiency (LipE) of potent compds. provided new insight for the design of potent, metabolically stable CB2 agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cihq9YHuO7Vg90H21EOLACvtfcHk0lh__DUIIbaNaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosVGlsrg%253D&md5=b62d97e5f52a594cfdd510f32d2e566f</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.05.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.05.062%26sid%3Dliteratum%253Aachs%26aulast%3DRyckmans%26aufirst%3DT.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DHorne%26aufirst%3DV.%2BA.%26aulast%3DCorreia%26aufirst%3DA.%2BM.%26aulast%3DOwen%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DL.%2BR.%26aulast%3DTran%26aufirst%3DI.%26aulast%3DTutt%26aufirst%3DM.%2BF.%26aulast%3DYoung%26aufirst%3DT.%26atitle%3DRapid%2520Assessment%2520of%2520a%2520Novel%2520Series%2520of%2520Selective%2520CB%25282%2529%2520Agonists%2520Using%2520Parallel%2520Synthesis%2520Protocols%253A%2520A%2520Lipophilic%2520Efficiency%2520%2528LipE%2529%2520Analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26issue%3D15%26spage%3D4406%26epage%3D4409%26doi%3D10.1016%2Fj.bmcl.2009.05.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keefer, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoest, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M.</span></span> <span> </span><span class="NLM_article-title">Evaluating the Differences in Cycloalkyl Ether Metabolism Using the Design Parameter “Lipophilic Metabolism Efficiency” (LipMetE) and a Matched Molecular Pairs Analysis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">6985</span>– <span class="NLM_lpage">6990</span>, <span class="refDoi"> DOI: 10.1021/jm4008642</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4008642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6985-6990&issue=17&author=A.+F.+Stepanauthor=G.+W.+Kauffmanauthor=C.+E.+Keeferauthor=P.+R.+Verhoestauthor=M.+Edwards&title=Evaluating+the+Differences+in+Cycloalkyl+Ether+Metabolism+Using+the+Design+Parameter+%E2%80%9CLipophilic+Metabolism+Efficiency%E2%80%9D+%28LipMetE%29+and+a+Matched+Molecular+Pairs+Analysis&doi=10.1021%2Fjm4008642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluating the Differences in Cycloalkyl Ether Metabolism Using the Design Parameter "Lipophilic Metabolism Efficiency" (LipMetE) and a Matched Molecular Pairs Analysis</span></div><div class="casAuthors">Stepan, Antonia F.; Kauffman, Gregory W.; Keefer, Christopher E.; Verhoest, Patrick R.; Edwards, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6985-6990</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have obsd. previously that modification of ring size and substitution pattern may be used as a strategy to mitigate the metabolic instability of cycloalkyl ethers.  In this article, we introduce a medicinal chem. design parameter named "lipophilic metab. efficiency" (LipMetE) that indicates that these changes in metabolic stability can be largely ascribed to changes in lipophilicity.  Our matched mol. pair anal. also indicates that this finding is a general phenomenon, widely obsd. across different chemotypes.  It is our hope that both the LipMetE design parameter and the results from our pairwise anal. will be useful tools for medicinal chemists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpiFJ_fPxurbVg90H21EOLACvtfcHk0lh__DUIIbaNaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFKgurvJ&md5=596673d35831b979b8daf5a4ccb8a218</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm4008642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4008642%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DKauffman%26aufirst%3DG.%2BW.%26aulast%3DKeefer%26aufirst%3DC.%2BE.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DEdwards%26aufirst%3DM.%26atitle%3DEvaluating%2520the%2520Differences%2520in%2520Cycloalkyl%2520Ether%2520Metabolism%2520Using%2520the%2520Design%2520Parameter%2520%25E2%2580%259CLipophilic%2520Metabolism%2520Efficiency%25E2%2580%259D%2520%2528LipMetE%2529%2520and%2520a%2520Matched%2520Molecular%2520Pairs%2520Analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D17%26spage%3D6985%26epage%3D6990%26doi%3D10.1021%2Fjm4008642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuck, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damian-Iordache, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, C.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimbach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnatry, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liederer, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettetal, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudra, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nijsen, M. J. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raybon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuck, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suryawanshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakilynejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span> <span> </span><span class="NLM_article-title">Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">473</span>, <span class="refDoi"> DOI: 10.1208/s12248-014-9716-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1208%2Fs12248-014-9716-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=25630504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslehsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=462-473&issue=2&author=E.+Schuckauthor=T.+Bohnertauthor=A.+Chakravartyauthor=V.+Damian-Iordacheauthor=C.+Gibsonauthor=C.-P.+Hsuauthor=T.+Heimbachauthor=A.+S.+Krishnatryauthor=B.+M.+Liedererauthor=J.+Linauthor=T.+Maurerauthor=J.+T.+Mettetalauthor=D.+R.+Mudraauthor=M.+J.+M.+A.+Nijsenauthor=J.+Raybonauthor=P.+Schroederauthor=V.+Schuckauthor=S.+Suryawanshiauthor=Y.+Suauthor=P.+Trapaauthor=A.+Tsaiauthor=M.+Vakilynejadauthor=S.+Wangauthor=H.+Wong&title=Preclinical+Pharmacokinetic%2FPharmacodynamic+Modeling+and+Simulation+in+the+Pharmaceutical+Industry%3A+An+IQ+Consortium+Survey+Examining+the+Current+Landscape&doi=10.1208%2Fs12248-014-9716-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape</span></div><div class="casAuthors">Schuck, Edgar; Bohnert, Tonika; Chakravarty, Arijit; Damian-Iordache, Valeriu; Gibson, Christopher; Hsu, Cheng-Pang; Heimbach, Tycho; Krishnatry, Anu Shilpa; Liederer, Bianca M.; Lin, Jing; Maurer, Tristan; Mettetal, Jerome T.; Mudra, Daniel R.; Nijsen, Marjoleen J. M. A.; Raybon, Joseph; Schroeder, Patricia; Schuck, Virna; Suryawanshi, Satyendra; Su, Yaming; Trapa, Patrick; Tsai, Alice; Vakilynejad, Majid; Wang, Shining; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">462-473</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The application of modeling and simulation techniques is increasingly common in preclin. stages of the drug discovery and development process.  A survey focusing on preclin. pharmacokinetic/pharmacodynamics (PK/PD) anal. was conducted across pharmaceutical companies that are members of the International Consortium for Quality and Innovation in Pharmaceutical Development.  Based on survey responses, ∼68% of companies use preclin. PK/PD anal. in all therapeutic areas indicating its broad application.  An important goal of preclin. PK/PD anal. in all pharmaceutical companies is for the selection/optimization of doses and/or dose regimens, including prediction of human efficacious doses.  Oncol. was the therapeutic area with the most PK/PD anal. support and where it showed the most impact.  Consistent use of more complex systems pharmacol. models and hybrid physiol. based pharmacokinetic models with PK/PD components was less common compared to traditional PK/PD models.  Preclin. PK/PD anal. is increasingly being included in regulatory submissions with ∼73% of companies including these data to some degree.  Most companies (∼86%) have seen impact of preclin. PK/PD analyses in drug development.  Finally, ∼59% of pharmaceutical companies have plans to expand their PK/PD modeling groups over the next 2 years indicating continued growth.  The growth of preclin. PK/PD modeling groups in pharmaceutical industry is necessary to establish required resources and skills to further expand use of preclin. PK/PD modeling in a meaningful and impactful manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcipAzVX5DQ7Vg90H21EOLACvtfcHk0lh3G3Cwfa4G0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslehsrw%253D&md5=a8156f55850d64d1a560512c21cf895f</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1208%2Fs12248-014-9716-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-014-9716-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchuck%26aufirst%3DE.%26aulast%3DBohnert%26aufirst%3DT.%26aulast%3DChakravarty%26aufirst%3DA.%26aulast%3DDamian-Iordache%26aufirst%3DV.%26aulast%3DGibson%26aufirst%3DC.%26aulast%3DHsu%26aufirst%3DC.-P.%26aulast%3DHeimbach%26aufirst%3DT.%26aulast%3DKrishnatry%26aufirst%3DA.%2BS.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DMaurer%26aufirst%3DT.%26aulast%3DMettetal%26aufirst%3DJ.%2BT.%26aulast%3DMudra%26aufirst%3DD.%2BR.%26aulast%3DNijsen%26aufirst%3DM.%2BJ.%2BM.%2BA.%26aulast%3DRaybon%26aufirst%3DJ.%26aulast%3DSchroeder%26aufirst%3DP.%26aulast%3DSchuck%26aufirst%3DV.%26aulast%3DSuryawanshi%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DTrapa%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DA.%26aulast%3DVakilynejad%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DPreclinical%2520Pharmacokinetic%252FPharmacodynamic%2520Modeling%2520and%2520Simulation%2520in%2520the%2520Pharmaceutical%2520Industry%253A%2520An%2520IQ%2520Consortium%2520Survey%2520Examining%2520the%2520Current%2520Landscape%26jtitle%3DAAPS%2520J.%26date%3D2015%26volume%3D17%26issue%3D2%26spage%3D462%26epage%3D473%26doi%3D10.1208%2Fs12248-014-9716-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nijsen, M. J. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw-Pierce, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liederer, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettetal, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuck, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chimalakonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spilker, M. E.</span></span> <span> </span><span class="NLM_article-title">Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape</span>. <i>CPT: Pharmacometrics Syst. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1002/psp4.12282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1002%2Fpsp4.12282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=29349875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=135-146&issue=3&author=M.+J.+M.+A.+Nijsenauthor=F.+Wuauthor=L.+Bansalauthor=E.+Bradshaw-Pierceauthor=J.+R.+Chanauthor=B.+M.+Liedererauthor=J.+T.+Mettetalauthor=P.+Schroederauthor=E.+Schuckauthor=A.+Tsaiauthor=C.+Xuauthor=A.+Chimalakondaauthor=K.+Leauthor=M.+Penneyauthor=B.+Toppauthor=A.+Yamadaauthor=M.+E.+Spilker&title=Preclinical+QSP+Modeling+in+the+Pharmaceutical+Industry%3A+An+IQ+Consortium+Survey+Examining+the+Current+Landscape&doi=10.1002%2Fpsp4.12282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape</span></div><div class="casAuthors">Nijsen, Marjoleen J. M. A.; Wu, Fan; Bansal, Loveleena; Bradshaw-Pierce, Erica; Chan, Jason R.; Liederer, Bianca M.; Mettetal, Jerome T.; Schroeder, Patricia; Schuck, Edgar; Tsai, Alice; Xu, Christine; Chimalakonda, Anjaneya; Le, Kha; Penney, Mark; Topp, Brian; Yamada, Akihiro; Spilker, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">CPT: Pharmacometrics & Systems Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">135-146</span>CODEN:
                <span class="NLM_cas:coden">CPSPBR</span>;
        ISSN:<span class="NLM_cas:issn">2163-8306</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A cross-industry survey was conducted to assess the landscape of preclin. quant. systems pharmacol. (QSP) modeling within pharmaceutical companies.  This article presents the survey results, which provide insights on the current state of preclin. QSP modeling in addn. to future opportunities.  Our results call attention to the need for an aligned definition and consistent terminol. around QSP, yet highlight the broad applicability and benefits preclin. QSP modeling is currently delivering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2yDgos1LCibVg90H21EOLACvtfcHk0lh3G3Cwfa4G0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGhs7s%253D&md5=f8007901081fedb9763b89782917ba37</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1002%2Fpsp4.12282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpsp4.12282%26sid%3Dliteratum%253Aachs%26aulast%3DNijsen%26aufirst%3DM.%2BJ.%2BM.%2BA.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DBansal%26aufirst%3DL.%26aulast%3DBradshaw-Pierce%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DJ.%2BR.%26aulast%3DLiederer%26aufirst%3DB.%2BM.%26aulast%3DMettetal%26aufirst%3DJ.%2BT.%26aulast%3DSchroeder%26aufirst%3DP.%26aulast%3DSchuck%26aufirst%3DE.%26aulast%3DTsai%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DChimalakonda%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DK.%26aulast%3DPenney%26aufirst%3DM.%26aulast%3DTopp%26aufirst%3DB.%26aulast%3DYamada%26aufirst%3DA.%26aulast%3DSpilker%26aufirst%3DM.%2BE.%26atitle%3DPreclinical%2520QSP%2520Modeling%2520in%2520the%2520Pharmaceutical%2520Industry%253A%2520An%2520IQ%2520Consortium%2520Survey%2520Examining%2520the%2520Current%2520Landscape%26jtitle%3DCPT%253A%2520Pharmacometrics%2520Syst.%2520Pharmacol.%26date%3D2018%26volume%3D7%26issue%3D3%26spage%3D135%26epage%3D146%26doi%3D10.1002%2Fpsp4.12282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, S.</span></span> <span> </span><span class="NLM_article-title">A Simple Practice Guide for Dose Conversion between Animals and Human</span>. <i>J. Basic Clin Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.4103/0976-0105.177703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.4103%2F0976-0105.177703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=27057123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A280%3ADC%252BC28fotV2hsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=27-31&issue=2&author=A.+B.+Nairauthor=S.+Jacob&title=A+Simple+Practice+Guide+for+Dose+Conversion+between+Animals+and+Human&doi=10.4103%2F0976-0105.177703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">A simple practice guide for dose conversion between animals and human</span></div><div class="casAuthors">Nair Anroop B; Jacob Shery</div><div class="citationInfo"><span class="NLM_cas:title">Journal of basic and clinical pharmacy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">27-31</span>
        ISSN:<span class="NLM_cas:issn">0976-0105</span>.
    </div><div class="casAbstract">Understanding the concept of extrapolation of dose between species is important for pharmaceutical researchers when initiating new animal or human experiments.  Interspecies allometric scaling for dose conversion from animal to human studies is one of the most controversial areas in clinical pharmacology.  Allometric approach considers the differences in body surface area, which is associated with animal weight while extrapolating the doses of therapeutic agents among the species.  This review provides basic information about translation of doses between species and estimation of starting dose for clinical trials using allometric scaling.  The method of calculation of injection volume for parenteral formulation based on human equivalent dose is also briefed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRDuPq7lwLZ_xwLZxei1HN8fW6udTcc2eZPPtuNh6mjlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fotV2hsQ%253D%253D&md5=527e4c74daabcb030b1e475cc22d8404</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.4103%2F0976-0105.177703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-0105.177703%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DA.%2BB.%26aulast%3DJacob%26aufirst%3DS.%26atitle%3DA%2520Simple%2520Practice%2520Guide%2520for%2520Dose%2520Conversion%2520between%2520Animals%2520and%2520Human%26jtitle%3DJ.%2520Basic%2520Clin%2520Pharm.%26date%3D2016%26volume%3D7%26issue%3D2%26spage%3D27%26epage%3D31%26doi%3D10.4103%2F0976-0105.177703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">West, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enquist, B. J.</span></span> <span> </span><span class="NLM_article-title">A General Model for the Origin of Allometric Scaling Laws in Biology</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>276</i></span> (<span class="NLM_issue">5309</span>),  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1126/science.276.5309.122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=10.1126%2Fscience.276.5309.122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=9082983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;key=1%3ACAS%3A528%3ADyaK2sXitl2jtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1997&pages=122-126&issue=5309&author=G.+B.+Westauthor=J.+H.+Brownauthor=B.+J.+Enquist&title=A+General+Model+for+the+Origin+of+Allometric+Scaling+Laws+in+Biology&doi=10.1126%2Fscience.276.5309.122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A general model for the origin of allometric scaling laws in biology</span></div><div class="casAuthors">West, Geoffrey B.; Brown, James H.; Enquist, Brian J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">5309</span>),
    <span class="NLM_cas:pages">122-126</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Allometric scaling relations, including the 3/4 power law for metabolic rates, are characteristic of all organisms and are here derived from a general model that describes how essential materials are transported through space-filling fractal networks of branching tubes.  The model assumes that the energy dissipated is minimized and that the terminal tubes do not vary with body size.  It provides a complete anal. of scaling relations for mammalian circulatory systems that are in agreement with data.  More generally, the model predicts structural and functional properties of vertebrate cardiovascular and respiratory systems, plant vascular systems, insect tracheal tubes, and other distribution networks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNkdfXXHt1P7Vg90H21EOLACvtfcHk0lguTj5y0MY6PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXitl2jtro%253D&md5=bb88c8dacfd9183a76c441d593b52ac7</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1126%2Fscience.276.5309.122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.276.5309.122%26sid%3Dliteratum%253Aachs%26aulast%3DWest%26aufirst%3DG.%2BB.%26aulast%3DBrown%26aufirst%3DJ.%2BH.%26aulast%3DEnquist%26aufirst%3DB.%2BJ.%26atitle%3DA%2520General%2520Model%2520for%2520the%2520Origin%2520of%2520Allometric%2520Scaling%2520Laws%2520in%2520Biology%26jtitle%3DScience%26date%3D1997%26volume%3D276%26issue%3D5309%26spage%3D122%26epage%3D126%26doi%3D10.1126%2Fscience.276.5309.122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01365&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-12%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01365%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01365" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667987c54b911943","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
